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ABSTRACT 
The molecular basis for the use of synthetic growth factors (GFs) in tissue reparation has been 
poorly investigated.  More recently, autologous derived platelet rich growth factor has gained 
popularity in the field of regenerative/ reparative medicine, mostly because it fits the description of 
an ideal naturally existing constellation of GFs. However, its efficacy remains controversial. Hence, 
this study is designed to further elucidate the physiological role of PRP in treating chronic diabetic 
foot ulcers.  
Platelet -rich plasma (PRP) and Platelet -poor plasma (PPP) were prepared from blood samples taken 
from healthy donors and diabetic patients through the use of platelet collecting and concentrating 
system. The GFs released were measured through immunoassay technique. The effects of the 
varying concentrations of PRP/PPP in culture media was assessed through tissue culture assay 
(proliferation, cell migration and angiogenesis assay) on human epithelia keratinocyte, dermal 
fibroblast and umbilical vein endothelia cell. Furthermore, immuno-histochemistry technique was 
used to evaluate the differentiation, proliferation, migration and extracellular matrix alterations 
occurring along wound margins of patients with chronic diabetic ulcers following PRP treatment. 
A significant difference was observed when the expression of platelet derived growth factor-AA, 
epidermal growth factor, vascular endothelia growth factor, transforming growth factor and 
thrombospodin-I released from PRP/PPP were compared between the two groups. There was a 
significant proliferative, migratory and angiogenic effect of PRP over PPP in the tissue culture 
assay; however this effect was most prominent with 5% PRP. Overall, hyperproliferative keratin, 
CD44 and β1-integrin were upregulated in diabetic ulcer keratinocytes as compared with normal foot 
skin. The clinical study showed that 3 of the 7 diabetic foot ulcer patients treated with PRP achieved 
complete wound re-epithelisation.  We have been able to demonstrate through in vitro studies that 
PRP has a positive biological effect which mimics normal physiological tissue reparation process. 
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DMSO                      Dimethyl-sulphoxide  
dH2O                        Distilled water  
EBM                        Endothelial Cell Basal Medium-2  
ELISA                     Enzyme linked immuno-absorbent assay   
EGF                         Epidermal growth factor  
ECM                        Extra-cellular matrix  
EHS                         Engelbreth-Holm Swarm  
EHS                         Engelbreth-Holm Swarm  
EDTA                      Ethylediaminetetraacetic acid  
FBS                         Fetal bovine serum 
FGF                        Fibroblast growth factor 
FAD                        Flavin adenine dinucleotide 
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FITC                       Fluroescein isothiocyanate 
FADH2                   Reduced Flavin adenine dinucleotide 
FMNH2                  Reduced Flavin mononucleotide 
FMN                       Flavin mononucleotide 
g                              Gram 
GF                           Growth Factor 
GM-CSF                 Granulocyte /macrophage colony-stimulating factor 
HEK                        Human epithelia keratinocyte 
HDF                        Human dermal fibroblast 
HUVEC                  Human umbilical vein endothelial cell 
IF                            Intermediate filament 
IGF-1                      Insulin-like growth-1 
IMS                         Industrial methylated spirit 
IL-1                         Interleukin 
KSC                        Keratinocyte stem cell  
KGF                        Keratinocyte growth factor  
kDa                         Kilo Dalton  
L                             Litre   
MMP-9                   Matrix metalloproteinase  
MTT                       (3-(4,5- Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  
μL                           Microlitre  
MFI                        Multiplex fluorescent immunoassay technique. 
ng                           Nanogram   
NADH                   Nicotinamaide adenine dinucleotide  
NADHP                 Nicotinamadie adenine dinucleotide phosphate   
NO                         Nitrous oxide  
HUGO                   Nomenclature of the Human Genome Organization  
ORS                       Other root sheath  
PDGF                     Platelet derived growth factor  
PF-4                       Platelet Factor-4  
PRP                        Platelet rich plasma gel  
PPP                        Platelet poor plasma gel  
PSS                        Platelet separation system  
PBS                       Phosphate buffer solution  
r-hFGF-B              Recombinant human fibroblast growth factor-B    
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rhEGF                   Recombinant human epidermal growth factor   
rhVEGF                Recombinant human vascular endothelial growth factor, 
R3-IGF-1             Recombinant long releasing insulin-like growth factor   
RADIL                 Research animal diagnostic laboratory  
 NaOH2               Sodium Hydroxide 
SDF-1                  Stroma cell-derived factor -1   
K-SF                    Serum free keratinocyte  
TSP-1                  Thrombospodin-1  
TA                       Transit amplifying cells  
TGF                     Transforming growth factor   
TNF                     Tumour Necrosis Factor  
VEGF                  Vascular endothelia growth factor  
V/V                     Volume for volume      
VWF                   Von Williebrand factor  
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1.1 Structure of the Human Skin 
The integument comprises the skin together with its appendages (Figure 1.1). These include the hair, 
sebaceous and sweat glands, nails and hair follicles. It covers a surface area of more than 1.8m
2
, 
making up in total 16% of the normal body weight.   It has a range of functions that support survival 
which include acting as a physical barrier to biological, chemical and ultra violet radiation. Other 
functions of the skin include homeostasis regulation for fluid, tactile function, thermoregulation, 
vitamin D synthesis, immune surveillance, excretory function, sociosexual communication and 
reproduction via production of pheromones. Embryologically, the skin is derived from the ectoderm 
and mesoderm respectively.  The skin can be divided into two parts namely, the hairy skin and non-
hairy skin. It comprises of 2 layers, the outer most layer is called the epidermis and the innermost 
part is called the dermis.  
 
1.1.1 The Epidermis 
The epidermis is said to be the stratified squamous epithelium made up of several cell types. These 
are melanocytes, langerhans cells, merkel cells and keratinocyte, of which keratinocytes make up to 
80% of the cellular population. The epidermis has four distinct layers, each showing a pattern of 
keratinocyte proliferation, differentiation and maturation. The layers are strata basale 
(germinativum), the spinosum, the granulosum and corneum (Watt, 1989).  A fifth layer exists in 
very thick skin called the lucidum, which is present between the granulosum and corneum layers. 
The cell layers represent the sequential differentiation process of keratinocytes as they migrate from 
the basal to the terminal differentiation. The process of terminal differentiation involves a series of 
biochemical and morphological changes, which results in the production of the cornified outer most 
layer. The average epidermal turnover takes about 14-30days (Latkowski and Freedberg, 1999). The 
stratum basale consists of a single layer of cuboidal basal cells attached to the basement membrane 
by hemisdesmosomes that contains intergrins. Each adjacent cell is attached by desmosomes 
containing cadhein. The cells in this layer are mitotically active and are involved in continuing 
replacement of keratinocytes by upward displacement. These mitotically active cells are believed to 
have originated from the tip of the dermal papillae and the deep rete ridges of the hairy skin (Jensen 
et al., 1999) and the bulge region of the outer root sheath (ORS) of the adult human hair follicles in 
hair skin (Cotsarelis et al., 1990; Lyle et al. 1998). Basal cell contains cytokeratins organised in 
bundles around the nucleus and insert into desmosomes peripherally.  
 
The stratum spinosum is the cellular layer above the basal layer. It consists of several layers of 
irregular polyhedral shaped cells that display spiny projection. As the basal layer cells move upwards 
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and away from their blood supply, their cell content and shape changes, and the cells become 
irregular in shape and form the spinous layer. However, some cells in this layer are still mitotically 
active. Cells become progressively flattened as they move up towards succeeding layers, these cells 
contains lamella granules and more demosomes for cell to cell adhesions. Above this layer, cells 
move into the granular layer which is a 3-5 cellular layer. The cells  are distant from the blood supply 
in the dermis, hence these cells begin to flatten and die. The cell cytoplasm contains lamellar 
granules, which consists of lipid and keratohyalin. Keratohyalin granules contain pro-filaggrin, 
which is a precursor of filaggrin that binds the keratin filaments together.  
 
The stratum lucidum consists of several flattened anuclei cells and keratin rich cytoplasm. The 
stratum corneum (‗horny layer‘) is the top layer of the epidermis. Cells here are flat and scale-like 
(‗squamous‘) in shape. These cells are dead and contain lots of keratin and are arranged in 
overlapping layers that impact a tough and waterproof character to the skin‘s surface.  Dead skin 
cells are continually shed from the skin‘s surface. This is balanced by the dividing cells in the basal 
cell layer to produce a state of constant renewal. Other proteins found as components of the cornified 
cell envelope include keratolinin, loricin, filaggrin-linked segment peptide and envoplakin. 
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Figure 1.1  a) Schematic representation of epithelia structure and b) H&E  (x20)  of human 
epidermis (Young B, Wheater PR. Wheater's functional histology: a text and colour atlas. 5th ed. 
[Oxford]: Churchill Livingstone Elsevier 2006, Wickett RR. Structure and function of the epidermal 
barrier.  American Journal of Infection Control.2006 December 2006; 34(10):S98-S110 C-corneum*, 
only found in thick Skin, L-lucidum*, G-granulosum, S-spinosum, B-basale). 
 
1.1.1.1   Keratinocyte Stem Cell 
Skin homeostasis and regeneration are maintained by the presence of keratinocyte stem cell (KSC) 
which gives rise to the differentiating cells of the interfollicular epidermis, hair follicles and 
sebaceous glands. The proliferative reserve of these cells is enormous; they can maintain 1-2m
2
 of 
skin for decades (Alonso, 2003). The pioneering in vitro study by Barrandon and Green 
demonstrated that keratinocytes were capable of generating three distinct colony types based on their 
differing capacities for multiplication; these include holoclones, meroclones and paraclones 
(Barrandon, and Green, 1987).  
 
Holoclones are generated by KSC which show the greatest proliferative capacity and can undergo 
more than 140 doublings before senescence (Pellegrini et.al 1999).  Meroclones form intermediate 
colonies of limited growth potential and are committed to a maximum of 15 divisions, which 
represent the largest group of dividing cells.  Transit amplifying (TA) cell are the progeny of the 
stem cells, with a limited proliferative capacity identified as a pool of rapidly proliferating cells that 
are lost from the basal layer to terminal differentiation within 4–5 days. 
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Finally, paraclones form the smallest colonies and are typical of mature, differentiated basal cells. 
The transition from holoclone to meroclone to paraclone is an irreversible, unidirectional process 
which occurs slowly during ageing as well as during repeated keratinocyte sub-cultivation (Pellegrini 
et.al 1999, Lajtha 1979). This transition process is often accelerated by inappropriate culture 
conditions causing a rapid decline in KSC number (Pellegrini et.al 1999). 
 
KSCs and TA cells can be isolated from terminally differentiated basal cells on the basis of protein 
expression. Stem and transit amplifying cells have been shown to express high levels of Keratins 5 
and 14 and the integrins α6, β1 (Jones, 1993; Li, 1998). Integrins are a family of heterodimeric 
transmembrane receptor proteins, some of which help attach basal cells to the underlying basement 
membrane.  Integrin (α6) is found exclusively in hemi-desmosomes and partners with β4 integrin to 
attach to the basement membrane component laminin 5 (Alonso, 2003). Fractionation of cultured 
keratinocytes via fluorescent-activated cell sorting (FACS) has shown that cells expressing high 
levels of β1 integrin (Jones, 1993)and α6 integrin (Li, 1998) have the greatest proliferative capacity 
in-vitro and produce holoclones. In addition, β1 integrin, like α6 is also involved in determining the 
strength of attachment of basal cells to the basal membrane zone (BMZ). Stem cells express high 
levels of β1 integrin and therefore exert stronger binding to the basement membrane. 
 
1.1.1.2   Epidermal differentiation 
Epidermal differentiation begins in the stratum basale. Basal cells commence on a journey towards 
the skin surface by breaking away from the underlying basement membrane. During transit, the cell 
undergoes a series of morphological and biochemical changes which culminate in the production of 
dead, flattened, enucleated squames called cornified cells (Fuchs, 1990). The stratum basale 
represents the only mitotically active area of the epidermis and consists of a single layer of cuboidal 
or low-columnar keratinocytes separated from the dermis by the BMZ (Fuchs, 1990). These are then 
shed from the skin surface and replenished by the next generation (Figure 1.2). Regulation of the 
process is largely controlled by growth factors such as epidermal growth factor (EGF) (Rheinwald, 
1975), transforming growth factor a (TGF-a) (Coffey, et.al 1987), keratinocyte growth factor (KGF) 
(Finch et.al 1989) and the cytokines IL-6 (Grossman, et.al 1989), IL-1a (Ansel, et .al 1988).  The 
stratum basale represents the only mitotically active area of the epidermis and consists of a single 
layer of cuboidal or low-columnar keratinocytes separated from the dermis by the BMZ (Fuchs, 
1990).  
 
Basal cells are secured to the BMZ and each other through specialised connections termed hemi-
desmosomes and desmosomes, respectively. Both exhibit similar structural characteristics containing 
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plaque structures which are specialised for the anchorage of keratin 15 intermediate filaments 
(Green, 1996).  Desmosomes are calcium activated membrane junctions that fix cells into a three 
dimensional lattice (Franke, 1987). Conversely, hemi-desmosomes contains just one plaque 
connected to the basement membrane component laminin 5 by integrin α6β4 (Sonnenberg, et 
al.,1991). In order for cells to be liberated from the basal layer and commit to terminal 
differentiation, down-regulation of α6β4 must occur. 
 
  
 
 
 
 
 
 
 
Figure 1.2 Schematic illustration of epidermal differential programme  (Adolphe C, Wainwright 
B. Pathways to improving skin regeneration. Expert Rev Mol Med. 2005 Sep 23; 7(20):  
 
1.1.1.3 Structure of Keratin 
The cytoskeleton of all epithelial cells including keratinocytes is formed from the three groups of 
filaments; actin (microfilaments), tubulin (microtubules) and intermediate filaments.  The keratin is a 
typical intermediate filament protein of epithelia origin. The keratin gene family consists of the 
highest members of numbered human keratin with 54 distinct functional genes (Moll, 2008). Keratin 
belongs to a multi-gene family of proteins that form filaments of 10nm in diameter, with keratin 
forming the two largest groups.  They are heteropolymeric filaments formed by pairing of type I 
(acidic) and type II (basic) molecule.  Keratins can only constitute their filamentous stage by 
heteropolymeric pair formation of type I and type II (1:1). They contain central rod domain of 
approximately 310 amino acids with helical confirmation flanked by non –helical rod domain of 
variable length.  The molecular weight of human keratins ranges from approximately 22 to 66 kDa.  
Keratins are among the subfamilies of intermediate filament (IF) proteins with high molecular 
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diversity.  IF are usually very stable, long with un-branched filaments of approximately 10nm in 
diameter.  
Keratin represents the typical IF category of epithelial cells. Inside the cell, keratin braids the 
nucleus, spans through the cytoplasm and is attached to the cytoplasmic plaques of the typical 
epithelial cell-cell junctions (the desmosomes). This feature already suggests that they are involved 
in structural integrity and mechanical stability of both the single epithelial cells and that of the 
epithelial tissue (Waschke, 2008). The keratins are clustered at 2 different chromosomal sites: 
chromosome 12q13.13 (type II) and chromosomes 17q21.2 (type I keratin except K18). The keratin 
genes are designated as KRT2, KRT3 etc. (Rogers et al., 2006).  In the cell they braid the nucleus, 
span through the cytoplasmic plaques of the typical epithelial cell-cell junctions, the desmosomes. 
This feature already suggests that keratins play a major functional role in the integrity and 
mechanical stability of both the single epithelial cells and via cell-cell contacts, of the epithelial 
tissues.  There are 28 types I of keratin genes (17 epithelial keratins and 21 hair keratins) and 26 type 
of II keratin genes (20 epithelial keratins and 6 hair keratins), Table 1 shows the location and the 
types of Keratin. 
1.1.1.4 Function of Keratin 
Keratins are part of the epithelial cytoskeleton, they are important for the mechanical stability and 
integrity of the epithelial cell and tissues. Their expression is highly specific in relationship to the 
epithelial type and cellular differential stage.  Thus keratin expression has been used as specific 
epithelial cell markers to assess epithelial proliferation and differentiation with the aid of immuno-
histochemistry. 
Other keratins are involved with intracellular signalling pathways, wounding, and apoptosis. Keratins 
also contribute to basement membrane attachment and the connective tissue compartment of a given 
epithelium. New functional roles of keratin are being defined and still emerging. These include the 
protection from apoptosis (Caudin et al., 2003), the regulation of protein synthesis and cell size 
during wound healing involving intracellular signalling pathways (Kim et. al., 2006). Beyond their 
biological functions, keratin expression patterns not only characterise cells as epithelial layer but also 
they are also characterises for distinct event– including the terminal stages during cellular epithelial 
differentiation from embryonal to adult cell or of internal maturation program during development.  
Epithelial tumours – including metastases most widely retain the keratin patterns of their original 
epithelia, thus the determination of the keratin patterns of tumours are being widely exploited for cell 
and tumour typing. Keratins have also been used in immuno-histochemistry for diagnosis of 
carcinomas. Therefore keratins have evolved to be one of the most potent epithelial differentiations 
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and tumour markers in cell biology, embryology and surgical pathology (Oshima 2007, Chu and 
weiss 2002b). 
 
Type I ( acidic ) Type II    Epithelia location 
K10 K1 Suprabasal epidermal keratinocytes 
K9 K1 Palmoplantar suprabasal keratinocytes 
K10 K2e Granular layer of the epidermis 
K12 K3 Cornea 
K13 K4 Non- keratinizing stratified squamous epithelial 
K14 K5 Basal  layer keratinocytes 
K15 K5 Basal layer of non –keratinizing epithelial 
K16 K6a Outer root sheath (hair), hyper-proliferative keratinocyte, 
oral epithelium 
K17 K6b Nail bed, myoepithelium, inflammatory conditions 
 K7 Various partners in transformed cells 
K18 K8 Simple epithelial 
K19  Bulge cells ( hair follicle), simple epithelial 
K21  Intestinal epithelium 
 
Table 1.1  Cytokeratin protein with their primary location of expression.  Freeberg I.  
Keratinocytes. Education 2009; Available on www. Aad.org/education/students/ keratinocytes 
  
1.1.2   The Basement Membrane 
The cutaneous basement membrane is also called the dermo-epidermal junction, (DEJ) which 
separates the epidermis from the dermis. DEJ is a complex structure, composed of a membrane of 
different macromolecules, which form an important network to provide structural stability between 
the epidermis and underlying dermis. The organization of basement membrane to form a 
morphologically identifiable structure results from a cooperative effort of both keratinocytes and 
  
 
 
29 
fibroblasts (Fleischmajer et al., 1993; Marinkovich et al., 1993; 1998; Moulin et al., 2000).  
Marinkovich et al. studied the cellular origin of various basement membrane molecules by probing 
skin equivalents that contains bovine keratinocytes and human dermal fibroblasts with species 
specific antibodies (Marinkovich et al., 1993).  
 
The basement membrane consists of lamina densa which is associated with hemidesomes, lamina 
Lucida and anchoring filaments and anchoring fibrils (Uitto & Christiano, 1992). The 
hemidesmosomal proteins associated with keratin filaments in the intracellular space of the basal 
keratinocyte extend through to the extracellular lamina Lucida (Pulkkinen and Uttio 1999). There are 
two inner and an outer hemidesmosomal proteins that are the transmembrane proteins which include 
the bullous pemphigoid antigen and the intergrin which is the receptors for laminin 5. These proteins 
function to anchor the basal keratinocytes to the underlying basement membrane. The lamina Lucida 
is traversed by anchoring filaments which are composed of laminin 5, which is made from three 
polypeptide chains, α3, β3 and γ2 chains. Furthermore, the lower portion of the network involves 
anchoring fibrils which are composed of collagen type VII. These anchoring fibrils extend from the 
lamina densa to the papillary dermis. Thus, securing the basement membrane to the underlying 
dermis. 
1.1.2.1 Integrins 
 
Integrins are a family of heterodimetric (transmembrane receptors) cell surface receptors composed 
of α and β subunits, which mediate cell-cell and extracellular matrix function.  Eighteen different α 
and 8 different β subunits are known in mammals, which can combine to 24 different integrin 
receptors (Hynes, 2002). The largest subgroup is formed by the β1 subunit containing integrins 
which consist of 12 members with different ligand binding properties. All β1 integrins bind to 
extracellularmatrix molecules and some β1 integrin containing receptors also interact with cellular 
receptors.   
Integrins plays a significant role in cell adhesion to the surrounding extracellular matrix and to other 
cells for maintenance of tissue integrity. In addition to this structural function, cell adhesion induces 
intracellular signalling mechanisms that regulate proliferation, apoptosis, cell polarity, differentiation 
and other processes. Analysis of β1 integrin function in vivo demonstrated that β1 integrin are 
important for attachment to and integrity of the basement membrane by mediating binding to 
basement membrane components. Various intracellular signalling pathways are elicited following 
the banding of ligands to integrin at the extracellular side. Finally, β1 integrin could be important for 
the migration of skin stem cells from the bulge region of the hair follicles to the interfollicular 
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epidermis and to the hair matrix region (Brakebusch et.al, 2000). Severe defects in adhesion and 
migration of β1-deficient keratinocytes were observed in vitro as well as during wound healing in 
vivo (Grose et.al, 2002). 
1.1.2.2.   Anchoring fibrils 
Anchoring fibrils are specialised structures in the skin, measuring 20-60nm in width, and 200 -
800nm in tlength. They are flexible, banded, fibrillary structures arising in the lamina densa and 
extending into the dermis. They are made up of aggregates of collagen type VII anti-parallel dimers 
as early studies demonstrates the correlation between the length and banding pattern of anchoring 
fibrils. The amino terminals domains attach to the lamina densa as well as condensing with the ends 
of the other anchoring fibrils and basement components to form anchoring plaques in the dermis 
(Burgeson, 1993). 
1.1.2.3   Collagen type VII  
Collagen type VII is the main component of anchoring fibrils  present in the basement membrane of 
stratifying squamous epithelia of the skin, mucous membrane and cornea (Burgeson 1993). It is 
synthesized by keratinocytes and fibroblasts, although epidermal keratinocytes are thought to be the 
major source of collagen type VII in vivo (Rynanen et. al, 1992). Each molecule of Collagen VII 
consist of a triple helix of three identical subunit of alpha chain and each alpha chain is produced as a 
precursor polypeptide, procollagen type VII (α1) (Uitto and Christiano, 1992). Collagen VII gene is 
known as COL7A1 and resides on Chromosomes 3p21 (Uitto and Richard), with a molecular weight 
of 300kDa. Each molecule consists of a central collagenous domain flanked by non–collagenous 
domains on either side (Lunstrum et .al 1986).  
Collagen VII is the major structural component of the anchoring fibrils that stabilize the basement 
membrane on the dermis in chronic human wounds and scars. The instability of the basement 
membrane zone observed in epidermolysis bullosa dystrophica, a blistering skin disorder that is often 
associated with mutations in the collagen VII gene (Uitto, 1992), could be a pointer to the structural 
role of collagen VII. The deposition of collagen VII in healing human surgical wounds has been 
demonstrated from day 7 following wounding (McGrath, 1992) and over a similar time course in 
healing human acute oral wounds (Larjava, 1993). Chronic wounds such as lower-limb venous ulcers 
are usually characterized by basement membrane destruction and it is likely that collagen VII 
synthesis is required for the restoration of a functional basement membrane zone. The presence of 
fibronectin type III, cartilage matrix protein and von Willebrand factor domains in the collagen VII 
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molecule indicates that collagen VII may have a role in modulating cell behaviour and matrix–matrix 
interactions at the wound site (Hopkinson, 1997).  
 
It has been observed that cutaneous wounds in which the basement membrane remains intact, hast an   
uninterrupted wound healing process. In addition, the intact basement membrane provides part of the 
cellular signals required for direct re-epithelialization.  On the other hand,  ulcers from which the 
basement membrane is histologically absent are usually slow to heal and restoration of the basement 
membrane is prerequisite to epithelialization. Synthesis and incorporation of Collagen VII into the 
anchoring fibrils is probably a prerequisite for the synthesis of a stable basement membrane in these 
ulcers and is required in order that healing can proceed (Hopkinson, 1997). 
1.1.3   The Dermis  
The dermis is a dense, irregular fibroelastic connective tissue composed of extracellular matrix 
(ECM) and thicker than the epidermal layer. The dermis can be subdivided into the papillary and 
reticular dermis. The papillary dermis and reticular dermis differ in both the composition and 
organization of their respective extracellular matrices. The papillary dermis is characterized by thin, 
poorly organized collagen fibre bundles, consisting primarily of type I and type III collagens, which 
contrast with the thick, well-organized fibre bundles in the reticular dermis (Cormack, 1987). The 
papillary dermis interdigital with the epidermal ridges along the DEJ and it contains more loosely 
arranged collagen and more cells.  The reticular dermis contains more tightly packed coarse collagen 
fibres.  There is a sub-papillary plexus of blood supply at the arbitrary interphase. Collagen fibre 
bundles in the papillary dermis contain more type III collagen than do those in the reticular dermis 
(Meigel et al., 1977).  
 
Other matrix molecules are also differentially apportioned between the papillary and reticular dermis. 
These regions differ in cell density as well as in the composition and organisation of ECM (Sorell 
and Caplan, 2004). Other ECM that makes the dermis includes the dermatan sulphate, chondroitin-6-
sulphate, chrondoitin -4-sulphate, heparin sulphate, amorphous ground substance that is made of up 
of glycosaminoglycans (GAG). Other skin appendages such as nerve, complex vascular and 
lymphatic networks and hair follicles pass through the dermis and often extend into the underlying 
subcutaneous layer. The cells that are resident in the dermis are the fibroblast, mast cells and the 
macrophages (Haake AR and Holbrook K,1999). 
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1.1.3.1 The Extracellular Matrix 
The ECM is a form of connective tissue, composed of a mixture of proteins and polysaccharides in 
which cells are embedded.  The main components of the ECM are the fibrous connective tissues, 
elastin and the collagen. The fibroblast found the ECM secretes the matrix macromolecules. The 
collagen component are mainly type I,III and V.  The type I is the most abundant, it constitute about 
80-90% of the total body collagen although the ration of type I: III collagens is higher in the reticular 
dermis compared with the papillary dermis. The papillary dermis also has smaller bundles of 
collagen fibres compared with the reticular dermis (Sorrell JM and Caplan AI, 2004). The elastin 
fibres lie between the collagen bundles and are also present in blood vessels. They are important for 
skin pliability and account for about 5% of the dermal matrix. The elastins fibres are structurally 
made up of a microfibrillary component embedded in an elastic matrix. The ECM‘s main function is 
to provide structural support and tensile strength for the skin. Its also provides substrates for cell 
adhesion and cell migration. Furthermore, it regulates cell behaviour, migration, proliferation and 
maintains their shape. There are 2 main types of extracellular macromolecules. 
 The structural proteins and the adhesive proteins: Collagens are part of the structural 
proteins that maintains the tensile strength; whereas elastins which are also structural 
proteins are know to give resilience to the matrix. The adhesive proteins (laminin and 
fibronectin) link components of the ECM which serves as the linkage to the cell surface  
Other cell surface receptor proteins are the glycoproteins and integrins 
 The proteoglycans: They are the main polymorphic macromolecules consisting 
predominantly of molecules with core proteins and glycosaminoglycans (GAG)  side chain 
extensions consisting of repeated disaccharide units. They are divided into the intracellular, 
membrane–bound and extra-cellular group. They function to regulate several cellular 
processes, such as morphogenesis, tissue repair, cellular proliferation and differentiation. 
1.1.3.2 Collagen I 
The extracellular spaces in tissues are filled with organized extracellular matrix (ECM), which is 
composed of proteoglycans like decorin and fibromodulin; Fibrous proteins like collagen, elastin, 
and fibrillin; adhesion molecules like fibronectin and laminin; and different types of matrix 
metalloproteinase‘s, and play important roles in cell signaling and cellular activities (Raghow,1994). 
Collagens are the major fibrous proteins in ECM. Different combinations of different α-chains make 
triple-stranded helical structure of different collagens. To date 19 to 20 types of collagens have been 
identified. The molecular nature and functions of several collagens have been characterized 
(Myllyharju, 2001). Type I collagen, the major component of ECM in skin, bone, ligaments, etc., is 
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composed of glycine- and proline rich two α -1 (I) and one α -2 (I) chains, α1 (I) and α 2 (I) are 
products of two genes.   
The pro-COL1A1 and COL1A2 polypeptide chains are synthesized by fibroblasts, osteoblasts, or 
odontoblasts and enter into endoplasmic reticulum where specific proline and lysine residues are 
hydroxylated to form hydroxyproline and hydroxylysine, respectively, which help the pro-α chain to 
combine with other chains by hydrogen bonds and form the triple helix pro-collagen structure. Pro-
collagens are secreted by the fibroblasts through the Golgi apparatus in the extracellular space where 
the N-terminal and C-terminal pro-peptides are cleaved by specific proteases. The mature processed 
collagen molecules aggregate to form larger collagen fibrils and help to form the ECM with other 
components. Therefore, normal structural and functional Type I collagen production and deposition 
in ECM to make normal physiological connective tissue needs regulation at several steps.  
1.1.3.3. Collagen III 
Collagen Type III is initially produced as pro-collagen, a protein which consist of three pro-alpha 
1(III) chains that form the triple-stranded, rope –like molecule. The main function of Collagen III is 
to add structure and strength to connective tissues.  Collagen III is found in many places in the body, 
especially in the skin, lungs, intestinal walls and blood vessel walls. COL3A1 is the gene responsible 
for producing the pro-alpha1 (III) chain of type III procollagen. After being synthesized, the 
procollagen molecule is modified by the cell. Enzymes modify the amino acids lysins and proline in 
the protein strand by adding chemical groups that are necessary for the strands to form a stable 
molecule and then later to crosslink  other molecules outside the cell. Other enzymes add sugars to 
the protein. The type III pro-collagen molecules are released from the cell and are processed by 
enzymes that clip small segments off either end of the molecules to form mature collagen. The 
mature collagen molecules assemble into fibrils. Cross-linking between molecules produces a very 
stable fibril, contributing to collagenous tissue strength function. 
1.1.4. Fibroblast 
The fibroblast is the predominant cell type in the dermis and  they are heterogenous cell population 
of mesenchymal origin.  Fibroblast exists as a highly diverse population such as the papillary and 
reticular dermis fibroblast.  Dermal fibroblasts represent a heterogeneous population of cells defined 
according to their location within the dermis. Two subpopulations of fibroblasts reside in distinct 
dermal layers: the papillary and reticular dermis (Cormack, 1987).  
 
Fibroblasts cultured from each of these layers have different characteristics (Harper and Grove, 
1979; Azzerone and Macieira-Coelho, 1982; Sorrell et al., 2004).  A third group is associated with 
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hair follicles. These cells synthesise and degrade connective tissue matrix proteins, and a number of 
proteins involved with structural support and basement membrane framework. They also synthesise 
growth factors that promote interactions between the epidermis and the dermis (Smola et al 1993: 
Maas-szabowski and Fusenig 1996), which are important in the regulation of normal skin physiology 
as well as in wound healing.  Some of the growth factors involved are Keratinocyte growth factor 
(KGF 1, 2), transforming growth factor-beta-1 (TGF-B1), vascular endothelia growth factor (VEGF) 
and granulocyte / macrophage colony-stimulating factor b (GM-CSF). They are spindle-shaped cells 
with a prominent rough endoplasmic reticulum and have an elliptical nucleus. 
 
1.1.4.1    Fibroblast heterogeneity and Subtypes 
 
Primitive mesenchyme cells are multipotential stem cells that differentiate and give rise to fibroblasts 
as well as other connective tissue cells such as mast cells, adipocytes, chrondrocytes and osteoblasts. 
Fibroblast from different anatomical sites has all been shown to have similar morphology and 
express the mesenchymal intermediate filament marker, vimentin (Chang et al., 2002).   However 
studies using microarray technology have demonstrated that fibroblast from different anatomical 
sites have their unique gene expression profile and characteristic phenotype, synthesizing 
extracellular matrix proteins and cytokines in a site specific manner (Chang et al., 2002). Human 
skin fibroblast cultured in modified conditions differentiate along seven terminal cell lineage 
pathway; the mitotic activity (I- III) to the post mitotic stage (IV- VIII) (Bayreuther et al., 1988b). 
Furthermore, as the cumulative population time increases, the proportion of mitotic and post mitotic 
fibroblast cell type changes and it has been suggested that theses proportions also change similarly in 
vivo with increasing age (Bayreuther et.al, 1988b).   
 
Cutaneous fibroblasts can be subdivided according to their location; papillary or reticular dermis or 
associated with hair follicles. There are no distinction in the in vivo characteristics but have different 
expression in the in vitro environment.  Through mechanical separation of skin (dermatome) into 
defined papillary and reticular layers allows for establishment of explant cultures of cells from each 
layer. Papillary fibroblasts divide at faster rates, have a longer replicative lifespan, are smaller and 
exhibit less of contact inhibition than do site-matched reticular fibroblasts (Harper and Grove, 1979; 
Azzerone and Macieira-Coelho, 1982; Schafer et al., 1985; Sorrell et al., 2004).  
 
Reticular dermal fibroblasts seeded into type I collagen lattices faster than do papillary dermal 
fibroblasts (Schafer et al., 1985; Sorrell et al., 2004). When grown to confluence in monolayer 
culture, the papillary cells attain a higher cell density partly because they are not fully contact 
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inhibited (Schafer et al., 1985; Sorrell et al., 2004). Co-culturing papillary dermal fibroblast with 
keratinocytes produce a more differentiated and organised epidermis with complete formation of 
dermoepidermal junction.  More of GM-CSF is produced by papillary fibroblast and relatively less of 
KGF as compared with reticular fibroblast.  Production of type I and III collagen are similar for both 
fibroblasts in vitro whereas type III is said to be more in papillary in vivo (Tajima and Pinnell 1981). 
 
Myofibroblast are a specialised form of fibroblast found in granulation tissue that plays a critical role 
in wound contraction. They are distinct from other fibroblast ultrastructurally, biochemically and 
functionally (Moulin et al. 2000). They are characterised by the presence of intracellular bundles of 
alpha smooth muscle actin, which is the actin isoform expressed by smooth muscle cells (Grinnell, 
1994) 
1.1.4.2   Fibroblast in Wound Healing 
 
The process of wound healing involves inflammation, granulation tissue lay down and tissue 
remodelling. Fibroblast contributes significantly to these stages. Activation of fibroblast occurred 
following cutaneous injury, whereas it remains in the quiescent state in the unwounded skin (Clark 
1996). Fibroblasts play a crucial role in cutaneous wound repair (Martin, 1997). These cells are 
attracted to wound sites by the localized release of growth factors/cytokines such as platelet derived 
growth factor  and TGF- β (Pierce et al., 1991;  Konig and Bruckner- Tuderman, 1992). The first 
wave of fibroblasts enters the wound site along with sprouting vasculature. These cells differentiate 
into a specialized, but non-lasting, cell type called the myofibroblast (Sappino et al., 1990; Grinnell, 
1994). In addition, they lay down extracellular matrix and contributes to basement membrane 
formation, partly by producing collagens types IV and VII , laminin 5 and nidogen, and through the 
secretion of cytokines  that have a  stimulatory effect on keratinocyte  that in turn produce basement 
membrane components. (Marinkovich et. al., 1993) 
 
Myofibroblasts in response to monocyte/macrophage derived factors, produce a provisional wound 
matrix that is enriched in fetal-like fibronectin and hyaluronan (Clark, 1990; Gailit and Clark, 1994; 
Juhlin, 1997; Singer and Clark, 1999). These cells also provide the motive force to contract the 
wound (Sappino et al., 1990). The wound is predominately populated with myofibroblast and display 
a different morphology compared with normal fibroblasts. Myofibroblast has the alpha smooth 
muscle actin filaments, deep folders in the nuclear membrane and numerous cellular connections all 
of which enhance wound contraction.  Myofibroblast disappear from the wound site, apparently by 
apoptosis, and are replaced by a second wave of fibroblasts that initiate the formation of a 
collagenous matrix (Grinnell et al., 1999). Fibroblasts/myofibroblasts are also intricately involved in 
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transforming granulation tissue into a mature scar, through continual collagen remodelling. However, 
their ability to seamlessly organise this process is often impaired, hence scar tissue formation occur 
(Gailit and Clark, 1994; Singer and Clark, 1999).  On the other hand, fetal skin is repaired without 
scar formation (Liechty et al., 2000). This is mainly due to differences in fetal and adult fibroblast 
phenotypes (Olsen and Uitto, 1989; Gosiewska et al., 2001). The low level of growth 
factors/cytokine production by fetal cells, especially TGF-b1, appears to be a major factor in the 
absence of scar formation (Shah et al., 1995; Eckes et al., 2000). 
1.1.4.3     Fibroblast Ligands  
 
Cell-cell, cell-matrix and matrix-matrix linkages are all important for regulating fibroblast activity 
and bringing about appropriate responses to changes in the environment. Fibroblast expresses 
receptors for binding of growth factors and cytokines, which leads to intracellular signal 
transduction, gene expression and a variety of cell responses. These responses include activation, 
proliferation, migration, differentiation, as well as ECM production.  Integrin receptors facilitate the 
binding of fibroblast to the surrounding ECM. The Alpha-1 beta 1(α1β1) and alpha-2 beta 1(α21β) 
integrin receptors are the main receptors in the processing of facilitating the binding of collagens I, 
IV, V and VII (Chen et al, 1999, Ruggiero et al 1996). The binding of collagen I to α1β1 receptors on 
fibroblast results in a negative feedback that down regulates collagen synthesis.  Fibroblasts are 
capable of forming cell-cell connections with other fibroblasts and collectively, these cellular mini-
networks are thought to be important in transmitting the contractile force across wounds, which 
ultimately enhance wound closure (Welch et al.1990.) 
1.1.4.4. Fibroblast Proliferation and Migration during Healing 
 
Fibroblast proliferation is influenced by growth factors, hypoxia, cytokines and physical factors such 
as radiation and laser therapy.  After tissue injury, the hypoxic  environment  and the presence of 
cytokines such as platelet derived growth factor (PDGF), insulin like growth-1 (IGF-1) and 
transforming  growth factor –beta ( TGF- β ) directly  stimulates fibroblast proliferation (Clark,. 
1996).  Movement of fibroblast occurs in 2 days, either by haptotaxis or by contact guidance (Clark,. 
1996). Haptotaxis refers to the movement of cells along an adhesion gradient whilst contact guidance 
represents the movement of cells guided by substances, such as fibronectin. Following skin injury, 
the provisional matrix is rich in fibrin, fibronectin and hyaluronic acid and consists of relatively little 
collagen.  For cell migration to occur degradation of ECM is needed and the release of ECM 
degrading proteases is produced by a number of cell types including keratinocytes, fibroblast and 
macrophages.  The activities of these proteases and their expressions (matrix metalloproteinase 
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MMP, serine and cystein proteinases) are controlled by growth factors and cytokines (pro-
inflammatory IL-1 and Tumor necrosis factor- alpha), following cell contact with ECM (Clark, 
1996).  
In the presence of PDGF and a provisional matrix environment, α5β1 integrin receptor is up-
regulated on their surface which enables them to adhere to fibronectin and migrate into the wound 
(Xu and Clark, 1996). Once the wound site is filled with fibroblast, the provisional matrix is replaced 
with granulation tissue, this environment leads to increased expression of collagen receptors α5β1 
and reduced α1β1 (Xu and Clark, 1996). Binding of fibroblast to collagen is enhanced under this 
condition. Hypoxic wound environment has also been shown to stimulate fibroblast migration on 
collagen gel (Li W et. al., 2005) 
Subcutaneous Fat 
The innermost layer of the skin is the layer of subcutaneous fat, and its thickness varies in different 
regions of the body. The fat stored in this layer represents an energy source for the body and helps to 
insulate the body against changes in the outside temperature.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                          Figure 1.3. Schematic diagram representing cross section of the Human skin 
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1.1.6   The Principle of Wound Healing  
1.1.6.1 Cellular and Molecular events Occurring during Acute Wound Healing 
 
The process of post inflammatory wound healing and tissue regeneration is characterized by a 
complex, multicomponent cascade of degradative and biosynthetic reactions that orchestrate 
underlying cell-cell and cell-ECM interactions (Howell, 1992). Theoretically, tissue remodelling can 
be divided into three somewhat overlapping phases, each stage exhibiting its own unique cellular and 
molecular interactions (Figure1.4). Tissue injury and wounding is promptly followed by the 
inflammatory phase, which eventually merges into the second phase characterized by granulation 
tissue formation; the third and final phase of wound healing is dominated by massive biosynthesis 
and restructuring of the ECM (tissue remodelling and repair). 
1.1.6.2   Inflammatory Phase 
 
Tissue injury from vascular damage triggers the inflammatory phase initiated by haemorrhaging; 
various cellular components of blood come in direct contact with other cells and constituents of 
ECM, with the net outcome of activation of the clotting cascade leading to hemostasis (Howell, 
1992). Clotting releases thrombin which in turn activates platelet, followed by the release of a host of 
potent chemotactic and growth-promoting cytokines through degranulation (e.g., PDGF, TGF I3, 
Tumour necrosis factor(TNF), and Interleukin-1(IL-1) at the site of inflammation.  The stimuli that 
initiate clotting diminish with time; this process is further facilitated by rapid proteolytic degradation 
of the coagulation factors V and VII by protein C. Concomitant release of plasminogen activator 
along with plasminogen helps dissolve the thrombus and prostaglandins, which inhibit platelet 
activation.  Fibrinogen and collagen activate platelets and also interact with thrombospondin, which 
binds to platelet-specific tyrosine kinase-containing receptor.  This concerted action on platelet 
surface results in strong activation and adhesion of platelets, culminating in degranulation and 
release of their contents ( Terkeltaub, 1988). 
 
Liberation and activation of potent cytokines are crucial  to the overall process of tissue regeneration 
and remodelling. In addition, intact TGF/3 and its proteolytic sub-fragments are potent 
chemoattractants which attracts massive influx of inflammatory phagocytes (e.g., polymorphonuclear 
cells and macrophages) toward the site of inflammation (Martin, 1992, Helmer, 1990). Combined 
action of different cytokines within the dynamic milieu of ECM thus determines the directional 
migration (Helmer, 1990) and function of the phagocytes (Berton, 1991). Furthermore, the adhesive 
interactions among various cells and the surrounding ECM profoundly modify the phenotypic 
features of mesenchymal and nonmesenchymal cells attracted to the site of tissue injury (Howell, 
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1992; Mast 1992). Differential proliferation and differentiation of various cells (e.g., fibroblasts vs. 
keratinocytes) by autocrine and pracrine processes are hallmark features of the inflammatory phase 
of wound. 
 
1.1.6.3   Formation of the Granulation Tissue 
 
The components of the provisional ECM, laid down during the clotting cascade, are modified and 
rearranged  to form the granulation tissue (Howell, 1992). Macrophages, in addition to keeping 
wound aseptic by active phagocytosis and debridement, release several potent cytokines and 
hydrolytic enzymes. Granulation tissue is made up of many mesenchymal and nonmesenchymal cells 
with distinct phenotypes, and an extensive neovasculature embedded within the loosely assembled 
matrix composed of collagens, fibronectin, and proteoglycans.  
 
Thus, reorganization of the granulation tissue is carried out by the components of the provisional 
ECM and the actions of the newly released cytokines. In contrast, the process of disassembly is 
accompanished through the action of collagenases, proteoglycanases, and other proteases, whereas 
the restructuring and renewal of ECM by the activated myofibroblasts.  Phenotypic modification of 
cells present in the granulation tissue as exemplified by the formation of blood vessels and enhanced 
ability of fibroblasts to contract collagenous matrix, contribute to the quality of the healing process 
and the strength of the healed wounds. All of these processes are dependent on cell-ECM interactions 
in the peculiar milieu of the granulation tissue. 
1.1.6.4 Biosynthesis and Remodelling of Extracellular Matrix 
The last and easily identifiable phase of wound healing involves a systematic dissolution of the 
granulation tissue. This phase of tissue regeneration is typically accompanied by a gradual loss of 
cells and vasculature and exhaustive restructuring of the ECM (Howell, 1992). During this phase of 
the repair process, macrophages continue to phagocytose and carry out extensive debridement, a 
necessity for the inward migration of the vasculature and mesenchymal cells deeper into the wound. 
The granulation tissue is gradually replaced with more organized and elastic ECM. Many observers 
suggest that appropriate healing and tissue remodelling, as well as fibrosis, are two sides of the same 
equation, and a delicate balance in the biosynthetic and degradative pathways of ECM restructuring 
may swing the pendulum toward one or the other.   
 
  
 
 
40 
 
 
 
Figure 1.4 Shows succession of the major 
cellular and biochemical reactions encountered 
during post-inflammatory tissue regeneration. 
Cell-ECM interaction, in conjunction with a 
variety of cytokines/growth factors actively 
modulate these reactions at all stages of tissue 
regeneration and determines outcome of wound 
repair. The complexity and feedback regulation 
involved in the entire process is not depicted in 
this schematic diagram. Diagram from Raghow 
1994, FASEB J; 8(11):823-31. 
 
 
 
 
1.1.6.5 Extracellular Matrix in Post-inflammatory Wound Healing 
 
The process of wound healing after an acute injury regardless of whether the cause of injury is 
physical, cytotoxic or immunological sum up the major event that occur during embryogenesis( 
Tranquillo, 1992). The various stages of wound healing are characterized by massive cell migration, 
proliferation, phenotypic differentiation and exaggerated biosynthetic activity at the site of repair 
(remodeling). Extracellular matrix (ECM) has been shown to play a central role in orchestrating the 
key steps in the programmed wound healing and repair (McGown, 1992).  ECM has the ability to 
generate extraordinary large arrays of structure through dynamic interactions with protein and non 
protein component. ECM modulates cellular behaviour and phenotypes, able to bind specific 
cytokines and growth factors, thus sequestering potent biological response modifiers in the wound 
microenvironment (Figure 1.5). In addition, ECM organizes the geometric framework that facilitates 
cell migration and modulates cell-cell interactions.  Furthermore, the releases of cytokines during this 
process are responsible for continuous dynamic cell-ECM interaction. This process is subject to a 
feedback regulation which is mediated by transcriptional, post transcriptional, translational and post 
translational mechanism elaborated during wound repair (Raghow, 1994). 
  
 
 
41 
 
 
 
 
 
 
Figure1.5. Cell-ECM interactions 
modulates many key mechanism 
involved in post-inflammatory 
wound healing and fibrosis. The two 
way arrows connecting ECM to 
various cellular responses reflect the 
dynamic reciprocity between cells 
and ECM. Diagram from Raghow 
1994, FASEB J; 8(11):823-31. 
 
 
 
1.1.6.6. Cell Cycling in Wound Healing  
 
Most cell-cycling studies in wound repair to date have focused on keratinocytes in models of 
reepithelization. Other studies have described a defect in fibroblast cell-cycling activity in chronic 
pressure ulcers (Vande Berg, 1998, Vande Berg, 2001). It was suggested that an abnormality in the 
proportion of wound repair cells restricted to cell cycle quiescence, senescence, or even apoptotic 
pathways might explain delays in wound healing (Figure 1.6). Fibroblasts confined to G1 arrest 
were measured by the expression of the cell cyclin inhibitor p21, and the proportion of fibroblasts 
capable of DNA synthesis was measured by the level of expression of the proliferating cell nuclear 
antigen (PCNA). The recruitment of  fascia fibroblasts out of the quiescence into a functional cell 
cycle remains unknown. It is possible that defects or delays in the recruitment of fascia fibroblasts 
into the cell cycle might contribute to delays in fascia repair and ultimately fascia dehiscence and 
incisional hernia formation. The mechanism that controls the balance between uninjured fascia 
fibroblast quiescence, cell cycle arrest, or functional cell cycle progression is unknown. 
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Figure 1.6. Abnormalities in the proportion of wound repair cells restricted to cell cycle 
quiescence, senescence, or even apoptotic pathways might explain delays in wound healing. 
Increased numbers of repair fibroblast confirmed to G1 arrest have been measured in non-healing 
ulcers and in a model of incisional hernia (thin arrows). Proliferating cell nuclear antigen (PCNA) is 
a classic maker of cells capable of DNA synthesis and cell cycle progression, whereas p21 is cell 
cycle inhibitor. Increased numbers of arrested fibroblast expressing p21 and reduced number 
expressing PCNA have been observed in non healing ulcers and in model of fascia wound failure 
leading to incisional hernia formation. M, mitosis, S, synthesis,  Thick arrow showed normal 
progress of cell cycle. (Dubay DA, Franz GM, acute wound healing failure. Surg clinic Am 
(2003):463-481. 
 
1.1.7   Aetio-Pathogenesis of Diabetic Foot Ulcers 
The physiological alteration in diabetic foot ulcer could partly explain the chronicity and/or the 
recalcitrant nature of the ulcer. The triad of neuropathy, vasculopathy, and immunopathy forms the 
cardinal point on which the chronicity of diabetic wounds rest (Boulton et.al, 2005, Reiber, 1999). 
The neuropathic effect on the foot produces a biomechanical abnormality, which could predispose 
areas of concentrated pressure to significant risk of ulceration, repetitive trauma, vasodilatation, and 
decreased sweating (Shaw et.al, 1998). Atherosclerotic plaque deposit contributes to the 
development of diabetic peripheral vasculopathy resulting in either occlusion or stenosis of the 
vessels. The vasculopathy causes decreased blood flow and ultimately ischemia will ensue. Infection 
has more deleterious effect in this group of patients, whose impaired immunity increase their risk for 
local and systemic infections. The wound infections may either be superficial or deep and are 
commonly poly-microbial in aetiology. Superficial wound infection may be treated with antibiotic 
therapy only whilst the deep-seated wound infection might require surgical debridement which may 
be followed by antibiotic and or other wound care adjunct. 
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1.1.8 Physiological Changes in Diabetic Foot Ulcers 
 
Aggressive sharp wound debridement is believed to convert chronic wounds to acute ones and allows 
growth factors to function more effectively. This allows the wound to progress through the normal 
phases of wound healing. Regular and frequent wound debridement removes collagenase, matrix 
metalloproteinase, and elastase which are inhibitors of wound healing (Steed, 1996, and Nwomeh, 
1999). The cellular and molecular alteration has a direct link with the major physiological changes 
mentioned earlier and there is evidence to support hyperglycaemia—related deleterious molecular 
and cellular alteration in the cellular environment. Hyperglycaemic non-enzymatic glycosylation has 
an inhibitory effect on structural and enzymatic proteins. In addition, glycosylated collagen is 
resistant to enzymatic degradation and less soluble than the normal protein products, which makes 
connective tissue inelastic (He, 2004). High deposition of sorbitol has been implicated in diabetic 
vasculopathy. This is associated with increase in dermal vascular permeability and results in peri-
capillary albumin deposition (Bucalo, 1993), which impairs oxygenation and nutrient distribution 
(Bennet, 1993). Bennett et.al. demonstrated increased destruction of growth factors by elevated 
levels of pro-inflammatory cytokines and metallo-matrix proteins following repeated trauma and 
infection (Bennet 1993, Yager, 1997).  
 
Most chronic wounds are characterized by increased protease levels, particularly matrix 
metalloproteinase‘s (MMPs) and neutrophil elastases. Furthermore, tumour necrosis factor–alpha 
(TNF-alpha) has been shown to increase the production of MMPS, whilst inhibiting the production 
of tissue inhibitory metalloproteinase (Palolahti; 1993, Chen et.al 1997). The response mounted from 
the host immune system following critical wound colonization by bacteria is followed by polymorph 
nuclear leukocyte reaction that releases protease and oxidant species. This is followed by degradation 
of cytokines and extra-cellular matrix which distort the internal cellular milieu, thereby contributing 
to the non-healing of wounds. The cellular response to injury is poorly coordinated in diabetic 
wounds, most of which are complex and inter-related biochemical activities. 
1.1.9   Molecular Mechanisms Involved in Chronic Wounds 
The understanding of the molecular mechanisms involved in chronic wounds holds the key to 
solving the huge problem posed by this disease entity. Several efforts made at understanding this 
process have been undermined by the absence of an easily reproducible animal model that mimics 
the human chronic wound. Keratinocyte biology has attempted to explain the mechanism involved in 
chronic wound healing through cellular injury. Keratinocytes are the first cells to respond to injury; 
they are programmed to maintain skin integrity based on their specific attachment to extracellular 
matrix and vice versa. The absence of normal migration and proliferation of cells caused by failure of 
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keratinocyte activation during wound healing results in non-healing (Morasso, 2005). The activation 
of C-myc affects epidermal biology directly and its relevance to wound healing. C-myc is required 
for transition from the G1 to S1 phase of the cell cycle and it also promotes proliferation of transit 
amplifying cells.  
 
Deregulation of c-myc results in depletion of epidermal stem cells thereby making the tissue non-
responsive to injury (Waikel et. al, 2001, Arnold, 2001 and Stojadinovic 2005). Stojadinovic and 
colleagues discovered that the stabilization of β-catenin (a subtype of keratinocyte adhesion 
molecule) inhibits keratinocyte healing of human skin in organ culture (Stojadinovic et.al, 2005). 
This is done through different mechanisms: (a) activation of c-myc, (b) blocking of epidermal growth 
factor (EGF) effects and by synergizing with glucocorticoids. Beta-catenin also participates in 
glucocorticoid signaling and repression of keratin genes, which are involved in cytoskeletal network 
and keratinocyte migration. The main features of chronic wound are; persistent inflammation, 
decreased activity of growth factors, and angiogenesis may be affected by the activities of β-catenin 
and c-myc. Other authors suggested that C-myc was found to inhibit the expression of platelet 
derived growth factor (PDGF)-BB and its receptors (Oster et.al, 2000), whereas fibroblast growth 
factor (FGF)-basic and EGF were shown to induce C-myc expression (Wang et.al 1999, 
Izadnegahdar, 1999). In contrast to their stimulatory effects, these growth factors may also stimulate 
negative feedback in chronic wounds by sustaining C-myc expression. 
1.1.10 Platelet Derived Growth Factors in Wound Healing 
Wound healing is a well-orchestrated and complex series of events involving cell-cell and cell-matrix 
interactions, with growth factors acting as messengers to regulate the various processes. The role of 
growth factors in wound healing has been well described in acute wound healing; growth factors are 
stored in the form of α-granules in platelets and when these platelets are activated, they in turn 
release a multiplicity of growth factors. After the formation of platelet coagulum, the activated 
platelets are interspersed among the fibrin strands forming a matrix within the clot, which helps to 
keep the growth factors within the mesh. They eventually diffuse out into the surrounding tissue.  
 
Growth factors act locally to recruit undifferentiated cells to the injury site by chemoattraction and 
also stimulate mitosis in the undifferentiated cells. Stem cells are attracted to areas of high 
concentration of growth factors and cellular movement occurs by forming attachments to the matrix/ 
scaffold. Growth factors attach to receptors on the stem cell membrane, thereby activating genes 
controlling cell division. They also attach to cell receptors and control the genetic expression of stem 
cells via the modulation of signal transduction pathways of secondary proteins, resulting in cellular 
division and differentiation. Mitosis occurs via a signal transduction pathway through the tryosinase 
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kinase located on the cell membrane. Receptor activation leads to the activation of secondary 
messenger proteins, which enter the cell nucleus and influence the expression of the genes 
responsible for triggering mitosis, angiogenesis, and macrophage activation (Alder, 2002). The 
growth factor that was first identified was the platelet derived growth factor, which has other isomers 
(αα, ββ, αλ).  
 
PDGF has been synthesized through recombinant DNA technology and has been used topically for 
treating chronic diabetic foot ulcers. The first efficacy study documented showed complete healing 
of non-ischemic foot ulcers in 25% of the placebo-treated group and 48% in the PDGF-treated group 
(p <.01) (Steed, 1995). The second efficacy study found complete healing in 35% of the placebo- 
treated group, and 50% of the PDGF-treated group, which represented a 43% improved healing (p 
<.007). The PDGF-treated group also showed a reduced healing time by 6 weeks (p <.013) (wieman, 
1998). Other identifiable growth factors include transforming growth factor (TGF-β), which has β1 
and β2 as its isomers; platelet derived angiogenesis factor; platelet derived epidermal growth factor; 
fibroblast growth factor; keratinocyte growth factor; insulin like growth factor; interleukin-1; 
vascular endothelial growth factor; epidermal growth factor; thrombospodin and platelelt factor-4, 
osteocalcin; osteonectin; fibrinogen; and fibronectin.  
 
The summary of the roles of the super-family growth factors in wound healing cascade is shown in 
Table 3.4 of Chapter 3. Growth factors have special roles they play at different phases of the wound 
healing, and they also appear to have synergistic effects on one another. The other groups of growth 
factors not discussed in the table are collectively called the adhesive proteins, these includes 
fibrinogen and fibronectin. They are known to participate in thrombus formation and some mitogenic 
action (Anitua, 2004). More recently, Kubota et al. 2004 described a new platelet growth factor 
known as connective tissue growth factor (CTGF). They showed in their experiment that CTGF is 
released after the activation of platelet rich plasma. They are said to be expressed along with the 
platelet coagulation process. The expression of CTGF following autologous derived platelet rich 
plasma gel (APG) activation is said to be more than a 20-fold increase when compared with any 
other platelet growth factors. 
 
1.1.11 Role of Exogenous Growth Factors in Acute or Chronic Wounds (Evidence to support our 
hypothesis) 
It has been shown that the messenger RNA for proteins may be expressed in some wounds, but the 
protein itself may be deficient, trapped or destroyed quickly. It has been postulated that repeated 
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trauma and infection increase the presence of pro-inflammatory cytokines and the levels of matrix 
metalloproteinase (TIMP), and decrease the level of growth factors (Bennett 1993).  It has also been 
shown in some chronic wounds that the levels of PDGF, BFGF, EGF or TGF-b are markedly 
decreased when compared with acute wound. Furthermore, a marked difference has also been 
observed in the quantity and quality of cytokines, proteases and their inhibitors when acute and 
chronic ulcers were analysed (Trengrove, 2000; Tarnuzzer, 1996; Trengrove, 1997). Proliferation 
abnormalities of fibroblast cell have been demonstrated in diabetic wounds and the use of exogenous 
growth factors on diabetic wounds has been found to stimulate fibroblast proliferation and facilitate 
wound healing. These exogenous growth factors may act to induce endogenous growths factors and 
their gene expression or as stimulator for tissue repair which  in turn accelerate acute or chronic 
wounds (Grazul-Bilska et. al, 2002) 
1.1.12   Proposed Gene Therapy 
A few studies have shown growth factors to be efficacious in treating chronic wounds, but a less 
dramatic effect than those predicted based on animal studies. Some authors therefore hypothesized 
that adenovirus containing EGF, PDGF-BB, TGF-B and other growth factors genes may produce 
large amplification of these growth factors if transfected into wound bed and may enhance wound 
healing (Andree et .al, 1994, Magrogolis et.al ,2000).  Phase 1 clinical trials using gene therapy 
transfer have been conducted; as of date no wound healing gene transfer technique has been 
approved for use in extensive human trials. Gene therapy might eventually find it application in 
promoting wound healing in chronic ulcers but may be difficult to popularize in clinic before it is 
proven to be safe, simple and effective. For this to be effective, multi-level gene therapy at specific 
wound healing stage will be required because different stages are modulated by different cytokines 
and growth factors during wound healing process. 
1.1.13 Dose related Issue with Growth Factors. 
It is worth mentioning that the final concentrations of GF used in topical applications are many times 
higher than those found normally in tissues and blood. There have been no reports of significant 
systemic absorption from topical application of GF significant enough to cause renal or liver 
impairment (Robson, 1992). 
1.1.14 Scientific basis for Wound Measurement 
Most wounds are caused by trauma and a large percentage of these wounds heal without any 
complications. Wound repair process is frequently impaired by the presence of significant co-
morbidity such as circulatory dysfunction and diabetic‘s mellitus. The rate of wound healing has 
been traditionally measured by conducting a physiological and or biochemical laboratory 
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measurement. Successful healing is evident by complete wound closure on the surface, a satisfactory 
endpoint so desired is to have the structure and function of the ulcerated area restored to original 
state before wounding. In most cutaneous lesions, wounds are measured by tracing the contour/ 
edges of the wound, which reliably estimate healing despite the errors introduced by flattening a 
curved surface.  
Wound photographs may be quantified simply by placing a linear scale within the field of view of 
the lens. Stereo-photograph can be used to measure wound volumes as well as area (Bulsstrode, 
1986).  More recently a novel method of video camera attached to a computer was developed (Jone, 
1995).  Measuring the square root of wound diameter have been proposed as possible tool in 
prognosticating to a degree of accuracy the wound process of a wound (Lawrence, 1995). Predicting 
outcomes of wound treatment is very useful clinically as well as from a resource management 
perspective. 
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1.1.15 Aim of Project 
 
The molecular basis for the use of synthetic growth factors in tissue reparation has been rationalised.  
However, its application as not been fully explored in all fields of surgical practice. It has also been 
proposed that use of combination growth factors might be more beneficial than the use of single 
growth factor in wound healing. More recently, autologous derived platelet rich growth factor has 
gained popularity in the field of regenerative/ reparative medicine, mostly because it fits the 
description of an idea naturally existing constellation of growth factors. However, there is conflicting 
evidence from published series on it clinical efficacy. Furthermore, there are insufficient studies that 
have investigated its in vitro and in vivo biological effect. Hence, this study is designed to test our 
hypothesis on the biological effect of autologous derived platelet rich plasma gel on in vitro cultured 
cell and in treating chronic diabetic foot ulcer 
 To characterise and quantify the expression of growth factors present in the autologous derived 
platelet rich plasma gel and as well to compare the pattern of expression of these growth factors 
between the  healthy volunteers and diabetic patients. 
 To determine the proliferative and migratory effect of autologous derived platelet rich plasma on 
Human derived keratinocyte, human derived dermal fibroblast and human umbilical vein endothelial 
cell. Furthermore, to determine the angiogenic effect of autologous derived platelet rich plasma on 
Human umbilical vein endothelial cell. 
 To investigate the immunohistochemistry alteration occurring at the epithelial and extracellular 
matrix margin of treated chronic diabetic ulcers. 
 To determine the average time to achieve complete re-epithelization in chronic diabetic ulcers 
patients  treated with autologous derived platelet rich palsma 
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2.1 Histological Procedures 
The steps described for both the immunohistochemistry and Haematoxylin and Eosin are in 
accordance to the operational standards of the Cellular and experimental pathology department of the 
institute of Cell and Molecular Science, Barts and The London School of Medicine and Denistry 
(ICMS) where experiments were performed. 
2.1.1 Preparation of Formalin Fix Tissue and Frozen Sections 
After taking a 6mm punch biopsy from a diabetic wound ulcer, the biopsy material was divided into 
two equal halves.  One halve of the biopsy sample  fixed in 10% (w/v) formal saline, which was later 
embedded in paraffin and then cut at 3μm using a rotary microtome. Sections were then picked up 
on 2% 3-aminopropyltriethoxysilane (APES) in acetone (VWR, UK) coated slides. The sections on 
the slides were stained with Gill‘s H&E or stored at 40°C in an oven for immuno-histochemistry use. 
The other halve of  the specimen was immediately snap frozen in liquid nitrogen and air dried for an 
hour before being stored at -20°C. The frozen sections were cut on a cryostat with Reichert-Jung 
2035 microtome at 5μm, after which the sections are air dry and picked up on Super Frost slides 
(VWR, UK) until required for H&E or immuno-histochemical staining.  
2.1.2   Haematoxylin and Eosin (H&E) 
For frozen sections, slides were air-dried for 30 min at room temperature and then rehydrated by 
transferring slides through absolute ethanol, 2x3min; 90% (v/v) ethanol, 3min 70% (v/v) ethanol, 
3min and tap water, 3min. on the other hand paraffin embedded sections were de-paraffinised 
through 2x5min xylene and then rehydrated as a frozen sections. All slides were then stained as 
follows: 
 
 15 min Gill‘s Haematoxylin 
 1min tap water 
 2 dips in acidified alcohol to differentiate satin 
 5min in tap water 
 2min Eosin 
 10-20 dips In water 
 
Slides were then dehydrated in ascending grades of ethanol 70% (v/v), ethanol 2min 90% (v/v) 
ethanol , 2min; absolute ethanol, 2x2 min and xylene 2x 5min slides were mounted on DePeX 
mountant (BDH Laboratories Supplies, U.K) under 22x64 mm coverslips (Chance Propper, Warley, 
U.K) . 
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2.2 Principle of Immuno-histochemistry 
2.2.1 Introduction  
Immuno-histochemistry allows the identification and localisation of antigens/proteins in tissues. This 
method is based on the utilisation of antibodies raised against the protein/antigen of interest for their 
subsequent detection. Immuno-hsitochemistry can be performed as a single step, two or three-layer 
method. During my research, the method employed was  the two layer method. With the two-layer 
method, tissue sections were incubated with normal serum from the same species the secondary 
antibody was raised in. The function of the normal serum is to block any cross-reactivity with 
endogenous immunoglobulin that would otherwise non-specifically bind to the primary or secondary 
antibodies.  Following serum blocking, the section was incubated with an unconjugated IgG primary 
antibody raised against and with high binding affinity to antigen of interest. Washing steps with a 
buffer was used to remove any unbound primary antibody.  
 
A secondary antibody was directed against the IgG in order to bind to primary antibody, which is 
bound to the antigen. The secondary antibody can be covalently linked to an enzyme, for example, 
horseradish perioxidase such as 3, 3‘- diaminobendizine (DAB) or 3-amino-9 ethylcarbazol (AEC) 
are applied which are converted by the enzyme to yield an insoluble (former) or soluble (latter) 
coloured product that indirectly stains the bound antigen and can be visualised using standard light 
microscopy. Alternatively, a molecule that fluoresces such as fluroscein isothiocyanate (FITC) can 
be attached to secondary antibody, which can be detectable by ultraviolet (UV) light microscopy. 
For the three-layer method, the secondary antibody is usually biotinylated (covalently linked with 
biotin). Following a washing step with buffer, a tertiary antibody covantley linked with an avidin or 
stretavidin (that has high affinity for biotin) linked to enzyme /FITC molecule is then applied. 
Visualisation of protein localisation can be achieved by standard light or UV microscopy. 
2.2.2 Immunoperoxidase  
Immunoperoxidase techniques were originally introduced by Hsu, et  al. which was aim for 
localizing a variety of histologically significant antigens and other markers. This procedure employs 
biotinylated antibody and a preformed Avidin: Biotinylated enzyme Complex and that has been 
termed the ―ABC‖ technique. Because avidin has such an extraordinarily high affinity for biotin 
(over one million times higher than antibody for most antigens), the binding of avidin to biotin is 
essentially irreversible. In addition, avidin has four binding sites for biotin, and most 
proteinsincluding enzymes can be conjugated with several molecules of biotin. These properties 
allow macromolecular complexes (ABC‘s) to be formed between avidin and biotinylated enzymes. 
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2.2.3 VECTASTAIN
®
 ABC Kits 
Vectastain contains Avidin DH and biotinylated enzyme, which are matched reagents and have been 
specially prepared to form ideal complexes for immuno-histochemical staining.  Although the 
structure of the Avidin DH: biotinylated enzyme complex is still not completely understood, 
evidence suggests that it consists of many biotinylated enzyme molecules cross-linked by avidin into 
a three-dimensional array. The complex apparently has few exposed biotin residues but has at least 
one remaining biotin binding site.  Formation of the complex is achieved by merely mixing Avidin 
DH and biotinylated enzyme in dilute solution and in defined amounts prior to use. After the initial 
incubation, there appears to be little change in the complex.  The complex remains stable for many 
hours after formation and in general, can be used for several days after preparation. VECTASTAIN
®
 
ABC has several advantages over the other commercially available kit. The kit is very simple to use 
and is highly sensitive. Figure 2.1 illustrates the main guiding principles involved in 
immunoperoxidas 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 2.1 Step involved in Immunoperioxidase .The first step  is to incubate the section with 
primary antiserum raised against the antigen of interest. Secondly, a biotin-labelled secondary 
antibody is added (biotinylated anti-rabbit IgG). This introduces many biotins into the section 
at the location of the primary antibody. The avidin: biotinylated enzyme complex (ABC) is 
then added and binds to the biotinylated secondary antibody. In the final step, the tissue 
antigen   is localized by incubation   with a substrate for the enzyme (Vectastain universal elite 
ABC kit).   
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2.2.3.1VECTASTAIN
®
 UNIVERSAL Elite ABC Kit 
 
 3ml blocking serum ( Normal Horse serum) 
 2ml containing 2.1mg Biotinlylated Universal Antibody that recognizes mouse and rabbit IgG 
 VECTASTAIN Elite Regent; 2ml Reagent A (Avidin DH solution) and 2ml of Reagent B 
(Biotinylated enzyme). {Vector Laboratories, Inc, 30 Ingold roads, Burlingame CA, 94010 USA. 
 Enzyme substrates; the chromogen used to localize peroxidase in tissue section is Di-aminobenzidine 
(DAB) which produces a brown color. 
2.2.4 Antibody Antigen Optimization Procedure 
All sections were stained using indirect immuno-histochemistry with the R.T.U Vectastain Universal 
Elite® Procedure ABC kit® (Vector Laboratories, UK). Wax sections were dewaxed through xylene 
and descending grades of ethanol to distilled water.  Antibodies were first optimized by testing a 
range of dilutions and antigen retrieval methods.  The table below illustrates the different optimizing 
antigen retrieval technique used for the different antibodies in these experiments.  This optimization 
technique has the advantage that it uses a single antigen retrieval technique with varying dilutions 
and it tests twelve possible combinations of the treatment in one go, giving an immediate indication 
of the most suitable method. Fourteen normal paraffin skin slides were used, except in some peculiar 
circumstances when antigen retrieving needs changing. Each of the slides is labeled from numbers 1 
to 12 and 2 negative control slides. The numbered slide corresponds to the individual optimizing 
condition (Table 2.1).    
 
 
 
 
 
 
 
 
 
Table 2.1   The standard antibody optimization layout used for all the different antibodies 
during the immuno-histochemtry experiment. This optimization protocol was adapted from the 
cellular and experimental pathology department of the ICMS. 
  
Table 2.1  Antibody optimization layout 
         Antibody Details :                                                                                Date : 
         Dilution :  based on manufacturer recommendation   
         Control Tissue : Human Skin 
pH Microwave 
10 mins 
Microwave 
40 mins 
Water-bath 
10 mins 
Water-bath 
40min 
Citrate buffer (6.0) Slide 1 Slide 2 Slide 3 Slide 4 
Citrate buffer (8.1) Slide 5 Slide 6 Slide 7 Slide 8 
Citrate buffer (9.0) Slide 9 Slide 10 Slide 11 Slide 12 
  Negative control  Negative control 
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There are few except to the optimization protocol. Anti Ki67 and antihuman endothelial cell (CD31) 
were initially optimized with appendix tissue section before been tested in normal human skin.  Six 
paraffin normal skin sections were used with microwave setting at 10 minutes and 40 minutes, with 
varying concentration of the citrate buffer i.e. pH 6, 8, and 9 respectively.  Another set of 6 sections 
were optimized in water bath at 97  C for 10 minutes and 40 minutes. A single negative control was 
used separately for the microwave and water bath respectively. Positive and negative skin controls 
were used to confirm antigen specific binding and identify non-specific staining.  
 
 After the antigen retrieving step, the slides were left under running tap water bath before the 
application of the endogenous peroxidase, which is met to prevent non specific binding of the 
antibody. This step was followed by blocking with normal horse serum, which helps to eliminate 
background staining. The biotinlylated anti rabbit and mouse secondary was added after the 
application of the specific primary antibody.  Diamino-bendizidine DAB, which was mixed with 1 
ml substrate buffer and 1 drop of DAB chromogen were applied at the final stage to allow for 
localization of peroxidase in tissue sections. The stepwise approach for the immuno-histochemistry 
can be found in Appendix 4, which is a modification of the VECTASTAIN universal instruction that 
have been adapted for use in the Cellular and experimental pathology laboratory of the Barts and the 
London School of Medicine and Dentistry. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
 Monoclonal & Polyclonal Antibodies used for Immuno-histochemistry. 
Antibody  Tissue Dilution 
Endogenous 
block 
Antigen retrieval 
Method Source  
keratin 1&10 
(LH1) 
 
 Wax 1/150 
Water/H2O2/ 
 15min 
PH 8.1 citrate 
 Buffer 
40 min microwave CRUK, London, UK  
keratin 10 
(LH2) 
 
 Wax 1i/50 
Water/ H2O2/ 
 15min 
PH 8.1 citrate 
Buffer 
40 min  microwave CRUK, London, UK  
Keratin 14 
(LL001) 
 
 Wax 1in 100 
Water/H202/ 
 15min 
PH 6.0 Citrate  
Buffer 
10 min microwave CRUK, London, UK  
keratin 16 
(LL025) 
 
 Frozen Neat 
Water/H2O2/ 
15min 
Antigen 
 Retrieval CRUK, London, UK  
keratin Ki67 
(NCL-Ki67-MMI) 
 
 Wax 1 / 300 
Water/H2O2/  
15min 
PH 6.0 Citrate 
 Buffer 
30 min microwave Novocastra  
Integrin β1 
(CD29) 
 
 Wax 1/100 
Water/H2O2/ 
15min 
PH 9.0 citrate  
Buffer 
10 min water bath CRUK, London, UK  
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Cell surface Maker 
Monoclonal(CD44) 
 
 Wax 1 in 75 
Water/ H2O2/ 
 15min 
PH 6.0 Citrate  
Buffer 
30min microwave 
Dako,  Glostrup, 
Denmark 
        
Antibody 
 
Tissue Dilution 
Endogenous 
block 
Antigen retrieval 
Method    Sources  
Endothelia  Cell  
Monoclonal 
(CD31) 
 
 
Wax 
 1 in  
Water/ H2O2/  
15min 
PH 6.0 Citrate 
Buffer 
25min microwave 
       Dako, Glostrup, 
Denmark  
Collagen I 
polyclonal(ab292) 
 
 Wax 1 in 50  
Water/ H2O2/ 
15min 
PH 6.0 Citrate buffer 
10 min microwave 
Abcam, Cambridge, 
UK  
Collagen III 
polyclonal(ab7778) 
 
 Wax 1/ 200 
Water/ H2O2/ 
15min 
PH 6.0 Citrate buffer 
20 min microwave 
Abcam, Cambridge, 
UK  
Collagen VII 
( NCL-COLL-VII) 
 
 Frozen 1 in 50  
Methanol/H202/ 
30min 
Antigen retrieval not 
used  Newcastle, UK  
 
Table2.2 Shows varying optimization conditions for the different antibodies employed in the 
immunoperoxidase, their sources, the antigen retrieving methods and the dilution ratios.  
 
For visualization of DAB slides, (Bio Genex, Inc, San Ramon, CA) sections were counterstained in 
Gill‘s Haematoxylin, washed in water, differentiated in 1% acid alcohol then washed again in water. 
Sections were dehydrated in industrial methylated spirit (IMS) cleared in xylene and then mounted 
on xylene-based mountant. (This automated machine was available for use in the department and the 
details of the steps involved can be found in Appendix 4). Frozen sections were air dried for an hour 
before use and then fixed with acetone (-20°C). These were then cleaned in wash buffer and an 
endogenous block applied (as for wax sections with the exception of diluting hydrogen peroxide in 
methanol instead of water), the antigen retrieving steps were skipped.  The remaining steps followed 
the standard R.T.U Vectastain Universal Elite protocol (Appendix 4).  
 
After the complete immuno-histochemistry staining, the slides are covered with a cover slip and 
allowed to air dry. Each slide were then examined under the microscope and graded based on the 
specified and expected characteristic staining pattern recommended by the manufacturer for the 
antibody. The slides were graded as; poorly stained, faint stained, average, good, very good  and too 
strong stained, these grading has a directly relation to the optimizing condition for the antibody 
tested. The optimization condition used for the slide that comes out as the very good stain was then 
adopted as the gold standard for that particular antibody. The same was repeated for all antibody 
used for the immunoperoxidase staining.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
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2.2.4.1 Enzymatic Antigen Retrieval 
Enzymatic antigen retrieval is one of the earliest ways of unmasking formaldehyde-fixed antigens, 
before exposing the slide to primary antibody, in a solution of a proteolytic enzyme. The rationale 
for using a proteolytic enzyme is on the basis that breaking some peptide bonds will make holes in 
the matrix of cross-linked proteins, allowing for the entry of antibody molecules. Enzymes other 
than trypsin have been used in similar ways, these includes pronase, proteinase, protease pepsin.  
Most of the antibodies employed in these experiments worked with the earlier described 
optimization method (See Table 2.2) with the exception of antibody keratins K16 and K5/K14 that 
needed enzymatic antigen retrieval step.  The proteinase and protease from streptomyces griseus 
type XIV (3.5 units/mg) solid power, Sigma Aldrich, UK, were used for enzymatic antigen 
retrieving when the earlier described optimization method was unsuccessful.   
 
2.2.4.2 Optimization Condition for K16 
 
The antigen retrieval protease ( from streptomyces griseus type XIV, ≥3.5 units /mg solid power) 
and proteinase were weighed (0.1g) and added to 100ml of PBS X1, which was mixed until all the 
powers have completely dissolved in PBS at room temperature. Three separate methods were 
employed in order to achieve the best possible immunoperoxidase staining protocol. Two slides were 
tested per optimizing condition, one as the positive and the other negative control.  
 
1. Each slide was dipped into a trough of proteinase and was quickly transferred into citrate buffer 
solution at PH of 6 and micro-waved for 10 and 40 minutes respectively. The same process was 
repeated with protease (WGK, Germany). 
 
2. The tissue section was left in a trough of proteinase mixture for 15 min at room temperature and each 
slide was then transferred into citrate buffer solution at PH of 6 and micro-waved for 10 and 40 
minutes respectively. The same process was repeated with protease 
 
3. The tissue section was dipped quickly into a trough containing proteinase mixture and the slide was 
then transferred into citrate buffer solution at pH 6 and left in water bath for 10 and 40 minutes 
respectively. The same process was repeated with protease.  
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4. After the antigen retrieval step, the other steps described in the Vecstain ABC protocol were 
followed. The antigen retrieval optimization process that produced the best and desired staining 
result was the slide left in proteinase mixture for 15 minutes and heated in water bath for 40minutes. 
This was adopted for the rest of the immunoperoxidase staining 
2.2.4.3 Optimization Condition for K5/K14  
The optimization process described for K16 was adapted for K5/K14 by using buffer solution at PH 
of 6 and 10, heating in microwave and water bath at 10 and 40 minutes respectively. The 
combination of slide left in protease for 15 minute and heated in water bath for 40minute produced 
the desired immunoperoxiadse staining pattern for K5/K14 cytokeratin antibody. K5/K14 antibody 
were out of stock (not available commercially) at the time of the study, hence the antibody was not 
tested on all the wound biopsy samples. 
2.3 General Principle of Cell Culture 
All cell types described were handled using an aseptic technique standard to all tissue culture 
laboratories. All procedures were carried out in sterile laminar hoods. Sterile disposable tissue 
culture dishes were purchased from Corning Inc USA. All tissue culture instruments, including tips 
and forceps were autoclaved. Cells were incubated in a humidified atmosphere at 37°C 90% air / 
10% CO2. Centrifuging was carried out at room temperature in an IEC Centra-3C Centrifuge 
(International Equipment Company, UK) at 1200 RPM. A Nikon Eclipse TE2000-S (Nikon, Japan) 
was used for light microscopy (LM). 
             
2.3.1 Mouse 3T3 Fibroblast Cell line 
 
Mouse 3T3 cell line was obtained from Cancer Research U.K (C.RU.K).  This cell line was first 
established by G. Todaro and H. Green in 1962 from disaggregated embryos of Swiss mouse (Todaro 
and Green, 1963). The Swiss 3T3 strain was used for the purpose of this research. The 3T3 cells 
were cultured in T75cm
2 polystyrene tissue culture flasks with Dulbecco‘s modified Eagle‘s medium 
(DMEM) {Invitrogen Life technologies, Paisley, Scotland, U.K}, supplemented with 10% Fetal Calf 
Serum (FCS) {PAA Laboratories GmbH, Austria,  5ml  of 1% L- glutamine (concentration) and a 
mixture of  5ml  of Penicillin  Streptomycin. The seeding density for 3T3 depends on number needed 
for the planned experiment. On the average 200,000 3T3 cells were seeded in to a 75cm2 flask with 
DMEM of 15ml.  The prepared flasks were incubated at 37
0
C in a humidified 10% CO2. The first 
media change was after 24hrs and subsequently on alternate days. When the cells reached 80-90% 
confluence, they were passage before contact inhibition sets in.  
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For further sub-culturing, old culture media was aspirated from the flasks, the cells are bath /washed 
in trypsin, the trypsin is then aspirated off.  The trypsin acts to chelate the divalent cations (Calcium 
and magnesium ions), weakening the adhesion of cells to each other and to the flasks.  Five 
millimetre of trypsin (0.0- ethylenediamino-tetraacetic acid (EDTA) (PAA, Laboratories GmbH) was 
added to the flask of T-75 and left in the incubator for 5 to 10 min. Incubation with trypsin cleaves 
extracellular cell adhesion proteins required for cell to cell attachment and cell to flask attachment. 
The flask can be given a gentle tap to enhance further detachment; the cells are checked under the 
microscope to determine the degree of detachment of the cells.  If all the cells have detached, equal 
volume of E4 medium (5mL) to inhibit the protease activity of the trypsin was added. If the cells are 
still attached, the flask was put back in the incubator or the old trypsin-EDTA is removed and a fresh 
warm trypsin-EDTA (37
0
C) was added to the cells and allows to incubate.  Leaving the cells too long 
in trypsin-EDTA is harmful to the cells.  An additional 10mL E4 medium were added to the solution 
of the cells to make a total of 20mL in a falcon tube (BD Bioscience, Oxford U.K.). At this point a 
cell count was performed before passaging or the 3T3 cells are treated as the case may be.   
 
The cells were re-suspended in the falcon tube; cell count was done by pipetting a few drops under 
the cover slip of a Neubauer haemocytometer (Weber Scientific International, West Sussex, and 
U.K). Cell concentration was calculated by taking an average of cell count in each of four 4 x4 
square grids under the microscope. The average number was then multiplied by 10
4
 to give the final 
cells/mL.  The solution of cells and medium in the falcon tube were centrifuged at 1,000rpm for 
5min using the IE 215A rotor (International equipment company, U.K).  The supernatant were 
removed and the pellets were left at the bottom of the tube, which was suspended in fresh volume of 
E4 media. The cells are now split into new fresh T-75 flask and return to the incubator at 37
0
C and 
10% of CO2. Media change is done after 48hrs and the cells are maintained in culture accordingly.  
2.3.1.1   Treating 3T3 for Feeder 
This involved treating known amount of 3T3 (NIH) with mitomycin in preparation for subculturing 
keratinocyte. 
2.3.1.2 Mitomycin Preparation 
Mitomycin C (Sigma Saint Louis, Missouri 63103 USA) is produced by a strain of actinomyces 
named streptomuces caespitous.  Mitomycin C inhibits DNA synthesis; it reacts covalently with 
DNA, in vivo and in vitro, forming cross-links between the complementary strands of DNA. This 
interaction prevents the separation of complementary DNA strand, thus inhibiting DNA replication.  
Mitomycin C is soluble in water; the 2mg vial is in a crystal form. Mitomycin C was dissolved in 
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4mL of water to make 0.5mg /mL. The recommended concentration for eukaryote cell culture is 10-
50 µg/mL. For the purpose of treating 3T3 or for scratch assay experiment we used 20 µg/ ml.  
Mitomycin C undergoes rapid degradation in acidic solutions with pH less than 6.0. The 
reconstituted vials are wrapped in aluminium foil, kept in the dark and stored at -20
0
C, this is 
because it light sensitive.   
 
2.3.1.3 Preparation of 3T3 Fibroblast for keratinoctye Isolation 
 
Murine 3T3 (NIH) fibroblasts were obtained from cancer research UK. Cells were cultured in T-175 
flasks with E4 medium (See Appendix 1) and incubated. Cells were maintained by media change 
every 3 days and passage once 80% confluences were reached (See Appendix 2). Cells were splitted 
into new flasks to generate stocks or frozen for long-term storage in liquid nitrogen (See Appendix 
2).  3T3 cells were splitted by washing in 5mL of 1x versene/EDTA (Invitrogen, UK) for 30 
seconds. EDTA chelates calcium ions thereby disrupting calcium-dependent cell junctions such as 
the cadherins found in desmosomes. It allows trypsin to digest these junctions, causing the 
dissociation of cells from each other and the flask. EDTA was then aspirated and replaced with 5mL 
of 0.25% trypsin-EDTA (Sigma Aldrich, UK). Flasks were then incubated for 5-10 minutes and 
checked by light microscope (LM) for cell detachment. Once all cells had detached an equal volume 
of E4 medium was added to the flask. Serum (FCS) within the medium inhibits trypsin activity. 
Cells were then re-seeded at a lower density. Growth arrested 3T3 ―feeder‖ cells were produced 
through Mitomycin-C treatment or irradiation (Appendix 2 stepwise process of Mitomycin 
treatment). This inhibits cell division but maintains cell viability therefore allowing 3T3s to produce 
paracrine growth factors to encourage keratinocyte growth. 
2.4 Preparing RM+ 
RM+ is a supplementary chemical needed to complement the keratinocyte media- Dulbecco‘s 
modified of Eagle‘s medium (DMEM). The reagents needed for RM+ was prepared individually and 
then mix together to produce the final product.  The insulin was re-suspended in 0.05M HCL and 
dH2O to make a final concentration of 5µg/ml in DMEM medium of 500ml. The other reagents were 
prepared after dissolving them in dH20 to the following required concentrations as shown in table 
2.3.  The volume of the stock needed to make  200ml 100 x RM+  is as shown in the table, was 
added to the cylinder, which was then toped up until it reached 100ml with distilled water, it was 
then filtered.  Another 100mls of E4/F12 (without serum) was added to the cylinder to give a total 
volume of 200ml. The mixture was again filtered   into another bottle and aliquot into 4ml of bijous 
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and store in -20
0
C. One of the bijoux was tested for bacterial infection by putting it in the incubator 
for 1 week and checking regularly for turbidity or cloudiness of the solution- this is the sterility 
check of the procedure. 
Product Name Company Stock Concentration  Volume in stock 
needed for 200ml 
100x Rm+ 
Final concentration 
in 100X Rm+ 
Cholera toxin Sigma 100µg/ml        2ml 0.84µg/ml 
Epidermal growth 
factor (Mouse) 
Serotec 100 µg/ml        2ml 1µg/ml 
Hydrocortisone Sigma 4mg/ml        2ml 40µg/ml 
Insulin( dissolved in 
0.05M HCl) 
Sigma 50mg/ml        2ml 500µg/ml 
Transferrin Sigma 50mg/ml      2ml 500µg/ml 
3,3‘,5 Triiodo-L-
thyroxine sodium Salt 
Sigma 2.6 µg/ml     100µl 1.3µg/ml 
          Table 2.3 Detailed description of RM+ and it constitutes. Details of the varying 
                  concentrations and the suppliers of the ingridents are shown in the above table. 
 
2.4.1 Isolation of Primary Cells. 
 
Human epidermal kerationcyte and dermal fibroblast were extracted from either redundant skin from 
breast reconstruction, abdominoplasty, and foreskin from circumcision and facial skin from facelift, 
using the method initially described by Rheinwald and Green in 1975. Ethical approval and inform 
consent was obtained from the patient before the procedure. 
2.4.2 Human Epithelial Keratinocyte 
 
Keratinocytes were isolated from redundant facelift skin obtained from plastic surgery 
(Appendix 2). Ethical committee approval was obtained from East London and The City 
research committee Authority (No. 08/H0704/17) and informed  consent obtained. Skin was 
transferred to the laboratory in transport medium at 4
0
C, upon arrival; skin was removed from its 
container by sterile forceps and placed into a 100 mm
2
 cell culture dish. It was covered with 2–3mL 
of EDTA in preparation for keratinocyte extraction (Appendix 2). 
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Primary keratinocytes were cultured based on the original methods described by Rheinwald and 
Green, 1975.  Keratinocytes were seeded at a density of 2x10
6
 onto a mitomycin-C treated layer of 
2x10
6
 3T3 ―feeders‖. These were grown in T75 flasks, suspended in 20mL of RM+ medium 
(Appendix 1). Flasks were then incubated and checked daily for healthy cell growth. Keratinocytes 
were maintained at sub-confluence with medium changes every 2 days, additional 3T3 feeders were 
added as necessary. Primary cultures were serially passage at 75% confluence, in order to prevent 
stratification and differentiation. Only passages one to three (p1-3) were used for the purpose of this 
research. Keratinocytes were passage by trypsinization (Appendix 2).  
 
First, culture medium was aspirated and the cells washed in PBS (PAA, Laboratories UK). This was 
then replaced with 5mL versene and the flask returned to the incubator for 5-10 minutes. Cell 
detachment was ascertain under light microscope (LM) every minute. As 3T3 adhesions were 
affected first, this method allows for the selective removal of all feeders before splitting the 
keratinocytes. If any 3T3 cells remained, the flask was given a gentle tap and re-incubated until only 
keratinocyte colonies were present. Once all 3T3‘s had detached, the versene was then aspirated and 
5mL of trypsin-EDTA added for 5-10 minutes at 37°C.  
 
Again cell detachment was confirmed by examination under light microscope, once all keratinocytes 
had detached, an equal volume of RM+ medium was added to the flask to neutralize the protease 
activity of trypsin. The flask contents were then transferred to a sterile 50mL falcon tube and 
centrifuged for 5 minutes. The supernatant was then aspirated and the pellet re-suspended in10mL of 
RM+. Cells were then counted using trypan blue (Sigma-Aldrich Ltd, UK) and a haemocytometer 
(Weber Scientific International) (Appendix 2) under LM and then re-seeded in T75 flasks with new 
3T3 feeders. Keratinocytes were routinely split at a ratio of 1:5. These cells grew in colonies and 
were serially passage every 8- 10 days.  After the 4th passage the doubling rate of keratinocyte slow 
day. 
2.4.3  Prevention of Fibroblast Contamination in Keratinocyte Cultures 
 
The addition of 3T3 feeder cells discourages the growth of dermal fibroblast in keratinocyte cultures 
but if the densities of 3T3 feeders are low, fibroblast contamination can occur. For the removal of 
these fibroblasts, the flasks were washed once in 0.02% EDTA and then incubated with 0.05% 
trypsin in 0.02% EDTA (1:4 dilutions) at 37
0
C for about 30-60 sec or until the feeders and human 
fibroblast had detached from the flask. Tapping the sides of the flask gently aided in the detachment 
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of fibroblast. Fresh medium was then pipette into the flasks that still contained attached keratinocyte 
and fresh feeders were re-added. 
 
2.5  NEB-1 Immortalised Cell line 
Neb-1 cells human cutaneous keratinocyte immortalize by human papilloma virus (HPV) - type 16 
(Morley, D‘ Alessandro et. al., 2003). They were obtained fron the Centre for Cutaneous Research 
ICSM, London UK), and cultured in DMEM/Hams F12 medium in T75flasks. The cell medium were 
refreshed every two to three days and cells passaged according to already described protocol.  Neb-1 
cells were used because they have similar biological behaviour as keratinocyte, easy to grow and 
maintain in culture with RM+ medium, which is changed every 48hrs. Passages from 6-10 were used 
in this set of experiments  
 
2.6 Isolation of Human Dermal Fibroblast 
 
There are 2 different techniques that could be employed in the isolation of fibroblast; the explants 
and the D- Collagenase methods.  
 
2.6.1 The Explants Technique 
 
The 6- 8 pieces of skin left over from keratinoctye extraction was placed in a scored treated sterile 
Petri-dish (Corning, Inc, USA) to  create a rough surface and a small amount of 10% FCS was added  
to the dish and left in the hood to air dry (10-15 min) until the skin piece sticks to the scored dish. 
Twenty mills of E4 media was then added to the dish, which was left to incubate at 10% CO2 and 
37
0
C. The media changed was carried out every 2-3 days, until the formation of new fibroblast which 
may take up to 7-10 days were formed.  The Petri-dish was checked for new fibroblast daily under 
the light microscope.  The skin pieces were discard once sufficient yield of fibroblast was 
established. Culturing of the fibroblast was continued until 70-80% confluent was reached and the 
same passage according to protocol for 3T3 mouse feeder cell line. Passages one to seven were used 
for study. 
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2.6.2 Collagenase D Technique 
 
Collagenase D (Boerhringer Mannheim GmH, Germany) from clostrium histolyticum, 0.05g of it 
was weighed under a sterile condition and added to 50ml of DMEM media with streptomycin 
penicillin without the other entire supplement, to make final concentration of 0.5µg/mL.  A 
micropore filter (0.2µm) was used to filter the dissolved solution.  About 6-8 piece of left over skin 
from keratinocyte extraction was  added to 10- 15ml of Collagenase D solution in the Petri dish 
(untreated dish)  and left over night in the incubator at C02 and 37
0
C, following which the suspension 
are collected into a 15ml falcon tube and are neutralized  with equal volume of E4 media. The tube 
was gently vortex to release as many cells as possible.  The suspension was then filtered using a 
sterile cell strainer (100µm) and the filtrate was centrifuged at 1200 rpm for 5min.  
 
After aspiration of the supernatant, the pellet left at the bottom of the tube was re-suspended in 
DMEM containing 10% FCS and the cells seeded at a density of 1x10
6
 per T75 cm flask.  This was 
then further sub-cultured by incubating at 37
0
C in a humidified 10% CO2/ 90% atmospheric air with 
full complement of E4 medium. Confluent cultures of fibroblasts were trypsinied using 0.05% 
trypsin in 0.02% EDTA (1:4 dilutions) and subculture using the same protocol as for 3T3 mouse 
feeder cell line. Passage one to five was used for the experiments in this study. 
 
2.7 Passaging Cells 
Cells that were not grown on feeder layer were passage when they were approximately 70% 
confluent by washing once with 5ml sterile PBS.  The cells were once again washed with 5ml of 
versene and incubated at 37
o
C for 5min with trypsin-EDTA in the case of 3T3 mouse fibroblast, or 
trypsin in the case of NEB-1cells. The process of trypsinisation was monitored under the light 
microscope and the flask was tapped to aid cell detachment. Once all cells had lifted off, the 
trypsinisation was halted by adding 5ml culture medium containing 10% FBS and the solution 
decanted into 5ml centrifuge tube. The cells were centrifuged at 200g for 5min at room temperature. 
The supernatant was aspirated, the cell pellet resuspended in 10ml culture medium and the cells 
counted using haemocytometer as previously described. Cells were then seeded for experiments, 
propagated at 10% of their original density or cyropreserved for storage. 
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2.7.1 Cryopreservation and recovery of   Cell types. 
 
Cells (3T3, HDF) for frozen storage were suspended at a density of 2x10
6
/mL in freezing medium of 
90% FCS and 10% dimethyl-sulphoxide (DMSO) (BDH Laboratory Supplies, UK),  whereas for 
Neb-1 cell and HEK 10% DMSO, 30% RM+ media and 60% of FCS was used. The DMSO protects 
against ice crystal formation which can rupture cell membranes (Lovelock, 1959). 1mL of 
suspension was pipette per cryogenic vial (Corning Inc, USA). These were then wrapped in six 
layers of paper towels which allowed the cells to freeze down slowly to -80 °C in a freezer. Cells 
were then transferred to liquid nitrogen for long-term storage. When retrieving cells from storage, 
vials were defrosted in a 37°C water bath, swabbed with industrial methylated spirit (IMS) and the 
contents then transferred to a 50mL falcon tube containing 10mL of medium. This helps to dilute the 
DMSO. The tube was then centrifuged for 5 minutes at 1200 rpm and the pellet re-suspended in a 
fresh medium and re-seeded.   
 
2.8 Preparation of the culture media for the HDF, HEK and HUVEC  
 
The stored aliquots of PRP and PPP in -20
0
C were carefully defrosted in water at 37
0
C and 
reconstituted into varying concentration of   5%, 10%, 25% and 50% were mixed with different 
culturing media. Studies have shown that storing growth factors in -20
0
C to -80
0
C does not affect the 
level of the growth factors released. For proliferation assay with  keratinocyte; Phenol red free 
DMEM/ Ham‘s F-12 with 1% FCS / 1% Bovine Albumin serum (BAS) and antibiotic,without the 
RM supplement (choleratoxin, epidermal growth factor, hydrocortisone, insulin, transferrin and 
thyronine sodium salt were used (Table 2.3).   For fibroblast; phenol red free high glucose DMEM 
with 1% FCS /1 % BAS and antibiotic without L-glutamine was used in diluting the PRP and PPP 
into the desired concentrations. 
For HUVEC, varying elimination and combination of the EMG-2 and its supplement was tried with 
PRP and PPP before arriving at a final concentration which allowed HUVEC to be sub-cultured 
successfully for a period of 5 days. The EMG media was reconstituted using the EMG only + 
heparin+ gentamycin + hydrocortisone +ascorbic acid and or 1% BAS and the remaining supplement 
were not used in the final concentration of PRP and PPP. The supplement recommended for optimal 
culturing of  HUVEC are  Hydrocortisone 0.2ml,fetal bovine serum  10ml( FBS), recombinant 
human fibroblast growth factor-B  2ml (r-hFGF-B),heparin 0.5ml, recombinant human epidermal 
growth factor in buffered bovine serum albumin 0.5ml ( rhEGF) , recombinant human vascular 
endothelial growth factor 0.5ml (rhVEGF), Gentamicin sulphate Amphotericin-B  0.5 ml (GA-100), 
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recombinant long releasing insulin-like growth factor-1 0.5ml (R
3
-IGF-1) and ascorbic  acid 0.5ml; 
which is the full complement for EMG media. 
2.9 Human Umbilical Endothelial Cell  
 
Clonetics Umbilical Vein Endothelial Cell Systems contains normal human Vein Endothelial cells 
(HUVEC); this system has the capability to generate HUVEC cultures for experimental application. 
The cryopreserved HUVEC (Lonza Walkersville, Inc. USA) are shipped as frozen primaries.  A 
cryo-vial on the average contains a total of 500,000 cells/ ml, stored at -80
0
C.  
The systems consists of umbilical vein endothelial cell product (cryopreserved) isolated in 
(endothelial growth medium ) EGM, endothelial cell medium (Bullet-kit- 500ml),  clonetics  EGM-2 
Bullet-kit contains one 500ml bottle of Endothelial Cell Basal Medium-2 (EBM) and the following 
growth supplements:  Hydrocortisone 0.2ml,fetal bovine serum  10ml (FBS), recombinant human 
fibroblast growth factor-B  2ml (r-hFGF-B),heparin 0.5ml, recombinant human epidermal growth 
factor in buffered bovine serum albumin 0.5ml (rhEGF), recombinant human vascular endothelial 
growth factor 0.5ml (rhVEGF), Gentamycin sulphate Amphotericin-B 0.5 ml (GA-100), recombinant 
long releasing insulin-like growth factor-1 0.5ml (R
3
-IGF-1) and ascorbic  acid 0.5ml,The HUVEC 
cells were cultured according to the manufacturers advice.  Passages 2 and 3 were used for all the 
assays types with HUVEC, this is  because the older passages have been shown to have less doubling  
rate compared to the earlier ones. 
2.9.1  Using the Clonetics Endothelial Cell System. 
 
1. Cryovials containing HUVEC are removed from dry ice pack and place into the liquid nitrogen until 
its ready for use.  When the cells are to be used immediately, they are thawed quickly in water bath 
and are transferred to the ready prepared flasks.  
 
2.  The cryovial are wiped with ethanol before opening, the vial was opened in a sterile field, the cap of 
the vial was twisted a quarter turn to relieve pressure, and then retighten.  The cryovial was thawed 
in water bath at 37
0
C quickly, this was not for more than 2minute and the vial was closely monitored 
to avoid submerging.    
 
3.  A cryovial contains about 500,000 cells; tryphan blue was used to determine the accurate number of 
viable cells. The cells were divided into equal volume/ number of culture vessel; for example, 
250,000 cells was seeded into a T-25 flask (25cm
2
). 
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4.  Before the addition of cells to the flask, appropriate amount of medium (1ml/5 cm2) required were 
added and allowed to equilibrate in humidified incubator for at least 30 minute in 37
0
C, 5% CO 2.   
Once the flask was ready for use (T-25 cm
2
 flask), the cells are re-suspended and dispensed into the 
culture vessels set up earlier. The cells from the cryovial are not centrifuged; this effect is more 
damaging than removing the residual DMSO in the cultured cell. 
 
5.  The growth factors are allowed to thaw after removal from dry ice and added to a decontaminated 
bottle of basal medium (EGM-2), which can then be stored in 4 
0
C  
 
 
2.9.2 Subculturing HUVEC 
Sub-culturing will be needed once the cell have reached about 70-80% confluent   and contains many 
mitotic figures throughout the flask.  
 
 The Reagent Pack TM   subculture reagents are sterile –filtered and stored at -200C. This pack 
consists of Trysin/ EDTA solution, HEPES –BSS (Buffered Saline Solution) and trypsin 
neutralizing solution (TNS). After thawing, they are immediately aliquot into a 15ml tube and 
stored in -20
0
C, for a longer shelf live.  
 
 To subculture an 80% confluent flask, each flask is done at a time, before removing the culture 
media; 5ml of HEPES-BSS, 8ml of Trypsin/EDTA and 4ml of TNS are allowed to thaw at room 
temperature. After removing the flask from the incubator, the media was aspirated off the cells 
and are rinse with HEPES-BSS, which helps to prevent the complex proteins and calcium from 
neutralising the action of trypsin. The HEPES- BSS is aspirated off the flask and the cells are 
cover with 4ml of Trypsin/ EDTA solutions and left in the incubator for 4-6minutes, this allows 
for trypsinization, until 90% of the cells are rounded up.  
 
 The flask was rapped against the palm to allow majority of the cells to be released from the 
culture surface. After cells are released, 4ml of TNS was added to neutralise the newly released 
cells. If some of the cells are not detached the reminding are re-trypsinized with fresh, warm 
trypsin/ EDTA solution and returned  into the incubator until the remaining are well rounded up. 
The trypsinized cells are transferred into a sterile 15 ml centrifuge tube. The harvested cells were 
examined under the microscope to briefly assess for cell viability. 
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 The tube containing the harvested cells was centrifuged for 700prm for 5 minute, after 
centrifuging, the supernatant was aspirated off and the pellet was left at the bottom of the tube. 
The pellet was diluted with fresh media to a total volume of 5ml for easy of cell counting. At this 
point, 20µl of the re-suspended harvested cells were collected into a separate sterile 15ml tube 
and 20µl of trepan blue was added to the cells and left for 5-10minute before determining cell 
viability as previously described.  A uniform suspension was ensured and the cells were re-
seeded into already prepared flask depending on total number of viable cells. When further sub-
culturing was desired, the number of flasks needed depends upon cell yield and seeding density 
needed. For my experiment, the cells are seeded at 250, 000cells/T-25c
m2 
flasks, which will reach 
full 80-90% confluent in 5- days. 
 
 To maintain the cell in culture, the media was changed after 24 hrs of seeding and then every 
alternate day. Once the cells become more confluent, the volume of the media for maintenance in 
cultured was increased by 2-5ml/25cm
2 
flask to cope with the metabolic demand of the 
proliferating cells. It is important to avoid repeated warming of the media. To prevent this 
occurrence only the required volume of media was taken out from the -20
0
C freezer and warm in 
separate sterile container.  The clonetics cells can be use for up to ten population doublings.  
Although additional population and doubling are possible but the growth rate, biological 
responsiveness and function deteriorate with subsequent passages. For this reason, all the 
experiments were carried out with the HUVEC in 2
nd 
or 3
rd
 passage. 
 
 The HUVEC cells were cryo-preserved after establishing a larger enough cell population beyond 
the number needed for the planned experiments.  The freezing media (which is made of 80% 
EGM-2, 10% FBS and 10% DMSO) was filtered using a sterile cell filter of 0.2micron size. The 
cells were harvested and centrifuged as described above.  The pellets collected are re-suspended 
in a cold freezing solution at 500,000 to 2,000,000 cells per ml quickly. The cell suspension was 
stored at 1ml per cryovial and sealed off. The cryovials were then transferred into a propanol 
freezing canister and stored in -80
0
C overnight, the cells were then transferred to the liquid 
nitrogen (- 180
0
C) after the initial 12-24 hours storage in propanol freezing canister. 
 
2.10 EA.hy 926 Cell line 
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EA.hy 926 cells are endothelial cell line obtained by hybridization of human umbilical endothelial 
vein cells with the A549/8 human lung carcinoma cell line, This cell line has maintained the 
phenotype of endothelial cell line, has high differentiation functions that are characteristics of human 
vascular endothelium, stable through passage number and offers reproducibility of results. Bauer et 
al. 1992, showed that EA. hy929 cells are capable of undergoing tube formation when grown on 
matrigel. The cell line is very easy and cost effective to maintain in tissue culture, EA.hy 929 was 
maintained with DMEM medium used for fibroblast, and they were obtained from Translational 
Medicine department, William Harvey Research Institute, Queen Mary University of London. 
 
2.11 Seeding Density for the different Cells ypes and the Assay  
 
At the initial stage of the research, the seeding densities for all the different cell types and assay was 
determined through optimisation experiments. 
 Optimization experiment with fibroblast cell were seeded at 1000, 3000, 4000, 6,000, 8000, 10,000, 
20,000, 40,000, 80, 000, 100,000 and 200, 000 respectively 
 Optimization experiment for HUVEC was seeded at 10,000, 40,000, 80,000,100,000, 400,000 and 
800,000/ well. 
 Seeding density of Fibroblast for experiment in 12 well plate; Proliferation assay is 1x104/well, 
Scratch assay of 5x10
5
 and  Transwell assay 5x10
4   
 
 Seeding densityfor HUVEC / EA.hy. 926 in 24 well plate; proliferation assay is 1x104 transwell 
assay is 1x10
4
 and  angiogenesis assay 2x10
5 
respectively. 
 Seeding density for Neb- 1 cell and primary keratinocyte; proliferation is 2x104 /well, Scratch 6x105 / 
well, transwell  5x 10
4
 /well-plate respectively. 
   
2.12  Principles of Cell Viability Assay with Alamar Blue 
 
Cellular activities can be detected directly or indirectly by measuring plasma membrane integrity, 
DNA synthesis, DNA content, enzyme activity and presence of ATP. Cellular reducing conditions 
are known indicators of cell viability and cell death. Alamar blue cell viability reagent functions as a 
cell health indicator by using the reducing power of living cells to quantitatively measure the 
proliferation of various human and animal cell lines. When cells are alive they maintain a reducing 
environment within the cytosol of the cell. Resazurin, the active ingredient of AB reagent, is a non 
toxic, cell permeable compound that is blue in colour and virtually non-fluorescent. Upon entering 
cells, resazurin is reduced to resorufin, a compound that is red in colour and highly fluorescent. 
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Viable cells continuously convert resarzurin to resorufin, thereby increasing the overall fluorescence 
and colour of the media surrounding cells. 
Alamar Blue (AB) is designed to quantitatively measure the proliferation of various human and 
animal cells by detecting the level of oxidation during respiration.  Alamar blue (AbD serotec, 
Kidlington, Oxford, UK) is an indicator dye which incorporates an oxidation-reduction (REDOX) 
which both fluorescences and changes colour in response to chemical reduction of growth medium, 
resulting from cell growth.  AB is able to detect oxidation by the whole of the electron transport 
chains.  The midpoint potential of AB is greater than that of any of the other component of the 
electron transport chain (Table 2.5).  The mid potential for any half reaction is defined as the voltage 
at equilibrium is obtained between the concentration of oxidized and reduced products.  Midpoint 
potential gives a measure of the strength of an electron donor. AB will be reduced by FMNH2, 
FADH2, NADH, NADPH and cytochromes, since their midpoint potential are lower than that for 
alamar Blue. Therefore, AB is an excellent detector of reduction of all elements of electron transport 
chains. 
Alamar Blue (AB) was added to cells in culture media at a 10% of the sample volume (i.e., add 10 
µL AB reagent to 10µL sample), followed by 4-8hrs incubation at 37
o
C. Longer incubation times 
may be used for greater sensitivity without compromising cell health.  In our study the optima 
incubation period was between 16-24hrs. The resulting fluorescence or absorbance was read on a 
plate reader or fluorescence spectrophotometer. Finally, the results are analyzed by plotting 
fluorescence intensity or absorbance versus the compound concentration. 
 
                                                  Half –Reaction Eo‘ (mV) PH 7.0 250C 
NAD +2H+2e
-
  ------- NADH+ H+                -320 
NADP+2H+2e
-
 ------- NADPH+H+                 -320 
FAD+2H+2e
-
 ------- FADH2                 -220 
FMN+2H+ 2e
-
 ------- FMN2                 -210 
MTTox, + 2H +2e
-
 ------- MTTRED                 -110 
Cytochromesox , + 
1e
-
 
------- Cytochromes RED            +80 to +290 
alamarBlue ox + 2e
-
 ------- AlamarBlue                  380 
02+4H+4e
-
 ------- 2H20                 820 
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Table 2.5: Oxidation reduction potentials in the electron transport system and alamarBlue. 
Reduced Flavin mononucleotide (FMNH2), Flavin mononucleotide (FMN), Flavin adenine 
dinucleotide (FAD), Reduced Flavin adenine dinucleotide (FADH2,), Nicotinamide adenine 
dinucleotide (NADH), Nicotinamide adenine dinucleotide phosphate (NADPH) and (3-(4,5- 
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).  The midpoint redox potential (Eo‘) 
values were determined at pH 7.0, 25
0
C .Table adapted from www.ab-direct.com/alamarBlue.    
 
2.12.1 Rationale for using Alamar Blue in Proliferation Assay   
 
Alamar Blue is advantageous over other redox indicator such as tetrazolium salt (also called MTT 
assay), in that it does not interfere in any way with the reactions of electron transport chain. This is 
because the midpoint potential of AB is greater than any of the component of electron transport 
chain.  Other salient advantages of AB includes; non-radioactivity, simplicity, less costly and non 
labour intense, rapid assessment of proliferation of large number of cell sample, non-toxicity and 
permits further analysis of proliferating cells by other method (Ahmed  et al. 1994 ) 
MTT has a similar oxidation-reduction interaction with the electron chain with a midpoint potential 
of -110Mv, which is intermediate between that of the electron donors and cytochromes, MTT will 
not be reduced by cytochromes.  Furthermore, following the interaction of MTT with the electron 
chain, the electrons released by these donors (FMNH2, FADH2 etc) will not be passed to the 
cytochromes as would normally happen in the electron transport chain, hence the respiratory chain is 
shut down. 
Alamar Blue allows the cells to remain fully functional and healthy, unaffected by the by presence of 
indicator during experiment.  This is property is unique to alamar Blue.  AlamarBlue functions by 
allowing growing cells to cause a chemical reduction, continued growth maintains a reduced 
environment (fluorescent, red colour) and inhibition of growth maintains an oxidized environment 
(non-fluorescent, blue colour). Quantifiable data from alamar Blue can be collected by using either 
fluorescence –based or absorbance –based instrumentation.  The fluorescence is monitored at 530-
560nm excitation wavelength and 590nm emission wavelength. The limitations of Alamar blue are 
few, high cell concentrations and prolonged culture times will show reversal of the reduction 
process. Microbial contaminants will reduce Alamar blueand yield erroneous results, but 
contamination would adversely affect any assay of the cells. Bovine serum and phenol red may 
slightly interfere with the colorimetric changes, although we have observed no sign of toxicity in our 
assays, long term toxicity from Alamar blue cannot be completely ruled out. 
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2.12.2 Prolifertaion Assay for HDF, HEK and NEB-1 CELL 
 
Cells were trypsinized from sub-confluent cultures by adding 3mL of trypsin solution (100 mg 
EDTA, 5 mL penicillin– streptomycin, 500 mL gentamicin in 500 mL trypsin) to 50 mL Falcon 
flasks with confluent cells followed by 10 min incubation at 37
o
C with regular gentle shaking. The 
trypsin reaction was stopped by adding 10 ml of appropriate culture medium containing 10 % FCS. 
The cell suspension was then centrifuged at 750g for 10 min. The cell pellet was suspended in 2 ml 
of medium with 1% FCS and thoroughly mixed by repeated pipetting. Cells were counted with a 
Fuchs–Rosenthl hemacytometer and brought first to a concentration of 1x106cells/ml and 
subsequently to serial 1:2 dilutions. The resulting different cell suspensions were seeded into 
triplicate wells of a 12-well plate and incubated at 37
o
C. After an initial 6hr period to allow cell 
attachment, 10% of AB solution was directly added to the medium resulting in a final concentration 
of 10%. 
 
For negative control, AB was added to the medium without cells. The plate was further incubated for 
24 h at 37
o
C. The absorbance/fluorescence of the test and control wells was read at 540 and 630 nm 
with a standard spectrophotometer. The number of viable cells correlates with the magnitude of dye 
reduction and was expressed as percentage of AB reduction (Ahmed et al., 1994; Goegan et al., 
1995). The values of % AB reduction were corrected for background values of negative controls 
containing medium without cells. In order to eliminate differences due to medium colour, serum free 
keratinocyte (K-SF) was used for keratinocyte proliferation and DMEM without phenol red was 
Fibroblast whilst the same EMG-2 was used for HUVEC proliferation. 
 
2.12.3 Proliferation Assay for HUVEC 
 
After culturing HUVEC from the initial clonetic endothelia cell systems, further subculturing and 
passaging was carried. An initial experiment was performed to determine the optimal seeding density 
and the cell survival period for proliferation assay. HUVEC proliferation assay was previously 
described by Segura et.al.  HUVEC cells were plated at varying cell density of 2,000, 4,000, 6,000, 
8,000 and 10,000 per 24- well plate to optimize the conditions needed for the proliferation assay. The 
experiment was carried out in triplicate. The first well seeded with full complement of EGM-2, 
second well contains the reconstituted EGM-2 (1% FCS and without the recombinant growth factor) 
and the third well-plate contains 1%EGM-2 plus PRP at 50%) this was monitored over 7 days.  Day 
  
 
 
72 
5 was the critical period were HUVEC survived with 1% EMG-2 media before the apoptosis sets in. 
Ten thousand was identified as the optimal seeding density for HUVEC proliferation assay. 
 HUVEC cultured with full complement of EGM-2, plated at a density of 1x104   in 24 well 
plate, allowed to attach for 24hrs. The medium was changed after the first 24hrs period The 
EMG media was reconstituted using the EMG only + heparin+ gentamycin + hydrocortisone 
+ascorbic acid and 1% FCS as the positive control. 
 The media was replaced  the following day and media with varying concentration of PRP 
from healthy volunteer at 50%, 25%, 10% and 5%, PPP and control media respective. The 
cell was left in the humidified incubator at 37
0
C, 5% CO2,   the cells were checked daily for 
features of cell growth and change in morphology. 
 On day 0, day 3 and day 5 of the experiment, growth response was assessed using the 
Alamar blue dye technique, this was measured by Fluostar optima this works on the principle 
of Fluorescence intensity- plate mode using 96- well microplate (Nunc-96), which was preset 
at excitation filter of 544nm and emission filters of 590nm.  
 The first experiment was performed with no media change (media + PRP). The plated wells 
were incubated with Alamar blue over 6hrs period.  10% of the total volume of the cell 
media was used for the microplate reading. A separate well plate was measured as the 
untreated control which is the blank that serve as the internal control for the experiment. All 
experiment were performed over 5 day period in triplicate and repeated to give N= 3.  
 Optimization experiment was carried out initially to determine the experimental end point 
time and the baseline seeding density for the proliferation assay. The experiment was carried 
out with varying cell density (10,000, 40,000, 80,000, 100,000, 400,000 and 800,000/ well 
plate) at 4hours and 16hrs ( See result section in Chapter 4) 
 
2.13  Principles of Wound-Healing Assay 
The wound-healing assay is one of the earliest developed methods to study cell migration in vitro 
(Torado, 1965). This method is based on observation of cell migration into an ―artificial wound‖ that 
is created on a cell monolayer. Although not an exact duplication of cell migration in vivo, this 
method mimics to some extent migration of cells in wound healing.  Depending on the cell type, cells 
migrate into the wound as loosely connected populations (e.g.fibroblasts) or as sheets of cells (e.g. 
keratinocyte and endothelial cells), which also mimic the behaviour of these cells during migration in 
vivo. In comparison with other popular in vitro methods, such as time-lapse microscopy and Boyden 
chamber assays, the wound-healing assay is particularly suitable for studies of directional cell 
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migration and its regulation by cell interaction with extracellular matrix (ECM) and cell–cell 
interactions.  Migration of the cells is regulated by both the ECM under the cells and soluble factors 
(Han, 2001) as well as intercellular interactions in the case of epithelial and endothelial cells 
(Underwood, 2002). The effects of each of these factors on directional cell migration can be studied 
using the wound healing method.  The basic steps involve creation of a ―wound‖ on monolayer cells, 
capturing of the images at the beginning and regular intervals during cell migration until closure of 
the wound, and comparison of the images to determine the rate of cell migration. 
2.13.1 In Vitro Wound/ Scratch Assay with HEK, NEB-1, HDF   
 
To determine whether there were quantifiable migration rate differences between different HEK, 
Neb-1 and Fibroblast samples in response to wounding, cell migration assays were performed as 
described (Zingers, 2003, Spurzem 2002) with slight modifications. The first set consisted of HEK 
samples derived from the epidermal layer of normal neonatal foreskin/ face lift skin from plastic 
surgery, were isolated.  These were grown to confluence on 12 well plates.  Neb -1/ HEK were either 
treated with mitomycin to eliminate the process of proliferation during the assay or were untreated. 
Mitomycin treatment was not used for fibroblast proliferation because the rate of cell proliferation is 
much slower compared to Neb-1 and HEK.   
 
The experiment was carried out in triplicate and cells were treated with varying concentration of PRP 
(5%, 10%, 25%, 50% and PPP) and the control experiment was with 1% FCS.  Scratch wounds were 
created using a 20μL pipett tip and the artificial wound photographed digitally at six-hour intervals 
from the start. Photographs were taken with microscope connected with a digital video camera. The 
images were later analyzed for distance cell migration on Image J. Custom software was then used to 
calculate the cell-free area, and the cell migration rate was calculated using the changes in this area 
over time.  The cell migration rate was calculated as the distance travelled by the cells over time. 
Using the cell-free areas measured at the specified time-points, we calculated the change in cell-free 
area. Because the wound was made in the vertical direction, the cells migrating into the previously 
cell-free area came from two directions, the top and bottom of the wound area were determined 
 
2.13.2    Materials and Protocol for In Vitro Wound Assay in HEK/NEB-1 Cell and HDF 
  A 12 well plate was marked on the outer bottom of the plate to be used as reference  points 
during image acquisition. Marking the well plate can be achieved by numerous methods to 
obtain the same field during the image acquisition. Etching lines lightly with a razor blade on the 
bottom of the dish provides a good reference under the microscope and can be visualized with 
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the naked eye for creating the wound itself.  Matching the images is essential for quantitative 
analysis. 
  The well plate was coated with either fibronectin for fibroblast (EMD Biosciences, Inc. La Jolla 
CA 92039-2087) or collagen for keratinocyte. Fibronectin at concentration of 250 µg was 
dissolved in 250µl of Hank balance salt solution (HBSS) to make 1:1 dilution.  Each of the well 
plate for fibroblast wound assay were coated  with  fibronectin at concentration of 25 µg/Ml and  
the  well plate for Neb-1 cell and keratinocyte wound assay were coated with type I rat collagen 
(150mcg/mL) dissolved in Hank‘s balance salt solution and left overnight in 40C or 2hrs in the 
incubator.  The ECM helps to enhance attachment of the monolayer confluent cells to the plate 
and prevent complete lifting of the cells of the plate. When ready to proceed with the experiment, 
the unbound ECM substrate (fibronectin and Collagen) were aspirated off and incubated for 1h at 
37°C. 
 Sub-confluent cells growing in the T-25 flask were washed once with PBS and re- suspended.  
Trypsin containing versene was added to the re-suspended cells with the complete media, and the 
desired cell counts were determined. Cells were dispersed gently by pipetting and/or rocking the 
well plate before incubation so that cells are distributed equally on the plate. 
 The plates were washed once with PBS and cells were seeded at the following density; HEK and 
Neb-1 cell 600,000 in a 12 well plate and for HDF 90,000 in 24 well plate and the cells were 
allowed to grow to full monolayer confluent. Optimization experiment was previously performed 
to determine the seeding density and the time it takes the different cell types to reach full 
monolayer confluent for the different cell types. 
 After HEK and Neb-1 cell has reached a full confluent, the cells were either treated with 
mitomycin (10µg/ml) or not treated.  The treated plates were incubated for 1hr at 37C 5% C02, 
after incubation the cells were washed thrice with PBS. Mitomycin treatment is believed to 
inhibit ongoing cellular proliferation during wound assay experiment. For human dermal 
fibroblast wound assay, the monolayer was not treated with mitomycin. 
 A vertical wound was manually created by scraping the cell monolayer with a p20 pipette tip. 
The cells were once again washed with PBS thrice to remove detached cell debris from the well.  
The wounds were created relative to the marking/ reference point on the plate.  Fresh media were 
added to the well plates at varying concentrations of PRP (50%, 25%, 10%, 5%) and PPP 
respectively. The control experiment was treated with 1% of the full complement of the 
appropriate media for the different cell types. 
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 Photo-micrographic documentation of the plated cell was taken at time 0 and at 12hrs, 24hrs and 
6hrs intervals or until the gaps was fully closed. The migrated cells were measured and the 
distance migrated were measured by either exporting the image into image J and or Photoshop.  
The artificial gap created at 0hr was compared with the distance left uncovered at the endpoint,  
to calculate the migrated distance. 
 
2.14 Transwell Migration Assay with HEK, NEB-1 cells, HDF and HUVEC 
2.14.1 Cell Migration Assay with Modified Boyden Chamber 
The Boyden chamber assay (Boyden, 1962) was originally introduced by Boyden for the analysis of 
leukocyte chemotaxis is based on a chamber of two medium-filled compartments separated by a 
microporous membrane. Random cell motility is generally described as chemokinesis, which is 
distinguished from directed cell motility toward increasing concentrations of soluble attractants, such 
as growth factors (chemotaxis), or along a concentration gradient of extracellular matrix (ECM) 
proteins for haptotaxis (Carter,1967). 
In general, cells are placed in the upper compartment and are allowed to migrate through the pores of 
the membrane into the lower compartment, in which chemotactic agents are present. After an 
appropriate incubation time, the membrane between the two compartments is fixed and stained, and 
the number of cells that have migrated to the lower side of the membrane is determined. Therefore, 
the Boyden chamber-based cell migration assay has also been called filter membrane migration 
assay, trans-well migration assay, or chemotaxis assay.  Alternatively, the assay is left for a long 
period and cell that migrated to the bottom of the lower chambers were quantify by the method 
described above. The method described in this research was intended specifically for measuring the 
migration of HEK/Neb-1, HDF and HUVEC/EA.hys to the bottom of lower chamber using a 24-well 
transwell insert after a given time interval 24 hrs 
 
2.14.2 Transwell Methodology 
The cell types are grown to 70%- 80% confluent (log phase of cell growth) in readiness for the 
experiment. The protocol previously described by Boyden et.al 1962, was slightly modified because 
of the peculiarity of the different cell type (Figure 2.2).  The transwell permeable support from 
Corning life science (900, Chelmsford St. Lowell, MA 01851) was used, which has 24 well plates 
with 12 transwell insert, with 8.0 μm micropore, growth surface area of 0.33cm2 and membrane 
diameter 6.mm, made with polycarbonate material.  
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The cells were seeded at 100,000/well for HEK and Neb-1 cell line, fibroblast 50,000/well and 
HUVEC/ EA. Hys at 10,000/ well. The cells were trypisinzed with trypsin-EDTA to allow the cells 
to remain unbound during the migration process and prevent the cells clumping together.  The cells 
were later re-suspended in a media appropriate for the cell type in ration 1:1.  Cells seeded at a 
volume of 100 - 200μl per insert.  A separate well plate without filter was used as the control 
experiment with equal density/volume of cell in the well treated with DMEM with FCS 1%. Varying 
concentration of PRP (PRP 50%, 25%, 10%, PRP), PPP and control were used for the repeat 
experiments and as appropriate for the different cell types.   
The cells were left to migrate in the incubator over varying period of 6-24hrs. An early experiment 
performed to optimize the protocol with varying cell density (40,000-400,000 cells) and migrating 
time showed the following results;   the maximum migration time was 24hrs and the cell density for 
HEK and Neb-1 (100,000/insert), HDF (50,000/insert) and HUVEC/ EA.hys cell (10,000/insert).All 
experiments were performance in triplicate.  
After the end of experiment, the insert was removed; the non- migrated cells left on the membrane 
were removed with moist cotton wool.  The cells that have migrated to the bottom of the well plate  
and the well-plate without the filter (positive control) were treated with Alamar blue which is 10% of 
the total volume of the treatment concentration. This was incubated for 16hrs and the 10% of the 
total volume with Alamar blue was measured in a 96 well plate (VWR, international) reader at 
570nm.  Experimental repeats were carried out in triplicate. 
Cells passing
through  filter 
pores
Polycarbonate 
Filter
Upper 
compartment 
with cells and 
medium
Lower 
compartment 
with chemo-
attractant
Polycarbonate filter 
with pores
Modified Boyden Chamber
Upper compartment
Lower compartment
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Figure 2.1 A diagrammatic illustration of the modified Boyden Chamber used in this experiment 
for transwell migration assay. The far left showed the insert seeded with cells (upper chamber) and 
the lower chamber containing the specific media. The far right showed the mode of cells 
transmigration through the membrane pores. 
 
A separate well-plate was seeded with the same initial cell density that was seeded into the upper 
chamber insert, which serve as the positive control, the cells in this well-plate was equally measured 
with AB technique. 
 % Cell migrated per well = Average fluorescence/ absorbance in treated well with filter   X 100 
                                                   Average Fluorescence/ absorbance in well without the filter 
Besides measuring the metabolic cell activity through AB technique, the cells that migrated to 
bottom of the well-plate were stained and counted manually under HPF with light microscope ( 
Figure 2.4) . To find the % of the migrated cell, the total migrated stained cell at the bottom of well-
plate was divided by the total original cell density which was represented by the cells in the positive 
control well plate.   
Percentage Cell migration =   Total number of stained migrated cell   x100 
                                               Total original cell density (positive control) 
2.14.3 Preparation of PFA and Methyl blue for Staining 
Eight gram of sterile of Para formaldehyde (PFA) 4% (manufacturer) was weighed and 80mL of 
2Molar of Sodium hydroxide was prepared.  The Para formaldehyde (PFA) was stored in -4
0
C after 
preparation. Distil water (180ml) was boiled to boiling point, and the prepared PFA was mixed with 
the boiled distil water in the fume hood, which was followed by the addition of 50mL of 10X PBS. 
The pH of the mixture was adjusted until a pH of 7.4 was obtained by using the pH reader.  0. 2% 
(weight for volume) of methyl blue (Sigma, UK) (0.2g) was weighed in a sterile condition.  3.23g of 
sodium acetate (0.4M) was dissolved in 100mL of distil water, 0.4M of sodium acetic acid (2.3mL 
was dissolved in 97.7mL of distil water) Sodium acetate and sodium acetic acid were prepared in 
100mL solution. 50mL from each solution was mixed together with 0.2g of methyl blue; methyl blue 
was stored in room temperature after preparation. 
PFA (400µl) was added to the migrated cells at the bottom of the well or the membrane in fresh well 
well-plate; the well-plate was left in the incubator for 10-12minutes and was washed 3 times with 
PBS. After incubating, 500µl of methyl blue was added to the well after washing and left on the 
bench for another 4-6minute and the methyl blue was washed off gently under running tape. The 
  
 
 
78 
well-plate was left to air dry and then examined under an inverted microscope at x20 high power 
field. 
 
 2.14.3.1 Staining Technique for Membrane and Cells in Well-Plate 
  A damp cotton swab was used to wipe the un-migrated cells from the top of the membrane.  The 
insert with the membrane was dipped into the freshly prepared 4% Para formaldhyde for 15-20 
min to fix the cell, and washed thrice in x1 PBS, with the side of the membrane with the 
migrated cells facing down. The insert with the fixed membrane was dipped in methyl blue (the 
side with migrated cells facing down) for another 5 min. The membrane de-stained by briefly 
rinsing it in x1 PBS.  The excess PBS is drained from the membrane and place (the side with 
migrated cells facing down) on the Petri dish cover.  
  The membrane was cut off from the insert and attached to the slide with a little amount of nail 
polish to a glass slide (super frost, VW international, UK) and was covered   with a cover slip 
(32 × 24 mm). Another method employed in analysing the migrated cells, was to stain the 
migrated cells at the bottom of the lower chamber with the same method described above. 
 Surveying the stained membrane under a light microscope at 20x and 40x magnification and 
selecting at least three wells for each experimental group on which the migrated cells are well 
stained and evenly distributed was an option. Counting the individual cells at the bottom of the 
lower chambers was easier and easily quantifiable under high power field of x10 or x20. There 
was no mistaking membrane pores for migrated cells, which was a common mistake with 
keratinocyte and Neb-1 cell. Micrographs are taken using a digital camera (Nikon 
COOLPIX995) connected to the microscope at 20x magnification and the cells were counted by 
moving the microscope in 5 times randomly and the average was calculated.  
2.14. 4 Quantification of Transwell Assay 
Another method employed in quantifying the amount of migrated cell was based on principle that not 
all the cells will transmigrate to the bottom of the well, because of the attachment property of the 
polycarbonated membrane.  Some of the cell will attach to the under surface of the membrane and 
these cells could potentially be fixed, stained and counted. At the end of the transmigration period of 
24hrs, the upper chamber (surface) of the transwell insert was cleaned with moist cotton wool, which 
helps to remove non-migrated cells.  The membrane was turned over so that the under surface was 
now facing upwards and membrane was fixed and stained as per the cell fixing and staining protocol 
(See section 2.14.3.1). After fixing and staining the membrane, the membrane was then gently 
placed unto a super frost plus slide (VWR international); a drop of dePex mounting medium (VWR 
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international) was applied to fix the membrane.  The slide was reviewed under HPF light microscope 
and the stained cells were calculated randomly in 5 places to determine the average cell migrated. 
The cellular clusters formed makes counting of individual cell practically difficult (Figure 2.3). For 
the purpose of this research, the method of quantifying the cell at the bottom of the well plate 
through AB technique was favoured over the other 2 above described methods. This was because the 
AB method provides a more reliable, accurate and reproducible quantifying method and more 
importantly the chance of human error in counting is completely eliminated. 
 
          
 
 
 
 
 
 
Fig. 2.3 Photomicrograph of stained migrated cells on the undersurfaced of transwell 
membrane  at x20 (A) HDF cells formed clusters of cell (B) HUVEC also formed complex cellular 
network.  Cells are in densed network, distinct from the uniformed size membrane pores.  Manual 
counting of individual cell was not possible because of cell clustering  
 
                   
Figure 2.4  Photomicrograph of cells fixed with PFA and methylblue at the bottom of well-
plate. (A) HDF at the bottom of the lower chamber (not transwell migrated) . (B) Transwell migrated 
HDF with a change in morphology. 
 
A B 
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2.15.   Endothelial Angiogenesis 
Angiogenesis, or neo-vascularization, is the process of generating new blood vessels derived as 
extensions from the existing vasculature (Auerbach and Auerbach, 1994). The principal cells 
involved are endothelial cells, which line all blood vessels and constitute virtually the entirety of 
capillaries. New blood vessels are formed by vasculogenesis or angiogenesis; vasculogenesis is the 
process of vessel formation from mesodermal-derived endothelial cells precursors called angioblast, 
and angiogenesis is remodelling from the primary plexus in the embryo or from pre-existing 
vasculature (Risau, 1997). Remodelling and pruning process are common to angiogenesis and 
vasculaogensis during embryonic development; both events are poorly understood but involved the 
growth of new vessels and regression of others. In adult mammals, physiological angiogenesis takes 
place only during wound healing and in the  female reproductive cycle; its nonetheless has a crucial 
role in pathological processes, such malignant tumour growth (Meier et al., 2000).  
 
To achieve new blood vessel formation, endothelial cells must first escape from their stable location 
by breaking through the basement membrane. Once this is achieved, endothelial cells migrate toward 
an angiogenic stimulus such as might be released from tumour cells, activated lymphocytes, or 
wound-associated macrophages. Behind this migrating front, endothelial cells proliferate to provide 
the necessary number of cells for making a new vessel. Subsequent to this proliferation, the new 
outgrowth of endothelial cells needs to reorganize into a patent three-dimensionally tubular structure. 
Each of these elements, basement membrane disruption, cell migration, cell proliferation, and tube 
formation, can be a target for intervention, and each can be tested in vitro. ((Auerbach and Auerbach, 
1994). 
The central mechanism of angiogenesis involves migration of endothelial cell, vascular tube 
formation, proteolytic digestion of extracellular matrix, cellular proliferation and connecting of 
newly formed channels with resultant new vessel formation (Risau, 1997). New insight into specific 
steps involved in angiogenesis has fostered the development of variety of models  in in vivo and in 
vitro assay, this tools have been instrumental in the development of quantitative methods of assessing 
efficacy of therapeutic agents that either up-regulate or down-regulate specific angiogenic  
mechanism (Auerbach et al., 2003). Angiogenesis needs to be looked at  from the view point of 
intercellular adhesions of endothelial cells, proliferation and endothelial cellular migration (Nehls 
and Drenckhahn, 1995). Reconstituted basement membrane provides a quick and effective means of 
studying angiogenesis, thereby circumventing the difficulty faced with the use of fibrin and 
collagens.  Matrigel induces endothelial cells to differentiate as evidence by both the morphogical 
changes and by reduction in proliferation. 
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2.15.1 Protocol for Angiogenesis using BD Matrigel
TM
  
 
BD Matrigel
TM 
Matrix Growth Factor Reduced is a solubilised basement membrane preparation 
extracted from Engelbreth-Holm Swarm (EHS) muse sarcoma, a tumour rich in extracellular matrix 
protein, purchased from BD Bioscience (OakPark, Bedford, MA 01730). Its major component is 
laminin, collagen IV, heparin sulphate proteoglycans, entacin nidogen (Kleinman et.al 1982). BD 
Matrigel Matrix Growth Factor Reduced also contains TGF-Beta, epidermal growth factor (EGF), 
insulin-growth factor (IGF), fibroblast growth factor (FGF), tissue plasminogen activator (Kleinman 
et.al 1986) and other growth factors which occurred naturally in EHS tumours. BD Matrigel reduced 
growth factor provides the substrate necessary for the study of angiogenesis both in vivo and in vitro 
(Vukicevic, 1992). BD Matrigel Matrix Growth factor Reduced was developed to enable 
reconstitution of basement membrane preparation purified and characterized to a greater extent than 
BD Matrigel Matrix. The method of preparation effectively reduced the level of a variety of growth 
factors except for TGF-beta which may be bound to collagen IV. The major components: laminin, 
collagen IV and entactin are conserved by the process whilst heparin sulphate proteoglycan is 
reduced by 40-50%. The table below compares the level of growth factors in the reduced BD 
Matrigel Matrix to BD Matrigel Matrix. 
 
   BD Matrigel Matrix Growth Factor Reduced may show colour variation, in frozen state  
     (straw yellow colour) or thaw (dark red ) , this is due to the interaction of carbon dioxide with  
     the bicarbonate buffer and phenol red , this variation does not affect product efficacy and it  
     disappear upon equilibration with 5% CO
2  
. 
 
 BD matrigel was allowed to thaw overnight on 40C ice. After thawing, the vial was kept on 
ice in a sterile tissue culture hood. For the purpose of my experiment, the original BD 
Matrigel (10mL) was diluted with serum free DMEM media in a ratio 1: 3, to make a total of 
30ml of BD Matrigel.  Two millimetre of reconstituted BD Matrigel was aliquot into pre-
cooled eppendoff, using a pre-cooled pipette and stored in -20
0
C to avoid repeated process of 
thawing. 
 
 A 24-well plate was pre-cooled for optimisation at -200c and the plate was kept on ice during 
the coating process. Wells required for experiment were coated with BD matrigel whilst the 
plate was on ice. The BD matrigel was mixed to homogeneity and suspended gently into the 
plate to prevent bubble formation, 175µL of BD Matrigel / cm
2
 of growth surface; for  
example  a 24 well-plate  has a  growth surface area of  is 2cm
2
, which makes a total of 
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350µL/ well. The well plate was placed in the incubator at 37
0
C for 40minute, which allows 
for gel polymerization. 
 
  Whilst the matrigel coated plate incubates, cultured HUVEC were trypsinized and counted 
according to earlier described protocol. An initial experiment was initially carried out to 
determine the optimal seeding density for subsequent experiments. HUVEC were seeded at 
varying densities of 50,000, 100,000,150,000 and 200,000 / well-plate. 
 
 The cells were suspended in 400 µL of media and additional 400 µL of EGM-2 was added to 
each well. The experiment was carried out in triplicate. The plate was then incubated 37
0 
C 
with 5% CO2.  The plates were examined at 6hrs, 12hrs, and 24hrs and 36hrs interval 
respectively to determine the optimal time for the experiment. Photographs were taken at this 
time point for documentation and a comparison of the morphological changes at different 
time point was made. 
 
 After optimization, the best result was obtained with 200,000 cells per well-plate after 36hrs. 
Subsequent repeat experiments were repeated in triplicates using full complement 1% EGM-
2 as the positive control (which basically represents reconstituted EGM-2; which means a  
reduction in the recommended 10ml fetal calf serum(FCS) to 1ml and  all the growth factors 
supplement which form part of a full EGM-2 complement were added (VEGF, R3-IGF-1, 
hFGF-B and h-EGF). This represents reconstituted 1% EGM-2. The 1% EMG-2 has been 
previously tested with HUVEC proliferation and the HUVEC cells survived in this media for 
5 days, before apoptosis sets in. 
 
 Other experimental repeats were conducted with PRP 50%. PRP 25%, PRP 10%, PRP 5% 
and PPP respectively. In this case, only the endothelia cell basal medium was used as the 
tissue culture media without the growth factor supplement. The PRP was reconstituted at 
50%, 25%, 10% and 5% volume/ volume of the endothelia cell basal medium. On the other 
hand PPP was reconstituted has 50% (v/v) of the endothelial cell basal medium. 
 
 The end point was set at 36hrs, after the time, the media and the gel in the well were 
aspirated off and the HUVEC which have been confirmed to form angiogenetic pattern were 
stained with method using paraformaldehyde and methlyene-blue (see 2.14.3 for the details 
of the staining technique). This allows for easy visualization of the cellular network pattern 
and more appropriate quantification.  
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Parameter BD Matrigel Matrix BD Matrigel Matrix 
Growth Factor Reduced 
bFGF(pg/ml)
4
                  0-0.1              0-0.1 
EGF (ng/ml)                  0.5-1.3              <0.5 
IGF-1(ng/ml)                 15.6                  5 
PDGF(pg/ml                  12                <5 
NGF(ng/ml)                 <0.2               <0.2 
TGF-beta (ng/ml)                   2.3                 1.7 
%Protein that gels                   80                  83 
                Table 2. 4. Comparing the levels of growth factors available in BD matrigel with BD  
                                  matrix growth factor reduced. Table excerpt from the BD science 
2.15.2 Angiogenesis Assay using Collagen  
 
Collagen is a fibrous protein that consists of three α-chains which can combine to form a rope like 
triple helix, proving tensile strength to the extracellular matrix. The chains contain GXY repeats: 
glycine (G) is a small amino acid that fits well with the triple helix. X and the Y are typically proline 
and hydroxyproline, which is critical for collagen stability. Type I (most common fibrillary collagen 
90%) is found in most tissue and organs, but most abundant in dermis, tendon and bones other 
connective tissue. Type 1 molecule is heterotrimer (alpha1 and alpha2) of 300nm length being 
composed of two alpha1 chains and one alpha 2 chains. Collagen binding intergrin receptors are α1β1, 
α2β1, and α3β1.  Collagen facilitates in vitro cell culture adaptation and enhances expression of cell-
specific morphology and function, when used as a gel. Other use includes promotion of attachment, 
tumour cell invasion and migration, fibrillogeneis studies and autographic studies of granulocytes 
and macrophages.  
2.15.2.1 Preparation of Collagen Gel for Angiogenesis Assay 
The angiogenesis model based on rat tail collagen type I (BD Biosciences Two Oak Park, Bedford, 
MA) was used after optimisation of the protocol. The original total concentration of the collagen was 
2.14mg/ml (Volume of 100ml). To determine the volume of collagen 1 needed, a sterile 10X 
phosphate buffer (PBS), sterile distilled water (dH2O) and sterile 1 molar of NaOH2 on ice were 
equally prepared. The recommended volume of collagen to produce a firm gel is 4mg/ml. The 
Following equation was employed to determine the concentrations of dH2O, PBS, NaOH and 
collagen required for the experiment. 
Volume of dH2O needed (V4) = Total volume (V) - (V1+V2+V3)  
Volume of collagen needed (V1) = (Final concentration of collagen x total volume) 
Initial concentration of collagen 
Volume of 10xPBS needed (V2) = Total Volume (V)  
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                                                         10 
Volume of 1M NaOH needed (V3) = Final volume of collagen needed (V1) x 0.0025 
 
 After determining the individual volume needed for dH2O, the 1 molar NaOH2 and PBS x10 
is mixed in a sterile tube. Collagen is slowly pipette into this mixture and mixed well, pH of 
7 was the optimal pH desired to produce the perfect gel, this was ensued by checking with a 
pH meter, this was titrated with a base or acid to achieve the desired pH. 
         
 After sub-culturing and determining the needed cell density, 2x105 of HUVEC were 
suspended in 100 µL of EGM-2 and 212µL collagen on a 24 well- plate, this was allowed to 
polymerize in an incubator for 40minute at 37
0
C of 5% CO2. After the incubation period, 1% 
EPES –BSS (6 µL) was added to 282µL of EGM-2, which was then added to the mixture of 
HUVEC and collagen gel. 
 
 The positive control for the experiment was carried out using full complement EMG-2; the 
negative control was done using varying concentration of DMSO at 1% and 5% respectively 
as substitute for HEPES-BSS.  The assay was also tested with varying concentration of PRP 
at 10%, 25% and50% respectively, 1% reconstituted EMG-2 for the control experiment ( a 
similar concentration was used  as earlier described for matrigel angiogenesis  assay). 
 
 The experiment was monitored over 7 days, but the plates were inspected daily for the 
formation of capillary network formation. Once satisfactory capillary network was formed 
the experiment was discontinued and the same protocol employed for fixing and staining the 
capillary network in matrigel BD was employed. 
2.15.3 Analysis of Angiogenesis Assay based on Morphometeric and Topological Parameters 
 
Following the completion of the angiogenesis assay, the cultured cells where fixed in 
araformaldhyde (PFA) and stained with methylene blue and which allows for a contrasting back 
ground. The phase-contrast images of the endothelial cell cultures were captured using a reverted 
phase –contract light microscope connected to a KS-300 system (Zeiss) at x10, and saved as JPEG 
files. This software allowed a control of the bright field illumination of the microscope to acquire 
images of comparable mean brightness. These images were processed and analyzed using computer-
assisted image analysis software KS400 (Zeiss), on a customized written macro designed program 
specifically for this study. The steps involved in processing the captured images are as follows: 
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1. A gradient detection algorithm was applied to the image; this was for enhancing the edges in an 
image. It produces a black & white image that has dark areas where the original image has smooth 
areas, and light areas where the original image has areas of rapidly varying intensity (particularly the 
near edges). 
 
2. Binary thresholding was achieved by selecting pixels of a given intensity in each of the three ( Red, 
Green and Blue) RGB color components.  Thresholding was intended to reduce the vast information 
content of a coloured or gray-scale image, while at the same time ensuring that the features of 
interest remain recognizable. The threshold levels are set in such a way that the features of interest 
are assigned to ―on‖ (or white) pixels in a binary image, while assigning all other pixels (the 
background) that are deemed to lack specimen information to the ―off‖ (or black) state. It allowed a 
good identification of the cell profiles present in the field.  A single set of threshold levels was 
selected interactively and then applied to all other images because they were captured under identical 
conditions. In order to remove artefacts from the resulting binary images as well as profiles 
corresponding to isolate inactivated cells, a geometric filter was applied, selecting only thresholded 
regions with an area greater than 400 pixels and circularity (Russ, 1995) less than 0.6. This process 
produced a network of tubules and interconnected cell clusters. 
 
3.  Furthermore, with the use of binary thinning procedures, the networks were skeletonised and pruned 
to remove small artefactual branches (Seul, et al., 2002). Skeletonization is a process for reducing 
foreground regions in a binary image to a skeletal remnant that largely preserves the extent and 
connectivity of the original region while throwing away most of the original foreground pixels.  
Skeletonization is the morphological thinning that successively erodes away pixels from the 
boundary until all that remains is line segments one pixel in thickness (Figure 2.5). 
 
4. The endothelial cell organisation was characterised by measuring the following variables; percentage 
area covered and the total length of the network. Size parameters are insufficient to fully characterize 
the complex pattern of endothelial cell network formation. The binary profiles of very similar size 
can be structurally quite different and create a different spatial texture. 
 
5.  Additional topological analysis of the skeletonised binary images was performed to identify 
branching points (nodes) and cellular area  in the zones image surrounded on all sides by 
skeletonised lines. Nodes are located by simply locating pixels of the skeleton with more than two 
neighbours (Russ, 1995). The meshes are identified by algorithms which eliminates area touching 
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one or more sides of the image (Seul et al, 2000). The number of nodes and meshes per field were 
determined. 
              
             Final capillary network          Binary threshold image           cellular network 
 
                                                  
    
 
 
 
 
 
                      Skeletinised   image             Total mesh area                 Superimposed skeletal  
           
 
 
 
 
 
             
 Figure 2.5 Steps involved in the processing of a final photodocumented HUVEC angiogenesis 
assay image. The image was processed by the KS400 Marco soft programme, which seperates the 
image into different components and allows for easy quantification.  
 
 2.16 Immunoassay Quantification 
 
Growths factors can be quantified by using bio-immunoassay techniques that allow for accurate 
measurement of the specific growth factor. In this study we employed the use of solid phase 
immunoassay technique (Luminex Xmap) and ELISA (Enzyme linked immunoabsorbent assay 
technique) in measuring growths from PRP/ PPP. The two techniques operates on very similar 
principles, however Luminex has an advantage over the traditional ELISA method. Luminex has the 
capacity of performing a variety of bioassays on the surface of fluorescent-coded beads known as 
microspheres. It also has the advantage of reducing time, labour and costs over the traditional 
method.   
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2.16. 1 Principle of ELISA Assay 
 
This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal 
antibody specific for the growth factor of interest has been pre-coated onto a micro-plate. Standards 
and samples diluent are pipetted into the wells and any proportion of the specific growth factor 
present is bound by the immobilized antibody. After washing away any unbound substances, an 
enzyme-linked polyclonal antibody specific for the growth factor of interest was added to the wells. 
Following a wash to remove any unbound antibody-enzyme reagent, substrate solutions were added 
to the wells and a colour develops in proportion to the amount of the specific growth factor bound in 
the initial step. The colour development was stopped and the intensity of the colour was measured 
through a microplate reader, the optical density obtained by measuring the wave length of the colour 
change was used in plotting the standard curve which helps in the determining the final 
concentrations. 
2.16. 2 ELISA Methodology 
 
1. All reagents are brought to room temperature before use.  All samples, standards and controls are 
assayed in duplicate. All reagents, working standards, wash buffers and samples were prepared 
according to manufacturers‘ instructions before this stage. The procedure described in this thesis was 
according to the manufacturer instructions- (R&D Systems, 614 McKinley Place NE Minneapolis, 
MN 55413 United States of America). 
 
2.  After mixing the diluents properly, 100 μL was added to each. This was followed by the addition 
of 100 μL of Standard, control, or sample to each well per well and the well was covered with 
adhesive strip. The well was incubated for between 2-3 hours depending on the manufacturer 
instruction for the particular growth factor. 
 
3.   Each well was aspirated and washed, this process was repeated thrice for a total of four washes. 
Each well was washed with 400 μL wash buffer using a squirt bottle. Complete removal of liquid at 
each step is essential to good performance. After the last wash, any remaining wash buffer was 
removed by aspirating or decanting. The plate was later inverted and blotted against a clean paper 
towels. 
 
4.  Detection antibody (specific growth factor conjugate) at 200μL  was added to each well.  The well 
was covered with a new adhesive strip and incubated for 1 hour at room temperature. After 
incubation aspiration/wash process was repeated again as described above. 
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5.  Substrate solution of 200μL  was added to each well, at this stage the wells are photosensitive, 
and hence they are protected from light with aluminium foil, the well was further incubated yet 
another 30 minutes at room temperature. Furthermore, a 50μL of stop solution was added to each 
well, at this stage a colour change was noticed in the well, this colour depends on the specific growth 
factor been assay. If no uniform colour occurs,  the plate was tapped gently to ensure thorough 
mixing. 
 
6.  The optical density of each well was determined within 30 minutes, using a microplate reader set 
to 540 nm and 450 nm. By subtracting the readings at 450 nm from 540 nm, the optical imperfection 
in the plate was corrected. The optical density was sued to plot the standard curves from which the 
concentration of the growth factor was derived. 
 
2.17 Principle of Luminex ® Xmap 
 
Milliplex is based on the principles of luminex technology. Luminex uses proprietary techniques to 
internally colour code microspheres with two fluorescent dyes. Through the precise concentration of 
these dyes, 100 distinctly coloured bead sets can be created, each of which is coated with a specific 
capture antibody.  The capability of adding multiple conjugated beads to each sample, results in the 
ability to obtain multiple results from each sample. This technique enables multiplexing of many 
types of bioassays, reduces time, labour and cost over the traditional methods of immunoassay. 
After an analyte from a test sample is captured by the bead, a biotinlylated detection antibody is 
introduced. The reaction mixture is then incubated with Streptavidin-PE conjugate, the reporter 
molecule, to complete the reaction on the surface of each microsphere.  The microspheres pass 
rapidly through a laser which excites the internal dyes marking the microspheres set. A second laser 
excited PE, the florescent dye on the reporter molecule. Finally, high speed digital-signal processors 
identify each individual microsphere and quantify the results of its bioassay based on fluorescent 
reporter signals (www.millpore.com/techilibrary/index.do)  
Briefly standards of known concentration and PRP/PPP samples were added to a microwell plate 
with an antibody against each factor. Any growth factor present was bound by the immobilized 
receptor. After any unbound substances were rinsed away, an enzyme-linked polyclonal antibody 
specific for each growth factor was added to the wells. After a second wash, a substrate solution was 
added, and the colour developed in proportion to the amount of bound growth factor in the first step. 
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The colour development was stopped, and the intensity of the colour was measured by running the 
plates on the Luminex 100
TM
 and the median fluorescent intensity data obtained was analysed.  
Samples were initially diluted 1:10 in assay buffer, and retested at higher dilutions if the median 
fluorescent intensity (MFI) was higher than the value of the top standard.  Samples were diluted 
1:100 for these assays in the kit diluents.  The concentrations of TGF-β1, EGF, VEGF, FGF-2, 
PDGF-AA and TGF-β1 were measured with the MILLPLEX TM MAP kit.  All samples were tested 
in duplicate. Manufacturer‘s control was available and run and was found to fall in the range 
indicated for the kit. Standards and samples were assayed in duplicate, and mean values were 
calculated. The results were multiplied by the dilution factor applied to the samples. 
2.18 Study Design for the Clinical Pilot Study 
2.18.1 Study Design 
The study was conducted at the Royal London Hospital between May 2008 and May 2009, in 
accordance with the Declaration of Helsinki.  Ethical approval was obtained from the City and East 
London research and ethic committee, with 08/H0704/17.  Informed written consent was obtained 
from each patient before entry to the study.  
2.18.2 Patient Recruitment Process 
Diabetic patients were recruited from diabetic and vascular clinics at the Royal London Hospital, 
Mile End Diabetic Clinic, and Newham Healthcare Services, as approved by a central office for 
National Research Ethic Service (NRES). Patients were provided with a full explanation of the 
nature, purpose and requirement of the study including information sheets and informed consents 
forms. Patients were invited to participate in a screening evaluation, which will include a medical 
history, physical examination of the ulcer and the affected limb, and blood tests. Results of the 
screening evaluation will determine eligibility for entry into the study.  Patients with active wound 
infection were treated by surgical debridement. Surgical debridement helps to  reduce the bacterial 
load, remove necrotic tissue  and ultimately convert chronic wound to acute wound and provide an 
environment were autologous derived platelet rich plasma gel could be effectively apply. 
2.18.3 Pilot Study Design 
In the pilot study, five patients were to be recruited into the treatment and control group alike, which 
should be sufficient to establish our hypothesis. The patients will be randomly assigned to either 
Active or Placebo treatment. The active agent was platelet rich plasma and the placebo is platelet 
poor plasma. The platelet gels are topically applied to the wounds, which will be followed by the 
trust conventional dressing protocol, moist dressing is preferred to prevent the gel from been 
absorbed into the dressing material (see Appendix for wound dressing protocol). At the end of the 
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study, patients with non-healing wounds were returned to routine clinical care and best wound care 
practice.  However, we could not recruit sufficient patients into different arms as planned, 7 patients 
were recruited in total, 1 dropped out at the end of week 3 week and the other dropped out at 5 week 
because of wound sepsis and a definitive treatment to save the patient‘s life was implemented. After 
the initial surgical wound debridement, punch wound biopsy (6mm) was taken before treatment. 
Accurate wound measurement was taken with the aid of a tracing planimetry and also a photographic 
documentation of the wound size before commencing treatment. Photo-documentation to determine 
the rate of wound closure was taken during each clinic visit.  
2.18.3.1 Inclusion Criteria  
In order to be eligible to enter the study, patients must meet the following criteria. 
     A patient with documented Type І or Type ІІ diabetes mellitus of not less than 2 years duration. 
 
    Only patients that are on pharmacotherapy treatment for diabetes mellitus 
 
    Only one ulcer on the foot of the Lower limb  
 
    The ulcer should have a surface area of between   2cm2 – 40cm2 . 
 
    The treatment is specific to clinically non-infected full thickness wounds 
 
    Ulcer present for a minimum of 4 weeks or more  
 
    Wounds extending through the dermis and may involve tendon, muscle or bone   
 
   The wound must have failed to respond to intensive conventional treatment. 
 
   The patient should be competent to give consent and have an appropriate support system to  
  facilitate his/her full participation in the follow-up care associated with the treatment of the wound. 
 
   An ankle brachial pressure index value of ≥ 0.8 
 
2.18.3.2 Exclusion Criteria 
 Patients with clinical evidence of platelet dysfunction and thrombocytopenia < 100,000.  
 
 Patients with documented malignant disease and connective tissues disease. 
 
 Patients with who are not ambulant from other reason other than the poor mobility due to the ulcer, 
except inpatients, will not be included. 
 
 Any other significant pathology, which might impair healing other than diabetes such as end stage 
renal impairment. 
 
  
 
 
91 
 Patients with clinically documented Hepatitis B & C infection and HIV. 
 
 Patients with documented MRSA in wound infections. 
 
 Patients with poor prognosis associated with other disease processes. 
 
 
 Ulcers from any cause other than diabetes will be excluded such as pressure sore. 
 
2. 18.3 3   Patients 
Patients with one ulcer on the foot were enrolled into the study from recruitment from vascular clinic 
or diabetic foot health clinic. The diabetic foot ulcers were classified according to the American 
Diabetic Association. Patients who fit with entry and exclusion criteria were treated. All patients had 
surgical wound debridement before been treated. Patient that require admission were admitted on the 
ward and input of the diabetologist were employed in glycaemia control. Concomitant medications 
for other illnesses were continued.  Patients were followed up in vascular clinic after the first 
treatment at regular interval.  During follow up digital photograph of the wound and computerised 
planimetry (Smithkline, see section on material and methodology for details on computerised 
planimetry) measurement were taken at every clinic visit.  
 
Patients were initially followed up weekly for the first one month and then bi-weekly until complete 
wound healing is achieved or until 16 weeks. Wound biopsy was taken from the wound margin after 
the initial debridement on day 0 and subsequently at day 8, week 4 and week 8. The biopsy samples 
are preserved in formalin saline or snap frozen in liquid nitrogen. The inclusion and exclusion 
criteria have been discussed under materials and methodology.  
 2.18.3.4 Ulcers  
The ulcers were adequately described and characterised with respect to its size, depth, appearance, 
and location, which helps in mapping wound healing progress. After describing the dimensions and 
appearance of the ulcer, the research doctor examined the ulcer by gently probing to detect sinus tract 
formation, undermining of ulcer margins, and involvement of tendon sheaths, bone, or joints.  In 
addition, the existence of odour and exudates, and extent of cellulitis are noted and documented. This 
detailed examination forms the bases for clinical classification of the ulcer.  The vascular status was 
assessed by measuring ankle brachial pressure index (ABPI), which is expected to be between 0.8-1 
in non-ischemic ulcers.  However some of the patients had an element of microvascular disease as 
well as calcification of the vessel, which may give a false ABPI reading.   
The presence of lower limb pulses and capillary refill are routinely documented. However, the 
absence of pedal pulses in the presence of a palpable popliteal pulse is a classic finding in diabetic 
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arterial disease because of the selective involvement of the tibial arteries below the knee in peripheral 
vascular disease. Non-invasive Doppler signals were also used to augment the clinical examination.  
Cultures are taken from purulent drainage or curetted material from the ulcer base. Classification of 
ulcerations can facilitate a logical approach to treatment and aid in the prediction of outcome. In this 
study a standardized Wagner classification was employed. 
2.18.3.5 Classification of Ulcer 
 
Several wound classification systems have been described, based on parameters such as extent of 
infection, neuropathy, ischemia, depth or extent of tissue loss, and location. The most widely 
accepted classification system for diabetic foot ulcers is the Wagner ulcer classification system, 
which is based on the depth of penetration, the presence of osteomyelitis or gangrene, and the extent 
of tissue necrosis. The main drawback of this classification is that, the severity of arterial 
insufficiency can be underestimated. Wagner classified diabetic ulcers as follows: Grade 0 -No open 
lesions; may have deformity or cellulitis; Grade 1- Superficial diabetic ulcer (partial or full 
thickness); Grade 2- Ulcer extension to ligament, tendon, joint capsule, or deep fascia without 
abscess or osteomyelitis; Grade 3- Deep ulcer with abscess, osteomyelitis, or joint sepsis; Grade 4- 
Gangrene localized to a portion of forefoot or heel and Grade 5- Extensive gangrenous involvement 
of the entire foot (Wagner, 1987). Most of the patients recruited into the study had a minimum of 
grade 3 ulcers, which meant that these patients required wound surgical debridement.  
 
2.18.3.6 Wound Debridement 
Wound debridement was carried out under general anaesthesia by the vascular surgeon in charge of 
the patient overall care. A mainstay of ulcer management is debridement of all necrotic, callus, and 
fibrous tissue.  Certain evidence suggests that the best results are obtained with aggressive wound 
debridement, a process which removes senescent fibroblast and pathogens (Steed DL, 1996). 
Necrotic tissues are removed by sharply debriding back to bleeding tissue to allow full visualization 
of the extent of the ulcer and detect underlying abscesses or sinuses. In this study, patients wound 
were debrided and a digital amputation was performed in the presence of gangrene and spreading 
infection.  Patients with grade 2 ulcers had non- surgical wound debridement; this is a form of sharp 
debridement on the non-sensate foot carried in the outpatient clinic. After the debridement, the 
wound was dried with gauze and ready for platelet gel therapy application. 
2.18.4 Technique for Wound Measurement 
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The patients that were recruited for the research had chronic and complex wound. The process or rate 
of wound healing was monitored by physiological and biochemical means but also geometrical 
wound measurement was also employed.  
VISITRAK (Smith &nephew, Healthcare house, Hull, U.K) is a portable digital device that provides 
accurate, reproducible data for tracking wound progress. By providing a standardised approach to 
wound measurement, it promotes best practice in wound management.  This device has 3 
components. 
2.18.4.1 Steps Involved in Measuring Wound with Visitrak. 
 Following wound debridement, the wound was cleaned to dryness, to allow its edges to be 
visible. The white backing layer was removed from the visitrak and the sterile grid was placed 
over the wound. 
 The wound edges were traced with the use of a permanent maker pen. Care was taken to ensure 
that the area remain within the grid area d the visitrak grid film. The perimeter of the viable 
(areas of epithelisation or granulation) or non viable tissue (necrotic or sloughy areas) was traced 
out. The traced out shapes of the wounds are often complex shapes.  
 The contaminated layer of the grid was removed and disposed off.  The transparent grid was then 
transfer to the visitrak digital for reading. Patient identification was inputted unto the visitark 
digital for identification purposes and the area of the wound was displaced as a number in 
centimetre square. 
2.18.4.2VISITRAK Digital  
This is a convenient and portable digital tablet which is easy to handle, provides a quick, convenient 
and accurate area measurement. Once the wound tracing is completed, the device emits an audible 
beep. The immediate default result is the wound area, but other functions are also provided to allow 
calculation of percentage wound area that is necrotic (percentage of the wound that is non viable) and 
width and length measurements. 
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2.18.4.3 VISITRAK Grid   
A tracing film (visitrak grid) has been specially designed as a three-layer pack to minimise the risk of 
cross-contamination and secondary infection. The patient contact layer is sterile, and the clean layer 
was used to record wound measurements which can be stored in patient records. The conformable 
film is easy to draw on and transparent, which makes it easy to see the wound through the film. 
2.18.4.3 VISITRAK Depth  
The disposable depth indicator is a sterile probe, which allows for easy measurement of wound dept 
in millimetres. 
 
                            
Visitrak Grid                            Visitrak digital device           Visitrak depth indicator 
Figure 2.6 visitrak devices for measuring wound area 
2.18.4.4 Advantages of Routine Wound Measurement 
Systematic assessment of a patient's wound is one of the most important means of optimising their 
chances of wound closure. By gathering information about the wound over time, a realistic and 
clearly defined management plan can be agreed upon. It has been shown that early identification of 
wounds that are not responding to treatment ensures the best possible outcome. This is because as the 
treatment regime is re-evaluated, more appropriate interventions can be initiated as necessary.  This 
is particularly relevant to diabetic patient were glycaemic control could be closely monitored, 
treating stenotic lesion in the lower limb vessel runs The more accurate the rate of wound healing is 
documented, the faster non-responsive wounds will be identified. There is now considerable 
published evidence that suggest that accurate percentage reduction in wound area is a useful 
measurement within the first few weeks of treatment, specifically, a percentage area reduction of less 
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than 20-40% over the first two to four weeks is a reasonable indicator that the wound is showing a 
poor response to the treatment. 
Visitrak has a number of benefits, including accuracy, flexibility, simplicity and reassurance. There 
are many methods of tracking wound progress. These include length and width measurement and 
counting grid squares. However, the most accurate method is to measure changes in precise wound 
area (www.Smith-nephew.com). 
2.18. 5 Protocol for Wound Care 
After treating the patient‘s ulcer according to APG treatment protocol (See appendix and chapter 6) 
the patients were encouraged to wear an offloading orthosis walker (medis shoe) to enhance easy 
mobility and pressure offloading after treatment. Some of the patients were followed up in the 
podiatry foot clinic; this was to ensure patient compliance and to allow for repeated non-surgical 
debridement. 
For the purpose of this research, biological wound dressing agents or devices that could aid wound 
healing were not used for wound dressing (See wound dressing protocol in Appendix 5). Wounds 
were initially inspected weekly for the first month and then bi-weekly until complete wound closure 
was achieved. Wounds with poor clinical signs of healing might require early re-application of 
platelet gel as recommended by the research doctor. Wound dressing will only be changed 5 days 
after the first application of the treatment except when otherwise stated. The second treatment will 
only be done 14 days after initial treatment when indicated. The second course of treatment may be 
carried out before day 14 only when otherwise stated by the research clinician. The size of the wound 
was serially monitored until complete wound closure or treatment is deemed to have failed (end of 
treatment which was stipulated as 16 weeks of follow up). The decision to perform further wound 
dedridement and platelet gel application after the first treatment depends on the clinical response 
elicited from the wound and this is decision was only made the research team. 
 
2.18.6 Procotol for Growth factor Measurement  
Six male diabetic patients with chronic foot ulcers, age ranging from 45 to 68 years as well as 
fourteen healthy volunteers (5 female and 9 male), age range of 18- 40 years were recruited. Ethic 
approval was obtained from the East and City of London Research Ethic Committee and informed 
consent was obtained from the volunteers and patient.  Platelet count from the whole blood and 
autologous derived platelet concentrate from the diabetic patients was analyzed. However platelet 
count was not measured in the healthy donors this was because the result obtained from the diabetic 
  
 
 
96 
group provided a template needed. The initial research design was to measure platelet count from 
both the diabetic patients and health volunteers. After the initially analysis of the result from the 
diabetic group, the result showed that the diabetic patient in spite of their other medical  co 
morbidity, they have sufficient thrombocyte count (100,000-300,000/μl), which generated good 
quality platelet gel. In addition, the blood samples collected from the diabetic patients were used to 
validate the concentrating capacity of the point-of-care device used in this study (Angle Sorin).  The 
concentrating ability was found to be adequate and within the manufacturer specific, hence we 
desired not to measure platelets count from the healthy volunteer group. 
Growth factor levels from PRP and PPP in both diabetic patients and healthy donors were measured. 
The following growth factors were analyzed using the traditional ELISA technique; P-seletin, 
Platelet factor 4 and thrombospodin -1 and IGF whilst the remaining GFs were measured using 
multiplex fluorescent immunoassay technique (MFI).  MFI has a few advantages over ELISA in that 
it has increased sensitivity, specificity, better reproducibility.  The GFs measured with ELISA were 
not available on the commercial multiplex kit.  However, in a study conducted by research animal 
diagnostic laboratory (RADIL), they showed a correlation of greater than 99.5% existed between 
MFI and ELISA techniques. 
2.18.6.1 Protocol Amendment  for Voluntary Donation of Blood 
 
The purpose of this amendment is principally to enable compliance with the recent developments and 
guidance of the Human Tissue Act 2004; which has recently come into force. Normally the 
collection of blood for diagnostic, validation and calibration purposes was viewed as outside of the 
Research Ethics Process. Now that assumption is questionable. To ensure compliance we request that 
we are able to recruit a further maximum of twenty Healthy Volunteers (both male and female) 
which comprise of a ―NON-TREATMENT‖ group. They have no ulcer or wound, they will not enter 
the main study and their participation is restricted to the provision of a raw material – fresh blood. A 
stand-alone consent form was prepared for this purpose. Volunteers that have participated or 
planning to participate in another clinical research study judged by the research team as conflicting 
or indicating ―over-volunteering‖  were not recruited into the study. 
2.18.6.2 Inclusion/Exclusion Criteria for Voluntary Blood Donation: 
 Maximum  volunteer needed 20 
 
 Duration of extended cohort and APG study – Completion on 1yr 
 
 Male and Female 
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 Adult – Aged between 18 and 40 years. 
 
 Healthy Volunteer. 
 
 Not on any medication known to have a vasoactive or anti-platelet effect. 
 
 Volume of blood collected 300ml of one occasion. 
 
2.19 Blood collection and Preparation of PRP 
 
This study was approved by the City and East of London Ethic Research committee (08/H0704/17). 
Fourteen healthy volunteers aged 20-45 (mean age, ration of Male: Female) and 6 diabetic patients 
were recruited into the study. The volunteer were informed of the purpose and procedure of the study 
and they were provided with written informed consent. One hundred and fifty millilitre of venous 
blood was taken from each person and was immediately mixed with 30mL of acid-citrate –dextrose 
(Sigma-Aldrich Co. St.Loius MO). The whole blood was processed according to the procedure 
described in Appendix 4 using the Sorin Angel platelet separating system. At the end of the process 
the platelet separating system, separates the whole blood into plasma (platelet poor plasma, the red 
cell and the platelet rich concentrate. Before and after the preparation of PRP, an aliquot was 
removed and the platelets in the whole blood and PRP were counted (using Beckman and Coulter). 
150ml whole blood will yield a harvest of 12-15ml of platelet rich concentrate.  
 
2.19.1 Preparation of Platelet –Rich Plasma  
 
 The PRP was processed in a sterile environment.  Six millimetres anticoagulant citrate dextrose–A 
(ACD-A) solution was drawn into 60-cc syringe, followed by 54 cubic centimetre of whole blood 
drawn from a large antecubital vein.  The acid citrate dextrose serves to preserve the integrity of the 
platelet membrane. The blood was gently agitated by mixing the anticoagulant with the blood. The 
60 ml of blood was injected into the angel system and centrifuged for 25 minute (first hard spin) at 
5200rpm, followed by a soft spin at 3200rpm for another 45 minute. The whole blood was 
sequestered into a semiautomatic controlled operation mode by centrifugation, through the whole 
blood separation processing system (Angel; Sorin Group, Mirandola, Italy), which separates the 
blood into PRP which contains platelet concentrate and leukocyte,  PPP and  erythrocytes. The 
desired end product (PRP) is usually 10% of the starting volume of the whole blood. 
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2.19.2 PRP and PPP Activation    
 
To initiate the release of the GFs from PRP, the platelets have to be activated, using the potent 
platelet activator thrombin.  Human thrombin was generated from a commercial thermogenesis 
which consists of [66% volume for volume of Ethyl Alcohol, U.SP.25 Mm Calcium Chloride U.S.P], 
stored at between 15– 30  C, as a kit called ―Activat‖ [Sorin Group, Mirandola Modena, Italy 41037].  
Thrombin was generated after 12ml of PPP was mixed with the Activat beaded material in a 
pressurized syringe for about 20-25minutes and the thrombin was squeezed out of the syringe, which 
generates a total of 4-6ml.  Autologous thrombin is preferred in the United Kingdom to pre-prepared 
bovine thrombin, which has been implicated in the development of antibodies to clotting factor Va, 
XI and thrombin.  The harvested PRP was combined with thrombin for platelet activation to produce 
the gelatinous material in ratio of 1: 10 [volume/volume].  Similarly, the PPP was activated using the 
thrombin in the same ratio.  Following activation the formed gelatinous material was left in a 15ml 
falcon tube over night at 4  C, this allow for maximum clot retraction (Figure 2.7). The supernatant 
from the gelatinous coagulum is removed after centrifuging for 10min at 3000rmp and was stored at 
-80   C, until GF analysis. The supernatant is much easier to handle when performing the ELISA as 
compared with gelatinous coagulum, hence in our research supernatant was the preferred serum in 
performing immunoassay and in tissue culture assay. 
Retracted clot
PRP Supernatant
Retracted clot
PPP Supernatant
 
Figure 2.7 The separation of the supernatant and retracted clot from the PRP and PPP was 
achieved by leaving the PRP and PPP to stand overnight in a 0-4
0
C refrigerator, followed by 
centrifuging for 3000g for10min before harvesting the supernatant. 
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2.19.3 Haematology Analysis of Whole blood and Platelet –Rich Plasma 
 
Blood samples from diabetic patients (5ml of whole blood and or 3-5ml of inactivated PRP) were 
retained in EDTA bottles and allow mixing properly.  Each sample was counted in triplicate and then 
average (mean +/-SD). Complete blood count was carried out with the Beckman Coulter LH750 
analyzer by the Haematology department of Barts and the London London Hospitals NHS Trust. 
This step was repeated for the platelet-rich plasma samples from the diabetic patient. 
2.19.4  Pitfalls in Autologous Derived Platelet Rich Plasma Gel Production 
 
Centrifugation forms the basis of the current methods for producing platelet-rich plasma. From the 
drawn whole blood, platelet fragmentation should be avoided during this process, which could result 
in the untimely release of high levels of proteins with compromised bioactivity. A large bore 
cannular (17G) is recommended for drawing the blood and possibly from a large anticubital vein 
under no tension. Veno-puncture done under tension could activate the platelet before the 
centrifugation, which may negate the yield. Low gravity force during centrifugation and minimal 
platelet activation should be used.  
 
Despite all the efforts to prevent activation, bioactive secretory proteins could still be produced 
properly, but lost during transferring to the surgical bed. This failure is largely due to the delivery 
technique used. It is important to achieve a good quality gel; the gel serves as a vehicle that delivers 
the secreted proteins to the wound site. It is imperative to safely transfer the gel to the surgical site 
and use it within 10 minutes of its production. Otherwise, the gel will retract and lose the originally 
expressed growth factors (Akingboye et .al, 2010).  It has been reported that the quality and quantity 
of the PRP produced is a function of the quality of the platelet. However, there are other conditions 
that are relatively contraindicated to the use of PRP, such as pre-existing coagulation defects 
(thrombocytopenia, hypofibrinogenemia) or potential hypersensitivity to bovine products (Grant et. 
al, 2005). 
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                                        CHAPTER 3 
Growth Factor Levels in Autologous Derived Platelet–Rich &Plasma and 
Platelet-Poor Plasma; Implication for Tissue    Reparation and  Wound 
Healing 
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3.1 Introduction 
Growth factors (GFs) released from activated platelets is believed to initiate and modulate wound 
healing in both soft and hard tissues.  A recent strategy to promote wound-healing is in the 
application of autologous derived platelet concentrate (APC) suspended in plasma, known as 
platelet–rich plasma.  Platelet-rich plasma (PRP) acts as storage vehicles for GFs.  GFs such as 
PDGF  [AA, AB, and BB], TGF-β 1 &2,   FGF- acid and basic, EGF, IGF and VEGF etc. have been 
identified in the wound healing cascade and are known to influence the process of tissue regeneration 
(Eppley,2004).  PRP has been most used in acute surgical conditions and in the management of 
chronic non- healing wounds (Margolis et.al 2001, Borizin, 2007).  
Point-of-care devices have the ability to fractionate the blood into platelet –poor plasma (PPP), PRP, 
and red blood cells (Weibrich, 2002). The PRP fraction, which is a mixture of concentrated platelets 
and leukocytes, can be activated by autologous thrombin to create a viscous solution known as PRP.  
PRP can be exogenously applied to soft tissue wound, bone or synthetic prosthesis as a spray-on or a 
solid gelatinous mass.  
3.1.1 Biological Effect of Growth Factors in Wound Healing 
 
PRP is believed to promote cell proliferation, differentiation, angiogenesis, chemotaxis, formation of 
extracellular matrix, and the migration of various cells involved in both wound healing and bone 
growth (Everts et. al 2007).  APC offers an easy, cost-effective way to obtain high concentration of 
growth factors for tissue healing and regeneration. Wounding healing is a well –orchestrated and 
complex series of events involving cell-cell and cell-matrix interactions, in which platelet growth 
factors serves as messengers to regulate various processes.  Tissue repair begins with platelet clot 
formation, activation of coagulation cascade and platelet degranulation (Werner, 2003). The GFs 
released bind to specific tyrosine growth factor receptors, which subsequently activate intracellular 
signal transduction pathways (Tabata, 2003). Beyond maintaining haemostasis, the fibrin clot then 
provides a matrix for the migration of tissue- forming cells, notably the fibroblast; responsible for 
collagen synthesis and endothelial cells involved in angiogenesis (Eppley, 2004). Tractional forces 
generated by these migrating cells on the fibrin clot can aid in contraction. These same migrating 
cells are also responsible for remodelling the clot into repair tissue. 
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During normal wound healing, trapped platelets become activated and degranulate, resulting in the 
release of α-granule content.  Release of PDGF into wound bed can have a chemotactic effect on 
monocytes, neutrophils, fibroblast, mesenchymal stem cells and smooth muscle and osteoblast. 
PDGF is a powerful mitogen for fibroblast and smooth muscle cells and is involved in all three 
phases of wound healing, including angiogenesis, collagen formation and wound re-epithelization 
(Eppley, Borzini, 2007) TGF–β is member of the super-family of growth and differentiating factors, 
including bone morphogenetic proteins.  TGF- β is a mitogen for fibroblast, smooth muscle cells, a 
potent mediator of collagen matrix formation and it promotes angiogenesis and extracellular matrix 
production. Another critical component of wound repair is neovascularization- granulation tissue 
formation.   
Presence of VEGF stimulates endothelia cell proliferation and capillary tube formation.  VEGF 
production is amplified in the presence of nitrous oxide, which has an important vasodilatory effect 
on microcirculation (Goldman, 2004). EGF acts as a mitogen for fibroblast, endothelia cells, and 
keratinocyte and is useful in healing chronic wounds. IGF is another platelet-contained growth 
factor, regulating bone homeostasis and modulating of cell apoptosis (Goldman, 2004). Other studies 
have found beneficial clinical outcomes from the use of PRP particular in maxillofacial, periodontal 
and oral surgery (Tawes, 1994; Seikdo, 1987).  Platelet activation during preparation of the platelet 
concentrate can result in early degranulation and loss of GF during the collection process. It is 
therefore critical to recognize that each PRP processing method may differ in regards to platelet 
number, activation and GF expression profile (Kevy, 2001). 
 
3.1.2 Surgical Applications of PRP/PPP 
Clinical trials coming from the use of Recombinant human- PDGF-BB (Beclapermin) reports a 
degree of success following it use in treating diabetic neuropathic ulcers.   Following several clinical 
trials on the efficacy of PDGF-BB, evidence suggests that best result are obtained with PDGF-BB in 
combination with aggressive debridement, a process which removes senescent fibroblast and 
pathogens from chronic wounds (Steed, 2006; Alsousou 2009; Steed, 1996). Autologus derived 
Platelet –rich Plasma has advantage over  single recombinant growth factor, in that, the  combined 
GFs has synergistic effect on each other and promotes mitogenesis of mesenchymal stem cells at the 
wound site (Goldman, 2004). PRP in orthopaedics surgery has yielded positive results in areas of 
cruciate ligament reconstruction, and in trauma involving soft tissue, tendon and ligament injury 
(Everts, 2007 and Alsousou 2009).  
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Recently, a novel PRP application has emerged for morbidly obese patients undergoing bariatric 
surgery. Brady et al., 2006 used PRP via an endoscopic delivery system, after laparoscopic Roux-en 
Y gastric bypass procedure to avoid haemorrhage, infection and anastomotic leaks.  He concluded 
that the use of PRP contributes significantly to wound healing and improved the overall clinical 
outcome.  Autologous fibrin derived from PPP, has been used as a biological sealant during aortic, 
thoracoabdominal- surgery and thoracic surgery as well as patch graft angioplasty. This material 
mimics the final stage in the coagulation cascade (Zhu, 2006). Saratzis et al, 2008; reported the use 
of PRP in endovascular repair of abdominal aortic aneurysm. He conducted a patient- assessor-
blinded controlled trial involving 100 patients, with 50 patients in the treatment group. He reported a 
significantly lower postoperative hospital stay and lower inguinal wound-related complication 
(Tawes, 1994). However, it is unknown whether autologous PRP (or PPP) from patients requiring 
GFs contains level similar to those of the healthy controls. The purpose of this study was to compare 
the levels of growth factors released from PRP from diabetic patients with chronic ulcers as 
compared with healthy donor.  
3.1.3 Physiology of Platelets as it Relates to Wound Healing  
 
Platelets are formed from megakaryocytes and are synthesized from bone marrow by pinching off 
pieces of the cytoplasma.  Platelets are small discoid blood cells, with the average platelet count 
ranging from 1.5–3.0 × 10 −5 /mL of the circulating blood, and with an average half-life of about 7 
days. They have a trilaminar cell membrane with a glycoprotein receptor surface overlying and are 
partially interspersed with a penetrating bilayer of phospholipids and cholesterol. Platelets lack 
nuclei but contain other organelles and structures such as mitochondria, microtubules, lysosomes, 
and granules (α, δ, λ). The cytoplasma contains an open canalicular system that increases the 
effective surface area for intake of stimulatory agonist and the discharge of effectors‘ secretions. The 
dense granules contain adenosine diphosphate adenosine triphosphate, serotonin, and calcium. The 
α-granule contains clotting factors, growth factors, and other proteins. Platelets are normo-
thrombogenic and require a trigger, before they become potent and active in haemostasis and wound 
healing. They are found intravascularly and are concentrated in the spleen.  
 
Hemostasis is the balanced interaction of platelets, endothelia cells, and plasma clotting proteins. 
Platelets are responsible for initiating the immediate and most important step in coagulation. Platelet 
adhesion occurs through the interaction of the damaged vessel wall and exposes the subendothetial 
collagen, which binds with von Willebrand factor, with a resultant change in the platelet structure, 
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thus, making it possible for its adherence to blood vessels.  This effect is accomplished through the 
activities of glycoprotein 1b, and 11b/111a receptors on the platelet membrane. After aggregation, 
the granular contents are then released; serotonin probably assists with vasoconstriction. Adenosine 
diphosphate (ADP) promotes release of granules, which further encourages platelets aggregation. 
Phospholipase A2, when activated, results in release of arachidonic acid, which is converted into 
thromboxane A2, resulting in further platelet aggregation and growth factor release. The process 
described attempts to produce a platelet plug—the primary haemostasis.  
 
The platelet plug acts as a barrier to micro-organism invasion of wounds, with the help of highly 
concentrated leukocyte buffer. The clotting cascade is also activated along with the complement 
system, producing the secondary haemostasis with a resultant fibrin network formation. 
Degranulation of α-granules results in the fusion of platelet cell membrane during which some of the 
secretory proteins (e.g., PDGF) are transformed to a bioactive state by the addition of histones and 
carbohydrate side chain (Marx, 2001). These active proteins then bind to the transmembrane 
receptors of target cells such as mesenchymal stem cells, osetoblast, and fibroblast, endothelial and 
epidermal cells. Once bound to the transmembrane receptors, intracellular signal proteins are 
activated, resulting in expression of gene sequence that directs cellular proliferation, matrix 
formation, and initiation of collagen synthesis (Marx, 2001). These proteins are secreted within 10 
minutes of clotting, with more than 95% of the pre-synthesized growth factors secreted within 1 hour 
(Akingboye et.al, 2010). 
3.2 Materials and Methods. 
The process of PRP and PPP preparation has been described in details in section 2.19.  
3. 2.1 Quantification of Growth Factors in PRP and PPP 
The supernatant (post activation) obtained from PRP and PPP that was allowed to thaw at room 
temperature after been in storage (-80  C.) The milliplex is based on the luminex Xmap technology, 
which performs immunoassays on the surface of fluorescent-coded beads known as microspheres 
[Millipore Corporation 290 Concord rd. Billerica].  The following growth factors were measured 
using the Milliplex 
TM
 map kit; PDGF-AA, TGF-β1, FGF-2, EGF and VEGF whereas IGF and P- 
Seletin ELISA kits were measured by ELISA (R&D Minneapolis Minn) according to manufacture‘s 
instructions.  The optical reading obtained for both the control and tested samples the experiments 
were fed into an automated analyser that generated the concentrations of the growth factors. 
Furthermore, PF4 and TSP-1 were also measured using the ELISA kit (Quantikine, R&D Systems, 
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Minneapolis, MN) but the automated analyser was not available to be used for this 2 immunoassay 
hence, the final concentration were derived from the plotted standard curves (Figure 3.2). 
3. 3 Statistic Analysis 
Statistical analysis was carried out using a linear model based on log transformed values of the 
growth factors. PRP and PPP groups for each of the diabetic and healthy groups separately. In 
addition, the mean difference, 95% confidence interval and the n-fold increase of PRP to PPP was 
derived.  The relationships between platelet count and growth factors were investigated using a linear 
regression model. Correlations between growth factors and platelet count were assessed by Pearson‘s 
correlations.  Non parametric student t-test was showed when comparing individual growth factors 
within a group and one way- ANOVA (univariate analysis) when the growth factors expression was  
compared between the groups. All analysis was carried out at the 5% (2 –tail) level of significance.      
3.4  RESULT 
3.4.1 Haematology Analysis of Platelet-Rich Plasma 
Complete blood count analysis was performed on the whole blood and platelet-rich plasma samples 
from the six diabetic patients. Thrombocyte baseline value ranged from 130,000 to 500,000 platelet 
/µL. The platelet separation system (PSS) increased the platelet count on the average from 334,000 ± 
117, 000 platelet/ µl to 1,995,000±805,000 platelet/µl, this an average 6-fold increase in platelet 
concentration. The platelet rich plasma group was significantly higher in platelet number than the 
baseline whole group, with a value of   p > 0.0005.  Thereby, confirming the concentration ability of 
the platelet separation system. 
3.4.2 Quantification of Growth Factors 
The quantification of the GFs from the PRP was determined in both the healthy volunteers and 
diabetic patients. Values of the GFs in both groups appear comparable. On the other hand when the 
values of GFs present in PRP were compared with that of PPP; TGF-b1, EGF, PDGF-AA, and 
VEGF were significantly greater in the PRP from both the diabetic patient and the healthy 
volunteers. Furthermore, the only statistic significance observed was the comparison of PRP/PP for 
TSP-1 in the diabetic group, with p value of 0.015; on the other hand the healthy volunteer group did 
not reach statistical significance.  
3.4.3 Comparison of Growth Factor Levels in Diabetic Patients (PRP vs. PPP) 
 In this study PPP was used as the benchmark in which the n-fold increase for the GFs from PRP was 
estimated. The mean ± standard deviation (SD) of PRP versus PPP in EGF was 234.9± 193.8 pg/mL 
vs 31.9 pg/mL with 5 fold increase, FGF-2; 49.2 ±33.64pg/ml  vs. 49.2 ± 42.21pg/mL with no 
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increase, PDGF-AA; 104.8 ± 101.ng/mL vs 1.125 ± 0.674ng/mL had 68 fold increase;  VEGF; 888 ± 
970ng/ml vs  167 ± 180ng/mL with a 4 fold increase, TGF-β1; 28.384 ± 14.63ng/mL vs 1.96 ± 
2.464ng/mL with a 27 fold increase.  No significant increase was found in IGF in this study, IGF in 
PRP was 115.1± 32.54ng/mL vs 106.1 ± 102.2 ng/ml in PPP.  The level of platelet activation was 
estimated by the concentration of the P-seletin, there was two-fold  increase in the value of the P–
Seletin in PRP (161.5 ± 113.6 ng/ml) compared  to PPP( 65.2 ± 17.67ng/mL), which is statistically 
significant <0.0001.  
3.4.4 Correlation of Platelet Concentrate with Expression of Growth Factors 
The correlation was done for the four most highly expressed GFs (VEGF, TGF, PDGF and EGF). 
Fig 2 is the graphic illustration of the correlation. None of the parameters was statistically significant 
predictor of PRP count; this might be due to the small sample size or to apparently paradoxically low 
secretion of the GFs in patients with very high platelet concentration. Overall there is no evidence of 
a linear relationship between platelet count and growth factor. Pearson correlation test revealed that 
none of the growth factors has a positive linear correlation with the platelet concentration (R
2
 for 
TGF, EGF, VEGF and PDGF-AA are 0.029, 0.008, 0.017 and 0.011 respectively). 
GF expression in diabetics did not correlate with the platelet count nor with PRP on the Pearson‘s 
correlation coefficients analysis (rp) (r (p) - >0.2 ≤0.9), Table 3.2 showed all the correlation for each 
of the GFs. Relationships between platelet count and growth factors were investigated using a linear 
regression model, was only performed for the four most expressed GFs and the p value results are as 
follows; PDGF-AA- 0.7157, VEGF-0.6616, TGF-1-0.3740, EGF- 0.6489.   
3.4. 5 Comparison of Growth Factor Levels in Healthy Donor (PRP vs PPP) 
A similar trend was noticed in the growth factor expression in the healthy group but the mean value 
appears higher in the healthy donor.  The exception is the expression of VEGF and TGF- β1 which 
are higher in the diabetic group. As explained above PPP was used as the benchmark in this study. 
EGF in PRP to PPP was (463 ± 259pg/mL vs 31.9pg/mL) which is an fold increase; FGF ( 136 ±  
110.6pg/ml vs 59.8± 48.98 pg/ml), a 2 fold increase, PDGF-AA (123.6 ± 8.30ng/ml vs 1.51± 
1.04ng/ml) a 70 fold increase, VEGF (688.3 ± 808.4ng/mL vs 136 ± 132ng/mL) a 4 fold increase, 
TGF- β1( 27.245 ± 31. 074ng/mL vs 0.833± 1.004ng/mL) a 40 fold increase and IGF (122.7 ± 
20.89ng/mL vs 128.4± 21.57ng/mL), no increase. The activities of P-Seletin estimating level of 
platelet activation of PRP (275.1 ± 115.2ng/mL) are again two-fold higher compared with PPP 
(117.9 ± 129.8ng/mL).  Table 1 showed the n-fold increase in the expression of the growth factors in 
both groups tested as it relates to the chosen confidence interval of P= 0.05.  Figure 1 also shows the 
mean expression of the growth factors in the diabetic and healthy donor.  
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3.4.6 Quantification and Comparison of PF-4 and TSP-1 in the Diabetic and Healthy Group 
The mean ± standard deviation (SD) for PRP for PF-4 was 91.2± 7.54 gn/mL and PPP was 89.0 ± 
20.50 ng/mL p value of 0.33 on analysis of variance.  The mean ± standard deviation value for TSP-1 
for PRP was 2408.60± 458.50ng/mL and PPP was 808.60±563.0ng/mL with a p value of 0.03  . 
Table 3.1 the expression of the 2 distinct growth factors, one way ANOVA (variance of analysis) 
was used to test the significance, when comparing PRP/PPP within the diabetic and healthy group a 
P value of< 0.0001 and 0.0055 was detected.  
Furthermore, the mean and standard deviation of TSP-1 in the healthy volunteer group was 2679.80 
±327.0 and PPP was 1326.40 ± 458.50  ng/mL with a p value of 0.07 when PRP/PPP was compared. 
On other hand, PF-4 for PRP was 105.2 ± 13.10ng/mL and PPP of 108.50± 8.25ng/mL and a p value 
of 0.354. Analysis of variance for TSF for PRP/PPP in diabetic and healthy volunteer group showed  
p values of 0.0001and 0.015 respectively.                            
Tested group Growth factor  Mean ±SD (ng/ml) P value Anova Analysis 
Diabetic patient   PF4- PRP 91.2± 7.54 0.33  
   PF4- PPP 89.0 ± 20.50  <0.0001 
Healthy Volunteer   PF4- PRP 105.2 ± 13.10 0.354  
   PF4-PPP 108.50± 8.25  <0.0055 
Diabetic Patient   TSP-1 -PRP 2408.60 ±458.50 <0.03  
   TSP-1 -PPP 808.60 ± 563.0  <0.0001 
Healthy Volunteer   TSP-1-PRP 2679.80 ±327.0 0.07  
   TSP-1- PPP 1326.40± 458.50  <0.015 
 
Table 3.1 Represents the expression of PF-4 and TSP-1 from the diabetic patient and health 
volunteer group with mean and standard deviation (±SD) expressed. A significant difference of P 
value< 0.05 was considered when comparing PRP/PPP for the 2 different GFs in each group and the 
overall univariate analysis for the 2 separate groups was analysed. 
Groups  Tested Growth Factors Comparison  n-Fold increases P- value 
 
Diabetic Patient EGF PRP vs PPP 4.5698 <0.003 
 
 FGF-2  1.0414 0.8480 
 PDGF-AA  68.6203 <0.0001 
 VEGF  4.2307 0.008 
 TGF-β1  27.3338 <0.0001 
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 IGF  1.0285 0.021 
 P-Seletin  2.2171 <0.0001 
     
Healthy Volunteer EGF PRP vs. PPP 11.0756 <0.0001 
 FGF-2  1.9372 0.0002 
 PDGF-AA  69.9147 <0.0001 
 VEGF  4.4117 <0.0001 
 TGF-β1  38.9119 <0.0001 
 IGF  0.9553 0.1272 
 P-Seletin  3.1759 <0.001 
 
Table  3.2 Comparison of PRP and  PPP between the Diabetic and Healthy donor. The 
difference with 95% confidence intervals for mean differences between PRP vs. PPP were derived 
and back transformed to provide an estimate of the n- fold increase of PRP to PPP
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Super-Family                                        Member     Role 
 
Platelet Derived Growth Factor          PDGF PDGF has three isoforms; PDGF-AA, AB, BB. PDGF affects cells of mesodermal origin and has its primary 
effect on these cells and could also be secreted from other polymorph nuclear cells, fibroblast, and smooth 
muscle cells. Its roles include stimulation of chemotaxis, proliferation, and new gene expression in these cells. 
Other reported activities for PDGF  includes stimulation of granule release by  neutrophils and monocytes, 
stimulation of neutrophil phagocytosis, inhibition of  natural killer (NK) cell activity,  stimulation of collagen 
synthesis modulation of  thrombospondin expression and secretion  and stimulation of  collagenase activity 
(Everts,2006) .    
                                                           
(VEGF)                               
VEGF also known as vascular permeability factor or vasculotropin is a homodimeric 34 – 42 kDa, heparin-
binding glycoprotein with potent angiogenic, mitogenic and vascular permeability enhancing activities 
specific for endothelial cells.  In normal tissues, VEGF expression has been found in activated macrophages, 
keratinocytes, renal glomerular visceral epithelium and mesangial cells, hepatocytes and smooth muscle cells.  
Its receptors are exclusive to the endothelial cells and   it acts as an effective mitogen during   angiogenesis.  
FGF-4, PDGF, tumour necrosis factor (TNF)-α, Insulin-like growth factor (IGF) and some interleukins 
stimulate VEGF production and others inhibit it (Neufeld, 1999). 
Epidermal Growth Factor             EGF    EGF binds to the same 170 kDa receptor, TGF-α, EGF is initially synthesized as a large (130 kDa) precursor 
molecule in which the mature, soluble EGF sequence (6 kDa) is located. EGF is released on degranulation of 
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platelets.  Most cells have receptors for EGF but epithelial cells have the largest number of receptors. Other 
sites for the receptors include endothelial cells, fibroblasts   and smooth muscle cells. In vitro, EGF is a 
mitogen for fibroblasts, endothelial cells and promotes colony formation of epidermal cells in culture. EGF is 
also chemotactic in nature, stimulates angiogenesis and collagenase activity (Lawrence, 1994 and Grotendorst 
et.al, 1989). 
 TGF-α                          TGF-α has 30% structural homology as EGF. TGF- α expression is characterized by a   relatively widespread 
distribution. Soluble TGF- acts in autocrine and paracrine fashions with a high affinity binding, via the EGF-
like motif, which is critical to the achievement of high affinity binding to its receptor and is common to all 
members of the EGF family.  TGF- α expression is exaggerated in transformed cells and tumours.  It is 
produced by activation of   macrophages, platelets, and keratinocytes. It stimulates mesenchymal, epithelial, 
and endothelial cells via chemotactic effect.  Although TGF- α is most often associated with its proliferation, 
differentiation, and transformation-promoting effects, it is also involved in angiogenesis, cell   metabolism, 
cell migration and wound healing (Lawrence, 1994   and   Grotendorst et.al, 1989).  
Fibroblast Growth Factor           FGF (a&b)                     FGF has 2 different forms; the acidic and basic, both have 50% homology. Cells known to express FGF 
acidic include skeletal and smooth muscle cells endothelial cells, macrophages keratinocytes and fibroblasts.  
It is suggested that both membrane receptor activation and internalization is necessary for a full mitogen 
response.  FGF acidic is best known for its mitogenic activity on endothelial cell.  Both forms stimulate 
endothelial cell proliferation and motility, thereby contributing to wound angiogenesis. FGF- basic is 10 times 
more potent as an angiogenic stimulator. FGF basic is chemotactic and mitogenic for endothelial cells in 
vitro, inducing endothelial cell production of factors involved in the breakdown of the basement membrane 
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and the migration of capillary endothelial cells into collagen matrices to form capillary-like tubes. Other 
stimulatory effects include collagen synthesis, wound contraction, epithelialization, and fibronectin and 
proteoglycan synthesis (Lawrence, 1994 and McGee et.al, 1998). 
 KGF I &II                                  Within the FGF family, KGF shows 29% amino acid sequence identity to FGF-2. The number of cells 
expressing KGF receptors is few and limited to epithelial cell types such as keratinocytes, transitional 
epithelium, embryonic lung epithelium and hepatocytes. In addition, KGF also binds to heparan sulfate 
proteoglycans; the biologoical role of heparin binding is unclear. High quantity of KGF is produced   after 
tissue damage, which is mainly produced by fibroblast. KGF-I is the most potent mediator of keratinocyte 
proliferation and motility. KGF-2 has been shown to increase granulation tissue formation by directly 
stimulating the migration of fibroblasts in wounds. KGF is synthesized by dermal or lamina propria 
fibroblasts, it is proposed to act locally on the overlying epithelial sheet. In addition to its ability to induce cell 
proliferation, it may also promote epithelial differentiation. During wound healing, KGF‘s role as a re-
epithelializing agent is complemented by the presence of proinflammatory molecules which appear as a result 
of tissue damage (Cross K, 2003 and Beer, 2000). 
Transforming Growth          TGF (β1, 
β2, β3)                       
TGF-β has been isolated from platelets, macrophages, lymphocytes, bone, and kidneys. TGF are also released 
after platelet degranulation. It stimulates monocytes to secrete other growth factors (FGF, PDGF, TNF- α, and 
IL-1). TGF is chemotactic for macrophages and   regulates its own production within the macrophages in an 
autocrine fashion. It also stimulates fibroblast chemotaxis and proliferation. The presence of other growth 
factors and the variability in concentration of TGF-b could modulate the role of TGF-b. This is either an 
inhibitory or stimulatory effect on cellular proliferation. TGF-b stimulates fibronectin, proteoglycan synthesis 
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by fibroblast. It organizes extracellular matrix and may be involved in scar remodelling and contracture. It 
also stimulates epithelial cell proliferation and inhibits endothelial cell proliferation, but with a co-factor it 
will  stimulate angiogenesis (Lawrence, 1994; Massague,1987;Wahl et.al 1987 and Fukamizu, 1990).      
Insulin Growth Factor            
 IGF (I&II)                        
IGF-II is most prominent during fetal development, where-as IGF-I persists throughout life and is synthesized 
in the liver, heart, lung, kidney, pancreas, brain, and muscle. IGF is stimulated by human growth hormone 
(especially in the liver) and the two together stimulate skeletal cartilage and bone growth. Degranulation of 
platelets will also produce IGF-I and the stimulation of fibroblasts. IGF-I is a potent chemotactic agent for 
endothelial cells, and is also involved in neo- vascularization. It may also act with PDGF to enhance 
epidermal and dermal growth. The effect of IGF-I on wound healing depends on the amount of available free 
IGF-I (Guler,1988 and Grant,2004).                       
Platelet Factor 4                          PF-4                               PF-4 is a very abundant platelet α-granule CXC chemokine that is released during platelet  activation. 
Chemokines are a subfamily of the larger chemokine family of small proteins. Mature human PF4 is a 7.8 
kDa in size. The biosynthesis of PF4 is almost exclusively limited to megakaryocytes from which mature 
circulating platelets are derived. PF4 binds with high affinity to heparin and to such negatively charged cell 
surface gylcos -aminoglycans (GAGs) as heparan sulfate (HS) and dermatan sulphate. PF4 may also affect 
hemostasis and thrombosis through inflammatory and vascular pathways and these possibilities have been 
explored in vitro. In the presence of a co- stimulus, such as tumour necrosis factor (TNF)-α, PF4 can activate 
neutrophils, cause exocytosis and promotE adhesion to protein matrices or endothelium. PF4 was found to 
have a number of different effects on circulating monocytes, preventing apoptosis and facilitating 
macrophage differentiation during the inflammatory process. PF4 also appears to augment monocytE  
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phagocytosis and the subsequent respiratory burst and to induce cytokine secretion (Pervushin et .al, 2004. 
Rucinski et al , 1990, Petersen et.al 1999). 
 
Thrombospodin                        (TSP 1)                             TSP-1 is a 150 KDa secreted member of the thrombospondin gene family of proteins. There are 5 structurally 
related extracellular matrice protein; TSP 1-5 and only TSP 1-2 are functionally and structurally related.  
TSP-1 is produced by megakaryocytes/ platelets, endothelial cells, vascular smooth muscle cells and 
fibroblasts. In conjunction with von-Willebrand factor (VWF) and fibrinogen, TSP-1 contributes to clot 
function. Following vascular injury, platelets bind to exposed vessel wall collagen via membrane GP- VI.  
This results in platelet activation with VWF and TSP-1, and subsequent VWF binding to platelet membrane. 
TSP-1 also prevent proteolysis by binding to VWF at site targeted by proteases.  TSP-1 is co-expressed with 
SDF-1 and MMP-9 in platelet α-granules. The expression of pro- angiogenic – MMP-9 and SDF-1 are 
regulated by TSP-1. It has also been shown that TSP-1 minimizes new vessel growth which may be through 
its ability to regulate nitrous oxide (NO). NO at low doses promote endothelial cell proliferation and 
migration.  These findings suggest that TSP inhibit angiogenesis by acting as sponges that absorb 
angiogenesis-stimulating molecules. Therefore, thrombopoietic cell TSP is well established by these findings 
as an angiogenesis suppressing switch (Armstrong and Bornstein 2003 and Legrand et.al 1997). 
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Table 3.4 is a summary of growth factor super families and individual growth factors with there respective functions, structural morphology and site of 
production.  
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Expression of PDGF-AA from both healthy
 donors and diabetic patients
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Graphic representation of growth factors expressed from
 Diabetic patients without PDGF-AA and TGF-b1
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Graphic representation of growth factors expressed
in healthy donor without PDGF-AA and TGF-b
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 Figure 3.1 Graphical illustrations represents the different expression of growth factors 
expressed from platelete-derived platelet gel from PRP vs. PPP. A) Compares the expression of 
PDGF-AA between PRP and PPP in the healthy, PRP showed a significance of p< 0.0001 over PPP 
and  similarly in the diabetic group, PRP has a significant difference over PPP <0.001. B). The 
expression of TGF-β showed p value of <0.004 when PRP and PPP were compared in the healthy 
donor group and <0.002 for the diabetic patient but there was no statistical difference when the PRP 
from both groups were compared. C&D) showed graphical representation of the less expressed 
growth factors, VEGF and EGF are the 2 most prominent with p values of <0.001 when PRP and 
PPP were compared in both groups. E) Pearson correlation test revealed that none of the growth 
factors has a positive linear correlation with the platelet concentration (R
2
 for TGF, EGF, VEGF and 
PDGF-AA are 0.029, 0.008, 0.017 and 0.011 respectively) 
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Overall expression of TSP-1 in Healthy
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Figure 3.2.  Graphic illustration of TSP-1 and PF-4 A & B) showed the standard plot for TSP-1 
and PF4 with there equations and the degree of correlation.  The final concentrations were derived 
through the equation obtained. C) Compared the expression of TSP-1  on-way analysis of variance, a 
significance of P value 0.015 was reached. The expression of PRP is significantly higher in the 
healthy group as compared to PPP with p value of <0.05, a similar pattern was noticed amongst 
diabetic patient with a p value of <0.05. Although, the expression of TSP-1 in PRP was higher from 
Healthy volunteers compared to diabetic patient it is not significant statistically D). The expression 
of PF-4 is was significant on one-way analysis of variance with P value of 0.005. However, no 
statistical significant was reached when comparing PRP and PPP in either group. 
3.7   DISCUSSION  
All measurements were performed in duplicate using validated commercially available ELISA and 
millpore kit, and coefficient of variance was < 5%.  For all growth factors analysed, specimen were 
used after storage in -80 ºC.  Studies have shown that deep freezing and thawing is a safe method for 
releasing intracellular thrombocyte growth factors (Saratzis, 2008).  Zimmermann et al., in there 
study showed that at the end of the 5-day storage period, the mean supernatant levels of PDGF-AB 
and PDGF-BB were about twice as high as they had been on the day of preparation. The supernatant 
levels of TGF-β1 remained constant.  At the same time, the total growth factor levels had decreased 
substantially.  However, Sekido et al. 1987; reported that PDGF activity of platelet concentrates in a 
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bioassay was at the same level during preservation for up to 5 days. Other researchers reported an 
approximate accumulation of three to five times the levels of PDGF and TGF-β1 in the supernatants 
of platelet components during storage (Ledent, 1995).  The platelet counts from the blood sample 
from the diabetic patients were within acceptance range. The platelet counts in the platelet 
concentrate were also in the expected range and corresponded to values previous reported in 
literature (Sekido, 1989). 
 
The correlation between the GFs and the platelet count from the PRP  were weak, this might be due 
to small sample size, or might be due to isolated incidents of inefficient concentration of PRP.  From 
the clinical point of view, it is important that the platelet concentration process is reliable by using an 
approved and tested platelet separation device. The data obtained from this study further supports 
other published series, that neither the direct platelet count nor the platelet in PRP could predict the 
expected expression of GFs (Weibrich, 2002). It is critical to minimize platelet activation that occurs 
during PRP preparation.  In our study P-Selectin was  measured  after activation of PRP as means of 
defining the degree of activation, and a 3 fold increase was noticed when  the value of P-selectin in 
PRP was compared with PPP in the healthy donor and the diabetic patient.  In a similar study by 
Eppley et al. P-selectin was measured after centrifugation of PRP before the activation and they 
reported that there was no significant change in the level as compared with the whole blood (Eppley, 
2004).  Although our approach was different to that of Eppley et al., the levels of GFs expression in 
our study compares favourably to other published series after activation (Alsousou, 2009, Weibrich, 
2002).
 
When comparing the GF profile from PRP and PPP. It is interesting to see that PPP has some degree 
of expression of GF, contrary to the popular opinion that it‘s merely useful as a sealant and it 
contains no growth factor. Hence, an added advantage could be derived when PPP is used a sealant. 
The theoretical levels of platelet- derived growth factors in PRP might be expected to depend on the 
number of platelet involved, which have previously been reported in some studies (Webrich, 2002). 
However, from our study were could not demonstrate a linear relationship. Eppley et al., concluded 
that at the very best correlation was seen with TGF-β1, which was still quite low, he suggested little 
correlation between platelet number and GF concentration and that content of the platelets varies 
from patient to patient.  These results might be explained by high individual variability in cellular 
production or storage of cytokines
 
(Marx, 1998). Of all the GFs identified in the wound cascade, the 
concentration of IGF-1 was not significantly increased. IGF-1 is primarily excreted by the liver into 
blood plasma; hence the value of IGF is marginally higher in PRP than PPR in both groups.  The 
findings in this study corroborate with previous reports that significant inter-patient variability of 
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growth factors occurs. Several other parameters influence the relationship between platelet 
concentration and GF level measured.  
There are other methods by which platelets can be activated such as the use of adenosine diphosphate 
and repeated freeze-thaw, but in this study human thrombin with a combination of calcium chloride 
was used.  The method of PRP preparation in our study achieved a greater yield of growth factors as 
compared to other published series. But has its inherent practical drawbacks such as; longer time of 
preparation and problem of fixed volume of whole blood needed to operate the device, which means 
the processor is unable to handle volume of less than 60ml. However, it‘s debatable whether this is 
the most effective method, but it‘s clinically convenient and user-friendly for the preparation process. 
In our study, there is a disparity in the age and gender profile of the healthy donors and the diabetic 
patients. The control did not matched age and gender for the diabetic group. Other studies have also 
suggested that gender and age are not predictive factors in determining GFs expressions (Kevy, 
2001).   
There were few in vitro researches that discussed the platelet gel composition, strength and 
degradation characteristics using point-of-care technologies. There must be a quantifiable way of 
determining the structural integrity of the resulting formed platelet gel thrombus. The 
thrombelastograph hemostasis analyzer (TEG) and sonoclot measure the elasticity of a clot as it 
forms and subsequently degrades naturally.  Cassidy et al., in there study on the role of TEG 
concluded that the technology to quantify platelet gels must first be standardized and that the TEG 
and the sonoclot are not equally capable of analyzing platelet gel clots. The TEG was a valid means 
for analysis, whereas the sonoclot provided unreliable analysis based on a Chi-squared test (Cassidy 
et al.,  2005). Further study with a control disease group will be more helpful to address the effect of 
chronic disease on GFs expression.  Reliable prediction of GFs levels in PRP samples is necessary to 
ensure reliable and reproducible use of PRP for clinical treatment, since the regenerative potency of 
PRP undoubtedly depends on its GFs Level (Kevy, 2004). 
3.8 CONCLUSION 
 
Results from this study demonstrated that platelets can be sequestered and concentrated 6-fold from 
whole blood and that PRP contains significantly higher levels  of GFs when with PPP; PDGF-AA, 
VEGF, TGF-1, with potential benefits on wound healing.  PRP also had significantly higher levels of 
IGF in diabetic PRP (but not healthy control PRP) and FGF-2 in healthy control (but not diabetic) 
PRP. Furthermore, we demonstrated that activating PPP will aid release of the above GFs as shown 
in PRP but to a lower degree.  Prediction of GFs levels based on platelet count or PRP have not been 
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possible in this study. Further investigation might be needed to resolve the issues of unpredictability 
release of growth factor from PRP.  Furthermore, a technique whereby GFs could be rapidly assessed 
in PRP before application may be of therapeutic benefit.  
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                                                  CHAPTER 4 
Biological Effect of Platelet–Rich Plasma & Platelet-Poor Plasma on 
Human Dermal Fibroblast, Human Epithtelia Keratinocyte and Human 
umbilical Vein Endothelial Cells 
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4.1   Introduction 
  
Platelet-rich plasma gel is generated by differential centrifugation, in which platelets are 
concentrated into a small plasma volume. The use of PRP is based on the premise that platelets 
constitute a reservoir of critical growth factors (GFs), such as platelet–derived growth factors 
(PDGF), transforming growth factors-β (TGF-β), vascular endothelia growth factor (VEGF), 
Fibroblast growth factor (FGF) and more which once released from the platelet alpha granules, may 
positively regulate the wound healing process (conway 2001 et al. and koveker 2000).   
 
There have been successful reports on the use of Platelet –rich plasma (PRP) in various clinical 
setting such as reconstructive plastic surgery, orthopaedic surgery and in treating cutaneous wounds / 
ulcers.  However, an increasing body of evidence suggests that the clinical benefits related to this 
technique may be limited (Weibirch 2002, & Weibirch 2004).  Steed and the Diabetic Ulcer study 
group have shown PDGF-BB to be effective in clinical controlled study in the treatment of diabetic 
ulcers.  They studied recombinant human PDGF-BB and reported significant difference in the 
percentage of patients that reached complete wound healing (48% in treatment group vs. 25% control 
group at the end of 20 weeks. (Steed et. al., 1995). 
 
Growth factors are a class of natural biological mediators that regulate key cellular events in tissue  
repair, including cell proliferation, differentiation and extracellular matrix synthesis. Previous studies 
have demonstrated that local application of GFs alone or mixed with bone allograft is capable of 
increasing bone growth and accelerate healing of soft tissue (Cochran and Woozney, 1999).  Based 
on in vitro studies, GFs have beneficial effect on wound healing, for example, PDGF stimulates the 
mitogenesis of mesenchymal cells, TGF-β stimulates matrix synthesis and activates pre-osteoblasts 
to initiate mitosis and promote their differentiation.   The use of autologous source of GFs (PRP) 
seen to be more beneficial because higher level of GFs concentration may be achieved, which could 
stimulate the process of tissue repair in a more physiological way than delivery of a single growth 
factor (Marx et.al 1998, Kim et.al 2001). Although individual purified GFs have been extensively 
studied in vitro prior to in vivo, PRP has only recently started to be assessed in a similar manner. 
However, studies investigating the effect of PRP on cell function in vitro have utilized a wide variety 
of cell types (periosteum derives cells, human osteoblast, mesenchymal cell and endothelial), which 
has shown conflicting results (Liu et.al. Lucarelli et. al 2003, Gruber et al 2004, kilian et. 2004; 
kanno shownet. al 2005). More basic research are still required in this growing field of regenerative  
science and its therapeutic applications. It still uncertain the concentration of PRP that is optimal in  
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regeneration and promoting wound healing.  It is assumed that PRP would act in a similar manner to 
individual growth factors and that the preparations containing maximal concentration of growth 
factors would be the ideal. However, there is little evidence to support this assumption, which may 
be flawed on the basis that PRP is a combination of different growth factors, each of which exerts a 
unique influence on the complex cascade of events that occur during wound healing and tissue 
regeneration.  
 
Furthermore, in vivo animal studies and clinical studies appeared to have benefit of PRP may be as  
results of different techniques of harvesting PRP, various animal model and methodologies used in 
assessing the effect of PRP and possible presence of negative regulators in PRP (Hsu et. al, 2009).  It 
has been observed that in addition to GFs released from platelets and their demonstrated positive 
effects on wound repair, thrombospodin (TSP) is also abundant in the α-granule of platelet 
(Switalska 1985). Thrombospodin consist of five members TSP 1-5, TSP is a glycoprotein, with 3 
identical di-sulphide–linked polypeptide chains. Thrombospodin -1 inhibits adhesion, proliferation 
and tube formation of endothelial cells in culture, and it has been found to block neovascularization 
of chick-chorioallantoic membrane (Iruela- Arispe et.al 1999). However, there is no evidence to 
suggest that TSP-3, TSP-4 and TSP-5 have such inhibitory functions on wound healing. In another 
study published by Hus et.al, 2009, abundant secretion of TSP-1 from concentrated PRP may 
contribute to the antiproliferative effect on oral cells via cell apoptosis.  In view of the controversies 
surrounding the efficacy of PRP in tissue reparation, we have developed an in vitro experimental 
model through which the basic principal elements involved in wound healing i.e. proliferation, 
migration and angiogenesis can be investigated. The study focuses on the biological effect of PRP on 
human endothelial, fibroblast and keratinocyte as it relates to the key principal element of wound 
healing through biological assay. 
 
4.2 Effect of Growth Factors on Cell Cycle and it Functions 
Growth factors play a key role in initiating and sustaining the different phases of tissue repair  
(Bennet and Schultz, 1993). Growth factors are characterized by their capacity to induce mitosis in 
different cell types in vitro. 
 FGF and PDGF-AB (competence factor) act by making quiescent cell in G0 phase of the cell cycle  
competent to respond to a second group of growth factors  called the progression factors (Flyvbjerg, 
1990) 
 Epidermal growth factor and Insulin like growth factor appears to drive cell through G1 of the cell 
cycle into the DNA synthesis, these growth factors are referred to as  the progression factor. 
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 Each growth factor uses a distinct tyrosine kinase receptor but the receptors share common signal 
transduction pathway. 
 PDGF-AB is a major serum mitogen and induces fibroblast proliferation, matrix production and 
maturation of connective tissue. 
 FGF-basic has its main stimulatory effect on the growth and differentiated function of fibroblasts and 
on proliferation of vascular smooth muscle cells and endothelial cells.  
 EGF stimulate cell proliferation by binding to it‘s on own receptor on the different cell types 
 
4.3 MATERIALS AND METHODOLOGY 
 
Quantification of GFs from PRP and PPP have been described and discussed in details in Chapter 3 
section 3.4 and 3.7 respectively. In addition,  measurement of TSP-1 and PF-4 was carried out from 
the same aliquot prepared at the start of the study, where other GFs were measured from. This was as 
an attempt to explain the decreasing dose phenomenon seen from the initial proliferation assay 
experiment. Hsu et.al, 2009 showed that TSP-1 might be an inhibitory cytokine expressed in PRP, 
hence, TSP-1 and PF-4 was measured. The GFs were measured according to the manufacturer‘s 
instruction.  
 
Isolation and subculturing of HEK/NEB-1 cell, HD, HUVEC/EA.hys used in the assay have been  
fully described in Chapter 2, sections 2.4, 2.5, 2.6, 2.9 and 2.10 respectively. Details of in vitro 
wound assay and transwell migration assay and the modification peculiar to this study have been 
fully described under Chapter 2, sections 2.13.1 and 2.14.2. Furthermore, the seeding density for 
the all the different cell types and the assay are detailed in Chapter 2, section 2.11. 
  
4.4 Morphological Changes Following Subculturing with PRP/PRP 
 
During optimization and cell viability experiments with PRP/PPP, morphological changes were 
observed with the varying concentrations of PRP/PPP over the 5 day time course (Figure 4.1 and 
4.2).  Observed cellular proliferation correlated with Alamar Blue cell quantification technique.  The 
plate was further incubated for 24 h at 37
o 
C. The number of viable cells correlates with the 
magnitude of dye reduction and is expressed as percentage of AB reduction (Ahmed et al., 1994; 
Goegan et al., 1995). The values of % AB reduction were corrected by deducting the background 
values of negative controls containing medium without cells from the true test. In order to eliminate 
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differences due to medium colour, serum free keratinocyte (K-SF) was used for keratinocyte 
proliferation and DMEM without phenol red was Fibroblast whilst EMG-2 was used for HUVEC 
proliferation assay. 
 
          Pre-culturing           Cont (1%BSA)              PRP 5%                    PRP 10% 
                               
              PRP 25%                   PRP 50%                     PPP                 un-activated PPP  
            
Figure 4.1  Morphological changes after sub-culturing Human dermal fibroblast with v/v of 
PRP/PPP and 1% BSA over 7 days period. 
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                 Pre –culturing                   1% EMG                      PRP 5%                
                  
                     PRP 10%                       PRP 25%                     PPP 
                   
Figure 4.2  Morphological changes after sub-culturing Human umbilical vein endothelia cell 
with v/v of PRP/PPP with 1% EMG after 5 days. 
                                                                          
4.5. Angiogenesis assay on matrix gels. 
Growth factor-reduced Matrix gels (Matrigel, Becton Dickinson) were allowed to polymerize in a 
24-well plate for 1h at 378C. HUVEC were seeded at 2x10
5
 per well and grown for 36hrs in a 
humidified 37
0
C, 5% CO2 incubator. In some experiments, cells were cultured in the presence or 
absence of different kinds of reagents. Tube formation was documented using an inverted 
fluorescence microscope and pictures were captured with a digital camera and stored in a computer 
system. Matrigel angiogenesis and collagen based angiogenesis were both optimized; the results 
from both were illustrated in Figure 4.3 and Figure 4.4 respectively. Complete angiogenesis process 
lasted 36hrs with matrigel, whereas it last last 7days with collagen based angiogenesis.  Matrigel was 
preferred in our study, because of quick turnover from the experiment, the methodology was more 
straightway and the final images were easily quantifiable, hence matrigel was the preferred technique 
in our study. 
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A B C
D E F
 
 
Figure 4.3. Complete process of angiogenesis assay with HUVEC on reduced Matrigel. A) Seeding 
of HUVEC, B) Process of sprouting and  tube formation  at 6hrs, C) tube formation and capillary 
networking at 12hrs D) angiogenesis at 20hrs , E) at 24hrs  and  F) complete angiogenesis at 36 hrs.   
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B C
D E F
 
Figure 4.4. Illustrates the Collagen based angiogenesis. A) Seeding of HUVEC on Polymerized 
collagen gel at 6hrs, B) Sprouting of HUVEC at 24hrs, C) Development of capillary and tube 
formation on day 3 day, D) Capillary network evolving on day 4 E) Capillary network are fully 
developed but the processes are short on day 6, F) Poorly defined but fully formed short and thick 
capillary network on day 7. 
       
A
B C
D E
F
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Fig 4.5  Illustrates the  final stages of  Matrigel angiogenesis assay with varying concentration  
of PRP/PPP A) Is the control experiment  (EMG 1%) with polygonal  tube -like network formation; 
B) 5% PRP+ RM , with more polygonal network formation; C) matrigel+ 10% PRP with tube-like 
network but less define mesh work formation; D) reduced matrigel +25% with thicker diameter of 
the tube-like structure; E) reduced matrigel +50% PRP with poorly defined network; F) PPP with  no 
particular  tube network formation pattern. 
 
                 
                      monolayer                0hr                          12hr                               36hr  
 Neb- 1                  
HEK                                                   
   HDF            
Figure 4.6 Showed photomicrographic images of scratch/ in vitro wound assay with Neb-1 cell, 
HEK and HDF respectively from the start of the experiment (monolayer), (0hr) a scratch was made 
with the tip of the pipette at the centre of the monolayer to mark the start of the experiment, changes 
in the scratch gap was observed over time; 6hr, 12 hrs and 36hrs respectively. The experiment can be 
terminated at any convenient point and the gap closure over time can then be analyzed either by 
directly measuring the gap at several points and finding the average or exporting the images to 
Photoshop and analyzed the area change over time.                                  
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4. 6 Statistical Analysis 
A standard curve of % AB reduction was plotted for each of the cell types during the optimization 
stage. For the proliferation assay; N-fold increase calculated from the Alamar blue fluorescence was 
used to represent the change in proliferation between day 0 and day 5. Results of cell culture 
experiments (Proliferation, transwell and scratch assay) were statistically evaluated using one-way 
analysis of variance, followed by post-hoc Turkey–Kramer multiple comparisons test. Results of the 
tube-formation assay were statistically evaluated, using one-way analysis of variance, followed by 
post-hoc Dunnett multiple comparisons test. The significance level for both tests was set at p<0.05. 
Calculations were performed in Graph Pad Instat, Version 5.01 (Graph Pad Software). 
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Figure 4. 7 Represents the mean ± SD of the three replicates  for the proliferation assay of 
HUVEC; A) the optimization experiment to determine the optimum incubation period for HUVEC 
with alamar blue. A Plot of N-fold increase against varying concentration of PRP/PPP was 
subsequently performed. B&C) showed proliferation assay of HUVEC with varying concentration of 
PRP/PPP derived from healthy volunteers and diabetic patients, both showed significance with p 
value of 0.02 and 0.002 ANOVA analysis of variance respectively.  A similar pattern of significance 
with 5% PRP over PPP and unaPPP was noticed in both groups (p of 0.05). D&E) were the results 
from EA.hy which showed a similar pattern with HUVEC; however no significance was reached 
either on analysis of variance or on multiple comparison post Hoc testing. 
 
                               Graphs for all the proliferation assay 
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Proliferation assay with Human dermal fibrolast
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          Effect of serum starving on Human Dermal
            Fibroblast during proliferation assay over 5 days
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Figure 4.8 Graphic illustration of fibroblast proliferation with PRP/PPP. A) Showed the 
optimization experiment with fibroblast proliferation and optimal incubation period was set at 16hrs. 
B). Showed proliferation over a 5 days with control at FCS 10% producing the maximal effect. There 
was no statistical significance when a repeated analysis of variance was performed over the 5 day 
period. C&D) Proliferation effect of PRP/ PPP from Diabetic and Healthy donor on fibroblast with 
maximal effect seen on PRP 5% (v/v) of 1% BSA and an inverse dose dependent relationship was 
observed.  C&D showed significance of 0.01 and 0.0001 on analysis of variance.  PRP 5% was also 
showed statistical significance over PRP 50%, PPP and unaPPP respectively. E&F) illustrates 
proliferation of fibroblast with 1% FCS mixed with (v/v) of PRP/PPP. Analysis of variance for E 
was not significant however  F reached significance at 0.04,  PRP 5%  from the healthy donor 
reached a significance  over  unaPPP at 0.04  G) Serum starvation effect on fibroblast proliferation  
over 5 days produced the most marked effect at PRP 5% with statistical significance of p< 0.0001. In 
addition PRP  5%, 10%, 25% and 50% all showed significant fold proliferation over the control 
experiment  at  <0.0001  for 5% PRP and < 0.001 for the other concentrations.  
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Figure 4.9 Showed proliferation assay with keratinocyte. A). Time course plot of keratinocyte 
proliferation over 5 days. Varying concentration of PRP/PPP with v/v of FCS 10% and control  at 
10% FCS. The proliferative effect was higher in the control experiment but was not statistically 
significance on repeat analysis of variance with p > 0.5.  B&C) Showed proliferation effect of PRP 
/PPP from with v/v 1% BSA for both experiment with most marked effect seen on the control, 
however the decreasing dose  pattern was still evident with the varying concentration of PRP. 
Univariate analysis showed of p< 0.02 and 0.008 for C&D respectively.  D&E) Kerationcyte 
proliferation with 1% FCS showed marked significance on control experiment and a similar pattern 
with BSA. Univariate analysis was p of 0.02 and <0.0001 respectively.  F&H)  Neb-1 cell 
proliferation assay behaved in a similar pattern to  keratinocyte, with  1% control displaying a 
statistical proliferative effect over all other treat with p value  of 0.02 and 0.0001. 
 
      
 
 
 
                              Graphs for transwell migration assay 
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Transwell migration assay with Ea.hy929
C
o
n
t1
%
P
R
P
 2
5%
P
R
P
 5
0% P
P
P
0
500
1000
1500
concentration of PRP/PPP
A
m
e
a
n
 f
lu
o
r
e
s
c
e
n
c
e
 o
f 
 m
ig
r
a
t
e
d
 c
e
ll
    
Transwell migration assay with HUVEC
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Transwell migration assay with Human Epithelia keratinocyte
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         Transwell migration assay with Human dermal fibroblast
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Transwell migration assay with Neb-1 Cell
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Figure 4.10  Represents the graphic illustration of transwell migration assay for all the 
different cell types. A)  Showed transwell with Ea.hys, there was no significance on the analysis of 
variance or on comparison of  the individual treatment groups. B) HUVEC showed significance of 
0.0031 on ANOVA and Post –Hoc test demonstrated that PRP 5% was statistically significant over 
cont 1%, PRP 50% and PPP with p value of < 0.005. C&E)  Keratinocyte and NEB-1 cell behaved 
in a similarly pattern  on transwell migration assay with  no significant amongst all the treatment as 
well on analysis of variance D)  fibroblast  has a p value  of 0.012 on analysis of variance and PRP 
5% showed a statistical significance over PPP with  p of 0.05. 
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                                 Graphs for in vitro wound assay 
      
Neb- 1 cell wound assay treated with mitomycin
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Neb- 1 cell wound assay treated without mitomycin
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Human epithelia keratinocyte wound assay with mitomycin
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Human epithelia keratinocyte wound assay without mitomycin
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Figure 4.11 Represents scratch / in vitro wound assay with HEK/ NEB -1 cell and HDF.  A&B) 
illustrates wound assay with NEB-1 cell with and without mitomycin treatment. Although the 
treatment concentration was for control, PRP 5%, 10% and PPP. There was no statistical significance 
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on analysis of variance or comparison of the treatment groups.  C&D) HEK behaved  in a similar 
pattern to NEB -1 cell. Although the treatment did not reach statistical significance,  PRP 5 % has the 
most positive effect on gap closure during the assay. E) HDF showed a different characteristic 
behaviour with PRP 5% showing statistical significance over the control, PRP 25% &50% and PPP 
treatment and reaching a statistical significance of <0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                   Graphs for angiogenesis assay 
         
Nodal formation in HUVEC angiogensis assay
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Mesh formation with HUVEC angiogensis assay
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Skeletal length measurement in HUVEC angiogensis assay
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Cellular area covered during  HUVEC angiogenesis assay
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Figure 4.12 Angiogenetic effect of PRP on HUVEC cell. Control 1% is the positive control (full 
complement of EMG with 1% FCS), PRP derivatives (without any of the EMG complement) ranging 
from 5% to 50% and PPP was the negative control. All experiments were performed in triplicate, the 
bars represent mean ±SD.  A) Considering nodal formation; PRP 5% showed a significance over 
50% and PPP at p value of <0.05 and <0.001 respectively and a p value of <0.0001 on one-way 
analysis of variance for the entire group. B) Mesh formation also showed a p value of <0.0001 on 
one-way analysis of variance.  PRP 5% showed a significance of <0.0001 over PRP 10%, PRP 25%, 
PRP 50% respectively and PPP but showed significance of <0.001 over the positive control. C) 
There were no statistical difference amongst the entire group either on one-way analysis of variance 
or on the post –hoc testing. D) PRP 25% and PRP 50% showed a level of significance over the other 
modes of treatment when considering the cellular area cover during angiogenesis. 
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 4.7 RESULTS  
4.7.1     Evaluation of Cell Proliferation 
After the initial experiment were carried out to determine the optimal seeding density and culture 
period.   Cells were seeded and incubated for a 5 days period, proliferation rate were determined 
using alamar blue (AB) technique. Proliferation measurement was done spectrophotometricaly using 
absorbance test wells at 540 and 630 nm and flurometeric measurement by exciting samples at 
560nm and measuring emission at 590nm. The number of viable cells correlates with the magnitude 
of dye reduction and is expressed as percentage of AB reduction (colour change in the medium, 
which is usually from blue to pink). To calculate AB reduction for a given test well plate, a blank 
reading (negative control medium without cell) was subtracted from the test well plate reading.   The 
readings were taking at the start of the experiment (day 0) and at the end (day 5) after incubation 
with alamar blue for 16hours. A fold change (increase or decrease) in the proliferation rate was 
calculated by dividing the day 5 plate reading with day 0. 
             Fold change = Plate reading at day 0 590nm - Blank reading at day 0 590nm 
                                      Plate reading at day 5 590nm – Blank reading at day 5590nm  
4. 7.1.1 Human umbilical Vein Endothelia Cell and Ea. Hys Cell 
When fluorescence reduction was plotted against the cell concentration, the standard curve was 
linear between 80,000 and 800,000 cells /mL with a (correlation value) r
2
 values of 0.8799 (Fig 
4.7a).  A significant increase in endothelial cell proliferation was observed on univariate analysis 
with the addition of PRP supernatants, as compared with minimal medium alone. The HUVEC 
proliferation with diabetic patient PRP and the healthy donor had  p values of 0.002 and 0.02 (Fig 
4.7b &c). A similar pattern was seen with EA.hy cells (Fig 7d &e), which reached significance at 
0.04 and 0.01 with healthy and diabetic PRP respectively. The proliferation of HUVEC and EA.hys 
cell is most marked at PRP 5% with p value of <0.05 over activated and inactivated PPP.  Although 
PRP 5% produced the most marked proliferative effect; there were no significant differences over the 
other forms of treatment (PRP 10%, 25% & 50%).  Furthermore, a decrease dose dependent pattern 
was observed in both the different sources of PRP (healthy and diabetic donors) and the two cell 
types. 
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4.7.1.2   Human Dermal Fibroblast 
When fluorescence reduction was plotted against the cell concentration, the standard curve was 
linear between 8,000 and 80,000 cells /mL with an r
2
 values of 0.9715 (Fig 4.8a). An initial 
proliferation experiment was performed with the positive control media at 10% of FCS (v/v) and the 
PRP were at 5% and 10% and PPP over a 5 day period (Fig 4.8b). The positive control showed the 
most promising proliferative effect over the other form of treatment, however did not reach statistical 
significance on repeated analysis of variance (p value >0.05).  The initial thinking was that by 
increasing the concentration of PRP to 25% and 50% and reducing the positive control media 
concentration a more positive proliferative result might be observed but a decreasing dose dependent 
was observed.    Furthermore, a different serum protein at 1% concentration was introduced (Bovine 
serum albumin, {BSA}), and a comparison was then made with 1% FCS.  
 
A significant statistical difference was observed when 1% BSA was used as the diluting media for 
PRP/ PPP concentration as well as for the positive control, with a p value of 0.001 and 0.01 on 
univariate analysis for PRP from healthy donor and diabetic donors. PRP 5% showed a significant 
fold increase over PRP 50%, PPP and inactivated PPP with p value of 0.01, 0.001 and 0.0001 
respectively (Fig 4.8c &d). On the other hand with 1% FCS as the diluting media (v/v) PRP/PPP, the 
supernatant from diabetic donor did not reach significance (p of >0.05), whereas the supernatant 
from healthy donor reached significance with p value of 0.04 (Fig 4.8 e& f). Although, the statistical 
significant was not reached with supernata from diabetic patients , the two sources of PRP/PPP still 
maintained a decreasing dose dependent relationship and  PRP 5% produced the most positive 
proliferative effect. Further more, the effect of serum starvation on fibroblast proliferation produced 
a more remarkable proliferative effect of PRP /PPP over the positive control media (Fig 4.8 g). With 
serum starvation all the varying concentration of PRP/PPP showed a statistical significance 
difference over the positive control experiment with p value of <0.001. 
 
4. 7.1.3    Human Epithelia Keratinocyte (HEK) and NEB-1 cell 
 
An initial proliferation experiment was performed with the positive control media at 10% of FCS 
(v/v) and the PRP were at 5% and 10% and PPP over a 5 day period ( Fig 4.9a). The positive control 
showed most promising proliferative effect, however did not reach statistical significance on 
repeated analysis of variance (p value >0.05). Further experimental repeats were carried out with 
further reduction in FCS to 1% and another serum protein was introduced (BSA).  HEK proliferation 
assay was performed as outlined for fibroblast above.  Both the positive control at 1% FBC and 1% 
BSA had a greater proliferative effect as compared to the varying concentration of PRP/PPP from the 
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2 different supernatants (Fig. 4.9b, c, d& e). Similarly, NEB-1 cell also used a similar pattern of 
proliferation as HEK (Fig 4.9 f &g). Overall, a lesser proliferative effect was observed with treating 
HEK with PRP/PPP as compared to the positive control. The decreasing dose dependent was still 
evident in amongst the well plates treated with PRP/PPP for both HEK and NEB-1 cell proliferation 
assay. 
 
4.7.2   In Vitro Cell Migration Assay 
4. 7.2.1  Transwell Cell Migration Assay   
Transwell migration with EA.hys cell did not reach statistical significance either on one-way 
ANOVA or on post –hoc testing (Fig 4.10a). Transwell migration with HUVEC was significant on 
one-way ANOVA with a p value of 0.0003 and trans-migration with PRP 5% was significant over 
the positive control, PRP 25%, 50% and PPP with P values of < 0.005 (Fig 4.10b). Interestingly, 
transwell migration with HEK and NEB-1 cell behaved similarly to wound/ scratch assay; the 
positive control showed better migration than the varying treatment concentrations of PRP (Fig 
4.10c&e). Finally, transwell migration with human fibroblast was significant on univariate analysis 
with a p value of 0.01 and transmigration with PRP 5%  has the most positive effect with a 
significant difference  over PRP 50% and PPP with p values of <0.05.  
4.7.2.2  Wound / Scratch Assay 
There were no demonstrable statistical difference between the mitomycin treated and non-treated 
wound assay for either HEK or NEB-1 cell (Fig 4.11 a, b, c & d). Treatment with PRP 5% used a 
promising migratory effect over all the other treatment although did not reach statistical significance. 
On the other hand, fibroblast wound assay (Fig 4.11e) with PRP 5% showed a significant cell 
migratory effect over the other treatment concentration with p value of 0.001.  Elimination of cell 
proliferation bias was not achievable with human fibroblast, the mitomycin had a strong apoptotic 
effect on fibroblast, and hence, the assays were performed without mitomycin treatment.  
Furthermore the decreasing dose dependent pattern was clearly demonstrated with fibroblast scratch 
assay. 
4.7. 3 Angiogenesis Assay with HUVEC 
Nodal formation with HUVEC showed significance on univariate analysis with p value of 
<0.0001and  PRP 5% has the most positive angiogenic effect and also reaching significance over 
PRP 50% and PPP with  p value of <0.005( Fig 4.12 a). Mesh formation analysis was similar to 
nodal formation, with significance on one –way ANOVA of variance of < 0.0001 and PRP 5% has 
the most angiogenic effect. PRP 5% was significant over positive control (p of <0.001) and p value 
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of <0.0001 for PRP10%, 25%, 50% and PPP (Fig 4.12b). The decreasing dose dependent trend was 
also observed with nodal and meshes formation. Skeletal length measurement did not show any 
significance both on univariate analysis and on post –hoc testing (Fig 4.12c). Finally, analysis of 
cellular area covered showed an inverse proportionality graphical when compared with mesh and 
nodal formation (Fig 4.12d). This could mean that this particular parameter is not a reliable means 
of assessing angiogenic effect.  
4. 7.3.1 Rationale for Combining Morphometric and Topological Parameters 
The combination of the morphometeric and topological parameters seems to sufficiently describe 
morphological changes in angiogenesis. Hence, the observation qualifies these 2 parameters as a 
significant characteristic of a 2D branching and anatomising structure.  Although, the matrigel assay 
does not simulate the whole process of angiogenesis, it provides valid and objective assessment of 
the two key angiogenic pathways which are the migration and differentiation of endothelial cells. 
Until recently, morphometric methods to evaluate the effects on Matrigel of angiogenic inducer or 
inhibitors were mostly descriptive. The changes in tubule formation present the principal angiogenic 
response in this assay.  
The combination of the topological and morphometric parameters provides an objective and 
reproducible measure in assessing anti or pro-angiogenic effect of a given experimental condition 
(Guidolin D et al,. 2004) in their recent study showed that total length of the formed capillary next 
work per unit field area appears to be more accurate descriptor since its values is less influenced by 
the presence of cell aggregates among the tubules. It is important to know that morphometric 
parameters do not fully characterise the architecture of the tubule pattern, in that there other 
physiological features of angiogenesis that this does not account for, such as branching density and 
sprouting. Also the topological parameters have the added advantage of allowing detection of 
changes in the cell arrangement even in the conditions where no meshes are formed, in cases of high 
inhibition and early stages of angiogenesis. New techniques are available that allow morphometry of 
three-dimensional structures  allowing quantitative measurement of vessel diameter and lengths, 
intervascular and interbranching distances as well as branching (Brey et al ,2002).   
4. 4  DISCUSSION 
 
The wound-healing process is a complex mechanism characterized by four distinct, but overlapping 
phases: haemostasis, inflammation, proliferation, and remodelling. The proliferative phase includes 
blood vessel formation by endothelial cells and bone synthesis by osteoblasts. We developed an 
experimental model to test our hypothesis that PPR has a biological effect in the wound healing 
process. It has been demonstrated that the release of PDGF-BB, TGF-β1, bFGF, and VEGF is 
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significantly regulated by the amount of calcium and thrombin added to the PRPs, and that PRP 
supernatants are more mitogenic for endothelial cells than whole-blood supernatants, reinforcing the 
scientific evidence for a beneficial role of PRPs in tissue regeneration (Lacoste et al., 2003; 
Martineau et al., 2004).  Other GFs such as epidermal growth factor (EGF), transforming growth 
factor-alpha (TGF- α), and insulin-like growth factor-1 (IGF-1), angiopoietin-2 (Ang-2), and 
interleukin-1beta (IL-1 β) are also known to play important roles in the wound-healing process 
(Werner and Grose, 2003). All these events are coordinated by cell-cell interactions and by soluble 
GFs released by various cell types. Thrombin represents a strong inducer of platelet activation 
leading to GF release (Furman et al., 1998). It is also known that particulate grafts, when combined 
with calcium and thrombin-treated PRPs, possess better handling characteristics and higher GFs 
content (Froum et al., 2002; Weibrich et al., 2002). Hence, in this study both the PRP and PPP were 
activated with autologous derived thrombin before quantification of the growth factors of interest. 
PRPs from 14 healthy donors and 6 diabetic patients were prepared according to the PCCS system, 
with platelet yields and recoveries similar to already published series. 
4.4.1 Proliferation of HDF, HUVEC and HEK 
PDGF is a powerful mitogen for fibroblasts and smooth muscle cells and is involved in all the three 
phases of wound healing ( Hosgood, 1993).  PDGF is composed of two polypeptide chains (A and 
B) combined in three disulfide-linked dimeric forms (AA, AB, and BB). Human platelets have all 
three PDGF dimmers, in quantities of approximately 65 percent AB, 23 percent BB, and 12 percent 
AA. In this study, PDGF-AA was evaluated because of its easy commercial availability. In contrast, 
the TGF-β family of proteins has a distinguishing ability in that they reversibly inhibit the growth of 
a number of cell types, particularly cells derived from the ectoderm such as keratinocytes and 
leukocytes (Olashaw et.al, 1986). However, it has been reported that TGF-β are weak mitogens for 
cells derived from the mesoderm, such as fibroblasts.   Furthermore, activated PRP has also been 
shown to be mitogenic for a variety of cell types, such as human mesenchymal progenitor cells, 
mesenchymal stem cells from adipose tissue, endothelial cells, and human osteoblasts and gingival 
fibroblasts. (Kilian et.al 2004, Kocaoemer 2007, Graziani et .al, 2006) 
 
Graziani et al. 2006, reported that the maximum effect of activated platelet-rich plasma was achieved 
in a concentration of 2.5 x platelet-rich plasma, with higher concentrations resulting in a reduction of 
cell proliferation.  Choi et al, 2005, examined the influence of platelet-rich plasma concentrations on 
the viability and proliferation of alveolar bone cells, and the results showed that the viability and 
proliferation of alveolar bone cells were suppressed by high platelet-rich plasma concentrations but 
were stimulated by low platelet rich plasma concentrations (1% to 5%).  Another study by Kakudo 
et. al, 2008, showed that activated PRP also stimulated the proliferation of human adipose–derived 
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stem cells and human dermal fibroblasts. This result showed that 1% and 5% were suitable 
concentrations for human adipose–derived stem cells proliferation, and 5% was a suitable 
concentration for human dermal fibroblasts.  Kakudo et. al, postulated that the difference in the 
degree of cell differentiation (adipose-derived stem cells and mature fibroblast) may have influenced 
the sensitivity of PRP to cytokines leading to differences in the appropriateness of concentrations.  
  
Endothelial cell proliferation, which represents a key step in the angiogenic process, was chosen as 
an in vitro model, based on the work of Knighton et al., who demonstrated that the use of thrombin-
treated platelets significantly increased the healing rate of the rabbit cornea, which directly 
correlated with the induction of angiogenesis. In this study, we found that supernatants collected 
after PRP activation with thrombin and calcium significantly enhanced proliferation of HUVECs in 
vitro. A similar decreasing dose dependent pattern was noticed with 5% producing the optimal 
proliferative effect. A similar biological effect of PRP on HUVEC has been published by Martineau, 
2004 and Bertrand-Duchesne, 2009.  Human epidermal keratinocyte behaved slightly different to the 
HUVEC and HDF cells, in that the control experiment showed the maximal proliferative and 
statistical significant effect over the various concentration of PRP. Although the decreasing dose 
trend was still maintained, the positive control cultured well showed a far more proliferative effect in 
both HEK and NEB-1 cell.  
 
Switalska et. al 1985, demonstrated that in addition to the growth factors released from platelets and 
their positive effect on wound healing, thrombospondin (TSP) is also abundant in the α- granule of 
platelets. TSP family consist of five members (TSP 1-5). TSP-1 is believed to inhibit adhesion, 
proliferation and tube formation of endothelial cells in celluture, and has been found to block 
neovascularization of chick chorioallantoic membrane (Bornstein, 1994). TSP-1 also inhibits the 
migration and proliferation of endothelial cells invitro. However, there is no evidence to suggest a 
similar inhibitory function on wound healing for TSP 3-5 (Armstrong, 2003).  Thrombospodin-1 is a 
well investigated angiogenesis inhibitor released by platelets, but this molecule is seldom mentioned 
in studies of PRP.  Weiberch et al., 2002, Okuda etal., 2003 and Eppley 2004 reported that the range 
of TGF-β1 concentration is 120-169.4 ng/mL and that of PDGF- AB is 117.-182 ng/mL.  In our 
study we reported quantified PDGF-AA and TGF- β1 from healthy donor as 131- 123.6 ng/ml and 
27.24- 32 ng / ml respectively.  
 
The concentration of TSP-1  in this study was reported as 1184- 2866 ng/ml which is obviously 
about 10 times the greater than PDGF-AA and 90 times  greater than TGF- β1.  It‘s currently 
unknown whether TSP-1 serves as a more potent negative healing factor than any of the specific 
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growth factors found to be released by platelets in PRP preparation. From the published series, Hsu 
et.al 2009 showed that TSP-1 has similar antiproliferative effect on human osteoblast, periodontal 
ligament fibroblast and endothelial cell. Although there were no sufficient prove that TSP-1 was 
responsible for the antiproliferative effect of high concentrations of PRP on the cell investigated. 
This result is very similar to our result, in that an antiproliferative effect was observed on Ea.hys 
cell, HUVEC, HDF, Neb-1 cell and HEK. This phenomenon appears to be in an increasing dose 
dependent fashion. Furthermore, HDF showed marked reduced cell proliferation when serum-free 
controls was tested, but cell proliferation markedly increased in the presence of activated platelet- 
rich plasma on day 5 of cell culture to more than 2-fold increase. It is worth mentioning at this point 
that platelet poor plasma and inactivated plasma showed some positive biological proliferative effect 
in  all the cell type, howbeit, little effect. 
 
Based on our study and other published data, the proliferative effects of PRP on cells have an 
optimal range of concentrations instead of a continuous linear relationship. One plausible 
mechanism for the nonlinear relationship may be the complex composition of proteins released by 
the platelets. Negative regulators may nullify or reduce the positive effect of growth factors released 
by platelet. Further research with TSP-1 neutralized antibody or a competitive assay to clarify the 
mechanism of TSP-1‘s negative effect on wound healing might be helpful in understanding this 
phenomenon.  In addition to TSP-1, there are other cytokines which may have a negative biological 
effect from PRP. In our study, we also measured Platelet factor-4 (PF-4) along with TSP-1 from 
activated PRP, PF-4 have been shown to have potent anti-angiogenic effect but has not been directly 
related to cell proliferation  (Taylor and Folkman, 1982). 
4. 4. 2 Migration Assay with HDF, HUVEC and HEK 
In this study, we have demonstrated using two different in vitro assays of cell migration (modified 
Boyden chambers and wound /scratch assay) that PRP has a positive migratory effect on HDF. In 
addition, PRP also produced a positive migratory effect on HUVEC and Ea.hys cell on transwell 
migration assay, however PRP show some migratory effect on HEK and NEB-1 cell but less 
pronounced as compared with the positive control experiment, the scope of this study did not allow 
us to fully explore this seemingly different response of keratinocyte to PRP. 
 
The mechanisms of keratinocyte motility are not fully understood however, Odland and Ross, 1968, 
demonstrated that lamellipodia formation occurs when human keratinocytes become migratory 
during reepithelialization. Ezrin, moesin, and radixin are constitutive proteins involved in the 
formation of lamellipodia (Pestonjamasp, 1995). Another mechanism involved in cellular motility is 
the expression of metalloproteinases (Pilcher, et.al 1997). It has been shown that dermal fibroblasts, 
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human keratinocytes synthesize and secrete type I and type IV collagenases (Petersen, 1990). 
Moreover, these collagenases exhibit increased expression when the keratinocytes are migrating. A 
matrix of interstitial collagen induces keratinocyte motility and the expression of collagenases 
(Petersen, 1990). In study coordinated by Decline and Rousselle, 2001, confirmed that keratinocyte 
migration on plastic, fibronectin or collagen IV substrates requires endogenous laminin-5 
depositions, which is predominantly detected under its unprocessed form. In addition, they evidence 
that the alpha2beta1 integrin-laminin 5 interaction is absolutely required for keratinocyte migration 
and that the alpha2beta1 integrin is responsible for cell spreading on laminin 5.  
 
O‘Toole et. al. 1997, in their study demonstrated motility of human keratinocyte on extracellular 
matrices under normoxic and hypoxic conditions in two independent migration assays. The colloidal 
gold assay measures the migration of single keratinocytes apposed to a matrix and used the in vitro 
scratch assay measures the migration of a confluent sheet of keratinocytes over matrix. The study 
showed that hypoxia significantly enhanced keratinocyte motility on collagens and fibronectin 
compared with normoxic conditions. The pro-migratory effect of hypoxia is comparable in potency 
to soluble factors like EGF, TGF-a, and IL-1a (Cha .et.al. 1996). This result is counter to the notion 
that reduced oxygen tension has a negative effect on wound healing (Conlon et.al .1994). While 
hypoxia may not be beneficial for overall wound healing, certain elements of the wound healing 
process such as re-epithelialization may be initiated and promoted by hypoxic conditions. 
  
Celotti et al. 2006 showed from their study that PRP in vitro has a strong, dose-dependent, 
chemoattractant activity on human (SaOS-2) osteoblasts cell line and the effect of PRP on SaOS-2 
cell migration is maximal with protein of higher molecular weight. Among the GFs released in PRP 
from platelet α-granules upon activation, are PDGF and TGF- β, which have higher molecular 
weight and more abundant.  To understand the role of these two growth factors in PRP-induced 
chemotaxis, PRP was preincubated with specific neutralizing antibodies directed toward human 
PDGF and TGF-β. The concentration of the antibodies was selected based on the reported 
concentrations of these growth factors in PRP and on the neutralizing capacity of the antisera.  
 
The data presented show that the chemotactic activity exerted by PRP on SaOS-2 cells is completely 
neutralized by the anti-PDGF. These results are in substantial agreement with those of Gruber et al., 
2004 and Fiedler et .al, 2004, whom have both shown that PRP of adult volunteers, obtained from 
thrombin-activated platelets, increases migration of bone marrow-derived mesenchymal progenitor 
cells and bone marrow derived cells. Furthermore, neutralization study indicates that TGF-b does not 
produce a significant effect on SaOS-2 cell migration. 
 
  
 
 
155 
4. 4. 3 Angiogenesis Assay  
The angiogenic process is regulated both by positive and negative cytokines that modulate the 
migration, proliferation, proteolytic activity, and differentiation of endothelial cells (Risau, 1997). 
One of the most specific tests for angiogenesis is the measurement of the ability of the endothelial 
cells to form three-dimensional structures (tube formation). Endothelial cells of all origins appear to 
be able to form tubules spontaneously, given time in vitro to lay down appropriate extracellular 
matrix components.  Note that tubule formation in vitro hardly simulate the whole process of 
angiogenesis, it has become a useful in vitro assay of at least two key steps in angiogenic pathway, 
the migration and differentiation of endothelial cells. The discovery of Matrigel has completely 
changed the in vitro assessment angiogenic properties. However, it is crucial to understand that most 
commercially available Matrigel has high level of growth factors and proteins that have been shown 
to have angiogenic property.  Therefore for the purposes of our study we used growth factor reduced 
Matrigel. 
The angiogenic effect of a compound is the ability to increase or decrease capillary-like structure 
formation in matrigel when added directly to medium covering endothelia cell. After completing the 
in vitro angiogenesis assay, we can categorically say that the observed angiogenic effect seen after 
incubating PRP with HUVEC Matrigel is a true reflection of the tubular forming potential of PRP.  
All the varying concentrations of PRP (5%, 10%, 25% and 50%) in our study showed a positive 
angiogenic effect, however this effect appears to be in the decreasing dose dependent pattern with 
PRP 5% showing the most positive effect.  PPP did not show quality or well define tubular 
formation; the HUVEC when treated with PPP appears to form clumps of cells. To justify this 
observation we decided to analyse the morphometeric and topological parameters after the complex 
tubular network process.  
With the use of matrigel assay, dimensional (percentage area covered by endothelial cells and the 
length of the cellular network per field), and  topological (the number of meshes and the number of 
branching points per field) parameters can easily be assessed. These two parameters collectively 
provide a measure of the amount of formed tubules. Changes in tubule formation represent the 
principal in vitro angiogenic response that can be used as a measure of angiogenic activity. 
Dimensional parameter does not fully characterize the architecture of the tubular pattern. 
Topological parameters in addition provide physiological information concerning endothelial cell 
organisation. Branching point appear more useful, because it allows for detection of changes in the 
cell arrangement even in conditions where no meshes are formed (Guidolin et.al, 2004) 
Qualitative and semi-quantitative were the mainstay of evaluating angiogenesis assay in the recent 
past, this technique has a number of inherent flaws. The nodal and mesh formation analysis which 
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are forms of morphometric measurement correlates with the pro-angiogenic process (Figure 4a 
&4b). PRP 5% showed the most predominant angiogenic effect and is statistically significant over 
the positive control and other varying concentration of PRP /PPP. Furthermore, a similar effect was 
noticed with measuring skeletal length but PRP 5% did not reach any statistical significance over 
other forms of treatment (Figure 4c). This is probably because the software analysed all connections 
on the acquired image without factoring the morphologic structure of the formed tubule.  Analysis of 
total cellular area showed a reversal of the angiogenic effect observed with PRP 5% (Figure 4d). 
This analysis may appear miss-leading because cellular area takes into consideration the whole field 
that is involved during the angiogenesis process without consideration for morphologic changes and 
the quality of the capillary network formation. This proposed method did not take into account the 
quality of capillary network formation.  From our study, we believe that with repeats of experiments 
that analysis of skeletinised length of the tubular network will be a useful parameter in the 
evaluation of angiogenesis assay.  Although this method of qualitative analysis has not been 
validated through testing with other endothelial cells from other sources; we proposed that analysing 
the nodal formation, mesh formation and the skeletinised length of the tubule as has a direct 
correlation to angiogenic effect.  
We concluded that the analysis of the complete process of angiogenesis will give a better 
quantitative description of angiogenesis assay as compared to analysing the whole process as other 
authors have argued. Basu et. al, 2008,  Movafagh et ,al 2006 and Xu et al. 2008, all  of these studies 
provides measurement of different steps of angiogenesis process. These approaches failed to take 
into account that a reorganization of endothelial cell occurs once cell-cell contacts have been 
established and thus this occur over time during angiogenesis. Another draw back of these 
approaches is that they tend to consider many variables such as the cell sprouting, cell connections, 
polygonal structure and total number of cells used in the angiogenesis process and the postulation of 
complex formula before angiogenic activity of a compound could be established. 
We have been able to demonstrate a positive angiogenic effect of PRP on HUVEC and a possibility 
of decreasing dose dependent effect which was also observed during cell proliferation and migration 
assay with HUVEC. This observed phenomenon raises the suspicion that there might be other anti-
angiogenic growth factors present within the PRP. Some authors have suggested that TSP-1 and PF-
4 are likely to account for this phenomenon. Jimenez et. al, 2000, demonstrated that TSP-1  inhibits 
angiogenesis in vivo and in vitro through CD36 binding, triggering a signalling cascade through 
caspase-3-like protease and stress-ac on such using TSP-1 neutralized antibody or a competitive 
assay to clarify the mechanism of TSP-1 negative effect on wound healing.  
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4. 5   CONCLUSION 
 
In conclusion, PRP is a easily available blood derivative containing high concentrations of growth 
factors and cytokines, when applied has the ability to potentiate tissue repair through acting on 
cellular recruitment, proliferation, angiogenesis and migration. The role of its individual constituents 
in promoting tissue repair remains to be fully elucidated. On the basis of the observations made from 
utilizing human primary cells and cell lines, PRP possess chemotactic effect on HUVEC, Ea.hys and 
HDF and also on HEK and NEB-1 cell howbeit weak.  The PRP also has a great potential to 
positively exert a  mitogenic effect on all the cell types used , although this effect appear minimal on 
HEK and  Neb-1 cell and did not reach a statistical significant level.  Perhaps, the net effect of PRP 
represents the result of agonist and antagonist actions of the different growth factors. Finally, a 
commonality was observed in all the assay and cells types, which is the decreasing dose-dependent 
effect, with 5% PRP concentration producing the most optimal condition for proliferation, migration 
and angiogenesis. PRP has the potential of promoting wound healing and soft-tissue remodelling 
without the risk of immune rejection or infection, which, when more clearly defined, might allow for 
better use of this platelet derivative in the future. 
 
.  
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                                               CHAPTER 5 
     Immuno-histochemistry Changes in Chronic Diabetic Foot   Ulcers    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.1 Morphological changes in the Epidermal Structure of Wounds during Healing. 
 
Although an orderly and carefully orchestrated series of events leads to successful repair of acute 
wounds but the repair of chronic wound is highly compromised. Chronic diabetic cutaneous ulcers 
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are the most common cause of lower limb amputation (Pecoraro et. al 1990). The inability to heal 
chronic ulcers has been attributed to impairment of a variety of biological mechanism such as 
senescent fibroblast, prolonged inflammatory response, cytokines and growth factors deficits, lack of 
protease inhibitors (Falanga 2004, Tomic-Canic et. al 2004). Failure of re-epithelisation may be the 
consequence of any combination of the above mentioned factors. 
During acute wound injury, basal keratinocytes at the dermal-epidermal junction (DEJ) in uninjured 
skin undergo differentiation to ultimately create the strong skin barrier to the external environment. 
The stratified layers of complex epidermis can be distinguished by expression of differentiation-
specific pairs of keratin intermediate filaments (Fuchs, 1995). Interfollicular basal keratinocytes 
express keratins 5, 14, and 15 are attached at the dermis at the DEJ. Expression of keratins 1, 10, and 
K2 in suprabasal keratinocyte is an indication of keratinocyte differentiation (Usui, et.al, 2008).  In 
acute wound injury, suprabasal keratinocytes adjacent to the site of injury from the wound margin 
begin to express keratins 6 and 16 after about 24hrs of wounding (Usui et.al 2005).  Keratin 6 and 16 
are associated with a change in keratin filament arrangement, conferring keratinocyte with a more 
activated phenotype (Paladini et.al. 1996). After about 48 hrs of wounding, keratinocyte in the 
migrating tongue of acute excisional wounds begin to down-regulate expression of keratins 1,10,2 
(Usui et.al, 2005) while expressing K6 and K16. Normal differentiation resumes after epidermal 
wound closure is achieved.  
In normal acute wounds, a proliferative burst of keratinocytes behind the migratory keratinocyte 
wound margin occurs between 24 and 72 hrs after injury, with resumption to a constitutive 
proliferative population of approximately 10% of the basal keratinocytes after wound closure (Usui 
et.al, 2005).  In addition to the changes in the keratinocyte and  its keratin expressions, deposition of 
laminin 5, epiligrin, kalinin and nicein starts from the leading edge of the keratinocyte, these are key 
basal membrane proteins (Hamil and McLean 2005; Marinkovich et.al 1992). There are also 
corresponding changes in the expression of trans-membrane receptors (integrins), which laminin 
ligates. Integrins function as adhesive proteins and play a role in cell signalling (Larjava et.al, 2003). 
In the wounded keratinocytes, integrin β1 ligates with the precursor form of laminin to mediate 
keratinocyte migration (Carter et.al, 1991) and also ligates with  laminin after undergoing excellular 
protelytic processing to mediate stable anchorage of keratinocytes to the basement membrane 
(Mercurio et .al 2001).  Integrins plays a   role in heterotypic cell-cell interactions, and is said to be the 
major players in cell matrix interactions and thus also responsible for structural tissue organization 
(Hynes, 1992). Furthermore, integrins are supposed to function as sensors for the extracellular 
environment and for mechanical forces activating cellular signal transduction systems which might in turn 
influence turnover and processing of extracellular matrix (Juliano, 1993). Integrins form obligatory 
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dimmers of one - and a genetically distinct -chain, and in normal adult human epidermis they are 
represented by 21, 31 and 64, which are all restricted to the cells in the proliferating basal layer 
 
The deposition of collagen VII in healing human surgical wound has been demonstrated from day 7 
following wounding and over a similar time course in healing human acute oral wound. Chronic 
lower limbs ulceration is usually characterized by basement membrane destruction and it is likely 
that collagen VII synthesis is required for the restoration of functional basement membrane zone 
(Hopkinson, 1997). The role of Collagen VII in maintaining the stability of the cutaneous basement 
membrane zone and identification of multiple conserved cell recognition domains may be a pointer 
to the fact that Collagen VII may be involved in healing of chronic lower-limb ulcers. The behaviour 
and morphopical changes of keratinocytes in acute wound healing are well understood and the 
changes are expected to follow a logical sequence that will end in complete re-epithelization. But the 
complexity and degree of molecular and physio-structural alteration seen in the chronic wound could 
not allow for a predictable outcome of healing process.  
There have been many studies regarding the role of growth factors in the skin, and several growth 
factors have been reported to have positive effects on skin regeneration through stimulative effects 
on the proliferation of collagen and fibroblasts, and on the growth of keratinocytes (Ehrlich et.al, 
2006; Gold 2007). However, the production, transportation and storage of growth factors require 
high costs, and unintended complications can develop during the processes. Therefore, if growth 
factors can be derived from the patients themselves, superfluous costs could be saved and concerns 
of complications could be set aside to a great extent. Recently, various clinical trials on the role of 
PRP in the treatments of chronic leg ulcers have been conducted, based on this background 
knowledge. However, so far, human studies concerning the mechanism of PRP in chronic diabetic 
wound healing are very limited, perhaps, because of the too many confounding factors and ethical 
consideration. It is debatable whether the favourable clinical effects reported in literature are the 
direct result of PRP treatment or other systemic response to healing. Therefore, we designed this 
current study to evaluate the effect of PRP in the treatment of chronic diabetic foot ulcers.  
Immnuno-histochemistry was performed on all the biopsy samples taken from all the patients, and 
redundant normal skin samples obtained from diabetic patients during debridement was used for 
control experiment. 
Connective tissue formations are meant to prevent scarring during tissue repair and optimum 
deposition of collagen I and III with their proper ratio is important (Wess, 2005). In particular, 
collagen I is responsible for higher tensile strength, whereas collagen III is predominantly found in 
early wound healing stages (Rajan and Murray 2008), and they maintain a particular ratio (Junge, 
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2004)  in healthy skin. The geometrical arrangement of fibrillar collagen and their optimum ratio are 
vital during healing progression to maintain required crosslinked density and mechanical toughness 
(Lehto, 1985).  
 
 
 5.2.1 Profile of Antibody used in the Study  
 5.2.1 Cytokeratin1 (K1) / Cytokeratin 10 (K10) 
Cytokeratin K1 is a member of the family of intermediate filament proteins  that assemble into 
filaments through forming heterodimers of one type I keratin (keratin 9-23) and one type II (keratin 
1-8). Keratin 1 is a differentiation –specific keratin that is predominantly expressed in the suprabasal 
keratincytes in stratified epithelia (De Berker D et.al 1995). The keratin pair K1 and K10 is a marker 
of differentiation. Mutations in keratin 1and 10 results in epidermolytic hyperkeratosis.  Cytokeratin 
1 is a type 1 subclass of keratin; keratin is a suprabasal marker of differentiation in stratified 
squamous (Porter et al.2000) 
5.2.2. Anti-keratin 5 and 14 Antibody profile (K5/K14) 
K5/k14  are predominantly expressed in the basal layer of the stratified epithelia; they demonstrate 
tissue and differentiation specific expression. Keratin 14 is one of two keratins that distinguish 
stratifying epithelia cell types from simple epithelial cell types. Mutations in keratin 5 and 14 cause 
the skin blistering disorder of peidermolyis bullosa simplex. K4/K15 may be useful as a basal cell 
maker and myoepithelial marker in stratified squamous or mixed epithelia (De Berker D et.al 1995) 
5.2.3 Anti-keratin 16 Antibody 
Keratin 16 demonstrates demonstrate specific tissue differentiation. Keratin 16 is expressed in 
suprabasal keratinocyte of wounded epidermis, in cell undergoing rapid turnover; it‘s often referred 
to as hyperproliferating–related keratin. Hyperproliferation keratins K6 and K16 are not found in 
normal skin, however they are expressed in oral mucosa, sole and palm skin. Expression of K6 and 
K16 is seen in wound healing and hyper-proliferative disease such as psoriasis.  
 
 
5.2.4. Anti keratin 14- antibody 
K14 distinguishes stratified epithelial cell types from simple epithelial cell types, it therefore 
characterises stratified / keratinocyte cell types. Found on all cells of keratinocyte lineage, including 
tumours and in glandular tissue found on basal layer (Karashima and Watt, 2002) 
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 5.2.5 Ki67 Antibody 
They are referred to as proliferative maker; this antibody reacts with a nuclear antigen present in 
proliferating human cells. It can be used to evaluate the ki-67 labelling index in various tumours. 
Ki67 antigen is the prototypic cell cycle related nuclear protein, expressed by proliferating cells in all 
phases of the active cell cycle (G1, S, G2 and M phase). It is absent in resting (G0) cells (McSheehy, 
2010).  Ki67 antibodies are useful in establishing the cell growing fraction in neoplasm and have also 
been used in hyper-proliferative wound edges and scars. 
5.2.6 Anti –Integrin β1 Antibody 
Integrins are heterodimers cell surface receptors composed of alpha and beta subunit, which mediate 
cell-cell and cell-extracellular matrix attachments. Loss of integrin β1 is associated with the 
development of some epithelial tumours (Marshall, 1998). Integrin β is expressed in the basement 
membrane. 
5.2.7   CD31 
CD31 is also called platelet/endothelial cell adhesion molecule. CD31 is a single chain type 
transmembrane protein with a molecular mass of approximately 135 kDA. CD31 binds in both a 
homophilic and heterophilic manner. The heterophilic ligands include heparin sulphate 
glycosaminoglycans, heparin and integrin αv β3. CD31 is involved in the adhesive interaction 
between leucocytes and endothelial cell. CD31 is expressed on all continuous endothelial surfaces 
for example arteries and vein, however, not on discontinuous endothelium surfaces, such as splenic 
red pulp. It is also expressed diffusely on the surface of platelets and myeloid cells and homeopoetics 
cells line. The antibody can be a useful tool in determining rate of new vessel formation during 
malignant  and or in wound healing process. 
5.2.8 CD44 
CD44 is also referred to as homing-associated cell adhesion molecule (H-CAM). CD44 is a type 1 
transmembrane adhesion molecule with molecular weight of 85-90 kDa. CD 44 is a glycoprotein 
with extensive 0-linked glycoslylated and 6 potential N-linked glycosylated sites. CD44 is a cell 
surface receptor for hyaluronate suggesting a role in the regulation of cell and cell substrate 
interactions as well as cell migration. CD44 is expressed on wide variety of cells such as on the 
haematopoietic system, epithelial cells, fibroblast, skeletal muscle and central nervous system white 
matter.  
5.2.9   Collagen I 
Collagen has a characteristic uninterrupted Glycine XY triplet repeat that is a necessary part of the 
triple helical structure. Collagen I is  found in bone, cornea, skin and tendon, with a molecular weight 
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of about 95 kDa. There may be a cross reactivity with other forms of collagen (Ponsioen et. al, 
2008). Some class of specific anti-collagens may be specific for three dimensional epitopes which 
may result in diminished reactivity with denatured collagen or formalin-fixed, paraffin embedded 
tissues. Mutations of the encoding gene are associated with osteogenesis imperfecta and Ehlers 
Danlos syndrome.  
5.2.10 Collagen III 
Collagen III is a fibrillar collagen that is found in extensible connective tissue such as skin and 
vascular system, frequently associated with type I Collagen.  This type specific collagen antibody 
only recognizes 3D epitopes, has negligible cross reactivity with type I, II, IV, V or VI collagens 
(Ponsioen et. al 2008).  Genetic mutations of this collagen are associated with Ehlers Danlos type IV, 
and with aortic and arterial aneurysms. 
5.2.11 Collagen VII 
Collagen VII is a basement membrane component which is the major protein in the anchoring fibrils 
projecting from the lamina densa into the subject of the connective tissue. Collagen VII is a 
homotrimer of α1 (VII) pro-collagen chains, with molecular weight of about 350kD, in which the 
central triple-helical collagenic domain includes 19 non- triple-helical interruption (Christiano, 
1994). The structural role of collagen VII may be inferred from the instability of the basement 
membrane zone observed in epidermolysis bullosa dystrophia, a blistering skin disorder that is often 
associated with mutations in collagen VII gene (Uttio J, 1992). Collagen VII has been found in the 
basal lamina of stratified epithelia such in as epidermis, oral oesophageal and cervical epithelium.  
 
5.3 MATERIALS AND METHODOLOGY 
After obtaining ethical approval from the east and city of London Committee, a single 6mm punch 
biopsy was allowed to be taken from patients with chronic diabetic foot ulcers recruited into the 
study.  (See details in chapter2).  Immunioperoxidase technique was employed for the antibody 
testing, however some antibody were not detectable on paraffin section, therefore frozen section was 
employed for K16 and Collage VII.  The optimization technique for each antibody has been fully 
discussed in chapter 2 under section 2.2.4 & 2.2.5 and tables 2.1 & table 2.2.   The initial design 
of the study was aimed at comparing 2 groups of patients treated differently. One group was to be 
treated with PRP (the active group) and the other group treated with PPP (non-active group).  
However, due to patient choice and time limitation for the study, we could only recruit patients to the 
active arm.  In order to have a comparison group, redundant part of the normal tissue samples from   
another patient undergoing wound debridement was used for control expierment. 
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5.3.1 Photomicrography 
 
All slide sections were viewed on a Nikon Microphot-SA microscope using either standard bright 
field or differential interference contrast. After confirmation of the desired staining intensity, all the 
slides were scanned using the Nano zoomer digital pathology system (Hamamatsu).  This scanner 
has the ability to capture a complete macro image on the glass slide, and the images are immediately 
transferred into soft ware programme which allows the acquired images to be viewed at varying 
magnification. It also allows for the acquired images to be archived, assessed by a separate assessor 
on stored file without having to carry the slides and microscope about. The software also allowed for 
annotation and geometric measurement on the scanned images.  
  
5.3.2 Quantification of Haematoxylin and Eosin  
 
After scanning and storing of the H&E slides, with the help of the NanoZoomer Digital pathology 
system, the epithelial layer of each of the biopsy sample was stratified into the corneum, garnulosum, 
spinosum and the basal layer and measured as a percentage of the whole epithelial layer (Figure 
5.1). Furthermore, the presence of inflammatory cells were assessed in the dermal layer and 
quantified from no inflammatory cell to severe inflammatory cell (Figure5.2). The results from all 
the 7 patients (Table 5.2) were plotted and represented on a histogram, which demonstrate the 
characteristic changes in the different epithelia layer during wound healing process of a chronic 
wound. The percentage change in the individual layers of the epithelium could possibly to be used to 
assess normal progression of wound healing towards complete re-epithelisation of the wound in 
question. 
 
 
 
 
Antibody Clone Clonality Subclass Species 
raised in 
Tissue 
Type 
Location 
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Antibody Clone Clonality Subclass Species 
raised in 
Tissue 
Type 
Location 
Cytokeratin 
K1 
LL017 Monoclonal IgM Mouse Paraffin  Suprabasal 
Cytokeratin 
K10 
LH2 Monoclonal IgG1 Mouse Paraffin Suprabasal 
Cytokeratin 
K5/k14  
LH8 Monoclonal IgM Mouse Frozen 
section 
Basal 
Cytokeratin 
K16 
LL025 Monoclonal IgG1 Mouse Frozen 
section 
Suprabasal 
Cytokeratin 14 LL01 Monoclonal IgG2ak Mouse Paraffin All keratinocyte 
layer 
Ki67 MM Monclonal IgG1 Rabbit Paraffin Basal & dermis 
 
integrin β1 4B7 Monoclonal IgG1 Mouse Paraffin Basement 
membrane 
CD31 JC70A Monoclonal IgG1 Mouse paraffin Endothelia cell 
CD44 DF 
1485 
Monoclonal IgG1 Mouse Paraffin Haemopoietic 
cells,epithelial 
and CNS cells 
Collagen I  Polyclonal IgG Human/ 
bovine 
placenta 
Paraffin Dermis 
Collagen III  Polyclonal IgG Human/ 
bovine 
placenta 
Paraffin Dermis 
Collagen VII LH7.2 Monoclonal IgG1 Mouse Frozen 
Section 
Basement 
membrane 
 
Table 5.1 Profile of the different Anticytokeratin, Cell surface maker and collagen Antibody 
used during immunohistochemistry experiment. 
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Corneum layer
Granulosum layer
Spinosum layer
Basal layer
Dermal layer
 
 Figure 5.1 Measurement of the stratified epithelial layer from microphotographic  H&E staining of 
biopsy skin. Measurement of individual layer was possible through the Nano Zoomer  Digial 
pathology system. 
               
Papillary
Dermis
Rete
Dermis
 
Figure 5.2  Microphotogarhic H&E staining of a wound biopsy with inflammatory cells 
distributed in the dermis. The rectangular space represents area of aggregation of inflammatory 
cells, the cell were counted at HPF x20 and graded; as zero for no inflammatory reaction for, + few, 
++ mild, +++ for moderate and ++++ for severe inflammatory reaction.  
 
  
 
 
167 
 
                   Completely re-epithelised ulcer                   Non- healed ulcer 
   Day 0              
                                                 
    Day 8          
         Wk 4       
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       Normal     
 
 
Figure 5.3 Microphotograhic H&E representation of the 2 categorises of chronic diabetic foot ulcer, 
A-D) represents ulcers that achieved complete re-epithelisation, E-H) represents ulcer that was not 
healed after 16 weeks of PRP treated and standard wound care. Comparing the histological changes 
between the 2 groups; the thick and nucleated corneum layer in the non-healed group is 
characteristic of a recalcitrant ulcer. There is a gross distortion in the structural architecture of the 
epithelial layer. There is a general decrease in cellular activity in the granulosum and spinosum layer 
from day 0 to week 16 as evident by decrease in the size of the layer as the wound progresses 
towards healing. On the contrary, the cellular activity in these layers remains perpetually active in 
the non healing group. I) represents the normal skin biopsy from a diabetic foot, whereas J) depicts a 
chronic diabetic foot ulcer with abnormal orientation in the epithelial layer interspared with dermis 
and thick corneum layer. Some of the characteristic histological features of chronic wound are 
evident on slides E-H such as  koilocytes, hyperkeratosis , hypergranulois and papillary hyperplasia. 
 
Patient ID % 
Corneum 
%  
Granulosum 
% 
Spinosum 
%   
Basal 
Papillary 
dermis 
inflammatory 
score 
Rete dermis 
inflammatory
score 
P1,Day 0 15 51 27 7 ++++ ++ 
P1,Day 8 19 59 17 5 +++ + 
P1 , Wk4 20 60 15 5 ++ + 
P2, day 0 6 44 38 12 +++ +++ 
P2, day8 0 70 22 8 ++++ ++ 
P2, wk4 0 77 17 6 ++ + 
P2, wk8 0 70 18 12 ++ 0 
P3, day0 18 50 24 8 ++ +++ 
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Patient ID % 
Corneum 
%  
Granulosum 
% 
Spinosum 
%   
Basal 
Papillary 
dermis 
inflammatory 
score 
Rete dermis 
inflammatory
score 
P3, day8 21 54 17 8 ++ ++++ 
P3, Wk 4 20 59 16 5 +++ + 
P3, wk8 30 50 15 5 ++ ++ 
P4, day0 58 33 6 3 ++ + 
P4,day 8 68 21 8 3 + 0 
P4,wk 4 64 27 6 3 + 0 
P4, wk8 67 24 6 3 + + 
P5,Day 0 Absent 
epithelia  
   ++ + 
P5, Day 8 Absent 
epithelia  
   ++++ ++ 
P5, wk8 53 28 16 3 + + 
P6, Day 0 38 13 40 9 + 0 
P6, Day 8 51 6 39 5 + ++ 
P6 wk 4 67 13 16 4 ++ ++++ 
P7 , Day 0 47 19 25 9 + +++ 
P7, Day 8 29 13 45 13 + ++++ 
N.diabetic
Dorsum 
skin 
56 21 13 10 + 0 
N.diabetic 
sole of foot 
71 21 6 2 + 0 
 
Table 5.2  Percentage stratification of biopsied epithelia layer from chronic diabetic foot ulcerson 
H&E staining. The degree of inflammatory reaction in the dermis was represented by the severity 
score of  0, +,++,+++ and ++++, which correlates to no inflammation, mild, moderate, severe 
respectively.  
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Figure 5.4 Illustrates the stratification of the epithelia layer obtained from the wound margins 
into  corneum, granlosum, spinosum and the basal layer through H& E staining at Day 0, Day 8, 
week 4 and 8 respectively during the wound healing process.  Figure A) represents the group of 3 
patients that achieved complete epithelisation; the common feature in this group is the increasing % 
of the granuosum layer as healing progresses. Figure B) on the other hand represents the group that 
were unable to heal. The common feature is the higher percentage of the corneum layer compared to 
the granuosum layer which may represent a sign of chronicity. 
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5.3.3 Quantification of CD 31 
  
            Quantitative analysis of angiogenesis is highly suitable for histodiagnosis application because it has 
been performed primarily by immuno-histochemistry on formaldehyde-fix on paraffin embedded 
tissue. All the slides were scanned by the NanoZoomer digital pathology system after 
immuoperioxidase staining. This system allows the area of the fixed histology section to be scanned 
in the original state; this can then be stored and viewed on the computer system either at the same 
time or at a later time.  Four large squares were drawn in the dermis, in the areas of pre-determined   
highest micro-vessel density on the tissue section, the drawn area measured 0.361mm
2
, which is 
perpendicular and away from the epithelia layer. The microvessels within the large square under x20 
magnification were only counted and the average was used as the vessel density (See Fig 5.5). The 
counting of the microvessel was performed by the researcher and also by a senior laboratory scientist 
to account for intra-observer variability. According to Vartanian and Weidner, 1995; any vessel that 
was clearly separate from adjacent vessel and other connective tissue element was considered a 
countable vessel. The vessel lumen, although usually present was not a criterion used to define a 
countable microvessel, red blood cells were not counted. Partially identified vessel, which are not 
contained within the squares were not counted. In each slide, microvessel density was represented by 
the mean number counted in the 4 larger squares in x20 high per field. 
 
                  
                                                                                                                                     
 Figure 5.5 Microphotographic representation of  immunoperioxidase staining for CD31 
antibody. A)   representation of densely populated microvessel area. B) micro-vessels are counted in 
each of the rectangular spaces and  the average represens the total microvessel density of the 
individual slide section.  
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5.4 Statistical Analysis 
 
After stratification of the epithelia layer into its respective percentages, the mean of each of layer was 
calculated for each of the time point of the biopsy and a plot of the mean against the time course was 
performed for individual patients Figure 5.4. Microvessel density was determined by counting the 
vessels as described above. The mean value of the counted microvessel on CD31 for each patient per 
time point was plotted as shown in Figure 5.6. For the immunoperoxidase staining for K14, k1/k10, 
k16, CD44, Collagen I, III and VII; the original slides were scanned through the NanoZoomer digital 
pathology system and achieved,  each slides were scored for staining intensity individually and 
separately by the researcher and a senior laboratory scientist.  The degree of agreement between the 
raters was determined by using the Bland-Altman test on Graph Pad Prism version 5.01 
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         B   
Quantification of CD31 using microvessel density
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Figure 5.6 Quantification of CD31 through the counting of the micro-vessel density. A) 
represents the expression of CD31 antibody taken at day 0, day 8, wk4 and wk8 for 3 patients that 
achieved complete wound healing and  B) represents  the patients‘ ulcer that was not healed. The 
common feature to both categories of patients is the decreasing trend in the microvessel density from 
day 0 to week 8.  Figure 5.4B showed that Patient 6 &7 did not complete the 16 weeks follow up 
program
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             Day 0                                             Day 8                                          week  4                                         week 8                     Unwounded skin (Control)  
K14                
K1/10               
 Figure 5.7 Represents photomicrograph from immuoperioxidase staining for cytokeratin antibody K14 (A-E). The cytokeratin stains the whole of the 
suprabasal layer of the epidermis from day 0 through to week 8, however the positive control in the normal skin was only expressed in the basal layer for a non- 
wounded normal skin.  The expression of cytokeratin K1/K10 antibody usually the two keratin are co-expressed, which was mainly in the suprabasal  layer ( F-
H), the basal layer appeared partly involved wound (I &J)  and a similar patter of expression was demonstrated in a unwounded  normal skin. However the basal 
layer appears to be more deeply stained. 
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                      Day 0                                             Day 8                                         Week 4                               week 8                                  UnWounded skin ( Control) 
                
CD44 
  β-integ          
Figure 5.8  Represents the photomicrograph from immunoperoxidase expression of Beta I- Integrin & CD44   from the biopsied wound margin. The 
expression of beta-I integrin extends from the basal layer (most deeply stained) through to the spinosum, sparing the granulosum layer, a similar pattern of 
expression was seen from day 0-week 8(K-N) and also  a similar pattern in the non-wounded skin (0).  CD44 showed normal distribution along the basal layer 
only both from the wound edge biopsy and from the unwounded skin.                 
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                        Day 0                                 Day  8                                           Week 4                                                Week 8                                    Unwounded skin (control) 
     K16           
C III              
Figure 5.9  Represents the microphotograph from immunoperoxidase expression of cytokeratin K16 antibody and Col III, K16 expression was seen 
throughout the suprabasal layer; the expression was more pronounced  on day  0 and day 8 (U&V), the expression in unwounded normal skin (Y) appeared 
similar to  week 4&8 (W,X). The structure integrity of extracellular matrix protein was maintained throughout the wound healing process (AA-AD). 
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                  Day 0                                        Day 8                                             Week 4                                   Week 8                                     Unwounded skin (control) 
 C. I             
C.VII          
Figure 5.10  Microphotographic representations from immunoperoxidase staining of Collagen I &III. The structure of Collagen I was undistorted 
throughout the wound healing process (AF-AI). Collagen VII synthesis and incorporation into the anchoring fibrils is a prerequisite for the synthesis of a stable 
basement membrane, which is a requirement to restore basement integrity as a prelude to re-epithelisation. Restoration of collagen VII was observed from day 0 
through week 8  and a similar expression was seen in the unwounded normal skin (A-O). ( C I- Collagen I, C VII- Collagen  VII) 
  
 
 
178 
                        Day 0                                                  Day 8                                      Week 4                               Week 8                                        Unwounded skin (control) 
Ki67           
 Ki67          
Figure 5.11 Microphotograpic representations from immunoperoxidase staining of Ki67 represents a proliferation marker; approximately 10% of 
interfollicular basal keratinocytes was seen in unwounded normal skin (E). Expression of Ki67 in wound margin of patients that achieved complete wound 
healing (A-D). Biopsy from ulcer margin from patients that did not achieve complete re-epithelisation, maintained a high expression of Ki67, which is a sign of 
hyper-proliferation, which is a hall mark of chronicity.  
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               K4/15                                                      CD 31                                                             CD 44                                                  K16 
        
 
Figure 5.12 Microphotographic representations from immunoperoxidase staining from positive control K)  Representation of K4/15;  a co-expression of  
keratins which typify differentiation process of keratinocyte. I) Expression of CD 31 in a area of high microvessel density (unwounded skin). M) Expression of 
CD 44 in the normal diabetic skin (Plantar surface of an unwounded skin). N) Expression of  K16 in the normal diabetic skin ( Plantar surface of an unwounded 
skin) 
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Researcher’s Assessment  Operator 2  Assessment  
Patient ID K14  
Granular 
K14 
Spinosum 
K14 
Basal 
K14  
Granular 
K14 
Spinosum 
K14 
Basal 
P1,Day 0 4+ 2+ 1+ 4+ 2+ 1+ 
P1,Day 8 4+ 2+ 1+ 4+ 2+ 1+ 
P1 , Wk4 4+ 3+ 2+ 4+ 3+ 2+ 
0P1, WK8 3+ 2+ 2+ 3+ 2+ 2+ 
P2, day 0 4+ 2+ 1+ 4+ 2+ 1+ 
P2, day8 4+ 2+ 1+ 4+ 2+ 1+ 
P2, wk4 4+ 4+ 2+ 4+ 3+ 2+ 
P2, wk8 4+ 3+ 2+ 4+ 3+ 2+ 
P3, day0 4+ 3+ 2+ 4+ 3+ 2+ 
P3, day8 4+ 3+ 1+ 4+ 3+ 1+ 
P3, Wk 4 3+ 3+ 2+ 3+ 3+ 2+ 
P3, wk8 3+ 3+ 3+ 3+ 3+ 3+ 
P4, day0 4+ 4+ 3+ 4+ 3+ 3+ 
P4,day 8 3+ 3+ 3+ 3+ 3+ 3+ 
P4,wk 4 4+ 4+ 4+ 4+ 4+ 4+ 
P4, wk8 4+ 4+ 4+ 4+ 4+ 4+ 
P5, day 0 3+ 3+ 1 
 
3+ 3+ 1 
P5 day8 No Epidermal  No Epidermal No 
epidermal 
No 
Epidermal  
No 
Epidermal 
No 
epidermal 
P5 wk4 4+ 3+ 3+ 4+ 3+ 3+ 
P5 wk 8 3+ 3+ 3+ 3+ 3+ 2+ 
  
 
 
181 
 
Patient ID K14  
Granular 
K14 
Spinosum 
K14 
Basal 
K14  
Granular 
K14 
Spinosum 
K14 
Basal 
P6 day 0 4+ 3+ 2+ 4+ 3+ 2+ 
P6 day 8 4+ 4+ 3+ 4+ 4+ 3+ 
P6 wk 4 4+ 4+ 2+ 4+ 4+ 2+ 
P7 day 0 4+ 3+ 3+ 4+ 3+ 2+ 
P7 day 8 4+ 3+ 2+ 4+ 3+ 2+ 
N.Diabetic 
skin 
1+ 2+ 4+ 1+ 2+ 4+ 
Normal skin 0 1+ 4+ 0 1+ 4+ 
 
Table 5.3 Immunoperioxidase staining for anticytokeratin K14 antibody examined under X20 
High power field. Staining intensity was assessed across the basal, spinosum and granulosum layer 
and were represented with scores from 0-4; 0- no stain, 1- faintly stained, 2-weak satin, 3- 
moderately stained and 4- strongly stained . The scanned images from NanoZoomer digital 
Pathology system were assessed separately by the researcher and a senior laboratory scientist, in 
order to ascertain the level of correlation between the 2 assessors. Bland–Altman test was used to 
determine the degree of agreement between the two assessors, the closer the average bias to zero the 
less the discrepancy in the degree of agreement between the assessors. The average bias for K14 is 
0.0512 
  
 
 
Researcher’s  Assessment  Operator 2 Assessment  
Patient ID K1/K10 
Granular 
K1/K10 
Spinosum 
 
KI/1K0 
Basal 
K1/K10 
Granular 
K1/K10 
Spinosum 
 
KI/1K0 
Basal 
P1,Day 0 3+ 3+ 2 3+ 3+ 2 
P1,Day 8 3+ 3+ 2 3+ 3+ 2 
P1 , Wk4 3+ 3+ 2 2+ 3+ 1 
0P1, WK8 3+ 2+ 2 2+ 2+ 1 
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P2, day 0 3+ 2+ 1+ 3+ 1+ 1+ 
P2, day8 3+ 2+ 1+ 3+ 2+ 0 
P2, wk4 3+ 3+ 1+ 3+ 2+ 1+ 
P2, wk8 3+ 3+ 1+ 3+ 3+ 0 
P3, day0 3+ 1+ 0 3 1 0 
P3, day8 3+ 2+ 0 3 2 0 
P3, Wk 4 2+ 2+ 0 2 2 0 
P3, wk8 3+ 3+ 3+ 3+ 3+ 2+ 
P4, day0 3+ 3+ 0 3+ 3+ 0 
P4,day 8 2 2 0 2 2 0 
P4,wk 4 2+ 2+ 0 2+ 2+ 0 
P4, wk8 3+ 3+ 0 3+ 3+ 0 
P5, day 0 2+ 2+ 0 2+ 2+ 0 
P5 day8 3+ 3+ 1+ 3+ 2+ 1+ 
P5 wk4 4+ 3+ 0 3+ 3+ 0 
P5 wk 8 4+ 3+ 1+ 3+ 3+ 1+ 
P6 day 0 3+ 2+ 1+ 3+ 2+ 1+ 
P6 day 8 3+ 2+ 0 3+ 2+ 0 
P6 wk 4 4+ 3+ 1+ 3+ 3+ 1+ 
P7 day 0 3+ 3+ 1+ 3+ 2+ 1+ 
P7 day 8 3+ 3+ 0 3+ 3+ 0 
N. Diabetic 
skin 
3+ 4+ 0 3+ 3+ 0 
Normal skin 3+ 4+ 0 2+ 3+ 0 
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Table 5.4 Immunoperioxidase staining for anticytokeratin K1/K10 antibody examined under 
X20 High power field. Staining intensity was assessed across the basal, spinosum and granulosum 
layer and were represented with scores from 0-4; 0- no stain, 1- faintly stained, 2-weak satin, 3- 
moderately stained and 4- strongly stained. The scanned images from NanoZoomer digital Pathology 
system were assessed separately by the researcher and a senior laboratory scientist. The average bias 
on Bland- Altman test was 0.0204 
 
 
 
Researcher’s  Assessment   Operator 2 Assessment 
Patient ID CD44 
Granular 
CD44 
Spinosum 
CD44 
Basal 
CD44 
Granular 
CD44 
Spinosum 
CD44 
Basal 
P1,Day 0 1+ 2+ 4+ 1+ 2+ 4+ 
P1,Day 8 1+ 2+ 4+ 1+ 3+ 3+ 
P1 , Wk4 1+ 3+ 3+ 2+ 3+ 3+ 
P1, WK8 0 0 1 0 0 1 
P2, day 0 0 3+ 4+ 1+ 3+ 4+ 
P2, day8 0 3+ 4+ 1+ 3+ 4+ 
P2, wk4 0 2+ 3+ 1+ 2+ 3+ 
P2, wk8 0 3+ 2+ 1+ 3+ 2+ 
P3, day0 1+ 3+ 4+ 1+ 3+ 4+ 
P3, day8 1+ 2+ 3+ 1+ 2+ 3+ 
P3, Wk 4 1+ 3+ 4+ 1+ 3+ 4+ 
P3, wk8 1+ 2+ 2+ 1+ 2+ 2+ 
P4, day0 0 3+ 3+ 1+ 3+ 3+ 
P4,day 8 0 2+ 4+ 1+ 2+ 4+ 
P4,wk 4 0 2+ 4+ 1+ 2+ 4+ 
P5 day8 0 3+ 4+ 0 3+ 4+ 
P5 wk4 0 2+ 4+ 0 2+ 4+ 
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Researcher’s  Assessment   Operator 2 Assessment 
Patient ID CD44 
Granular 
CD44 
Spinosum 
CD44 
Basal 
CD44 
Granular 
CD44 
Spinosum 
CD44 
Basal 
P5 wk 8 0 3+ 4+ 0 3+ 4+ 
P6 day 0 0 3+ 3+ 0 3+ 3+ 
P6 day 8 1+ 3+ 3+ 0 3+ 3+ 
P6 wk 4 1+ 3+ 2+ 1+ 3+ 2+ 
P7 day 0 0 3+ 4+ 0 3+ 4+ 
P7 day 8 1+ 2+ 3+ 1+ 2+ 3+ 
Normal 
Diabetic skin 
1+ 2+ 4+ 1+ 2+ 4+ 
Normal skin 1+ 3+ 4+ 1+ 3+ 4+ 
Table 5.5 Immunoperioxidase staining CD44 antibody antibody examined under X20 High 
power field. Staining intensity was assessed across the basal, spinosum and granulosum layer and 
were represented with scores from 0-4; 0- no stain, 1- faintly stained, 2-weak satin, 3- moderately 
stained and 4- strongly stained. The scanned images from NanoZoomer digital Pathology system 
were assessed separately by the researcher and a senior laboratory scientist. The average bias on 
Bland-Altman test was -0.0307. 
 
 
  Researcher’s  Assessment  Operator 2 Assessment 
 
Researcher Operator 2 
Patient ID Colg I 
P. Dermis 
Colg I 
R. Dermis 
Colg I 
P. Dermis 
Colg I 
R. Dermis 
Beta-1 int Beta- 1 int 
P1,Day 0 4+ 4+ 4+ 4+ 3+ 3+ 
P1,Day 8 4+ 4+ 4+ 4+ 3+ 3+ 
P1 , Wk4 4+ 4+ 4+ 4+ 4+ 4+ 
P1, WK8 4+ 4+ 4+ 4+ 4+ 4+ 
P2, day 0 3+ 4+ 3+ 4+ 4+ 4+ 
P2, day8 4+ 4+ 4+ 4+ 3+ 3+ 
P2, wk4 4+ 4+ 4+ 4+ 3+ 3+ 
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  Researcher’s  Assessment  Operator 2 Assessment 
 
Researcher Operator 2 
Patient ID Colg I 
P. Dermis 
Colg I 
R. Dermis 
Colg I 
P. Dermis 
Colg I 
R. Dermis 
Beta-1 int Beta- 1 int 
P2, wk8 4+ 4+ 4+ 4+ 3+ 3+ 
P3, day0 4+ 4+ 4+ 4+ 3+ 3+ 
P3, day8 4+ 4+ 4+ 4+ 3+ 2+ 
P3, Wk 4 4+ 4+ 4+ 4+ 3+ 3+ 
P3, wk8 4+ 4+ 4+ 4+ 3+ 3+ 
P4, day0 3+ 3+ 3+ 3+ 3+ 3+ 
P4,day 8 4+ 4+ 4+ 4+ 2+ 2+ 
P4,wk 4 4+ 4+ 4+ 4+ 2+ 2+ 
P4, wk8 4+ 4+ 4+ 4+ 4+ 3+ 
P5, day 0 4+ 4+ 
 
4+ 4+ 
 
3+ 3+ 
P5 day8 3+ 4+ 3+ 4+ 4+ 4+ 
P5 wk4 4+ 4+ 4+ 4+ 4+ 4+ 
P5 wk 8 4+ 4+ 4+ 4+ 4+ 3+ 
P6 day 0 4+ 4+ 4+ 4+ 3+ 2+ 
P6 day 8 4+ 4+ 4+ 4+ 3+ 3+ 
P6 wk 4 4+ 4+ 4+ 4+ 3+ 2+ 
P7 day 0 4+ 4+ 4+ 4+ 3+ 3+ 
P7 day 8 4+ 4+ 4+ 4+ 3+ 3+ 
Normal 
Diabetic 
skin 
4+ 4+ 4+ 4+ 4+ 4+ 
Normal 
skin 
4+ 4+ 4+ 4+ 3+ 3+ 
  
  
 
 
186 
 
Table 5.8 Immunoperioxidase staining for Collagen I and beta-1 integrin antibody examined 
under X20 High power field.  Staining intensity was assess in the papillary and rete dermis and were 
represented with scores from 0-4; 0- no stain, 1- faintly stained, 2-weak satin, 3- moderately stained 
and 4-strongly stained. The scanned images from NanoZoomer digital Pathology system were 
assessed separately by the researcher and a senior laboratory scientist. The average bias on Bland-
Altman test was 0 for collagen 1 and 0.0054 for beta-1 integrin, which means that there was 100% 
agreement between the 2 assessors for collagen 1. 
 
 
 
Researcher’ s Assessment Operator 2 Assessment  
Patient ID Colg III 
P.Dermis 
Colg III 
R. Dermis 
Colg III 
P.Dermis 
Colg III 
Rete Dermis 
Colg VII 
BM 
P1,Day 0 4+ 3+ 4+ 3+ 0 
P1,Day 8 4+ 4+ 4+ 4+ 0 
P1 , Wk4 4+ 4+ 4+ 4+ 1+ 
P1, WK8 4+ 4+ 4+ 4+ 2+ 
P2, day 0 4+ 3+ 4+ 3+ 3+ 
P2, day8 4+ 4+ 4+ 4+ 2+ 
P2, wk4 4+ 4+ 4+ 4+ 1+ 
P2, wk8 3+ 4+ 3+ 4+ 2+ 
P3, day0 4+ 3+ 4+ 3+ 3+ 
P3, day8 4+ 3+ 4+ 3+ 1+ 
P3, Wk 4 4+ 4+ 4+ 4+ 2+ 
P3, wk8 3+ 3+ 3+ 3+ 3+ 
P4, day0 3+ 3+ 3+ 3+ 4+ 
P4,day 8 3+ 3+ 3+ 3+ 2+ 
P4,wk 4 3+ 3+ 3+ 3+ 3+ 
P4, wk8 4+ 4+ 3+ 2+ 2+ 
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Researcher’ s Assessment Operator 2 Assessment  
Patient ID Colg III 
P.Dermis 
Colg III 
R. Dermis 
Colg III 
P.Dermis 
Colg III 
Rete Dermis 
Colg VII 
BM 
P5, day 0 4+ 4+ 4+ 4+ 4+ 
P5 day8 4+ 3+ 4+ 3+ 2+ 
P5 wk4 3+ 3+ 3+ 3+ 3+ 
P5 wk 8 3+ 3+ 3+ 3+ 2+ 
P6 day 0 4+ 4+ 4+ 4+ 0 
P6 day 8 4+ 4+ 4+ 4+ 0 
P6 wk 4 4+ 4+ 4+ 4+ 0 
P7 day 0 4+ 3+ 4+ 3+ 0 
P7 day 8 4+ 3+ 4+ 3+ 1+ 
Unwounded 
Diabetic skin 
4+ 4+ 4+ 4+ 3+ 
Normal skin 4+ 4+ 4+ 4+ 4+ 
 
Table 5.7 Immunoperioxidase staining for Collagen III antibody examined under X20 High power 
field.  Staining was assessed in the papillary and rete dermis. Collagen VII staining was assessed 
across the basement membrane. The intensity were represented with scores from 0-4; 0- no stain, 1- 
faintly stained, 2-weak satin, 3- moderately stained and 4- strongly stained. The scanned images 
from NanoZoomer digital Pathology system were assessed separately by the researcher and a senior 
laboratory scientist. Average bias on Bland –Altman test was 0 for collagen III (100% agreement 
two the 2 assessors) and 0.066 for collagen VII. 
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Researcher’
s  
Assessment Operator 2 Assessment 
Patient ID K16 
Granular  
 
K16  
Spinosum 
K16 
Granular  
 
K16  
Spinosum 
P1,Day 0 2+ 2+ 1+ 2+ 
P1,Day 8 3+ 3+ 2+ 2+ 
P1 , Wk4 3+ 3+ 2+ 3+ 
P1, WK8 3+ 3+ 3+ 3+ 
P2, day 0 4+ 4+ 4+ 4+ 
P2, day8 4+ 4+ 4+ 4+ 
P2, wk4 4+ 4+ 4+ 4+ 
P2, wk8 4+ 4+ 4+ 4+ 
P3, day0 3+ 4+ 3+ 4+ 
P3, day8 4+ 4+ 4+ 4+ 
P3, Wk 4 3+ 4+ 3+ 4+ 
P3, wk8 3+ 3+ 3+ 3+ 
P4, day0 4+ 4+ 4+ 4+ 
P4,day 8 4+ 4+ 4+ 4+ 
P4,wk 4 4+ 4+ 4+ 4+ 
P4, wk8 3+ 3+ 3+ 3+ 
P5, day 0 4+ 4+ 4+ 4+ 
P5 day8 4+ 4+ 4+ 4+ 
P5 wk4 4+ 4+ 4+ 4+ 
P5 wk 8 4+ 4+ 4+ 4+ 
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Researcher’
s  
Assessment Operator 2 Assessment 
Patient ID K16 
Granular  
 
K16  
Spinosum 
K16 
Granular  
 
K16  
Spinosum 
P6 day 0 3+ 3+ 3+ 3+ 
P6 day 8 3+ 3+ 3+ 4+ 
P6 wk 4 3+ 3+ 3+ 2+ 
P7 day 0 3+ 3+ 3+ 3+ 
P7 day 8 3+ 3+ 3+ 3+ 
Unwounded 
Diabetic skin 
4+ 3+ 4+ 3+ 
Unwounded 
normal skin 
4+ 3+ 4+ 3+ 
 
Table 5.8 Immunoperioxidase staining for K16 antibody examined under X20 High power field.  
Staining was assessed in the papillary and rete dermis. Collagen VII staining was assessed across the 
basement membrane. The intensity were represented with scores from 0-4; 0- no stain, 1- faintly 
stained, 2-weak satin, 3- moderately satined and 4- strongly stained. The scanned images from 
NanoZoomer digital Pathology system were assessed separately by the researcher and a senior 
laboratory scientist. Finally, the Bland-Altman test showed that the average bias between the 2 raters 
was 0.0062. 
 
5.5 RESULTS  
There was vast heterogeneity among ulcers from the patients with diabetes. Some ulcers showed no 
sign of active infection requiring only sharp debridement in the clinic (plantar ulcers), whereas others 
were severally infected and ulcer with clinical gangrenous required surgical debridement and or 
digital amputation. The thickness of ulcer edge epidermis ranged from normal (6-10 cell layers) to 
very hyperplastic (20-40 layer) see figure 5.3.  There were some structural changes noticed on some 
of the biopsy samples which resulted in some form of tissue loose either during wound biopsy or 
tissue processing. The documentation of dates and frequency of treatments, such as debridement, 
were recorded and discussed in chapter 6. The heterogenous nature of the ulcers treated may 
account for some of the variability of results. All 7 patients recruited were tested with all the 
antibodies at different time points. A summary of the antibody used and qualitative evaluation of 
immmunohistochemical data are showed in tables 5.1, 5.3-5.8.  
  
 
 
190 
5.5.1 Suprabasal Keratins (K16,K1/K10)/ Basal keratin 
K16 staining was entirely suprabasal, the pattern of expression was similar in the healed and non 
healed groups (Fig 5.11), although not all the patients in the healed group expressed the similar 
staining intensity (Table 5.8), and the average bias between the 2 raters was 0.0062 on Bland-
Altman agreement test which is very close to zero. 
 
K10 mirrored K1 in all samples, the expressions were mainly suprabasal, however some biopsy in 
the non-healed ulcer group showed an altered pattern with involvement of basal layer which are 
deeply stained on the immunoperoxidase (Table 5.4). A similar pattern was seen in the unwounded 
normal skin. The average bias between the 2 rater was 0.0204 on Bland-Altman test. Although the 
main expression of K14 should be mainly basal, we observed that  the entire epidermal layer were 
stained in both groups with the predominate staining in the basal layer, however in the unwounded 
normal skin and diabetic skin (Fig 5.7), the expression of K14 was limited to the basal layer. The 
average bias was 0.0512 on Bland-Altman agreement test. 
 
The distribution of ki67 is mostly in the basal layer although, Ki67 were occasionally seen in the 
suprabasal layer. Ki67 is a marker of hyperproliferation which is a hall mark of chronic ulcer. The 
distribution of Ki67 in the group of patients that achieved complete wound healing decreases as 
normal pattern of healing is restored. In the unwounded skin, Ki67 stains approximately 10% of the 
basal interfolicular keratinocyte (Figure 5.11). The distribution and amount of Ki67 in the week 8 
biopsy when normal wound healing is almost guaranteed wass comparable to the unwounded skin. 
However, the non-healed group the expression of Ki67 remained throughout the 8 weeks of up. 
 
5.5.2 Basement Membrane Zone (Beta-1 integrin, Collagen  VII) 
 Beta -1 integrin was restricted to the basal keratinocytes in the unwounded skin (Figure 5.8), 
however in the wounded biopsy wound margin, although its mainly found in the basal layer, some 
extension towards the spinosum was observed. There appear to be increasing pattern of β1- integrin 
expressing in the basal keratinocyte and some variable expression in the suprabasal layer (Table 
5.6). The average bias between the two raters was 0.0054 for beta-1 integrin on Bland-Altman 
agreement test. 
 
Collagen VII is a basement membrane protein, which is evenly distributed and stained in the 
unwounded skin, however the degree of staining improves as normal re-epithelisation is restored 
during wound healing process (Figure 5.10). The average bias between the two raters was 0.0667 on 
Bland-Altman agreement test (Table 5.7).  
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Cell surface marker CD44 were found in the basal and spinous cell layers, but not present in the 
stratum granulosum and stratum corneum. The expression of CD 44 was more intensed in the post 
debridement biopsy sample (day 0), the intensity decrease as the wound process towards full re-
epitheliasation (Figure 5.8). The average bias was 0.037 on Bland-Altman agreement test (Table 
5.5) 
5.5.3 Extracellular Matrix Marker (Collagen I and III) 
Collagen I and III were assessed both in the rete and papillary dermis for staining in intensity, there 
are to be no difference in the staining intensity. The distribution and integrity of the fibrils appeared 
undistorted during the process of wound in healing (Figure 5.9& Figure 5.9). The average bias was 
zero for both Collagen on Bland-Altman agreement test, which translate to 100% agreement between 
the 2 raters (Table 5.6 &Table 5.7). 
 
5.4.4 Microvesel/ Endothelial Cell Marker (CD31) 
Changes in micro-vessel density from the wound margins were assessed by manually counting the 
number of microvessel in 4 rectangular boxes from a predetermined area of high vascularity. The 
average count represents the microvessel density for that slide (Figure 5.5). The common trend 
noticed from both the healed and the non-healed ulcer group was that, the microvessel density of the 
wound decreases as the wound approaches week 8, which is presumably a sign of wound maturity 
(Figure 5.6). 
 
5. 5   DISCUSSION 
 
Wound healing occurs as a cellular response to injury and involves activation of keratinocytes, 
fibroblasts, endothelial cells, macrophages and platelets. Many growth factors and cytokines released 
by these cell types are needed to coordinate and maintain healing. A number of physiological factors 
have been identified to be contributory to poor wound healing. These include decreased or impaired 
growth factor production and angiogenic response, macrophage function, collagen accumulation, 
epidermal barrier function, quantity of granulation tissue, kerationcyte and fibroblast migration and 
proliferation, balance between the accumulation of ECM component and their remodelling by MMPs 
(Falanga, 2005  and Lobmann et.al 2002) 
  
Molecular analyses of biopsies from the epidermis of patients have identified a pathogenic marker 
that correlates with delayed wound healing. These include inhibition of keratinocyte migration, over 
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expression of c-myc and nuclear localization of β-catenin (Stojadinoviv et.al, 2005 and Brem et. al 
2007). In diabetic foot ulcers, the nonhealing wound edges shows absence of keratinocyte migration, 
hyperproliferation and incomplete differentiation.  Fibroblast from similar ulcers demonstrates a 
phenotypic change as well as decreased migration and proliferation. Lack of healing is also 
demarcated by a thicker epidermis, thicker cornified layer and presence of nuclei in the cornified 
layer Brem and Tomic-Canic, 2007. From our result it is also evident that wound categorised into the 
non-healing group exhibited thicker epidermal layer and distorted architectural pattern,  with thicker 
and nucleated corneum layer (Figure 5.3). In agreement with studies conducted on venous ulcers by 
Andriseen et. al 1995, our results showed that the epidermis of ulcers margins from patients with 
diabetes are highly proliferative, no matter the thickness of the ulcer edges. The epidermis adjacent 
to the ulcer, with no gross indications of being affected by the ulcer, is also highly proliferative.  
Freedberg et al., 2001, reported that signals initiating the keratinocyte activation cyle (Ki67) seem to 
result in sustained proliferation in the epidermis even at great distance from the ulcer margin. 
Natarajan et. al .2006, demonstrated that p16 is activated in migrating keratinocytes, and co 
expresses with uncleaved precursor of 3-alpha chain of lamini 5. This has also been associated with 
growth arrest. In the absence of p16, transcription for genes encoding proteins necessary to initiate 
chromosome replicates takes place. Keratinocyte that express p16 are migratory and not mitotic. This 
study excluded diabetic ulcer; thus we can not draw conclusion about expression of p16 in epidermal 
margins of diabetic ulcers.  
 
There existed a striking difference between the pattern of immunostaining expression of keratins 
K14, K1/K10, Ki67  when chronic ulcer margins are compared with the unwounded normal skin.  
All keratinocyte layers of the chronic wound stained with K14 similarly between days 0 to week 8.  
Usui et al., 2005 showed that K14 is restricted to the basal keratinoocyte layer after 28 days of 
wounding in an acute wound. K1/K10 expression is suprabasal and the pattern of expression is very 
similar in the chronic diabetic ulcer and the unwound skin. Usui et.al 2005 also showed the same 
result in the migrating wound tongue of acute normal wounds.  In chronic ulcer margins and in 
apparently normal tissue adjacent to the ulcer K16 is dramatically stained throughout the epidermis. 
Despite the presence of K16, an activated, migratory keratinocyte phenotype, keratinocyte at the 
ulcer margin are not activated to migrate. Our immunohistochemical studies indicated that all of the 
samples tested with K16 antibody showed intense staining which is similar to result published  in 
migrating tongue of acute wound studied by  Usui et.al, 2008, However there appear to be more 
intense in the non healing group (Figure 5.9)  
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It has been observed that cutaneous wounds in which the basement membrane remains intact  heals 
rapidly and with little scarring, this may partly be due to the relatively small wound size and or tissue 
lose but also because the intact basement membrane (BM) provides essential signals required to 
direct re-epithelisation. Ulcerated lesion in which the BM is histologically absent are usually slow to 
heal and some form of BM is required before re-epithelisation.  We observed a similar pattern with  
collagen VII synthesis when comparing immunostaining patterns from  the completely re-epithelised 
group and the recalcitrant group. There was impairment of collagen VII expression in the BM of the 
4 patients with the non- healed ulcer, the expression and synthesis of collagen VII were inconsistent 
over the 8 weeks period (Table 5.7). On the other hand adequate and consistent synthesis of 
Collagen VII was an evident feature amongst the 3 patients that achieved complete wound healing. 
(Figure 5.10). Collagen VII synthesis and incorporation into anchor fibrils is probably a prerequisite 
for the synthesis of BM which is essential for adequate wound healing (Hopkinson et.al, 1997). In a 
study conducted by Hopkinson et.al, they showed active collagen VII transcription from 13 out of 15 
chronic leg ulcers, indicating Collagen VII biosynthesis. Of the two patients that Collagen VII 
transcription was not detected from, one of the patients was known to have insulin independent 
diabetic mellitus and the other patient as a non-specific lower limb chronic ulceration.  
 
Under regular culture conditions all integrins present in human epidermis were found in 
keratinocytes, consistent with previous reports (Carter, 1990). Virtually no integrin staining was 
observed in cells harbouring differentiation markers, such as keratins K1 and K10, which were 
mainly in a suprabasal position.  In a study conducted by Breitkreutz et al., 1997, on integrin and 
basement membrane normalization in mouse grafts of human keratinocytes, they demonstrated that 
the staining for 1 integrins (21, 31) was diffuse and extended to suprabasal cell layers, 
besides a variably intense reaction at the matrix interface. After 1 week, the 1 distribution became 
more restricted and showed the highest concentration in the basal or the lowermost two layers. The 
final tissue consolidation with a well-defined BM was underlined by strictly pericellular 1-location 
in the basal layer.  
 
It has been suggested that 1 could well be an indicator of the actual proliferative potential and 
elevated 1-levels have been proposed as one criterion for an epidermal subpopulation harbouring 
putative stem cells (Jones, 1995). In our result a similar pattern of 1 intergrin was noticed as the 
wound progressed towards week 8 (Figure 5.8), with the expression of 1 more restricted to the 
basal layer. Furthermore, if the assumption is correct that the 1-distribution spatially defines the 
compartment of proliferation-competent cells in concert with attachment via 64 (Tennenbaum, 
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1996). The down-regulation of these integrin functions should be involved in the process of 
regaining tissue normalization, which includes the timely onset of differentiation.  
 
The findings on collagen I and III (Figure 5.9 &5.10) in post-intervention biopsies revealed gradual 
restoration of collagens towards normalcy in terms of their density distribution in the group of 
patient that achieved healing. The staining intensity appears the same in both groups of patient 
treated.  However, there appeared to be some distortion in the architectural array of collagen fibrillar 
in the non healed group. 
 
 
CD44 is a ubiquitous transmembrane glycoprotein is expressed on the plasma membrane of both 
epidermal keratinocytes and leucocytes (Wang, 1992 &Tuhkanen, 1999). Previous studies 
demonstrated that CD44 plays an important role in cutaneous function. For example, CD44 
knockout mice was shown to exhibit the following features (Bourguignon et al., 2006);  (i) a defect 
in epidermal permeability barrier homeostasis; (ii) epidermal thinning; and (iii) decreased 
keratinocyte differentiation. Likewise, in cultured keratinocytes, hyaluronan–CD44 interaction 
stimulates keratinocyte differentiation and lamellar body formation (Bourguignon, 2006). 
Accordingly, hyaluronan induces keratinocyte proliferation both in primary cell cultures and 
epidermal hyperplasia in wild-type, but not in CD44-deficient mice (Bourguignon et al., 2006; Kaya 
et al., 1997). It remains controversial whether CD44 is pro-inflammatory or anti-inflammatory in 
skin, however, CD44 regulates lymphocyte proliferation, maturation, activation, homing, 
extravasations and infiltration (DeGrengele, 1997, Zoller, 2007). From our study there are appears to 
be down-regulation of CD44 as wound progresses towards epithelial restoration. 
 
5.6 CONCLUSION 
In summary, chronic diabetic foot ulcer may be converted to acute ulcers following adequate 
debridement and display cellular pattern similar to acute wound. Keratinocyte at the margins of 
ulcers are highly proliferative, they show an activated phenotype as indicated by presence of K16. In 
addition, the keratinocyte demonstrates evidence of differentiation as exemplified by the expression 
of K1/K10. Reduction in the expression of Ki67 was seen as proper wound healing process ensures. 
The expression of CD44 tends to decrease as healing heads in the normal direction. The expression 
of beta -1 integrin  remained unchanged and when compared to the unwounded skin. The restoration 
of collagen VII in the basement membrane could be a predictable sign of re-epithelisation. The 
quality and the architecture of collagen I & III remained unchanged during the course of wound 
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healing.  To further understand the effect of PRP on the molecular mechanism involved in 
keratinocyte migration, basement membrane restoration and changes occurring in extraceullar matrix 
during healing, a control group (treated with PPP) or a group receiving standard wound care for 
diabetic ulcer should be equally tested.  A better understanding of molecular mechanism involved in 
the keratinocyte and ECM behaviour may lead to possible molecular targets for therapeutic benefits 
of  chronic diabetic foot ulcers. 
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                                            CHAPTER 6 
Autologous Derived Platelet-rich Plasma Gel may have Therapeutic 
Implications in the Treatment of Chronic non-    Ischaemic Diabetic Foot 
Ulcers 
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6.1 Introduction 
Chronic wounds pose a major management problem in the health sector, often requiring a multi-
disciplinary approach. The majority (90%) of chronic wounds result as a progression from diabetic 
wounds, venous ulcers (chronic venous insufficiency ulcers), and pressure sores. Diabetic foot ulcers 
(DFU) seem to account the most for the global burden of the disease, especially with the attending 
complications of recurrence, chronicity, and the resultant lower limb amputation (Boulton, 2005). 
There is a global increase in the prevalence of diabetes mellitus, particularly type II diabetes mellitus, 
which is directly linked with obesity and a sedentary life style. It is believed that 20% or more of the 
United Kingdom adult population over the age of 65 years suffer with type II diabetes mellitus 
(Ragnarson, 2004). Two studies from North European countries reported the annual incidence of foot 
ulcers in the general population to be just more than 2% (Abbott et. al, 2002). The annual incidence 
rates in diabetic neuropathic individuals vary from 5–7% (Abbott, 1998). The lifetime risk for a 
diabetic patient to develop a foot ulcer could be as high as 25% (Singh, 2005). Of this population, 
15% will either suffer foot or limb amputation (Singh, 2005).  
 
It is likely that the cumulative lifetime incidence of foot ulcers may be as high as 25% (Singh, 2005). 
Shearer et al.  confirmed that diabetic patients with neuropathic risk factors incur five times more 
direct medical costs for ulcers and amputations, and live for 2 months less than individuals without 
neuropathy (Shearer, 2003). Lower limb amputation is performed 15 times more frequently among 
diabetics, as compared with non-diabetic patients (Most, 1983). The American Diabetic Association 
did a cost analysis of medical expenditure for the United States population with and without diabetes 
in 2002; the study was based on national health care survey data. The direct and indirect expenditure 
attributable to diabetes was estimated at 132 billion U.S. dollars. The direct medical expenditure 
alone totalled 91.8 billion U.S. dollars (23.2 billion U.S. dollars for diabetic care, 24.5 billion for 
chronic complications, and 44.1 billion U.S. dollars for excess prevalence of general medical 
conditions). The attributable indirect expenditure resulting from lost workdays, restricted activity 
days, mortality, and permanent disability due to diabetes totalled 39.8 billion U.S. dollars (Hogan, 
2003 and Saar, 2005). Fundamentally, the development of diabetic foot ulcers and the resultant 
chronicity could be said to have resulted from peripheral vasculopathy, peripheral neuropathy, and 
immunopathy. There are other contributory factors which stems from these three major risk factors. 
These include repetitive trauma to areas of the foot exposed to moderate to high pressure, reduced 
resistance to infection, immunologic disturbances, and microcirculation alterations. 
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 Different authors and researchers have attempted to classify diabetic wounds from the view point of 
aetio-pathogeneses and failure to demonstrate significant improvement following good clinical care 
as a guide to determine poor outcome. Presently, there are no early predictive factors to guide 
clinicians to differentiate patients who will heal readily from those who will have a protracted course 
of treatment. The American Diabetic Association has attempted to offer a lasting solution by 
clarifying the definition of a chronic wound, which they defined as; ―failure to show continuous 
progress towards healing. These are wounds that remained unhealed after 4 weeks, were a source of 
concern and were associated with worse outcomes including amputation‖ (American Diabetes 
Association, 1999). In addition, the decision to change to advanced therapeutic intervention should 
not be based solely on timing, but also in conjunction with careful monitoring of the percentage of 
the wound closure. A reduction in wound area of 10–15% per week represents a normal healing 
process and should not necessitate a change in wound management strategy or re-evaluation 
(Sheehan, 2003). Other authors have demonstrated that chronic diabetic wounds lack significant 
growth factors which are stimulatory agents for wound healing. These growth factors play important 
roles in the tissue-remodelling phase through mesenchymal cell recruitment and extra matrix 
synthesis. This understanding has led to the development of recombinant platelet derived growth 
factor-BB (becaplermin) that has been approved for use and has shown a degree of success in 
treating DFU (Robson, 1992). 
 
6.2 Rationale for the Use of Autologous Platelet Gel 
In the late 1970s the importance of growth factors within the wound-healing cascade was first 
identified. This began with platelet-derived growth factors and the subsequent identification of many 
other growth factors now known to be important within the different stages of the wound healing 
cascade. These growth factors aid the three phases of wound healing which are the inflammatory, 
proliferative, and remodelling phases. These phases involve complex paracrine mediated growth 
factors which influence mitogenic and cellular differentiation activities. Chronic wounds are thought 
to have increased proteases, increased pro-inflammatory cytokines, decreased protease inhibitors, 
and decreased growth factor activities. Cooper et al. showed that a number of growth factors were 
markedly reduced in wound fluid from chronic wounds as compared with acute wounds (Cooper, 
1994). Also, FGF and TGF-β concentrations are down regulated in chronic wounds and are 
significantly lower when compared with acute wounds (Cooper, 1994). It has also been shown that 
the use of a synthesized single growth factor in treating chronic diabetic wounds has only produced a 
limited degree of success. However, with the recent understanding of bio-tissue engineering, 
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autologous derived platelet rich plasma gel can effectively and safely deliver all the needed growth 
factors to stimulate tissue reparation.  
The rationale for employing this technique is to mimic the normal physiological wound healing and 
reparative tissue process. Autologous derived platelet gel (APG) has a wide and safe application 
within the post operative surgical field both as a wound sealant and as a tissue repair agent. Its 
application has extended to patients that are prone to higher surgical complications, and this is also 
true of diabetic patients. The modification of cell saver technology has made it possible to synthesize 
AGP with structural and functional properties, as close as possible, to those of natural soft tissue and 
epidermis. Besides, the ability of AGP to deliver multiple growth factors with a synergistic effect to 
wound sites, the clot formed from AGP serves as a scaffold and a protein reservoir, thereby locally 
concentrating and magnifying their effect. The platelet plug acts as a barrier to micro-organism 
invasion of wounds, achieved with the help of highly concentrated leukocyte buffer, present within 
APG.  
 
The availability of concentrated leukocyte with about 5-fold the baseline value makes the graft 
matrix infection free. It also promotes mitogenesis of mesenchymal stem cells at the wound site. As a 
three dimensional volumetric soft connective tissue replacement, it provides a matrix medium for 
cell migration, granulation tissue formation, and epithelia wound contracture in addition to serving as 
a non disturbed wound patch. The overall efficacy of AGP in treating wounds is likely to be a 
function of many variables such as the platelets concentration, the volume of AGP delivered to the 
wound, the extent and the type of injury and perhaps, the overall medical condition of the patient 
AGP contains autologous-derived living cells, which are able to deliver a program of healing to the 
wound that may not be achieved with a single growth factor. Another added advantage of autologous 
preparation technique is the inherent safety and therefore freedom from concerns of transmissible 
disease, such as, human immunodeficiency virus, hepatitis, and Creutzfeldt-Jakob disease. There is 
anecdotal evidence to suggest APG is effective in the treatment of chronic diabetic ulcer. To our 
knowledge, there are few studies that have collaborated on the effectiveness of APG with 
histological changes from treated ulcers. Therefore we analyzed the therapeutic effect of APG and its 
local biological effect on chronic non-ischemic diabetic foot ulcers. The primary purpose of the pilot 
study was to determine the number of patients that achieved complete re-epithelisation at the end of 
16 weeks treatment. 
6. 3   Anti-bacterial Effect of Autologous Derived Platelet rich Plasma 
 
Existing evidence suggests that platelets have many functions in the antimicrobial host defence 
systems (Krijgsveld et.al, 2000). These include expression of immunoglobulin-G Fc receptors, 
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C3a/C5a complement fragments, and the capacity to generate antimicrobial oxygen metabolites 
including superoxide, hydrogen peroxide, and hydroxyl free radicals (Yeaman, 1997). Tang in 2002, 
reported the isolation and tentative identification of seven antimicrobial peptides from human 
platelets after stimulation by thrombin as follows: fibrinopeptide A, fibrinopeptide B, thymosin β-4, 
platelet basic protein, connective-tissue-activating peptide 3, RANTES and platelet factor 4. These 
antimicrobials were found to be more potent against bacteria than fungi, and their activities were 
dose-dependent.  This findings support direct antimicrobial effect of PRP.  Platelet-rich plasma also 
has a high concentration of leucocytes. Furthermore, PRP has been found to possess markedly 
increased leukocyte counts (more than sevenfold) compared with baseline levels (Bielecki, 2006).  In 
a study by Bielecki, et.al 2007, a strong effect of platelet-rich gel against, E. coli, methicillin-
resistant staphylococcus aureus, and methicillin-sensitive staphylococcus aureus was demonstrated.  
No PRP activity was found against K. pneumoniae, E. faecalis, or Pseudomonas aeruginosa. In 
contrast PRP was observed to induce the growth of Pseudomonas aeruginosa, suggesting that it may 
induce a flare-up of infection.   
 
6.4 Evidence to Support the Clinical Application of Platelet Rich Plasma Gel 
 
Different authors have proposed that platelet-rich plasma technology has relevant application in 
promoting hard and soft tissue wound healing; and potentially decreasing postoperative wound 
infections, blood loss, and pain. Platelet rich plasma has found clinical application in most fields of 
surgical practice. There are scientific literatures to support its efficacy in periodontal and oral 
surgery, maxillofacial surgery, aesthetic plastic surgery, heart bypass surgery, orthopaedic and spinal 
fusion surgery, and in the treatment of chronic skin and soft tissue ulcers (Eppley, 2004, Marx, 2001 
and Marx, 2004). Although the various published data appears promising on its efficacy in wound 
healing, most are case studies or series; hence, most of the evidence is anecdotal. There are very few 
prospective randomized controlled clinical trials to support the acclaimed potentials. Knighton et al. 
reported that 17 of 21 patients with chronic lower limb ulcers achieved complete re-epithelization  
over an average period of 8.6 weeks, with a course of twice-daily wound treatment with platelet 
release suspended on a collagen base, compared to two of 13 similar wounds treated with placebo 
(Knighton,1986). After crossover of the placebo group, all the remaining 11 chronic ulcers were 
treated with the same bio-active agent (platelet release suspended on a collagen base). All patients in 
the placebo group eventually achieved 100% re-epithelization in an average of 7.1 weeks after 
crossover.  
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6.5 Multidisciplinary Approach to Wound Management and its Future 
The complexity and the poor outcome associated with healing chronic diabetic foot ulcers necessitate 
the need for a multi-disciplinary approach to treating these groups of patients. Most physicians 
involved with the care of these patients are increasingly advocating for an integrated wound care 
centre. This centre will foster an environment for effective communication and collaboration for all 
care givers involved with this patient at each stage of their treatment. Some of the specialists include 
podiatrists, Plastic, Vascular and Orthopaedic surgeons, diabetologists, nutritionists, radiologists and 
neurologists. In addition, this centre has the potential of galvanizing already available resources, 
streamlining protocol implementation, reducing cost, and ultimately accelerating wound healing. 
This approach has demonstrated significant improvements in outcomes, including reduction in the 
incidence of major amputation (Dargis, 1999). 
 
6.5.1 Other Adjuvant Treatment   
The treatment of diabetic foot ulcers requires management of a number of systemic and local factors, 
including:
 `
Precise diabetic control which is vital in achieving resolution of the current wound, but 
also in minimizing the risk of wound recurrence.  Close monitoring of Hb1 AC and glycaemia level 
are vital, as well as management of contributing systemic factors, such as hypertension, 
hyperlipidemia, atherosclerotic heart disease, obesity, or and  renal insufficiency (Margolis , 2001) 
The management of diabetic foot ulcers requires offloading pressure from the wound by using   
appropriate footwear,
 
daily dressings to provide a moist wound environment,
 
debridement when 
necessary and  the use of  antibiotic therapy when  superficial infection supervene (Hilton,2004). 
Non-healing deep cavity wounds may require application of negative pressure under vacuum-assisted 
closure (Evan, 2001)  and  other adjunct such as cultured human cells (Veves, 2001).to achieve 
wound coverage and complete healing  
6.5.2 The Role of Vascular Surgeon in Managing Chronic Diabetic Foot Ulcers 
All patients harbouring diabetic foot ulcers should be evaluated by a qualified vascular surgeon who 
will consider debridement, revisional surgery, vascular reconstruction, and options for soft tissue 
coverage. As part of the wound assessment process, the vascular surgeon evaluates blood flow to the 
wound area by means of handheld Doppler. A triphasic Doppler signal indicates normal blood flow, 
a biphasic signal indicates adequate blood flow and a monophasic signal warrants further 
investigation. A questionable blood flow or signal may necessitate a formal non-invasive arterial 
Doppler evaluation or a conventional angiogram combined with a computerised tomographic scan. If 
an inadequate flow is established, the wound debridement may be initially delayed in the setting of 
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dry gangrene until the blood flow is restored. Restoration of blood flow may be by means of 
endovascular intervention by way of angioplasty and stenting or conventional open bypass surgery. 
Premature debridement of a devascularised wound may cause future loss of potentially salvageable 
tissue. However, immediate debridement is mandatory in the presence of wet gangrene, ascending 
cellulitis from a necrotic wound, or necrotizing fascitis are present.  Revascularization should follow 
as soon as the infection is under control (Attinger, et. al 2001) 
6.5.3 Debridement 
Proper debridement is defined as the removal of hyperkeratotic, infected, and nonviable tissue from a 
wound, which is essential to accelerate the process of wound healing (Steed, 1996). Surgical 
management is indicated for debridement of nonviable and infected tissue from the ulceration, 
removal of excess callous, curettage of underlying osteomyelitic bone, skin grafting, and 
revascularization. The potential benefits derived from frequent debridement include removal of 
inhibitors of wound healing (metalloproteases, collagenases matrix metalloproteinase 1 and 8 and 
elastases) and more effective growth factor function (Trentgrove, 1999).  Furthermore, aggressive 
removal of all necrotic, infected, and nonviable tissue prevents the establishment of protease rich 
proteins in the wound base. The wound usually requires an initial surgical debridement and probing 
to determine the depth and involvement of bone or joint structures. Visible or palpable bone implies 
an 85% chance of osteomyelitis. Surgical wound closure: Delayed primary closure of a chronic 
wound requires well-vascularized clean tissues and tension-free apposition; it usually requires 
undermining and mobilization of adjacent tissue planes by creation of skin flaps or myocutaneous 
flaps. In general, the indications for vascular surgery in the presence of a reconstructible arterial 
lesion include intractable pain at rest or at night, intractable foot ulcers, and impending or existing 
gangrene (Faries, 2004).  
 
 6.5.4 Soft Tissue Coverage Options 
There are few options available for soft tissue coverage of the clean but non-healing wound: Once a 
wound has reached a steady clean state, a decision has to be made about allowing healing by natural 
processes or expediting healing by a surgical procedure. Clinical experience and observation of the 
healing progress in each case dictates the appropriate management. Surgical options include skin 
grafting, application of bioengineered skin substitutes, and flap closures (Ehrenreich, 2006). 
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1. Autologous skin graft is the gold standard for viable coverage of partial thickness wounds. 
Meshing the graft allows wider coverage and promotes drainage of serum and blood.  
2. A cadaveric skin allograft is a useful covering for relatively deep wounds following surgical 
excision when the wound bed does not appear appropriate for application of an autologous skin graft. 
The allograft serves as a bridge whilst a more definitive closure method is being planned for. 
3. Surgical wound closure: Delayed primary closure of a chronic wound requires well-vascularized 
clean tissues and tension-free apposition; it usually requires undermining and mobilization of 
adjacent tissue planes by creation of skin flaps or myocutaneous flaps. 
4. Tissue-cultured skin substitutes: Bioengineered skin (Apligraf) and human dermis (Dermagraft) 
are new types of biologically active implants for ulcers that are derived from fibroblasts of neonatal 
foreskins (Veves, 2001). These bioengineered products enhance healing by acting as delivery 
systems for growth factors and extracellular matrix components through the activity of live human 
fibroblasts contained in their dermal elements.  
a. Dermagraft (Smith & Nephew) is a cryopreserved human fibroblast–derived dermal substitute 
produced by seeding neonatal foreskin fibroblasts onto a bio-absorbable polyglactin mesh scaffold. 
Dermagraft is useful for managing full-thickness chronic diabetic foot ulcers. It is not appropriate for 
infected ulcers, those that involve bone or tendon, or those that have sinus tracts. Allergic reactions 
to its bovine protein component have been reported  
b. Apligraf (Organogenesis) is a living, bilayered human skin substitute.
 
It is not appropriate for 
infected ulcers, those that involve tendon or bone, or those that have sinus tracts. Allergic reactions 
to the agarose shipping medium or its bovine collagen component have been reported (Streit, 2000). 
The use of bioengineered skin substitutes has been questioned because the mechanism of action is 
not clear, the efficacy is questionable, and the cost is high.  
c. Xenograft is a xenogeneic acellular collagen matrix derived from porcine small intestinal 
submucosa in a way that allows an extracellular matrix and natural growth factors to remain intact. 
This provides a scaffold for inducing wound healing. Xenograft is avoided in patients with allergies 
to porcine materials.  
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6.5.5 Biological/ Cellular Therapy 
 
Tissue engineering is a biological science that specializes in the development of biological 
substitutes to restore, maintain, or improve the function of the skin. It seeks to create a readily 
available tissue replacement with the biologic and pharmacologic properties of the human skin 
(Fohn, 2007). The principle of implementing this method in treating chronic wounds is called 
biological or cellular therapy. Implementation of cellular therapy is recommended when wound size 
cannot be decreased by more than 10% within 3 weeks. There are a number of commercially 
available dermal matrices that have been approved by the United States Food and Drug 
Administration. This includes Alloderm TM (Life Cell Corp., The Woodlands, TX), altered allograft; 
Integra TM (Integran Life Science Corp., Plainsboro, NJ), dermal regeneration template; Dermagraft 
TM (Smith and Nephew, London, UK), synthetic dermal replacement/dermal regeneration template; 
Apligraf TM (Organogenesis, Inc., Canton, MA), composite skin replacement, and Hyalograft-3D 
TM (Fidia Advanced Biopolymers, Abano T., Italy). Biological therapy may be an ideal treatment 
for diabetic foot ulcers because it adds cells that release growth factors to a growth factor dependent 
environment, increases cytokines and matrix proteins, and promotes angiogenesis (Trent, 1998). It is 
also believed that they accelerate healing time and decrease the risk of wound infection. Of all the 
available cellular therapy techniques, Apligraf TM (organogenesis, and Hyalograft-3D TM 
(esterified hyaluronic acid beneath silicone) have shown efficacy in the treatment of chronic diabetic 
foot ulcers (Stark, 2004).  
 
6.6 Rationale for Gene therapy in wound healing 
 The combination of bioengineered skin substitutes and the standard of care in treating  diabetic foot 
ulcer, have only achieved a wound  healing  rate of about 50%, which highlights the critical need for 
a more practical, safe and effective therapy for non-healing diabetic foot ulcers (Steed et.al., 2006). 
Delivery of the gene encoding growth factor will resolve the problem of transient expression of GFs 
at wound site. This could potentially overcome the limited maintenance of the protein at the ulcer site 
and the need for daily protein administration. In chronic diabetic peripheral neuropathic ulcers, the 
healing process is impaired in part by the deficiency of growth factors (Cooper, 1994).  
 
GAM501 utilizes a replication-defective adenoviral vector containing the human platelet-derived 
growth factor-B gene (Ad5- PDGF-B) incorporated into a biocompatible matrix (2.6% bovine 
collagen) and is applied topically to the ulcer. Preclinical studies have shown GAM501 causes 
enhanced migration into and proliferation within the ulcer and gene-containing matrix of 
inflammatory cells, endothelial cells, fibroblasts, and other connective tissue cell types from 
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surrounding viable tissues (Gu et.al, 2004). The collagen component of GAM501 has two key 
beneficial functions: (i) it holds the Ad5-PDGF-B vector within the ulcer site until infiltrating cells 
arrive; and (ii) it promotes the ingrowths of migratory cells responsible for generation of granulation 
tissue. Once in the matrix, fibroblasts and other cell types take up the Ad5-PDGF-B vector, 
transcribe, express, and secrete the gene product acting as local in vivo bioreactors that produce 
PDGF-BB protein. Although the protein is synthesized only as long as the gene persists in the cell 
(the adenoviral vector transgene does not integrate into the chromosomes of the transfected cells and 
is inactivated over time), its availability is substantially prolonged relative to topical protein therapy. 
 
In a preliminary  study of GAM501 Phase 1 & 2 clinical trials conducted  by  Mulder et al., 2009, 
fifteen patients enrolled into the study with chronic, non-healing ulcers received either a single 
administration of GAM501 at one of three dose levels, or up to four administrations of GAM501 at 
1-week intervals. All the patients received standard of care treatment including debridement and 
were required to wear an off-loading shoe. GAM501 was found to be safe and well tolerated with no 
evidence of systemic or local toxicity at all doses, no maximum-tolerated dose was reached. Serum 
antibody titres to platelet-derived growth factor-B homodimer and collagen were negative and 
adenoviral DNA was not detected in the blood. In the 12 patients that completed the study, ulcer 
closure was observed in 3 months in 10 patients, seven of whom received a single application of 
GAM501. In conclusion, GAM501 did not appear to have any toxicity at doses that showed 
biological activity. GAM501 holds promise as a potentially effective treatment for non-healing 
diabetic foot ulcers. 
 
6.7 MATERIALS AND METHODS  
 
The protocol employed in conducting the pilot study, the study design, the recruitment process and 
ethical consideration issues have been discussed in Chapter 2 section 2.18. Also details of 
preparation of PRP can be found in section 2.19 
6. 7. 1 Characterization and Preparation of PRP 
 
Before undertaking the application of PRP in chronic ulcers, a full characterization of the growth 
factors present in the patients PRP was carried out.  In addition to quantifying the amount of growth 
factors present in patients‘ own PRP, we conducted a study to determine the variability in the 
expression of growth factors amongst the diabetic patients and the healthy non-diabetic subjects 
(Details in chapter 3).  Briefly, platelet-rich fibrin matrix was formed by adding the human derived 
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thrombin to the platelet rich concentrate. The PRP was divided into two halves: a part was used for 
wound treatment and the other half was allowed to retract over night for supernatant extraction. The 
released supernatants  was assayed for the expressions of  PDGFAA, TGF-b1, IGF-I, VEGF-A, FGF,  
TSF-1, PF-4 and EGF through the commercially available enzyme-linked immunosorbent assay kits 
(Quantikine colorimetric ELISA kits, R&D, and Minneapolis, MN). Full details of the processing 
and quantification of the growth factors have been fully discussed in chapter 3 section 3.4 
 
6.7.2 Application of PRP and Study Design 
All the patients‘ recruited into the pilot study received platelet gel therapy in addition to standard 
wound care (details of standard wound care: Appendix 5). The study protocol included an initial 
period of wound debridement in operating room; application of gel was either carried out in the 
operating room or a sterile mini- theatre in the surgical Out Patients‘ Department.  Wounds were 
dried to prevent further diluting of the platelet gel before application. The platelet gel was applied 
directly over the debrided wound surface; the patients‘ foot was left for 5- 10 minutes to allow the 
platelet gel to set.  This was followed by gentle application of damp mepitel on the wound to prevent 
disruption of the germinal layer of the wound. Two layered moist sterile saline gauze were applied 
on the mepitel layer,  to prevent absorption of the gel into the dressing material, followed by a four 
layer of sterile moist gauze to further protect the wound.  An opsite (adhesive dressing material) was 
applied on the dry gauze, followed by another layer of velband and crepe bandage. Patients with 
large wound cavity and post digital amputation were admitted for short hospital stay. However, 
patients  who needed a second application of platelet gel were followed up as day cases and given an 
orthotic foot wear (medisure) to off-load pressure and to allow mobilisation as tolerated. 
 
The first wound inspection was carried out by the research doctor, and post debridement wound 
biopsies were also taken. Pictures of the ulcers were obtained with a digital camera. Visitrak 
computerised planimetry was used to determine the surface area of the wound. The percentage of 
surface area healed was estimated as ―initial ulcer surface -final ulcer surface/initial ulcer surface 
x100‖. Patients were followed up until complete wound healing (full epithelization) was achieved or 
16 weeks of treatment period.  The standard treatment for all patients was to receive a single 
application of platelet gel therapy. A repeat application when necessary was decided by the research 
team and the doctor. If a second application was recommended, it must not be repeated within 14 
days of initial first treatment.  
 
Wounds with superficial slough were debrided in the sterile mini-theatre. The presence of purulent 
discharge or offensive smell from the wound necessitated taking of wound swab and placing the 
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patient on empirical antibiotics, pending the outcome of microbiology sensitive pattern. Wounds that 
showed signs of deep seated infection and sloughiness underwent further surgical debridement and a 
repeat application of platelet gel therapy. Patients that continued to show signs of delayed wound 
healing and poor healing progress were reviewed by the principal investigator. Patients in this 
category were withdrawn from the study and treated appropriately. The primary endpoint of the 
study was to determine the number of patients that achieved complete re-epithelisation at the end of 
the study period.   
6.8 RESULTS 
 
Patient 
ID 
Age 
(yrs) 
Aetiology of  
ulcer 
Pre-treatment 
Duration  
of ulcer  
Duration  
of 
Diabetes 
ABPI Location of 
ulcer 
P1 42 Neuroischemic 8wks 3yrs 1.4 Post amp big 
toe 
P2 
 
58 Neuroischemic 6 wks 10yrs 1.25 Post amp 4
th
/5
th
 
toe 
P3 49 Neuroischemic  
8wks 
15yrs 1.18 Post amp 5
th
 toe 
P4 64 Neuropathic 4yrs 18yrs 
 
1.2 Plantar ulcer big 
toe 
P5 59 Neuropathic 
 
 
10mth 10yrs 1.2 Plantar ulcer 
Big toe 
 
P6 56 Neuropathic 12 wks 30yrs 1.2  Post amp 2
nd
 
toe 
 
P7 
 
50 Neuroischemic 8 wks 6yrs 1.07 Post amp big 
toe 
Table 6.1 Shows the general demographic data, aetiology, location of ulcers, ankle brachial 
pressure index (ABPI) and Patient‘s individual identity were represented as P1-P7 (Amp- 
Amputation). 
 
Patient 
ID 
Size of  
Ulcer 
cm
2
 
Debride
ment 
Type 
Hb1 
AC 
% 
 Platelet 
Count 
(x10000) 
No of 
treatment 
Duration of 
follow up 
Complete 
Treatment 
Duration 
P1 4.2 surgical 12.9 309 single 10weeks Yes 
P2 32.1 surgical 10.8 470 single 16weeks No 
P3 14.3 surgical 15.7 354 twice 16 weeks Yes 
P4 3.3 Non-sur 6.9 280 single 16 weeks Yes 
P5 1.8 Non-sur 6.8 319 twice 16weeks Yes 
P6 4.1 surgical 7.2 293 single 8 weeks No 
P7 16.2 surgical 11 230 single 3weeks  No 
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Table 6.2 Provides information about ulcer size, pre-treatment glycosylated Haemoglobin (Hb1 
Ac)  pre-treatment platelet count, duration of follow up and number of platelet therapy application. 
   
Patient 
ID 
DM 
Type 
Previous  
amputation 
Renal  
failure 
Mobility Wagner 
Grading 
Hospital  
stay 
Complete 
Re- epithelisation 
P1 NIDDM Nil Nil Yes 4 No Yes 
P2 IDDM Nil mild Yes 5 Yes Yes 
P3 IDDM  Nil mild Yes 4 Yes Yes 
P4 NIDDM Nil mild Yes 3 No No 
P5 NIDDM Yes nil Yes 3 No 
 
No 
P6 NIDDM Yes End- 
stage 
Yes 4 Yes No 
P7 NIDDM Yes nil Yes 4 Yes No 
 
Table 6.3 Provides the information about the patients’ pre-morbid state as it relates to the type 
of Diabetes, previous amputation history, and presence of renal impairment, patient mobility and 
severity of the ulcer as represented by Wagner classification. 
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Figure 6.1 Represents the process involved in processing Autologous derived platelet- gel. A) 
Represents the automated centrifuging machine called the platelet separating system, which has 2 
collecting bags connected to it; B) represents the separated red blood cells and after the 2 cycles of 
centrifuging and C) is the separated  fresh plasma. D)  The platelet concentrate from the process; E) 
shows the process of fresh thrombin production. F) The mixing of platelet concentrate with freshly 
prepared thrombin in 2 separate mixing chambers; G) the final product is the autologous derived 
platelet rich plasma (APG).  H) Demonstrates the process of application of AGP to a debrided 
wound. 
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Figure 6.2  Graphical illustration of the wound healing  rate for all the groups of patient treated 
during the follow up period of 16 weeks. P1-P3 achieved complete re-epithelisation, whereas P4-P7 
did not heal during the study period. 
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Figure 6.3 Graphic representation of the rate of re-epithelisation  shows that P1 achieved complete 
re-epithelisation at 10 weeks, whereas P2 and P3 were completed healed at 16 weeks. 
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    A B C  D  
      E  F    G    
 
Figure 6.4 Patient I achieved complete re-epithelisation following single treatment with PRP 
after 8 weeks: A)  debrided  ulcer with platelet gel therapy at day 0, B) a day 8, C) week 1, D) week 
3, E) week 4 , F) week 8 and G) week 10. 
 
       A  B  C  
                  D   E  F  
  
Figure 6.5 Patient II;  evolution of a typical ulcer treated with PRP: A) debrided ulcer with PRP 
treatment; B) at week 1, C) week 4, D) week 6, E) week 10, and F) week 16 
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Figure 6.6 photographic representations of Patient IV and V ulcers that were unable to heal 
despite treatment with PRP and good standard wound care. The common feature in these patients 
was that the ulcer was on the weight bearing point (base of the 5
th
 Metatarsal). Biomechanical 
pressure off-loading was a major challenge with these patients, they were both fully ambulatory, and 
orthosis prothesis booth was used as a means of pressure offloading devise. Clinical feature seen 
from ulceration includes hypergranulosis, hyperkeratosis and raised wound edges; these features are 
in keeping with recalcitrant ulcers 
 
6.9 DISCUSSION 
 
In spite of available evidence that both recombinant PDGF (becaplermin) and platelet-derived 
growth factors administered as autologous platelet gel, can be effective in treating chronic cutaneous 
wounds (Crovetti et. al, 2004 and Papanas, 2007) and that this treatment can be cost effective ( 
Dougherty, 2008), the consensus on the therapeutic use of PG is still controversial. The difficulty in 
recruiting large number of  chronic diabetic foot ulcer patients‘ with reasonably comparable lesions 
is the main handicapping situation that have resulted in setbacks in organising randomised controlled 
clinical trials in this peculiar disease entity (Martinez-Zapata et.al). The main challenge with the 
clinical use of PRP is not whether it can be used in the treatment of cutaneous ulcer, but at what 
time-point and how often in the treatment course. Furthermore, the elaborate organisation involved 
in the processing of PG and also the need for repeated application of the therapy in most cases, in an 
already physiologically compromised patient is a major rate limiting step in its implementation. 
 
Based on the above considerations, we planned a pilot study aimed at validating the production and 
characterization of growth factors derived from PRP (details in chapter 3). In addition, we assessed 
its safety and efficacy amongst diabetic patients with difficult to treat ulcers. In carrying out this 
study the following issues were pivotal to our study: 1) to validate production of PRP (aliquots of 
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concentrated platelets) that would satisfy several requirements of routine process of periodic blood 
collection and processing of varying blood components; 2) to maintain closed and aseptic conditions 
through the entire process; 3) to ensure a reproducible and predictable  quality and quantity of PRP 
produced; 4) to ascertain that the PRP used is able to deliver adequate level of GF to promote wound 
healing and finally to report any adverse reactions directly or indirectly related to the use of PRP 
during this study. Although our study sample was small, our experience supports the feasibility and 
safety of our operational model; no undesired side effect related to the treatment occurred. 
 
 All seven male patients were treated with PRP, over a mean follow up period of 12weeks. Most 
ulcers were treated with a single application of PRP; however 2 patients were treated twice, making 
a total of 9 different applications.  It was not possible to establish a clear correlation between number 
of applications and reduction in wound size, but this could be due to the small sample size of the 
study. The result from our pilot study could be summarized thus (Table 6.1); 7 patients were treated. 
All patient received the initial treatment with Platelet rich plasma gel after wound debridement. 
Furthermore, 5 patients later underwent surgical debridement and digital amputation and the 
remaining 2 others with plantar ulcers were debrided non-surgically. It is worth mentioning that all 
of our treated patients had ABPI of greater than one, which could be a reflection of the ongoing 
diabetic process and possibly vessel calcification, which by itself compromises blood supply to the 
lower limb. None of our treated patient had treatable peripheral vascular disease at the time of 
treatment. 
Most of our patients received single treatment with PRP (71.4%), whilst 28.6% were treated twice.  
Furthermore, continuous non–surgical debridement were carried out in most of the patients at the 
outpatient clinic, with a cautious use of  short term antibiotic for patients that appeared to have 
clinical and microbiological evidence of raging wound infection, two (28.6%)  patients required 
antibiotic in the course of the follow up. Two (P6 & P7) patients (28.6%) were withdrawn from the 
study at 4 and 5 weeks respectively, because the ulcers became grossly infected and both required 
transmetatarsal amputation and application of vacuum assisted closure device, as a result of the large 
wound cavity. At the end of the 16 weeks study, 3 patients (42.8 %) of the 7, achieved complete re-
epithelisation. If the 2 patients that were withdrawn from the study were to be adjusted for, we 
would have achieved 60% complete wound healing rate. Bearing this in mind, our result can be 
compared to results from Anitua et.al 2008. In their pilot study on 14 ulcers in nine patients, it was 
reported that 72.9% of the lesions which were treated with autologous platelet derived factors 
healed. Whereas only 21.7% of the lesions treated conventionally healed during the same period of 8 
weeks. Similarly Mc Aleer , 2006, reported 20 (60%) out of 33 chronic ulcers lasting for 6 months 
achieved complete closure in a mean period of 11.1 weeks after treatment with APG. In a series of 
32 patients with diabetic foot ulcers, 68.4% treated with PRP achieved complete closure compared 
to 42.9 % of the ulcers under conventional treatment (Driver. et.al, 2006).  
Other confounding factors that was considered when analysing the outcome from this treatment were 
patients age, duration of ulcer before debdridement, size of ulcer post debridement, glycaemic 
control using glycosylated haemoglobin which is a reflection of the glycaemic control 2-3month 
before treatment, presence of systemic co morbidity such as renal impairment and the platelet count 
before concentration and the Wagner classification as shown in Tables 6.1. In view of the small 
sample size, we could only make observational remarks from our study and no significant statistical 
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inference could be drawn from it. It appears that patients with grade 4 Wagner classifications and 
long standing type 2 diabetes did not achieve complete re-epithelisation. The 2 patient with plantar 
ulcers did not achieve wound closure despite the fact that they had input from the podiatrist team. In 
addition, they were given adequate foot care to off load the biomechanical pressure off the big toe 
with the aid of appropriate footwear (Figure 6.6).  A graphic illustration of the wound size-time 
course can be seen in Figure 6.1.  
This study has its inherent pit falls. As stated earlier, it was a small pilot study aimed at 
demonstrating the safety and efficacy of using APG. In addition, although the sample size was small, 
it gave us the opportunity to study the immuno-histochemistry behaviour and cellular alterations that 
occur in diabetic ulcers. This would have been impossible with a larger series. Premature withdrawal 
of patients from the study and difficulties encountered in recruiting patients into the control arm of 
the study are part of the major limitations of our pilot study. The study was designed originally to 
recruit 5 patients into each arm of the study comprising of the active group (treatment with PRP) and 
control group (treatment with PPP). This was however not achievable, because of patient‘s 
preference even though we had originally obtained ethic approval for this small comparative pilot 
study.  The patients that failed to heal after the 16 weeks of follow up were treated appropriately by 
the principal investigator. The 3 patients that achieved complete epithelisation were also followed up 
for a further 1 month in our joint multidisciplinary clinic to ensure that the wound did not breakdown 
again.  
 
Although, in our small pilot we did not look at cost-effectiveness analysis, Dougherty, 2008 
reported, that the use of PRP gel resulted in improved quality of life and lower cost of care over a 5-
year period than other treatment modalities for non-healing diabetic foot ulcers. PRP represents a 
potentially attractive treatment alternative for health centre providers to address the cost burden and 
health effects of non-healing diabetic foot ulcers. In another study Mazzucco et al. observed that 
treatment of dehiscent sternal wounds with platelet gel reduced the complete healing rate (3.5 vs. 6 
weeks) and hospital stay in 21 days when compared with conventional treatment. (Mazzucco et al, 
2004).  
 
However, some other studies on the efficacy of platelet rich products have no reported beneficial 
effects on the treated ulcers. One of such example, Stacey et al. compared 42 patients receiving a 
platelet lysate preparation with 44 patients having conventional treatment.  The results showed that 
the platelet lysate product had no influence on the healing of chronic ulcers. These discrepancies 
may lead to a general controversy about the potential benefits of platelet-rich products. However, 
this result should be interpreted in the context of the aetiopathogenesis and the heterogeneicity of the 
patients‘ ulcers studied. 
 
  
Weibrich, 2004 showed that platelet derived growth factor (PRGF) contains moderately elevated 
platelet concentration (2–3-fold increase), which has been reported to induce an optimal biological 
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benefit. In our study, we achieved about 6 fold increase in platelet concentrate.  The platelet 
concentration and separation system is designed in such a way to avoid contamination of PRGF with 
leukocytes. However, it has been noted that neutrophil contamination could be as high as 1-3% 
during PRP production. PRGF without contamination improves the homogeneity of the product and 
equally reduces the donor-to-donor variability. Another disadvantage of neutrophil contamination is 
that neutrophils are an important source of MMP-8 and -9 and secrete other proteases, such as 
elastases (Yager et al., 1996) that are destructive for growth factors and release reactive oxygen 
species deleterious for cell survival Zimmermann, et al. (2001), showed that the lowest 
concentration and the highest activation of platelets, as well as, the highest WBC concentration in 
platelet concentrate occur from tube technique.   
It has been observed that the plantar pressure is higher in subjects with callus formation (Pitei, 
1999). There appears to be a relationship between callus and reduced tissue thickness. It is suggested 
that callus reduces the cushioning effect of plantar skin thickness which protects the skin from 
breaking down. Increased pressures under the metatarsal head (MTH) have also been shown 
prospectively to predict ulcer development (Pham, 2000). Preliminary data from diabetic and 
rheumatoid arthritic patients suggested that plantar foot pressures are strongly associated with 
reduced plantar tissue thickness under the MTHs (Young, 1995).  Diabetic patients, especially those 
with foot ulcers, have been reported to have reduced plantar soft tissue thickness compared with 
non-diabetic subjects, indicating that this could be an important contributing factor in the 
development of foot ulceration (Brink, 1995).  
Debridement is aimed at ensuring physiological progression of chronic wounds through the normal 
stages of healing, provided that they are maintained in an environment conductive to anabolic 
metabolism. Surgical wound debridement remains the most crucial step in enhancing the healing 
process of all chronic wounds, irrespective of the aetiopathogensis of the wound.  In this study, 
wound debridement appears to be the commonest denominator to the 2 categories of the wound 
treated (the healed ulcer and the recalcitrant ulcer). Wounds may require additional measures to 
promote healing when they fail to progress despite adequate debridement or the progress of 
debridement has left vital structures (bone, tendon or neurovascular bundle) exposed that can not be 
left to heal by secondary intention. Also, when the wound closure rate is less than 10 to 15% per 
week, negative pressure therapy may be used to assist closure.  Negative pressure wound therapy is 
an excellent tool that stimulates formation of granulation tissue as well as decreasing local oedema 
and controlling bacterial proliferation (Defranzo et al. 2001).    
It was recently reported that fluid exudates from long-standing venous ulcers inhibit experimental 
angiogenesis (Drinkwater, 2002). This inhibiting effect could be related to presence of anti-
angiogenic agents such as tissue inhibitors of metalloproteinase-1 (TIMP-1) in wound fluids, which 
counteract the proangiogenic effect of growth factors contained in topical platelet products (Herouy 
et al., 2000).  Fibroblasts isolated from venous ulcers are more senescent compared with fibroblasts 
isolated from healthy skin, and have decreased proliferative ability, dependent on ulceration 
(Stanley, 2000). Indeed, chronic wound fibroblasts generally exhibit a decreased mitogenic response 
to PDGF-AA, PDGFBB, bFGF, TGFβ1, and EGF, compared with normal or acute wound 
fibroblasts (Agren, 1999).  This may explain the poor healing response to topical recombinant 
growth factors (Agren 1999) and to platelet products of long-standing venous ulcers.  The absence of 
the healing effect of platelet products on venous ulcers could also be due to destruction of its 
components by wound proteases. High levels of proteases are found in wound fluids from chronic 
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venous ulcers, impairing the healing process by degradation of exogenous added growth factors, 
such . 
6.10 CONCLUSION 
In summary, this study allows us to draw a number of conclusions; 1) the preparation of well 
standardized PRP is feasible within a routine surgical practice; 2)  After adjusting for withdrawals, 
60% of our patients achieved complete re-epithelisation. The healing observed can not be said to be 
entirely as a result of PRP treatment. However, it is not unreasonable to conclude that a well 
organised frequent standard wound care with appropriate foot care in conjunction with platelet gel 
therapy can facilitate healing of chronic diabetic foot ulcers. Furthermore, we can say that PRP is a 
safe and potentially reasonable adjunct in the treatment of chronic diabetic foot ulcers; 3) The safety 
of APG was not in question as there were no adverse events reported during this study period 
(howbeit a small sample size).  Many other studies support the fact that PRP is responsible for 
actively extruding growth factors, which initiate soft tissue healing and recruitment of stem cells. In 
the light of all the confounding factors and difficulties encountered in conducting this study, we 
proposed that a multicentre clinical randomised control trial with adequate statistical power might 
provide the missing link and answer some of the questions raised in this study. This will be the 
beginning of standardizing the use of PRP as an adjunct for treating chronic diabetic foot ulcers.  
Sharp wound debridement and a combination of many other discussed treatment modalities hold a 
promising future.  
 
6.11 Overall Summary of the Thesis 
 
The initial work in this project began by establishing a standard protocol for the production of 
autologus–derived Platelet rich plasma (PRP) and Platelet poor plasma gel (PPP) through the use of 
Platelet collecting and concentrating system (PCCS) {Sorin-Angel}. Through series of repeated 
production, we were able to establish a consistently high quality PRP/PPP gel. The next step was to 
characterise the expression of growth factors (GFs) which have been implicated in wound healing 
process. Furthermore, two groups of patients were recruited for the characterisation of GFs from 
PPP/PRP; 14 healthy volunteer donors and 6 diabetic patients, with the aim of comparing the 
expression of the different GFs from PRP/PPP.  
Chapter 3 focussed on the 2 different immunoassay technique employed in measuring the 
expression of the GFs and the rationale for using the techniques.  The GFs were measured using 
immuno-assay technique; Platelet derived growth factor (PDGF-AA), Fibroblast growth factor-2 
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(FGF-2), Transforming growth factors-beta1 (TGF-β1), vascular endothelia growth factor (VEGF), 
epidermal growth factor (EGF), Thrombospodin-1(TSP-1) and Platelet factor-4 (PF-4). The 
scientific basis for generating GFs from Platelet were founded on the principle that, alpha-granule of 
Platelet contains secretory proteins which on activation releases GFs. In our study, we used the 
Platelet count from the diabetic patient group as a prototype to demonstrate that the PCCS used in 
this research as the ability to increased Platelet concentration to an accepted published level. The 
average Platelet baseline value ranged from 130,000 to 500,000 platelet /µl. The PCCS increased the 
platelet count on the average from 334,000±117,000platelet/ µl to 1,995,000±805,000 platelet/µl; 
this is a 6-fold increase. The PRP group was significantly higher in platelet number compared to the 
baseline Platelet count, with a significance value of   p > 0.0005.  
Furthermore, a comparison was made between the various GFs expressed from PRP/PPP and the 2 
groups. The details of the actual values were described in chapter 3. However it will suffice to 
mention that a 5-fold increase in EGF, 68-fold of PDGF-AA, 4-fold  of VEGF,  28-fold of TGF-β1, 
2-fold of P-Selectin and a 3-fold increase of TSP-1  was found when PRP and PPP was compared in 
the diabetic group. On the other hand, there was no significant increase in the expression of FGF-2, 
IGF and PF-4 in the diabetic group. Similarly, the same pattern of GFs expression was observed 
with the healthy donor with the exception of 69-fold increase in PDGF-AA and 38-fold increase in 
TGF-β1. It has been postulated that by increasing the concentration of Platelets, the expression of 
GFs released will invariably increase. There are existing controversies surrounding these 
postulations; from our study, by using the more expressed GFs as a prototype (PDGF-AA, VEGF 
and TGF-β1) from PRP derived from both the diabetic and healthy volunteers, we were unable to 
establish any correlation between platelet counts and amount GFs expressed. 
We went a step further in Chapter 4, by obtaining supernatant from PRP/ PPP (from both the 
healthy volunteers and group diabetic patients) and were preserved in -80
0
C.  Primary human cells 
(fibroblast and keratinocyte) were extracted and cultured from redundant plastic surgery procedures 
such as foreskin, face lift.  The cells were maintained in tissue culture and passage to established 
cells that were used for the purpose of different experiments. In addition, human umbilical 
endothelia cell (HUVEC) was commercially procured and used in the study.  Other cell line used in 
the study were the NEB-1 cell, fibroblast cell line (mouse 3T3) and EA.hys cell, all of which were 
either used to maintain primary cells in culture or in optimizing experimental protocol (See Chapter 
2 and 4 for detailed description).  
In chapter 4, we used experimental model through tissue culture assay to test our research 
hypothesis. The preferred assay and cells used in this study were those with direct involvement with 
wound healing process.  The hypothesis been tested were to assess (i) the proliferative effect of 
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PRP/PPP on HDF, HEK, NEB-1, EA.hys and HUVEC; (ii) to assess migratory effect of PRP/PPP on 
all the cell line  mentioned above and finally (iii) to assess angiogenic effect of PRP/PPP on 
HUVEC. Proliferation assay was assessed through Alamar blue fluorescence technique, a positive 
proliferative effect of PRP/PPP was observed on all the cell types following experimental repeats. 
The proliferative effect observed with HUVEC, EA.hys and HDF were very similar, with 5% PRP 
showing the most prominent effect over other varying concentration of PRP (10%, 25% and 50%), 
PPP and the positive control (Media with 1% FCS or 1% BSA). It is worth mentioning that this 
effect also reached statistical significance.  It is interesting to also note that a decreasing dose 
response phenomenon was observed in all 3 cell types mentioned above.  
A further experiment will be needed to elucidate and explain this phenomenon (see section on 
future work). HEK and NEB-1 cell showed a slightly different pattern, in that the, the positive 
control showed a better proliferative effect over the varying concentration of PRP/PPP.  Although, 
the positive control showed the most positive effect, the decreasing dose response effect was still 
preserved with the PRP/PPP treated cells. To further ascertain that the effect observed was not 
dependent on the type of the culture media used,  the experiments were repeated with HDF/HEFK 
using Bovine serum albumin (BSA) and Fetal calf serum as the medium, it was interesting to note 
that proliferation  for both cell types were better in BSA. In another experiment, the effect of serum 
was eliminated from fibroblast proliferation,  we observed that all the varying concentration of PRP 
and PPP produced a far better proliferative effect than the control experiment which was a serum 
starved, in the 5% PRP produced the most positive effect. We therefore concluded that, the 
decreasing dose response phenomenon was possibly due to either the presence of an inhibitory 
growth factor in the constitution of PRP or there exist an antagonist effect of the GFs amongst each 
another. Furthermore, we suggested that presence of TSP-1 and PF-4 in PRP/PPP which are believed 
to possess anti-proliferative and anti-angiogenic effect might be responsible for this effect.  BSA 
produced the optimal serum condition for sub-culturing fibroblast and keratinocytes and in addition 
PRP/PPP is capable of maintaining cell in tissue culture without the serum protein. 
The migratory assay was aimed at evaluating the chemotactic effect of PRP/PPP on the different cell 
types through the use of modified Boyden chamber (Transwell migration assay) and wound/scratch 
assay technique. The details of how the two assays were conducted can be found in Chapter 4. A 
positive transwell migratory effect was observed with HUVEC, EA.hys and HDF when treated with 
varying concentration of PRP/PPP, with a statistically significant effect over the control treatment. A 
similar pattern of decreasing dose response which was initially observed with proliferation assay was 
also seen with transmigration assay, 5% PRP showing the most migratory effect. NEB-1 cell and 
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HEK also behaved in a similar pattern to their proliferation assay, with the control treatment 
producing the most positive migratory response. 
Several attempts at conducting a wound/scratch assay with HUVEC were unsuccessful. The wound 
assay with HDF was only possible without mitomycin treatment. A statistically significant migratory 
effect was observed with 5% PRP over the control, and also with the decreasing dose response 
maintained.  On the contrary, HEK and NEB-1 cell were both tested with and without mitomycin; 
we observed that there were no statistical difference after comparing the mitomycin treated with the 
non-treated group. The positive control showed a better migratory effect over the PRP/PPP 
treatment.  In conclusion, some inference could be drawn form our study; i) the decreasing dose 
response seen with at 5% PRP could not have been an observational error, ii) the decreasing dose 
response is consistent with HUVEC and HDF across 3 different assay types, iii) we may infer that 
PRP dose not have a strong enough proliferative and migratory effect on HEK, or perhaps, the age 
and the site of keratinocyte extraction may down play the biological effect of PRP on HEK. 
Finally, in chapter 4, we evaluated the angiogenic effect of PRP on HUVEC cell through matrigel 
angiogenic assay.  Details of the 2 angiogenesis assay technique employed (Collagen/ matrigel) was 
discussed in full details in chapter 4. Following adequate literature review we identified that 
morphometric and topometric method of quantifying certain parameters from the angiogenesis assay 
may represents a better quantification method as oppose to either purely descriptive of semi-
quantitative analysis. Hence, we developed our own macro-system which analyses micro-
photographic images obtained at the end of the assay.  This system analyses 2 morphometric 
parameter (nodal and mesh formation) and 2 topometric parameters (length of the skeletinised 
network and cellular area).  The details and rationale for proposing this method has been discussed 
in great details in Chapter 2 and 4.   
We observed that PRP had a positive and statistically significant angiogenic effect on HUVEC over 
the positive control.  We can categorically say that nodal and mesh formation are reliable parameters 
with direct correlation to the degree of angiogenic activity. Measuring the length of the skeletinised 
capillary network, appear promising from our result, but we believe a repeat of the experiments may 
produced a more reliable quantification result. Surprisingly, one would expect that measuring the 
cellular area will give a better index of angiogenic activity, but to our surprise the soft programme 
was unable to distinguish between the properly formed capillary network and clump of cells. For 
example, PPP demonstrated a very weak angiogenic effect on matrigel assay, but formed large area 
of clumpy cells, during analysis, the cellular area under PPP larger as compared with PRP 5% which 
had a better angiogenic effect morphologically. It is worth mentioning that the formation obtained 
from cellular area is inversely proportionally to the angiogenic effect, and must be interpreted with 
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caution. Once again, it is interesting to note that 5% PRP produced the most angiogenic effect over 
other concentration of PRP/PPP and the positive control. Although, this method needs validating 
through experimental repeats with different endothelial cell types and angiogenic agents, we 
proposed that this may be a simpler, less cumbersome and more effect way of quantifying 
angigogenic properties of potential compounds. 
 
In chapter 5, we endeavour to understand the possible alterations and histological changes that 
might be occurring between day 0 (post debridement) and week 8 (when complete re-epithelisation 
is in view or guaranteed).  Wound biopsies taken from the wound margin of chronic ulcers of 
diabetic patient‘s after been treated with PRP  at different time points (day 0, day 8, weeks 4 & 8) 
were subjected to both histological and immuno-histochemistry analysis. Details of the histological 
and immunohistochemistry techniques and method of tissue preservations employed were discussed 
in Chapter 2 & 4. A histological comparison was made between the patients‘ that achieved 
complete re-epithelisation and non-healed group. The cellular activities of the epithelia layer were 
monitored and measured at day 0, day 8 and week 4 & 8 respectively. In general, the thick and 
nucleated corneum layer in the non-healed group is characteristic of a recalcitrant ulcer. There was a 
gross distortion in the structural architecture of the epithelial layer. Furthermore, a general decrease 
in cellular activity in the granulosum and spinosum layer from day 0 to week 8 as evident by 
decrease in the size of the layer as the wound progress towards normal healing in the group that 
achieved complete wound healing. On the contrary, the cellular activities in the non-healed group 
remained perpetually high.  
There are striking differences in the immunostaining patterns for keratins K14, K1/K10, Ki67 when 
comparing chronic ulcer margin to the unwounded normal skin. A suprabasal expression of K14 in 
all the keratinocyte layers was seen from day 0 through week 8 for both the healed and non-healed 
group; in contrast to the unwounded skin it remained at the basal layers. K1/K10 showed a purely 
limited pattern of expression to the granulosum layer on the immediate post debridement sample but 
as the wound progresses towards week 8, the expression becomes suprabasal. K16 showed an up-
regulation of its expression in a suprabasal layer from the day 0 until week 8, this expression is 
similar in both categories of patients. This is a sign of hyperproliferation in chronic ulcers. Ki67 
showed a decreasing trend in its expression as the wound progresses towards normal re-
epithelisation, on the contrary the expression of Ki67 remained static in the non-healing group.  The 
expression of beta-1 integrin and CD 44 was also observed to be up-regulated in both categories of 
  
 
 
221 
patient ulcers which could both represent a sign of ongoing inflammatory changes in the wound. The 
proinflammatory role of CD44 remains debatable in chronic wounds.  
The restoration of Collagen VII has been shown as a hall mark of true re-epithelisation. From our 
study we were able to clearly demonstrate that collagen VII was completely restored as major 
basement membrane component in the group that achieved complete re-epithelisation whereas it 
remained distorted in the non-healed group. There no changes in the alignment of collagen I and III 
either from the 2 categories or during the wound healing process. The main limitation of this study 
was the fact that we were unable to recruit patients into the control arm of the study; hence the 
changes observed were not directly attributable to PRP treatment. To better understand the effect of 
PRP on the molecular mechanism involved in keratinocyte migration, basement membrane 
restoration and changes occurring in extraceullar matrix during healing, a control group (treated with 
PPP) and or a group receiving standard care for diabetic ulcer will be required for comparison. 
Immunohistochemistry technique to analyze the expression of various chemotactic and growth 
factors and their receptors in the margin of diabetic foot ulcers and in normal non diabetic foot skin 
might in give a better insight to molecular changes at the wound edges. 
 
In Chapter 6, we evaluated the treatment outcomes of diabetic patients with chronic foot ulcers after 
been treated with PRP. The initial protocol and ethic approval allowed recruited of patients into 2 
arms of treatment; the PRP group (active) and the PPP group (placebo), however due to patient‘s 
preference we were unable to recruit into the placebo arm. The details of the inclusion and exclusion 
criteria, the treatment protocol for PRP and the routine post treatment standard care of the patients 
have been discussed in chapter 2 and 6. The clinico-demographic data of the 7 patients recruited is 
detailed in chapter 6. Three of the 7 patients achieved complete re-epithelisation; two patients were 
withdrawn mid week into the study. Both required below knee amputations because of worsening 
foot sepsis. The other two patients with recalcitrant plantar ulcer we followed up to 16 weeks. It is 
very difficult to categorically attribute both the success and failure of this wound to PRP treatment, 
this because of the so many irresolvable confounding factor in the process and the patients 
themselves. This further illustrates the difficulty that other researchers are encountering in the 
planning of a randomised control trial which is the way forward in standardising the use of PRP.  We 
are of the opinion that PRP is able to deliver constellation of GF to wounds which are believe to 
have potentials to accelerate the process of wound healing. 
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6.12 Future work 
The biological and cellular mechanisms of impaired healing in chronic diabetic foot ulcers are not 
well known, due to a lack of appropriate experimental animal models. Previously reported studies 
have focused on analysis of wound fluids, and also on biopsied tissues, but sufficient specimen 
samples needed for research studies are difficult to obtain for practical and ethical reasons. Several 
concepts have recently emerged from the molecular and cellular analysis of the chronic wound 
environment.  Chronic diabetic foot ulcers exhibit a long-standing inflammatory cellular infiltrate in 
tissues, and elevated levels of proinflammatory cytokines. Measurement of wound pro-inflammatory 
cytokines and anti-angiogenic agents from wounds treated with PRP and placebo may begin to 
provide new insight to the cellular mechanism of chronic wounds.  Fibroblasts isolated from chronic 
diabetic foot ulcers are more senescent compared with fibroblasts isolated from healthy skin, and 
have decreased proliferative ability and exhibit a decreased mitogenic response to recombinant 
growth factor treatment.  Proteases present in chronic wounds are believed to destroy growth factors 
delivered to wound. This suggests that delivery of PRP in combination with protease inhibitors, by 
means of a polymeric device to control release of the growth factors and prolong the biological 
effects of the various components, may provide a solution on the early degradation of PRP.  
 
In a study conducted by Birc et al., 2009, they used gelatin hydrogel as a sustained release carrier for 
growth factors in PRP to investigate its angiogenic properties in wild type C57BL6 mice after 
inducing hind limb ischemia by excising right femoral artery. The conclusion from the study was 
that sustained release of PRP containing potent angiogenic growth factors helps restore blood 
perfusion presumably by stimulating angiogenesis, arteriogenesis, as well as vasculogenesis in 
mouse hind limb ischemia. A similar clinical trial may be tried in humans to see if the same results 
can be obtained.   
 
Furthermore, understanding of how fibroblasts respond to keratinocyte–derived stimuli is important 
in understanding the role of TGF-β activity in the transformation of fibroblast to myofibroblast. This 
is crucial for the formation and regulation of quality granulation tissue. A coculture experiment 
(fibroblasts and keratinocytes), comparing messenger RNA (mRNA) expression pattern obtained 
from non-diabetic human wound edges should be compared with that from human  diabetic wound 
edges. A similar study conducted by Werner et. al 2007, which compares the RNA expression of co 
cultured and control fibroblast, revealed a differential expression of growth factors, extra cellular 
matrix, protease, and intracellular structural protein transcripts. The RNA expression showed that 
several gene characteristics of TGF- β signalling were up regulated; for example smooth muscle 
acting alpha and collagen type 1. To further understand the role of PRP in wound healing and the 
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kinetics involved in this process, a  study to understand the role of autologous derived platelet-rich 
plasma at the micro-circulatory level may answer specific questions on how PRP influence micro-
vascularity at the capillary bed. A similar study was conducted using a mice model by Eberhard et 
al., 2003. Microvascular perfusion can be measured by using laser Doppler perfusion imager, which 
will provide information on red blood cell influx. Intravital fluorescence microscopy will provide 
information on microcirculatory changes such as the inner diameter of arterioles and venules, as well 
as the number of rolling and adherent leucocytes in post capillary venules. 
 
Most of the study published on PRP has mainly been to investigate its role in tissue reparation. More 
research will be needed in the area of tissue regeneration if the potentials of PRP were to be fully 
explored.  Understanding the role of PRP at the embryological stages (pre-differential and progenitor 
cellular level), will open a new horizon for its use.   In a study conducted by Wen-Cheng Lo et. al., 
2009, the group investigated the potential use of fibroblasts in combination with platelet-rich plasma 
(PRP) to achieve bone regeneration in osteoporotic mice. In the study, a senescence-accelerated 
mouse (SAM) model was developed to depict a pathophysiologic scenario of senile osteoporosis. 
NIH3T3 embryonic fibroblasts were used for osteoinductive cell transplantation and served as tracers 
for this study. PRP medium was used to stimulate proliferation and differentiation of NIH3T3-G 
cells into osteoblast-like cells before transplantation. The result demonstrated that transplantation of 
PRP treated NIH3T3-G cells into ovariectomized SAMP8 mice induced bone regeneration and 
significantly reversed osteoporosis not only at the implantation site, but also in other regions of the 
skeleton.  
 
The future role of platelet- rich plasma is hanging in the balance and to some extent it remains at the 
potential and anecdotal level at this present time. Many more large controlled clinical studies will be 
required to establish clear cut treatment benefit significance in specific groups of patients and 
conditions. The dose-dependent relationship and time of its application when treating such conditions 
will need to be made more specific. In addition, there is need to conduct a cost-effectiveness analysis 
study on  the potential economic benefit of an autologous, platelet-rich plasma (PRP) gel to 
alternative therapies in treating non-healing diabetic foot ulcers.   This study will centre on economic 
models using peer-reviewed data to simulate clinical and cost outcomes and quality-adjusted life-
years (QALYs) associated with PRP gel and other treatment modalities. A comparative cost analysis 
study looking at other modalities of treating chronic diabetic foot ulcers particularly in patients with 
neuropathic ulcer versus  platelet rich plasma therapy, will provide a very useful data  on the use of 
PRP .   
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Appendix 1 – Materials 
Transport Medium (TM) 
Dulbecco‘s modified eagles medium (DMEM) supplemented with 5% FCS (v/v) +antibiotic/ 
antimycotic solution of 600 units/mL Penicillin-G, 600mg/nl Streptomycin sulphate, 
250 mg/mL Gentamycin (Sigman-Aldrich Company Ltd, Dorset, UK.) and 2.5 mg/mL 
Fungizone  (Invitrogen, Paisley, UK.) 
 
E4 Medium 
Dulbecco’s modified eagle’s medium (DMEM) 4.5g/L glucose, supplemented with 10% FCS (v/v) 
and 1% glutamine 
Add the following to 400mL to Dulbecco‘s modified eagles medium (DMEM) 
· 5mL Penicillin (10,000 units/mL)/Streptomycin (10mg/mL) (1%) 
· 5mL L-Glutamine (1%) 
· 50mL FCS (10%) 
Penicillin/Streptomycin contains 10,000 units/mL penicillin and 10mg/mL streptomycin in 0.9% 
sodium chloride. 
 
RM+ Medium 
3 parts DMEM + 1 part HAMS F12 medium + 10% FCS + 1% Penicillin/Streptomycin + 1% 
L-Glutamine + 1% RM+ supplement 
Add the following to 400mL of 3 parts Dulbecco‘s modified Eagle medium (DMEM) and 1 
part Ham‘s F12 medium: 
· 40mL FCS (10%) 
· 5mL Penicillin (10,000 units/mL)/Streptomycin (10mg/mL) (1%) 
· 5mL L-Glutamine (1%) 
· 5mL RM+ supplement (1%) 
RM+ supplement contains the following mitogens: 0.4mg/mL hydrocortisone, 10-10 M 
Cholera toxin, 5mg/mL transferrin, 2-11 M lyothyronine, 1.8-4 M adenine, 5.5mg/mL insulin.  
 
Antibiotic/Antimycotic solution600 units/mL Penicillin-G, 250 mg/mL Streptomycin sulphate, 250 
mg/mL Gentamycin(Sigma-Aldrich Company Ltd, Dorset, UK) and 2.5 mg/mL Fungizone 
(Invitrogen, Paisley, UK) 
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Freezing medium 
Add 5mL DMSO (Dimethyl Sulfoxide) to 45mL FCS 
 
Reagent Manufacturer Catalogue 
No. 
Lot No. 
Dulbecco‘s PBS(1X) 
without Ca& Mg 
PAA, Cell Culture company, UK H15-002 H00208-1984 
Trypan Blue (0.4%) Sigma-Alrich Company Ltd, Dorset T8154 107K2360 
Dimethyl Sulfoxide BDH Laboratory Supplies, Poole UK 23500260 07L190523 
Trypsin (0.25x) PAA, Cell Culture company, UK L11-004 L00408-1885 
Versene(1x) Invitrogen ,paisley, UK 15040-066 473989 
DMEM/F12 Modified PAA, Cell Culture company, UK T15-276 T27608-1982 
DMEM High 
Glucose(4.5g/L without L-
glutamate with sodium 
pyruvate 
PAA, Cell Culture company, UK E15-011 E001108-1017 
Paraformaldehyde (10%) VWR International, UK 361367L N/A 
Table showing the material used for tissue culture and the manufacturer 
 
Antigen Unmasking Solutions for Immuno-histochemistry 
Vector antigen unmasking solution pH 6 
Ready to use solution; prepared by mixing 15 ml of the stock antigen unmasking solution with 
1600mL of distilled water 
 
Tris-EDTA- Citrate Unmasking Solution pH8.1 
This is at X10 strength stock solution in bottles; 900mL of distilled water is added to the stock before 
use. The stock is prepared from 15g EDTA, 7.5 g Tris Base, 9.6g Sodium Citrate and 3000ml 
distilled water. Sodium hydroxide is added to it to achieve the desired pH of 8.1 
 
Tris-EDTA Unmasking Solution pH9.0 
This is at X10 strength stock solution in bottles; 900mL of distilled water is added to the stock before 
use. The stock is prepared from EDTA 11.1 g, Tris Base 36.3g, and distilled water 3000ml. The pH 
is checked with a pH-meter. 
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Appendix 2 – Protocols 
Cell culture 
3T3 (NIH) Fibroblasts 
Passaging 
3T3 cells should be passage at 75% confluence, higher confluence may result in Mitomycin-C 
resistant cells. 
1. Aspirate E4 medium and add 5mL of PBS to wash flask 
2. Aspirate off PBS 
3. Add 5mL versene/EDTA to flask and leave for one minute 
4. Aspirate off 
5. Add 5mL trypsin-EDTA 0.05% and leave for a  10- 15 minute, watch for cell detachment 
6. Tap flask gently and confirm cell detachment by looking under a microscope. Once 
     all cells are detached; add 5mL of E4 medium to neutralize trypsin-EDTA 
7. Using a pipette transfer contents to falcon tube 
8. Check flask once more under microscope for any remaining cells, if present, wash 
     flask with E4 and retrieve remaining cells and add to existing tube. 
9.  Depending on confluence of flask and requirement of cells split e.g. 1:5 (1 part returned to flask, 4  
     parts used for experiments) 
10. Add 15mL E4 medium to flask to a T75 Flask 
11. Label flask with date, name, and cell type and passage number 
12. Put flasks back into incubator (10% CO2), check confluence daily 
 
Mitomycin -C Treatment 
3T3 cells are treated with Mitomycin C to produce 3T3 ―Feeder‖ cells as described by Rheinwald 
and Green, these cells become incapable to proliferation after treatment and therefore can be used to 
grow keratinocytes. 
1. Cells obtained from passaging should be centrifuged at 1200 revolutions per   minute (RPM) for  
     5minute and resuspended in 10mL E4 medium in a falcon tube 
2. Add 20microgram /ml of Mitomycin C to resuspended cells in media. (Mitomycin-C is light  
     sensitive, so vials should be wrapped in aluminium foil) 
3. Attach lid to tube and mix gently 
4. Place in incubator for 2 hours (10% CO2) with gentle mixing every 15 minutes (to ensure all 3T3s  
    are exposed to treatment) 
5. Centrifuge for 5 minutes at 1200 RPM 
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6. Aspirate off liquid, being careful to leave remaining cell pellet 
7. Resuspend pellet in 10mL PBS thrice allowing pellet to settle for 5minute between  
    each of the washes and mix well with pipette 
8. Repeat steps 6-7 two more times (i.e. 3x PBS wash) 
9. Resuspend cells in 10mL E4 
Irradiation treatment of 3T3 
1. A cell density of 1 million per mL prepared from subculturing,  
2. A total of 40million / ml were resuspended in equal volume of media 
3. The falcon tube was left on ice and transfer to the gamma radiation room 
4.  The cells were irradiated at 6,000gyrad for 40minute. 
5.  Following irradiation, the cells were used for the experiment as described earlier ( 2 million 
     feeders/ T-75 flask) and the remaining were cryopreserved.  
Keratinocytes 
Extraction ( Done under sterile condition in clean Tissue culture hood) 
1. Using a disposable scalpel, cut out an appropriate size of redundant abdominal  skin or face fit.  
     The forceps and scissors used are sterile in 70% ethanol during extraction 
2. Using forceps transfer to a large Petri dish a portion of the sample and add enough versene  
     (EDTA) to cover 
3. Using scalpel, forceps and scissors aim to remove as much fat from the underlying dermis as  
    Possible. The more fat removed, the greater the keartinocyte yield. Alternatively a 1-2mm thick  
    dermatome can be used to isolate epidermal sheets. 
4. Repeat step 2 as necessary to keep the skin clean 
5. Once the bulk of fat is removed, focus on using the scalpel to scrape off any remaining  
    subcutaneous fat 
6. Cut the skin into small squares (~5mm x 5mm) and place into a 50mL falcon tube 
7. Add 20mL of 0.25% trypsin and swirl tube 
8. Place tube into an incubator at 37°C 10% C02 for 1-2 hours until the cells have detached (Regular  
    checking of the medium to see when media go cloudy and the  skin pieces will ( begin to  float to 
     The surface). Check every 15 minutes. 
9. Place skin pieces back into a new Petri dish and fill with culture medium (E4) to inhibit trypsin  
     action. 
10. Using two needle tips carefully scrape off the epidermis from the dermis. Use one needle to fix  
     the piece to the dish, whilst scraping with the remaining needle. Keep the dish organised, i.e.  
      separate scraped from non-scraped skin pieces. 
11. Transfer dish contents back into a falcon tube 
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12. Pour contents through sterile gauze into a new falcon tube leaving behind  scraped skin pieces i.e.  
      dermis. The remaining dermis can be used for fibroblast   extraction. 
13. Centrifuge falcon tube at 1200 RPM, for 5 minutes 
14. Aspirate off supernatant, being careful to leave pellet behind. Resuspend in an appropriate  
      volume of medium e.g. 20mL RM+ 
15. Cell count with trypan blue 
16. Seed cells into a T75 flask containing 2x106 3T3 mitomycin treated / or irradiated feeders 
17. Incubate at 37°C/10% CO2, media change after 24hours  
18. After 48 hours, add more feeders if necessary and change media. Use solutions (wash solutions,  
      trypsin solutions etc) that is low in calcium, or calcium and magnesium free. Calcium exposure  
      encourages differentiation and decreases growth. 
 
Passaging 
Keratinocytes should be passage at 75% confluence; higher confluence may result in decreased 
growth or failure to adhere to the flask. 
1. Aspirate RM+ medium and add 5mL of PBS to wash flask 
2. Aspirate off PBS 
3. Add 5mL versene/EDTA to flask 
4. Check every minute under the microscope to confirm 3T3 feeder detachment, tap  flask as  
    necessary to encourage detachment 
5. Once all feeders are detached, aspirate off versene/EDTA 
6. Add 5mL trypsin EDTA 0.05% and leave for a 10-15 minute 
7. Tap flask gently and confirm cell detachment by looking under a microscope, cells  will become  
    rounded. Once all cells are detached, add 5mL of RM+ medium to  neutralize trypsin 
8. Using a pipette transfer contents to falcon tube 
9. Check flask once more under microscope for any remaining cells, if present, wash  flask with  
    RM+ and retrieve remaining cells and add to existing tube. 
10. Depending on confluence of flask and requirement of cells split e.g. 1:5 (1 part  returned to flask, 
     4 parts used for experiments) 
11. Add 30mL RM+ medium to split flask 
12. Label flask with date, name, cell type and passage number 
13. Put flasks back into incubator (10% CO2), check confluence daily 
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General 
Media changes 
Media changes should be performed every 3 days to maintain optimal growth conditions. 
1. Attach pipette to aspirator, aspirate out old medium 
2. Add 5mLL PBS to wash flask, aspirate 
3. Add appropriate type (E4/3T3, RM+/KC) and volume (15mL / T75 flask, 30mL /T175 flask) 
 
Cell counting 
The most effective method for cell counting is to use a haemocytometer. This instrument is 
composed of a thickened glass slide containing a small grid chamber in the centre. Cells are counted 
with trypan blue dye, which allows cell viability to be assessed; dead cells take up the dye appearing 
blue on the haemocytometer. 
 
1. Add 20µL cell suspension to 20µL Trypan blue dye into an eppendorf™ Microcentrifuge tube. 
2. Leave for one minute and prepare haemocytometer by cleaning and drying off ethanol. Place a  
    coverslip onto the haemocytometer and look for Newton rings to confirm correct setup. 
3. Pipette 10 µL of cell suspension/trypan blue solution onto haemocytometer channel  
4. Place under microscope and count all 4 large square quadrants.  
5. Obtain average. 
6. Double average to obtain number of cells (n): n x 104/mL. 
7. Depending on volume of cell suspension, factor in the total e.g. 20mL cell suspension is n x 20. 
 
Cryopreservation and cell recovery 
 
Cell preservation and recovery follow the same procedure but different cell have varying 
concentration of DMSO/ Fetal Calf Serum/Medium 
1· Determine cell count and then resuspend 2x10
6 
cells/1mL freezing medium per cryovial 
2· Label the cryovials with name, date, cell type and passage number 
3· Wrap cryovials in paper towels and use tape to make a parcel 
4· Store in freezer at -80°C 
5· For long term storage (>28 days) transfer to liquid nitrogen storage 
6· To retrieve cells warm cryovials in waterbath, once thawed, pipette cell suspensioninto a falcon  
    tube and add equal volume of culture medium (i.e. E4/3T3 or RM+) 
7· Centrifuge 1200RPM/5 minutes 
8· Resuspend in culture medium 
  
 
 
230 
                                         Appendix 3 
Macro progamme for analysing angiogenesis assay image 
# mesh.mcr SEG April May 2010 
# read angiogenesis images and do topological anbalysis according   
# Guidolin, D et al. Microvascular Res, 67, (2004) 117 - 124 
 
DBdelete "database" 
DBnew "database",5 
DBsetcolumn "database",1,"Specimen","String","<none>" 
DBsetcolumn "database",2,"No_of_nodes","Int","<none>" 
DBsetcolumn "database",3,"No_of_meshes","Float","<none>" 
DBsetcolumn "database",4,"Skel_length","Float","micron" 
DBsetcolumn "database",5,"Cell_area","Float","micron" 
 
imgsetpath "c:\ks400\conf\images\femi\angiogenesis_assay" 
# imgload "c:\ks400\conf\images\femi\angiogenesis_assay\ag100007.jpg",1  
MSload "femi_node"                                     #min area only 1 pixel instead of default 4 
 
thresh[6] := 1                 #storage for  2 sets of colour threshold values  
 
##########################Calibration############################# 
#All images x10 objective. Previously calibrated by Femi using 250 micron blob on my calibration 
slide 
MSsetprop "SCALEX",0.9328          # micron/pixel 
MSsetprop "SCALEY",0.9328 
MSsetprop "UNIT","micron" 
################################################################ 
 
# Make colour threshold database, get previously stored values and store in thresh array 
DBnew "thresholds",1  
DBsetcolumn "thresholds",1,"thresh_val","Int","<none>" 
DBcopy "mesh_thresholds","thresholds",0,1 
DBfirstline "thresholds"  
for i=1; i <= 6; i = i+1   
    DBgetvalue "thresholds","1",temp   
    thresh[i] = temp      #for some reason, can't write va directly into an array  
    DBnextline "thresholds"  
    # write i, thresh[i]       
endfor   
 
another = "yes" 
while another == "yes" 
    Gclear 0 
 
    #get image and extract name for later saving of modified image 
    ! imgload in_file_name,1  
    imgstatus 1,_sizex,_sizey   #needed for editbina, to edit images of any size 
    entire_path = imgload_1 
    write entire_path  
    in_file_name = imgload_1 
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    # Knock off dot plus suffix for outfile name only 
    len_in_file_name_s= flength(in_file_name) - 4 
    in_file_name_s := ""  
    pos = 0 
    for i2 = 1; i2 <= len_in_file_name_s;i2 = i2 + 1 
        in_file_name_s = in_file_name_s + "x"  
        pos = pos + 1 
        z = (in_file_name[i2]) 
        in_file_name_s[i2] = z 
    endfor 
 
# Initial processing according to Guidolin, D et al. Microvascular Res, 67, (2004) 117 - 124 
    imgdisplay 1 
 
    showwindow "Messages", 1 
    write "Threshold image. Don't forget to click on left thumbnail"  
    dislevrgb 1,2,1,0,thresh[1],thresh[2],thresh[3],thresh[4],thresh[5],thresh[6],10,"RGB"   
    !dislevrgb 1,2,1,0,thresh[1],thresh[2],thresh[3],thresh[4],thresh[5],thresh[6],10,"RGB"   
    write "@"  
    binscrap 2,3,0,200,0 
 
    # thresh values for later writing in case they've been changed 
    thresh[1] = dislevrgb_5 
    thresh[2] = dislevrgb_6 
    thresh[3] = dislevrgb_7 
    thresh[4] = dislevrgb_8 
    thresh[5] = dislevrgb_9 
    thresh[6] = dislevrgb_10 
 
    passes = 8 
    satisfied = _FALSE     
    while satisfied ==_FALSE 
        read passes,  "How many passes?" 
        ! binclose 3,4,7,passes 
 
        # Generate skeleton in image 9 and count nodes by Paul Sheperd's method (email 26-03-10) 
        binthinning 4,5,3,158 
        binscrap 5,6,0,30,0 
        lowpass 6,7,3,1 
        binand 6,7,8             # Not in Paul's method but necessary because low pass filter generates lines 
> 1 pixel wide 
        dislev 8,9,112,113,1 
        imgdisplay 6 
        Gclear 0 
         
        node_count = 0 
        RGnew 9,9 
            RGfirstregion  
            while _STATUS == 1 
                MSmeasregion 1  
                node_count = node_count + 1 
                MSdrawregion 
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                RGnextregion 
            endwhile 
        RGdelete  
     
        # Overlay skeleton onto original image then add dilated nodes, result in image 14 
        Gextract 6,128,253,11 
        imgclear 10,0 
        Gmerge 10,255 
        Gclear 0 
        binthinning 10,11,3,0 
        bindilate 11,12,7,1 
        imgdisplay 12 
        Gextract 12,128,255,10 
        add 1,6,14,2                                      # display net on original image 
        Gmerge 14,255 
        Gclear 0 
 
        # Generate meshes in image 17 and count them 
        binfill 6,15 
        binxor 6,15,16 
        binerode 16,17,7,1   # count won't work if mesh boundaries are only 1 pixel wide 
         
        mesh_count = 0 
        RGnew 17,17 
            RGfirstregion  
            while _STATUS == 1 
                MSmeasregion 1  
                mesh_count = mesh_count + 1 
                MSdrawregion 
                RGnextregion 
            endwhile 
        RGdelete  
     
        Gclear 0 
        imgdisplay 14 
 
        MByesno "Satisfied?" 
        satisfied = _STATUS 
    endwhile 
 
    # Measure length of thinned skeleton (img. 18 thinned from img. 6) 
    binthinning 6,18,1,1 
 
    RGnew 18,18 
        RGfirstregion  
        while _STATUS == 1 
            MSmeasregion 1  
            MSgetvalue "PERIM",length 
            MSdrawregion 
            RGnextregion 
        endwhile 
    RGdelete  
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    # Measure area of filled cells (img. 4) 
    RGnew 4,4 
        RGfirstregion  
        while _STATUS == 1 
            MSmeasregion 1  
            MSgetvalue "AREA",area 
            MSdrawregion 
            RGnextregion 
        endwhile 
    RGdelete  
     
    #Write values into database 
    DBaddline "database"   
    DBsetvalue "database","Specimen", in_file_name_s 
    DBsetvalue "database","No_of_nodes", node_count 
    DBsetvalue "database","No_of_meshes", mesh_count 
    DBsetvalue "database","Skel_length",length/2.0 
    DBsetvalue "database","Cell_area", area 
    # Save orig imag showing skeleton outline      
        MByesno "save  image"  
        if (_STATUS == _TRUE)  
            outname = in_file_name_s + "m.jpg"  
            ! imgsave 14,outname   
        endif  
     
    DBflush "database"  
    datalist "database",0,1  
    MByesno "Another?" 
    if (_STATUS == _TRUE) 
        another = "yes" 
    else     
        Valid = 1 
        another  = "no" 
    endif 
    write "@"     
endwhile   another 
 
# This stores the colour threshold database on disk  
DBfirstline "thresholds" 
for i=1,i <= 6,i = i+1 
    DBsetvalue "thresholds","thresh_val",thresh[i]    
    DBnextline "thresholds"       
endfor  
DBcopy "thresholds","mesh_thresholds",0,1 
 
datalist "DATABASE",0,0 
pause "Don't forget to paste" 
write "@" 
showwindow "Messages",0 
showwindow "Display",0 
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APPENDIX- 4 – Protocol for Imunohistochemistry 
Histology and Immuno-histochemistry 
Note: all reagents and consumables are purchased from VWR labs Ltd UK unless otherwise 
stated. 
Tissue processing for paraffin sections 
1. Tissue was fixed for a minimum of 24 hours in 10% formal saline or longer is need be 
2. Tissues were processed on a Shandon Excelsior ES™ Tissue Processor (See below) 
3. Specimens were embedded in paraffin wax 
4. Blocks were then cut on a rotary microtome (Leitz), sections cut at 3μm and sections 
picked up on APES coated slides 
5. Slides were dried either at 45°C overnight for immunohistochemistry staining. Slides 
    were stored at 37°C if not used  immediately. 
6. Shandon Excelsior ES™ Tissue Processor Programme Step Reagent Temperature 
 
Shandon Excelsoir ES
TM    
Tissue Processor Programme 
Step Reagent Temperature 
(
0
C) Hold/Use 
Time (Hr) Vacuum 
1 10% Formalsaline Abmient/45 1:30 NO 
2 Industrial methylated 
spirit (IMS) 
30 1 Yes 
3  30 1 Yes 
4  30 1 Yes 
5  30 1 Yes 
6  30 1 Yes 
7  30 1 Yes 
8  30 1 Yes 
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9  30 1 Yes 
10  30 1 Yes 
11  62 1:20 Yes 
12  62 1:20 Yes 
13  62 1:20 Yes 
 
Tissue processing for frozen sections 
1. Fill dewar with liquid nitrogen 
2. Fill small container with approximately 2 inches of isopentane 
3. Suspend isopentane container from clamp on ring stand and lower the container  into the liquid  
    nitrogen. The base of the container should just touch the top of the  Liquid nitrogen and cause it to  
    bubble as it cools the container. If you insert the container too far into the liquid nitrogen the  
    isopentane will freeze. If this happens,  just remove the container and allow the isopentane to thaw  
    and then  place it back in the liquid nitrogen. 
4. Label a cryomold with the identifying data of the tissue. Make sure to use a  marker resistant to  
   organic solvents 
5. Place a small amount of Cryo-M-Bed in the bottom of the cryomold 
6. Remove the tissue to be frozen 
7. Place the tissue oriented with the side you are interested in at the bottom of the cryomold 
8. Fill the cryomold with Cryo-M-Bed compound. Use caution not to move the tissue when adding  
   the Cryo-M-Bed and be sure to remove any bubbles that form near  the tissue with a forceps as  
   these will cause problems with sectioning (cracking and fragmentation) 
9.  Place the cryomold into the isopentane. Use caution not to tip the cryomold and dislogding the  
    tissue. A little preparation here and ordering a pair of long handled forceps that can open wide  
    enough to grasp the entire cryomold help here quite a bit 
10. The Cryo-M-Bed will freeze into a solid white color. The tissue should be covere and not visible    
      as you look down on the mold. Allow approximately 1 minute for freezing of the entire block 
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11. Transfer the tissue to and ice bucket with dry ice and continue with the rest of  the tissues 
12. Place tissues in plastic bag or other airtight container and store at -80ºC 
 
R.T.U Vectastain Universal Elite Procedure 
Immuno-cytochemistry Manual Version 1 - Courtesy of Queen Mary University, ICSM Core 
Pathology Group (for staining paraffin) 
1. The following controls should be used. 
Positive  control section for each primary antibody used. 
Negative control section [omitting primary antibody] 
2. Place the sections into a black plastic staining rack 
3. De-wax the sections in xylene for 2 changes of 2 minutes each 
4. Remove the xylene in Alcohol for 2 changes of 2 minutes each 
5. Place the sections into the sink and wash in tap water for 5 minute  If the particular antibody you  
    are going to use does not require antigen retrieval  then continue with the next step. Otherwise  
    perform antigen retrieval technique first. 
6. Prepare the endogenous peroxidase blocking solution by adding 6mL of hydrogen peroxide to  
    194mL of distilled water in a black staining trough. 
7. Place the sections into the endogenous peroxidase blocking solution for 15  minutes. 
8. Remove the rack and place into the sink and wash in tap water for 15 minutes 
9. Wash out the black plastic staining trough previously used for the endogenous  block  with  
     distilled water and fill it with wash buffer. 
10. Place the rack of slides into the wash buffer and leave to soak for 5 minutes. 
11. Prepare an immuno-staining tray by adding a few drops of wash buffer to it to create a moist  
      chamber. 
12. Taking each slide in turn, wipe around the section to remove excess wash buffer and using a 
PAP pen draw a line across the slide above and below the section. 
13. Place the section onto the rack in the immuno-staining tray and cover with wash buffer. Do      
      allow the sections to dry out. 
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14. When all of the sections are on the rack tip off the wash buffer. 
15. Apply sufficient drops of normal blocking serum (Normal horse serum – yellow  bottle from the 
     R.T.U. Kit) to cover each section 
16. Place the lid on the immuno-staining tray and leave for 20 minutes 
17. Prepare the primary antibody at the appropriate dilution using antibody diluent. 
18. Tip off the normal blocking serum. 
19. Apply the primary antibody to each test section and the positive control section. 
20. Apply antibody diluent alone to the negative control section. 
21. Replace the immuno-staining tray lid and leave for 40 minutes. 
22. Rinse off the primary antibody with wash buffer. 
23. Cover each section with wash buffer, replace the immuno-staining tray lid and leave for  
      2minutes. Rinse with wash buffer and cover each section again and  leave for a further  minutes. 
24. Tip off the wash buffer. 
25. Apply drops of the Universal biotinylated secondary antibody (Biotinylated AntiRabbit/mouse –  
      blue bottle from the R.T.U. kit)  to cover each section. 
26. Replace the immuno-staining tray lid and leave for 30 minutes. 
27. Rinse off the secondary antibody with wash buffer. 
28. Cover each section with wash buffer, replace the immuno-staining tray lid and leave for  
      2minutes. Rinse with wash buffer and cover each section again and leave for a further 2 minutes. 
29. Tip off the wash buffer. 
30. Apply sufficient drops of the Vectastain Elite ABC Reagent (Grey bottle from the R.T.U. kit) to  
      cover each section. 
31. Replace the immuno-staining tray lid and leave for 30 minutes. 
32. Rinse off the ABC reagent with wash buffer. 
33. Cover each section with wash buffer, replace the immuno-staining tray lid and  leave for  
      2minutes. Rinse with wash buffer and cover each section again and leave for a further 2 minutes. 
34. Into a yellow topped tube place 1mL of substrate buffer from the Biogenex Two Component  
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      DAB kit. 
35. To this, add 1 drop of the DAB Chromogen from the kit and mix well. 
36. Tip off the wash buffer from the slides and apply the DAB solution to each of the slides, leave  
      for 5 minutes. 
37. Wash the slides in tap water for 5 minutes. 
38. Load the slides into a machine staining rack ensuring that all of the sections are  facing in the 
      direction of the  arrow on the rack. 
39. The remainder of the technique is carried out using machines and involve  staining the sections 
      with the dye Haematoxylin. This stains the nuclei a light- blue colour, giving contrast against the 
      brown immuno-cytochemical  staining. The sections are then dehydrated in alcohol to remove  
      water and then washed in Xylene before having a glass  cover slip placed over the section to  
      protect it and produce a permanent preparation. 
 
Staining procedure for frozen sections 
Immediately before staining, fix sections with acetone or appropriate fixative for the antigen. 
Antigen retrieving step is not needed for frozen sections. For endogenous peroxidase blocking 3% of 
hydrogen peroxide with distilled water for 15 minutes or 0.3% peroxide in methanol for 30 minute is 
used. Continue with step 8 -39 as described above. 
                    
Embedding of Specimens Procedure 
The following procedure is observed for processing paraffin embedded wax tissue after obtaining the 
tissue biopsy sample 
1. The cassette basket is lifted from processing machine and the excess wax allowed to drain. It‘s  
     then taken  to the Embedding centre in a plastic tray. 
2. The cassettes are carefully tipped into the storage tray in the embedding centre that is kept at 60
0
C  
    to prevent the  specimen solidifying. 
3. The processing basket and the lid are then placed into the plastic tray ready to receive the used  
     cassettes lids. 
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4. Cassettes are taken one at a time from the storage tray and the metal lid carefully removed  
    ensuring that the tissues  does not fall out. There must never be more than one cassette at a time  
    with its lid removed. 
5. The lids are checked to make sure that the tissue is not attached to it‘s before discarding it into  
    basket or in the case of  plastics lids into the waste bin. 
6. Very small specimens may be enclosed either in speciwrap or between two pieces of foam biopsy  
     pad.  If enclosed in paper it is essential that the paper is kept on the hot part of the embedding  
     centre to prevent the wax with which it is impregnated from solidifying. If enclosed in biopsy  
     pads, the top pad should carefully be removed and checked to ensure that the specimen is not  
     attached to it. The bottom pad can either be left in the cassette or removed and placed on the hot  
     area with  specimen uppermost. 
9.  A mould of appropriate size is selected and partially filled with wax from the built in dispenser. 
10. The tissue is removed from the cassette /speciwrap/ biopsy pad using warm forceps, placed in  
      the mould and oriented. 
10. It is important that the tips of forceps are checked each time they are used, to avoid any carry  
      over which may be attached  to the forceps from the previous specimen. 
11. The mould is then carefully moved to the ‗cold spot‘ and a film wax allowed to form on the  
       bottom sufficient to hold  the specimen in place. 
12. The plastic cassette is placed on the mould and completely filled with wax. 
13. The mould is then carefully moved to the cold plate and left until solid. 
14. Once set, the block can be removed from the mould and placed into a plastic box ready for 
cutting. 
15. The basket lid are placed in the tray in the wax oven to allow the wax to drain. Any excess wax  
is cleaned out using a tissue. Accumulated wax in the tray should be cleaned out when the cassettes 
are removed for cleaning. 
16. The cassettes are finally cleaned by placing in the processing machine on an extended flush      
cycle, after which they dried in the oven. 
17. The cassette is returned to the embedding centre tray 
18. The cassette centre was cleaned down and the wax reservoir topped up.  
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APPENDIX – 5 
Invitation to participate in a Research Project 
 
Title: Study to elucidate the role of autologous platelet rich Plasma gel 
(APG) in treating chronic non-ischemic Diabetic foot ulce 
Investigator: Mr Costas Kyriakides and Prof. Harry Navsaria. 
We invite you to take part in a research project, which we think may be 
important. The information, which follows, tells you about it. It is important 
that you understand what is in this leaflet. It says what will happen if you take 
part and what the risks might be. Try to make sure you know what will happen 
to you if you decide to take part. Whether or not you do take part is entirely 
your choice. Please ask any questions you want to about the research and we 
will try our best to answer them. 
Part 1 
Invitation 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it 
will involve. Please take time to read the following information carefully and 
discuss it with friends, relative and your GP if you wish. Ask if there is 
anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
 
1. Part 1 tells you the purpose of this study and what will happen to you if you 
take part.   
2. Part 2 gives you more detailed information about the conduct of the study.  
 
Ask us if there is anything that is not clear or if you would like more 
information.  Take time to decide whether or not you wish to take part. The 
study is sponsored by Barts and The London Hospitals NHS Trust. 
Introduction to the study 
Diabetic foot ulcers are a condition that diabetics need to handle with every 
care. Treatment of these ulcers, which range from superficial to deep, can take 
months to years to heal in some patients, while others can quickly resolve. 
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With the help of medical research and biotechnology techniques, we are now 
able to successfully process various parts of human blood to make new 
potential treatments for these ulcers 
Diabetic foot ulcers result mainly from two causes: poor circulation and 
peripheral neuropathy. Poor circulation in the feet will result in a diminished 
ability to heal.  Peripheral neuropathy results in localised nerve damage, which 
causes a loss of sensation in the feet and further contributes to inadequate 
circulation and increases the likelihood of injury. 
Because of the difficulty the body has in delivering blood supply to the 
diabetic foot, finding a way for us to copy the normal healthy healing could be 
an important factor in treating these ulcers.  
Most diabetic ulcers can be traditionally managed by bandages, dressing and 
controlling infection with antibiotics; but a large proportion will not respond to 
these conventional treatments. With our increasing understanding of normal 
wound healing systems in the body, it has been shown that growth factors are 
necessary for effective wound healing. 
 
Platelets and Growth Factors 
Several kinds of cells contribute to the wound healing process. Among them 
are blood cells called platelets. Platelets are cells essential to clotting, and are 
the first cells to gather at the wound site. They start the healing process by 
releasing various growth factors. 
Growth factors are proteins that act as signals between cells to control 
communication. They summon useful cells and proteins to the wound site; 
promote cell movement and growth of new skin. 
This new method uses the patient‘s own blood to produce the treatment gel. 
Blood is collected from a vein in the arm, just like a blood test. The blood is 
then processed into its different parts using a portable machine. The amount of 
blood collected depends on the size of the ulcer. The gel is made when a 
clotting chemical and the processed blood are mixed; this component contains 
platelets and other growth factors. We gently spray the gel into the wound until 
the gel-like substance fills the area. This is then dressed as per usual. 
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This treatment is currently used by the Barts & The London NHS Trust for 
some patients with non-healing ulcers. This study wishes to understand more 
about this new treatment and also to prove how well it works. 
Benefits of the treatment  
 Your own blood will be used for your treatment. 
 The gel can be applied as many times as required on the wound. 
 Your treatment may help heal your ulcer quicker. 
 The treatments will be carried out in Out Patient clinics. 
 
The purposes of the study are: 
To study the natural role of platelet rich plasma gel in treating non-healing 
diabetic foot ulcers. We also want to determine the rate of wound healing and 
how many wounds will heal during the study period. 
 
Furthermore, the study will enable us to understand the cell changes in the 
wound that take place in the diabetic ulcer and healing process. 
Why have I been ask to participate? 
This is because you have a non-healing diabetic ulcer and we believe that you 
may benefit from this relatively new treatment option. We hope to recruit 
twenty patients for this pilot study. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do, you will be 
given this information sheet to keep and be asked to sign a consent form. If 
you do not wish to take part, your Doctor will discuss with you other options 
for trying to treat your ulcer. 
 
You are still free to withdraw at anytime and without giving a reason.
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Before you can begin the study 
You may read the full study protocol as well as this information, which gives 
you many details about the study. The recruiting investigator will tell you more 
about the study. You will be given adequate information about the study and 
your involvement. You are encouraged to ask questions to clarify anything you 
are not clear about. 
 
Screening Visit 
You will be examined by the study doctor, who will take a detailed medical 
history and conduct a physical examination. The Doctors will also review your 
medical records.  We will ask you for a sample of your urine (40mL) for 
routine safety analysis. 
 
Study Protocol 
 
On the first day of the study, you will be allocated into one of two groups after 
you have been found eligible during the Screening. 
 
The choice of group will be random, (like tossing a coin) with ten patients in 
each group. You will not be told which group you are in. These groups will 
receive slightly different treatments.  Group (1) will be treated with a gel 
containing your platelets and growth factors and Group (2) will be treated with 
a gel, which contains some growth factors but no platelets. All other treatments 
and care will be the same for both groups. 
 
The study doctor, will review your ulcer by taking photographs of it and 
measuring its size. This photograph will not identify you as a person, but the 
picture may be use in educational meetings or for publications. At this time, we 
will measure the blood flow to your legs and around the ulcer. These 
measurements are entirely non-invasive and painless. 
You will have a needle inserted into a vein of one of your arms. A single blood 
sample will be immediately collected from this needle. A total amount of blood 
will be determined by the size of your wound (about 10 times the estimated 
size). This blood will be carefully labelled with your details and made into the 
treatment gels. At this time we will also collect about a 15mL blood sample for 
routine safety tests. This total blood collection will always be less than half a 
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standard blood donation, which in your case is not a medically significant 
amount.  
If medically indicated, you might undergo surgical wound debridement; which 
is a surgical procedure under general anaesthetic to adequately remove all the 
dead tissue in and around you foot ulcer. You may have already had this 
treatment in the past. We will keep this material to make measurements in the 
laboratory to learn more about your ulcer and healing processes.  
We will be collecting fluid from your wound; this will be done with the help of 
a device called vacuum assisted closure therapy (VAC). Which simply means 
applying a small portable machine with a dressing device on the wound for up 
to one hour to collect the fluid? This is procedure should not be painful, but it 
may cause some discomfort. 
We will also be taking a small punch biopsy (6mm) of your wound before 
applying the gel, so that we can measure any healing that occurs during the 
study. The biopsy should not hurt you, but if necessary we can use a topical 
anaesthetic cream to numb the area. After the biopsy, the gel will be applied 
into the ulcer and the normal dressings applied. 
You will be given an appointment for your wound review 4 days after the first 
treatment, at one week and then weekly at clinic for the first one-month and 
then every two weeks until the wound has completely healed. The details of 
the tests, treatments and the frequency of your visits to clinic are shown in the 
table at the end of this Information Sheet. 
 
Routine measurement of the wound and photographs will be taken at every 
clinic visit before and after the gel application. This will give us a guide to how 
well your wound is healing.  
Depending on the response of the wound to the gels; if the wound is not 
improving, another gel treatment will be applied but not until after 14 days 
from the initial application. 
 
Further wound fluids and biopsies will also be taken from the wound on the 4
th
 
day, week 4 and week 8 respectively.  At the same time, blood flow around the 
ulcer will also be measured as before. The exact timings will depend upon your 
clinic visits and the stage of the healing. 
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If it has not healed before the end of the study (16 weeks), your Doctor will 
discuss with you other treatment options to treat your ulcer. 
 
You will be encouraged to get involved in the care of your ulcer and follow 
routine instructions from the Podiatric and Vascular nurses. 
 
 
Expenses 
Transportation arrangements will be made to transport patients outside their 
routine clinic attendance. The Research team will meet all reasonable travel 
expenses. 
 
What do I have to do? 
You will need to come to the treatment clinic at the times requested and remain 
there for the duration of time required. If you are unable to make any of the 
appointments, kindly contact us to make an alternative appointment. 
You are requested not to participate in any other form of research or study 
whilst you are involved with this research. 
What are the other possible risks of taking part in the study? 
There are no known risks from the autologous platelet gel in our experience.  
But if you encounter any unusual reaction, please report it to your G.P or 
contact us immediately. 
There are very few risks involved in inserting a cannula into a vein in the arm. 
You may feel some discomfort and sometimes there may be a small bruise 
around the area, which may be sore and last for a couple of days.  
Taking of a wound biopsy should not be painful in your case, but local 
anaesthetic may be applied to further numb the area. The wound may bleed 
slightly, but should stop quickly after application of gentle pressure. There is 
also a small risk of infection; however, but we will regularly and closely 
review your wound during the study. 
 
The use of vacuum assisted closure therapy device to collect wound fluids 
should also not be painful, but if any discomfort is experienced the procedure 
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will be discontinued immediately.  This device is used routinely in our wound 
care clinics and is very safe. 
 
PART 2 
What if relevant new information becomes available? 
If new information becomes available during the research period about the 
treatment, your research doctor will discuss these issues with you and will 
advise you on the best available option about your involvement. 
 
Also on receiving new information your research doctor might consider it to be 
in your best interests to withdrawal you from the study. He will explain the 
reasons and arrange for your care to continue. 
If the study is stopped for any other reason, you will be told and your 
continuing care will be arranged. 
 
What will happen if I don’t want to carry on with the study?  
If you withdraw from the study, we would like to use the data collected up to 
withdrawal date.  Any  blood or tissue samples that can still be identified as 
yours will be destroyed if you wish. 
If your participation in the study is discontinued after you have received the 
study treatment you may be asked to undergo a final examination for your own 
safety. If the reason for ending the study is, for example, an adverse event or a 
side-effect of the treatment, you will be asked to give information on these in 
order to protect the other patients taking part in this clinical study. 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm will be addressed.  If you have a concern about any aspect of 
this study, you should ask to speak with the Research Team who will do their 
best to answer your questions. 
Mr. Costa Kyriakides, telephone: 0207 3777134 
Mr. Femi Akingboye, telephone 07859062928 
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Complaints:  
If you remain unhappy and wish to complain formally you can do this by 
contacting the National Health Services complaint session, which be done 
locally through Patient Advisory Liaison Service (PALS), Telephone 020 7377 
6355 or email pals@bartsandthelondon.nhs.uk. 
 
You may make a formal complaint via Jarrard O‘ Brien, Quality Development, 
Barts and The London NHS Trust, Healthcare Governance Directorate, 3
rd
 
Floor, Prescott Street, tel. 0207480 4857, or email 
jarrard.obrien@bartsandthelondon.nhs.uk 
 
Will my taking part in this study be kept confidential? 
All the information obtained about you in the course of the study is 
confidential and will be kept in a secure locked room. The investigators 
performing the study and a study Monitor will have access to the data collected 
in this study.  They may also be looked at by representatives of regulatory 
authorities and by authorised people from Barts and the London NHS Trust to 
check that the study is being carried out correctly. All will have a duty of 
confidentiality to you as a research participant and nothing that could reveal 
your identity will be disclosed outside the research site. 
If you consent to take part in the research, the research team will abide by the 
Data Protection Act 1998, and the rights you have under this Act. 
Involvement of the GP / Family doctor 
With your permission we will contact your General practitioner to advise them 
of your potential participation in the study. 
What will happen to any samples I give? 
All your blood, tissue and urine samples taken for safety screening will be 
tested immediately in the clinic and once the results obtained, they will be 
destroyed. Other samples taken will be stored until they are tested. The 
samples will be anonymised and will contain only your unique study number, 
time and date of the sample. Once the results have been obtained they will be 
destroyed. 
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All blood and tissue samples collected during the research will be analysed 
with Barts and the London Hospital NHS Trust and the Institute of cell and 
molecular science, Queen Mary Medical School, London  
Will there be genetic testing? 
We shall not be performing genetic screening during this study period, but 
proteins involved in wound healing process will be evaluated. 
 
What will happen to the result of the research study? 
The results of this study may be published or presented at meetings. You will 
not be identified in any report/ publication or presentation. 
Who is organising and funding the research?   
This research is being Sponsored and funded by Barts and the London NHS 
Trust. 
What happens if you are worried or if there is an emergency? 
You will always be able to contact an investigator to discuss your concerns 
and/or to get help 
Mr. Costa Kyriakides and or Femi Akingboye 
Vascular Surgery Unit, 
Department of General Surgery, 
The Royal London Hospitals NHS Trust, 
White Chapel, 
London. E1 1BB. 
Or contact Surgery department via switchboard for the on call Vascular 
Surgeon on 0207 3777000. 
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What happens if something goes wrong? 
We believe that this study is basically safe and do not expect you to suffer any 
harm or injury because of your participation in it. However, we carry insurance 
to make sure that if your health does suffer as a result of your being in the 
study, then you will be compensated. In such a situation, you will not have to 
prove that the harm or injury, which affects you, is anyone‘s fault. If you are 
not happy with any proposed compensation, you may have to pursue your 
claim through legal action. 
 
Who has reviewed the study? 
This study has been reviewed and approved by National Research Ethics 
committee. 
Thank you for taking the time to read this information sheet. 
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Invitation to Donate Blood for a Research Project 
 
Title: Study to elucidate the role of autologous platelet rich Plasma gel 
(APG) in treating chronic non-ischemic Diabetic foot ulcers 
Investigator: Mr Costas Kyriakides and Prof. Harry Navsaria. 
We invite you to take part in a research project, which we think may be 
important. The information, which follows, tells you about it. It is important 
that you understand what is in this leaflet. It says what will happen if you take 
part and what the risks might be. Try to make sure you know what will happen 
to you if you decide to take part. Whether or  not you do take part is entirely 
your choice. Please ask any questions you want to about the research and we 
will try our best to answer them. 
Part 1 
Invitation 
You are being invited to donate blood that will be used for a research study. 
Before you decide it is important for you to understand why the research is 
being done and what it will involve. Please take time to read the following 
information carefully and discuss with us if you have any doubt.  Take time to 
decide whether or not you wish to take part 
  
Ask us if there is anything that is not clear or if you would like more 
information.  Take time to decide whether or not you wish to take part. The 
study is sponsored by Barts and The London Hospitals NHS Trust. 
 
Introduction to the study 
Platelets are cells essential to clotting, and are the first cells to gather at 
the wound site. They start the healing process by releasing various growth 
factors. They summon useful cells and proteins to the wound site; promote 
cell movement and growth of new skin. Blood is collected from a vein in 
the arm, just like a blood test. The blood is then processed into its 
different parts using a portable machine.  The gel is made when a clotting 
chemical and the processed blood are mixed; this component contains 
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platelets and other growth factors. This gel produced will be analysed and 
used for laboratory experiment.  
The purposes of the study are: 
To study the effect of platelet rich plasma gel on cells involved with wound 
healing in the laboratory, which have a processed and experimental 
relationship with human wound. Furthermore, the study will enable us to 
further understand changes that occur in the cells that are involved in wound 
healing process. 
 
Why have I been ask to participate? 
This is because we believe you might be able to donate your blood voluntarily 
for the purpose of the study 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do, you will be 
given this information sheet to keep and be asked to sign a consent form.  
You are still free to refuse to participate without giving a reason. 
If you decide to participate 
At this time, blood will be collected from your arm vein, which will be about 
300ml in total, less than the total amount of blood donated for regular blood 
donation.   
 
There are very few risks involved in inserting a cannula into a vein in the arm. 
You may feel some discomfort and sometimes there may be a small bruise 
around the area, which may be sore and last for a couple of days.  
What will happen to the blood donated?  
Any blood samples taken from you will be processed into the platelet gel, part 
of the gel will be analysed immediately for presence of different growth factors 
and the remaining will be stored and use for the laboratory experiment.  
The samples will be anonymised and will contain only your unique study 
number, time and date of the sample. Once the study is over any blood 
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products remaining will be destroyed. All blood samples collected during the 
research will be analysed with Barts and the London Hospital NHS Trust and 
the Institute of cell and molecular science, Queen Mary Medical School, 
London.  
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm will be addressed. If you have a complaint, please contact the 
following person in the first instance, Mr. Costa Kyriakides 0207 3777134. 
 
Complaints:  
If you remain unhappy and wish to complain formally you can do this by 
contacting the National Health Services complaint session, which be done 
locally through Patient Advisory Liaison Service (PALS), Telephone 020 7377 
6355 or email pals@bartsandthelondon.nhs.uk. 
 
If the patient wishes to make a formal complaint: Jarrard O‘ Brien, Quality 
Develeopment, Barts and The London NHS Trust, Healthcare Governance 
Directorate, 3
rd
 Floor, Prescot Street, tel. 0207480 4857, or email 
jarrard.obrien@bartsandthelondon.nhs.uk 
  
Will there be genetic testing? 
We shall not be performing genetic screening during this study period but 
proteins involved in wound healing process will be evaluated. 
 
What will happen to the result of the research study? 
All the information obtained about you in the course of the study is 
confidential and will be kept in a secure locked room. The investigators 
performing the study and a study Monitor will have access to the data collected 
in this study.  They may also be looked at by representatives of regulatory 
authorities and by authorised people from Barts and the London NHS Trust to 
check that the study is being carried out correctly. All will have a duty of 
confidentiality to you as a research participant and nothing that could reveal 
your identity will be disclosed outside the research site. 
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If you consent to take part in the research, the research team will abide by the 
Data Protection Act 1998, and the rights you have under this Act. 
The results of this study may be published or presented at meetings. You will 
not be identified in any report/ publication or presentation. 
Who is organising and funding the research?   
This research is being Sponsored and funded by Barts and the London NHS 
Trust, London. 
  
Who has reviewed the study? 
This study has been reviewed by National Research Ethics committee, and has 
been given approval by the local ethics committee. 
Thank you for taking the time to read this information sheet. 
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Patient Information Sheet (Tissue donation)  
Study Number  : APG-1 
Study title   : A study to elucidate the role of autologous platelet rich 
       plasma gel (APG) in treating chronic non-ischemic diabetic foot ulcers 
Investigators   : Prof H. Navsaria & Mr. Constantinos Kyriakides 
Sponsor   : Barts and The London Hospital, NHS Trust, London 
You are being asked to take part in this study because you are an adult 
who is about to undergo a planned surgery procedure on your foot to treat 
your diabetic ulcer. 
     
Part 1 
Invitation 
You are being invited to take part in a research study.  Before you decide it 
is important for you to understand why the research is being done and what 
it will involve.  Please take time to read the following information carefully. 
Talk to others about the study if you wish.  
 
 Part 1 tells you the purpose of this study and what will happen to you if 
you take part.   
 Part 2 gives you more detailed information about the conduct of the 
     study.  
 
Ask us if there is anything that is not clear or if you would like more 
information.  Take time to decide whether or not you wish to take part. 
     Barts and The London Hospitals NHS Trust, is the sponsor of this research. 
 
     What is the purpose of the study? 
Diabetic foot ulcers are a condition that diabetics need to handle with every 
care. Treatment of these ulcers, which range from superficial to deep, can 
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take months to years to heal in some patients, while others can quickly 
resolve. 
 
With the help of medical research and biotechnology techniques, we are 
now able to successfully process various parts of the patient‘s own blood to 
make new potential treatments for these ulcers. 
 
Platelets or thrombocytes are the cell fragments circulating in the blood that 
are involved in cellular mechanisms which are essential for clotting, and are 
the first cells to gather at the wound site. They start the healing process by 
releasing various growth factors. They summon useful cells and proteins to 
the wound site; promote cell movement and growth of new skin.  
 
We are conducting experimental studies to enable us understand how this 
process, together with how healing may be accelerated and improved, 
through special techniques which colour the cells and identify areas of 
interest. 
 
To further enable these studies, we would like to collect a skin sample 
which will be removed from diabetic patients undertaking routine surgical 
debridement operations (cleaning of the wound and removal of dead tissue). 
This skin is removed as part of your normal surgery and it is generally 
discarded and incinerated.  
     Why have I been chosen? 
You are being asked to take part in this study because you are a diabetic 
adult who is about to undergo a planned surgical procedure on your foot. 
We are requesting that you donate a small piece (about 1cm) of the skin 
which is going to be removed from your foot. 
 
     Do I have to take part? 
No.  It is up to you to decide whether or not to take part.  If you do, you will 
be given this information sheet to keep and be asked to sign a consent form. 
You are still free to withdraw at any time and without giving a reason.  
     Before you can begin the study 
You may read the full study protocol as well as this Information sheet, 
which gives you more details about the study. The research doctor will tell 
you about the study and any adverse events, which could occur. You will be 
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told exactly what the study entails and what will be required of you. You 
are encouraged to ask questions of the Investigators conducting the study, 
until you are satisfied that you fully understand the nature of the study and 
the requirements. 
What do I have to do? 
If you agree to take part and to sign the research section of your Consent 
Form, we will review your medical records and collect details relating to 
your health, diagnosis and planned treatment. 
 
In relation to the study, we only request that you donate a piece of the skin 
left over from surgery, which would otherwise be destroyed in the clinical 
waste. Participation in the study will have no impact on your planned 
treatment or health. 
What are the alternatives for diagnosis or treatment? 
This study is not related to your planned surgery. Your surgeon will have 
already discussed your treatment with you. If you have any concerns about 
your planned treatment, please discuss them with the surgery team. 
     What are the other possible disadvantages and risks of taking part? 
We do not believe that there are any disadvantages or risks in you taking 
part. 
     Expenses and payments: 
There will be no payment in exchange for your participation in this study or 
for the donation of your skin sample. 
     What are the possible benefits of taking part? 
None, although you will be contributing to our understanding of the reasons 
behind diabetic wounds and this knowledge may help others such as you in 
the future. 
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     What if there is a problem? 
Any complaint about the way you have been dealt with during the study or 
any possible harm you might suffer will be addressed.  The detailed 
information on this is given in part 2. 
If you have a complaint please contact the following in the first instance:  
Mr. C. Kyriakides or Mr. Femi Akingboye 
If you are employed by Barts & The London NHS Trust or Barts & The 
London School of Medicine & Dentistry, non-participation or dropping out 
of the study will not affect your training or career. 
 
     Any complaint about the way you have been dealt with during the study the 
     detailed information on this is given in Part 2.    
      A contact number for complaints will be given. 
     Will my taking part in the study be kept confidential?  
Yes. All the information about your participation in this study will be kept 
confidential.  The details are included in Part 2. 
     
       
     Contact Details: 
     If you require any further information please contact:   
Mr. Constantinos Kyriakides 
Vascular Surgery Department, 
The Royal London, White Chapel 
London, E1 1BB 
Tel Number: 02073777020 
     Or: 
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     Mr. Femi Akingboye 
Vascular Surgery Department, 
The Royal London, White Chapel 
London, E1 1BB 
Tel Number: 02073777020, 07859062928 
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                 PATIENT RECRUITMENT INFORMATION 
A STUDY TO ELUCIDATE THE ROLE OF AUTOLOGOUS PLATELET RICH 
PLASMA GEL (APG) IN THE TREATMENT OF CHRONIC NON-ISCHAEMIC 
DIABETIC FOOT UCLERS 
 
Ethnics Approval by the East and City of London Ethnics Committee Local REC 
Number: 08/H0704/17 
Study is Sponsored by : 
Barts & The Royal London  Hospitals NHS Trust, 
Joint Research Office, 3
rd
 Floor, Rutland House, 42 – 46, New Road, 
The Royal London Hospital,  White chapel, London. E1 1BB. 
 
Principal Investigator: Mr. C. Kyriakides (Consultant Vascular Surgeon) 
Clinical Research Fellow: Femi Akingboye 
INCLUSION CRITERIA 
In order to be eligible to enter the study, patients must meet the following criteria. 
 A patient with documented Type І or Type ІІ diabetes mellitus of not less than 
2 years duration. 
  Only patients that are on pharmacotherapy treatment for diabetes will be used 
in the study. 
 Only one ulcer on the foot of the Lower limb (medial malleolus to the toes). 
 The ulcer should have a surface area of between 4cm2 –40cm2.    
 The treatment is specific to clinically non-infected full thickness wounds 
 Ulcer present for a minimum of 4 weeks  
 The wound must extend through the dermis and may involve tendon, muscle or 
bone exposure. 
 The wound must have failed to respond to intensive conventional treatment. 
 The patient should be competent to give consent and have an appropriate 
support system to facilitate his/her full participation in the follow-up care 
associated with the treatment of the wound. 
 A case control method will be applied to counter the effects of variables that 
might affect the study outcome. 
 An ankle brachial pressure index value of ≥0.7 and transcutaneous oxygen 
tension on the foot with the ulcer of ≥ 40mmHg 
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 EXCLUSION CRITERIA 
 Patients with clinical evidence of platelet dysfunction and thrombocytopenia < 
100,000. 
 Patients with documented malignant disease and connective tissues disease. 
 Patients with who are not ambulant from other reason other than the poor 
mobility due to the ulcer, except inpatients, will not be included. 
 Any other significant pathology, which might impair healing other than 
diabetes such as end stage renal impairment. 
 Patients with clinically documented Hepatitis B & C infection and HIV. 
 Patients with documented MRSA wound infections. 
 Patients with poor prognosis associated with other disease processes. 
 Ulcers from any cause other than diabetes will be excluded such as 
        pressure sore. 
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           Flow chart illustrating events that will occur from recruitment to the end of the study 
Interval  
 
Day 
0 
Day 
4 
Wk 
1 
Wk 
2 
Wk 
3 
Wk 
4 
Wk 
6 
Wk 
8 
Wk 
10 
Wk 
12 
Wk 
14 
Wk 
16 
SCREEN 
↓  ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ 
Consent ☼             
Demo ◙             
Urinalysis ◘      ◘      ◘ 
              
STUDY              
Haematology  ●     ●      ● 
Biochemistry  ♦     ♦      ♦ 
Microvascular  ♥ ♥    ♥      ♥ 
Photography  ♣  ♣ ♣ ♣ ♣ ♣ ♣ ♣ ♣ ♣ ♣ 
Planimetry  ♠ ♠ ♠ ♠ ♠ ♠ ♠ ♠ ♠ ♠ ♠ ♠ 
Debridement  ◄            
APG 
treatment 
 ▼            
APG analysis  ►            
Biopsy  ▲ ▲    ▲  ▲     
Wound Fluid  ▓     ▓  ▓     
Dressing  ▒ ▒ ▒ ▒ ▒ ▒ ▒ ▒ ▒ ▒ ▒ ▒ 
Kindly contact Mr. Femi Akingboye, Vascular research Fellow on 07859062928 for 
patient recruitment. 
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Title of research proposal:  A PILOT STUDY ON THE   ROLE OF AUTOLOGUS 
PLATELETRICH PLASMA (APG) FOR THE TREATMENT OF DIABETICFOOT 
ULCERS 
Name of Researchers: Mr. Costa Kyriakides & Prof H.Navsaria 
Name of Patient / Volunteer (Block Capitals): 
Address: 
SCREENING CONSENT FORM (Initial boxes to agree with statement) 
 
________________________ ____________            ______________________ 
Name of Patient   Date    Signature 
_______________________    ____________    ____________________ 
Name of Person taking consent Date    Signature 
__________________________   ____________    _____________________ 
Researcher    Date    Signature 
 
1. I confirm that I have read and understand the information sheet 
dated ............................ , (Platelet Plasma Gel) for the above study. I have 
had the opportunity to consider the information, ask questions and have had 
these answered satisfactorily. 
 
  
2. I understand that my participation of the SCREENING is voluntary and that I 
am free to withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected. 
 
  
3. I understand that relevant sections of any of my medical notes and data 
collected during the study, may be looked at by responsible individuals from 
Queen Mary University of London Medical School and from regulatory 
authorities, where it is relevant to my taking part in this research.  I give 
permission for these individuals to have access to my records. 
 
  
4. I agree to my GP being informed of my participation in the study and 
subsequently informed any significant information relevant to my 
participation. 
 
  
5. I agree to take part in the above study.  
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Title of research proposal: A study to elucidate the role of autologous platelet 
rich plasma gel (APG) in treating chronic non-ischaemic diabetic foot 
ulcers 
 
Name of Researchers:  Professor Harry Navsaria & Mr. Constantinos Kyriakides  
Name of Patient / Volunteer (Block Capitals): 
Address: 
DONATION OF REDUNDANT TISSUE CONSENT FORM (Initial boxes to agree 
with statement) 
 
___________________  ____________ ______________________ 
Name of Patient              Date    Signature 
______________________  ____________ ______________________ 
Name of Person taking consent Date    Signature 
(if different from researcher) 
________________________         ____________  ______________________ 
Researcher                                           Date                                     Signature 
 
1. I confirm that I have read and understand the information sheet  dated 10
th
  Jan 
2009 version 1.0, for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
  
2. I understand that my participation of the DONATION  is voluntary and that I am 
free to withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
 
  
3.  I understand that relevant sections of any of my data generated during the study, 
may be looked at by responsible individuals from Queen Mary University of 
London Medical School and from regulatory authorities, where it is relevant to my 
taking part in this research.  I give permission for these individuals to have access 
to my records. 
 
  
  
4. I agree to take part in the above study. 
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     Date    Signature 
Title of research proposal: Study to elucidate the role of autologous platelet rich 
plasma gel (APG) in treating chronic non-ischaemic diabetic foot ulcers 
 
Name of Researchers: Professor Harry. Navsaria & Mr. Constantinos Kyriakides 
Name of Patient / Volunteer (Block Capitals): 
Address: 
BLOOD DONATION CONSENT FORM 
(Initial boxes to agree with statement) 
 
______________________  ____________ ______________________ 
Name of Patient   Date    Signature 
_______________________            ____________               ______________________ 
Name of Person taking consent Date    Signature 
(if different from researcher) 
________________________          ____________              ______________________ 
Researcher                                       Date                                          Signature     Date    Signatu
1. I confirm that I have read and understand the information sheet dated 15th 
Jan 2009 version 1.1, for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
 
  
2. I understand that my participation in the DONATION is voluntary and that I 
am free to withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected. 
 
  
3. I understand that relevant sections of any of my data generated during the 
study, may be looked at by responsible individuals from Queen Mary 
University of London Medical School and from regulatory authorities, where 
it is relevant to my taking part in this research.  I give permission for these 
individuals to have access to my records. 
 
4. I agree to take part in the above study.  
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  APPENIX 6-                      Procotol for PRP preparation 
WOUND DRESSING PROTOCOL FOR PATIENTS TREATED WITH 
AUTOLOGUS PLATELET GEL  
Barts & The London Standard Operating Procedure – Specialist wound care services in conjunction 
with the Vascular Research team. 
1. Patient with chronic diabetic foot ulcers who have been found suitable will have their wound treated 
according to the platelet gel treatment protocol. 
 
2. Autologous platelet gel therapy is believed to promote wound heeling. There are no documented 
severe adverse effects from the treatment. This is because patients own blood is used in healing 
patients wound. 
 
3. The treatment is carried out under an aseptic technique either in operating room or treatment room. 
 
4. Graft/gel is produced by a group of clinical perfusionists, who are trained personnel in this field.  
 
5. To allow the graft/gel to stay on the wound, we recommend the following wound dressing protocol, 
after the initial application of the platelet gel graft 
 
6. Gentle application of damp mepitel on the wound (This will prevent disruption of the germinal layer 
of the wound). 
 
7. Apply 2 layers of damp sterile gauze (normal saline) on the mepitel. This is to prevent absorption of 
the gel into the dressing material. 
 
8. Then apply 4 layers of dry sterile gauze on the damp gauze. This is to further protect the wound. 
 
9. Apply an Opsite on the dry gauze, which will serve as an adhesive dressing material. 
 
10. Gently apply a crepe bandage, which should not be too tight to keep all the dressing material in 
place.When appropriate patient should be given medics shoe to promote the wound and to encourage 
patient ambulation. 
 
11. The first change of dressing after gel/graft therapy will be carried out by the research team. 
 
12. The initial dressing after gel application is left on for 96hrs (4days). This is preventing distortion and 
good take of the gel, the gel is believed to be a form of haemopoetic team cell.  Wound biopsy will 
be taken during this change of dressing 
 
13. Wound will be reviewed weekly during the first month of the treatment and then alternate weeks 
until the end of the treatment. 
  
14. If worried about any deterioration in wound condition kindly contact the research team, (Femi 
Akingboye 0 785906 2928), or the wound specialist nurse at the wound clinic in the Outpatient 
department of the Royal London Hospital, White Chapel. The contact person is Sis. Deborah 
Conway 02073777788. 
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15. District Nurses will be invited to attend our autologus platelet gel treatment and wound dressing 
sessions to allow for continuity of care in the community 
 
Blood Sequestration Protocol. 
Blood sequestration is used to separate different components of the blood for use in autologous blood 
therapies. Blood drawn (directly from the patient or via a donated bag) can be divided into 3 separate 
bags of:              - 1) Platelet rich plasma (PRP) 
  2) Platelet poor plasma (PPP) 
  3) Red blood cells (RBC) 
The machine used to sequestrate the blood is the Dideco Electa Cell Saver. It can be used with a 
variety of bowl sizes but information given relates to the 125ml and 55ml bowls. 
Blood should be taken from the patient at the earliest opportunity to counter the activation of the 
clotting cascade, which starts from the insertion of the first cannular in the anaesthetic room. Care 
must be taken to remove blood in the least aggressive manor possible in order not to activate the 
platelets with the donated blood. Where possible the use of a large bored lumen is advocated, (such 
as those used for venous canulation of the neck vessels). 
Enough blood must be taken to insure that the bowl size selected can be completely filled with 
packed red blood cells. It is possible to ascertain the amount needed from details in the patients notes 
and use of the table located in the ‗blood volume for platelet gel‘ section of this protocol‘. 
Blood should only be collected into an appropriate sterile collection unit. To stop coagulation of the 
collected blood, it should be drawn directly into pre-anticoagulated bag. (CPDA-1 Single Blood 
Collection System, Baxter, ref R8101). Each of these bags is pre-filled with 63ml of the 
anticoagulant solution and to this a maximum of 450ml of whole blood can be harvested. This gives 
a total of 493ml volume into the bag. If more volume than this is required (see blood volume table), 
then a second bag should be used to avoid the risk of under anticoagulation. 
 
Specific care should be taken with all aspects of health and safety when handling any body fluids 
including universal precautions. 
 
Initial Set Up 
 
 
 Set up cell saver as for normal cardiac case (see cell saver protocol), but do not add saline bags 
to the end of the wash lines. 
 
 Change the program to PRP2 
 
 Change set up of the cell saver using Dideco COD. 150 BLOOD COMPONENTS 
COLLECTION SET (ref 04025). 
 
 Remove the bags and 4-way adapter from the collection set packaging and close the roller 
clamps on the plasma collection bags. 
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 Connect the plasma collection bags to the lines of the 4-way adapter. 
 
 Hang the plasma collection bags on the I.V pole ensuring the inlet lines are face up (i.e. hanging 
upside down) WARNING: POSITIONING THE BAG WITH THE INLET LINE FACE 
DOWNDOES NOT PERMIT CORRECT EXECUTION OF THE PROCEDURE. 
 
 Disconnect the connection between the bowl outlet and the waste bag inlet.  
 
 Connect the inlet of the 4-way adaptor to the outlet male connector of the bowl. 
 
 Connect the inlet of the waste fluid bag to the single remaining line from the 4-way adaptor.  
 
 If necessary disconnect the blue (wash) line from the blood connection reservoir and connect it 
to the drawing line found in the blood components collection set. 
 
 Attach the spike adaptor to the end of this line and connect it to the collected blood. 
 
 
 Sequestration Procedure. 
 
 
 Before starting check that the line between the bowl and the collection bag is open and the lines 
between the bowl and the waste bags are closed. 
 
 Carefully spike donated autologous blood collecting bag. 
 
 Press the BLUE prime button to start the ‗PRIME PHASE‘ and follow the on screen instructions.  
 
 Blood will slowly fill the centrifuge until packed red cells fill the bowl. The displaced plasma is 
collected in one of the plasma collection bags. 
 
 When the bowl is full of packed red cells, the program will pause for approximately 60 seconds 
before automatically changing into the ‗SPILL PHASE‘. 
 
 You will be asked to close the PPP bag line and open the PRP bag line. 
 
 Further ‗spilling‘ will now occur with the platelets being collected into the PRP bag. During this 
spill, it is possible to increase the spill volume by 5ml from 30ml to 35ml. This dips further into 
the red cell region of the blood to ensure maximum yield of platelets. 
 
 Great care should be taken of the PPP and PRP bags, so as not to activate the platelets or damage 
the collected product. 
 
 The red cells are pumped into the remaining blood collection bag (for re-infusion to the patient), 
and the process may be restated in necessary. Once a sufficient quantity of blood has been 
sequestrated the bags may be closed and the products removed ready for application. 
 
 EACH BAG SHOULD BE CAREFULLY LABELLED WITH THE CORRECT PATIENTS 
DETAILS, INCLUDING THEIR NAME, DATE OF BIRTH AND HOSPITAL NUMBER. 
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                                             APPENDIX 6 
 RAW DATA FROM ALL THE EXPERIMENT IN THE THESIS 
Data from quantification of growth factors from Platelet rich and Platelet poor plasma as    
graphically represented in Chapter 3 of the main thesis 
Patient 
ID 
HPPP 
EGF 
HPPP 
FGF-2 
HPPP 
PDGF-AA 
HPPP 
VEGF 
HPPP 
TGFb1 
HPPP IGF HPPP P-
Sel 
P1 32. 32.000000 1068.559000 0.000000 344.676700 154.284800 55.999100 
P2 32. 0.000000 2023.134000 291.218200 724.270400 103.316700 56.481250 
P3 32. 0.000000 466.890000 476.456000 803.489500 141.818800 33.388360 
P4 32. 32.000000 778.406700 154.653000 1529.222000 142.449000 49.610210 
P5 32. 0.000000 1254.991000 56.799660 172.430700 112.195100 319.465900 
P6 32. 211.668900 1041.089000 273.205000 142.814000 159.756400 348.579200 
P7 32. 0.000000 1076.121000 0.000000 2224.928000 114.278200 408.501800 
P8 32. 62.956070 2044.020000 0.000000 1412.898000 150.971100 55.900880 
P9 32. 32.000000 1163.501000 170.773700 162.734800 117.920400 38.982190 
P10 32. 0.000000 1463.833000 0.000000 347.785700 105.461100 61.783010 
P11 32. 32.000000 1965.068000 82.919290 3526.818000 124.319900 48.463070 
P12 32. 32.000000 4775.592000 0.000000 127.099400 101.283600 67.477350 
P13 32. 0.000000 1290.483000 32.000000 64.000000 116.033700 41.690680 
P14 32. 86.590760 722.012500 56.799660 79.808840 154.041600 64.252700 
 
Table 1 . The raw data from the quantification of growth factors of platelet poor plasma (PPP) 
from health volunteers using the immunoabsorbent technique. Concentration of all the growth 
factors was measured in ng/mL
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Patient ID HPRP 
EGF 
HPRP FGF-2 HPRP 
PDGF-AA 
HPRP 
VEGF 
HPRP 
TGFb1 
HPRP- IGF HPRPP-   Sel 
P1 459.22670 101.9610 97767.020 1327.1980 2454.8530 149.66240 308.52180 
P2 523.4370 173.27190 109620.10 1057.4620 28558.780 114.78920 425.10590 
P3 565.12570 377.8320 157814.0 3186.4160 78634.53 137.43730 387.56140 
P4 517.75340 0.000000 147228.10 765.99560 109560.40 137.97060 319.46590 
P5 769.57070 309.11940 190001.60 334.01230 10337.780 158.24590 319.46110 
P6 917.36160 231.2810 167508.00 230.42160 11138.250 121.49170 221.29220 
P7 698.16910 0.000000 183361.90 586.83620 18266.790 135.31680 391.0410 
P8 553.48580 204.52430 275348.70 1006.7520 47962.460 130.69350 334.90160 
P9 485.50780 117.65320 222237.20 304.21530 34282.750 98.75160 347.00740 
P10 61.63388 0.000000 40302.630 105.80710 9395.3310 92.935730 103.91490 
P11 63.12603 0.000000 42657.850 239.23030 13051.390 107.75110 118.83720 
P12 177.61730 0.000000 49813.820 314.07420 5501.3350 109.85440 136.38280 
P13 146.48810 32.000000 8551.2610 132.76840 4118.7020 96.034070 104.83600 
P14 544.70840 32.000000 37982.380 0.000000 8161.1840 127.37730 333.27790 
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                     Table  2. The raw data from the quantification of growth factors from platelet rich plasma (PRP) from healthy volunteers using  
                                         the immunoabsorbent techniuque. Concentration of all the growth factors was measured in ng/Ml  
 
Patient 
ID 
DPPP 
FGF-2 
DPPP  
PDGF-AA 
DPPP  
VEGF 
DPPP  
TGFb1 
DPPP- IGF DPPPP-Sel 
P1 0. 260.000000 113.000000 599.000000 97.000000 64.173100 
P2 0. 744.211900 74.983260 64.000000 75.914570 66.538180 
P3 32. 761.303900 119.767100 2195.280000 109.857600 74.304000 
P4 32. 620.411500 56.799660 389.135900 68.192550 51.238020 
P5 32. 4216.464000 90.395170 6980.553000 106.081200 72.747730 
P6 0. 148.327400 546.402100 1518.187000 179.055300 25.154690 
                     
                              Table  3. The raw data from the quantification of growth factors from  PPP from Diabetic patients using the 
                                          immunoabsorbent  technique. Concentration of all the growth factors was measured in ng/ml 
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Patient  
ID 
DPRP  
EGF 
DPRP  
FGF-2 
DPRP  
PDGF-AA 
DPRP  
VEGF 
DPRP  
TGFb1 
DPRP IGF DPRP P-Sel 
P1 32.000000 32.000000 23758.0000 104.000000 14792.0000 127.000000 131.254800 
P2 580.513400 32.000000 215261.3000 828.443400 35284.29000 72.518970 384.656500 
P3 230.442300 32.000000 27986.07000 178.252600 32349.16000 121.35120 192.111700 
P4 294.019800 0.000000 112601.8000 1058.524000 37076.07000 81.966420 131.300700 
P5 240.904300 62.956070 247629.000 2816.444000 45755.68000 121.06700 247.968400 
P6 32.000000 0.000000 1504.464000 343.672600 5047.802000 166.38780 39.677700 
                      Table  The raw data from the quantification of  growth factors from PRP from Diabetic patients using  the immunoabsorbent  
                                                     Technique Concentration of all the growth factors was measured in ng/ml  
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                                                                        Data for standard plot for Thrombospodin -1 (TSP-1)  
 
                             
                              Table showing the optical density and pre-determined concentration of TSP-1 for determining the standard plot 
Conc (ng/ml) Mean optical density 
  0.000000 0.0810 
7.810000 0.2190 
15.600000 0.2890 
31.300000 0.4810 
62.500000 0.8105 
125.000000 1.2310 
250.000000 1.8760 
500.000000 2.4755 
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                                                                Data for standard plot for   Platelet factor -4 (PF-4) 
Conc (ng/ml) Mean optical density 
0.0 0.0855 
0.5 0.7030 
1.0 1.2850 
2.0 1.9930 
5.0 3.1330 
10.0 3.7260 
                                
                            Table showing the optical density and pre-determined concentration of PF-4 for determining the standard plot 
 
Patient ID Conc (ng/ml) Patient ID Conc (ng/ml) 
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HV1 PRP 1581.32768 HV1 PPP 534.06736 
HV2 PRP 1526.42528 HV2 PPP 593.20784 
HV3 PRP 1496.95136 HV3 PPP 419.1576 
HV4 PRP 1521.03136 HV4 PPP 543.892 
HV5 PRP 1461.5056 HV5 PPP 395.65552 
HV6 PRP 1576.51168 HV6 PPP 403.16848 
HV7 PRP 1566.87968 HV7 PPP 363.09936 
HV8 PRP 1527.19584 HV8 PPP 619.5032 
HV9 PRP 1447.82816 HV9 PPP 487.83376 
HV10 PRP 1445.32384 HV10 PPP 557.47312 
HV11 PRP 1439.352 HV11 PPP 555.83568 
HVI2 PRP 1424.904 HVI2 PPP 647.82128 
HVI3 PRP 1223.78784 HVI3 PPP 467.51024 
HV14 PRP 1432.03168 HV14 PPP 324.86032 
                                                                 Table represents the mean values of TSP-1 from PRP amd PPP from healthy volunteers (HV) 
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Patient’s ID Conc (ng/ml) Patient’s ID Conc (ng/ml) 
P1 PRP 1359.4064 P1  PPP 372.73136 
P2  PRP 1423.55552 P2   PPP 342.87216 
P3  PRP 1405.44736 P3   PPP 618.15472 
P4  PRP 997.62848 P4   PPP 131.44976 
P5  PRP 1406.21792 P5   PPP 405.38384 
P6  PRP 1303.34816 P6   PPP 243.66256 
                                                                          
                                                                 Table represents the mean values of  TSP-1  from PRP amd PPP of Diabetic patients 
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Patient ID Conc (ng/ml) Patient ID Conc (ng/ml) 
HV1 PRP 107.8999408 HV1 PPP 106.1364308 
HV2 PRP 113.4085738 HV2 PPP 108.0897623 
HV3 PRP 105.6978558 HV3 PPP 110.7009436 
HV4 PRP 100.0801923 HV4 PPP 103.8286804 
HV5 PRP 98.26233002 HV5 PPP 103.8907138 
HV6 PRP 104.7611536 HV6 PPP 97.53992172 
HV7 PRP 98.20202595 HV7 PPP 108.85074 
HV8 PRP 93.85059684 HV8 PPP 97.90078754 
HV9 PRP 103.4568754 HV9 PPP 98.26233002 
HV10 PRP 100.2629089 HV10 PPP 106.3874586 
HV11 PRP 101.8535391 HV11 PPP 92.61736751 
HVI2 PRP 113.343721 HVI2 PPP 93.61505695 
HVI3 PRP 104.0769264 HVI3 PPP 102.7769901 
HV14 PRP 166.3166437 HV14 PPP 104.1390349 
                                                   Table represents the mean values of PF-4  from PRP and PPP from healthy  volunteers (HV) 
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Patient’s ID Conc (ng/ml) Patient’s ID Conc (ng/ml) 
P1 PRP 103.3949736 P1  PPP 103.9528 
P2  PRP 110.9573847 P2   PPP 98.32265 
P3  PRP 40.63717655 P3   PPP 40.98318 
P4  PRP 95.74574244 P4   PPP 102.4687 
P5  PRP 89.2543672 P5   PPP 90.4647 
P6  PRP 84.21685524 P6   PPP 83.10532 
                                            Table represents the mean values of  PF-4  from PRP and PPP  from Diabetic patients 
RAW-DATA FROM PROLIFERATION ASSAY EXPERIMENTS AS REPRESENTED GRAPICALLY IN CHAPTER 4 FROM THE MAIN THESIS 
Cell Density/ well      4hrs  16hrs 
1,000 198 1050 
3,000 274 1414 
4,000 343 1810 
6,000 863 2871 
8,000 1092 4290 
  
 
 
278 
10,000 1192 4792 
20,000 1754 5573 
40,000 4423 6506 
80,000 5955 7084 
100,000 6332 7130 
200,000 7186 7541 
                            Table represents data from standardization of human dermal fibroblast with alamar blue. The cell density were  
            measured with spectrometry (plate reader). The data represents the mean fluorescence of three readings from each well plate  
Treatment Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 
Cont 10% 0.521137 0.526406 0.861687 1.118666 1.175634 1.306982 
PRP 10% 0.440331 0.372725 0.861687 0.938643 0.947486 1.201527 
PRP 5% 0.498876 0.391294 0.751412 0.796107 1.037223 1.089046 
PPP 0.551951 0.467411 0.890793 0.863293 1.147179 0.995886 
                    Table represents proliferation of HDF with 10% FCS as the diluents media over 5 days Proliferation measured as redox reaction of  
                                              Alamar blue dye. The redox reaction was measured as absorbance with the plate reader. 
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Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 5536.00 4798. 4788. 4733.333 4992.6670 4688.3330 4990.0 
EXP 2 5362.667 4876. 4879. 4239.00 4943.3330 4887.3330 4803.667 
EXP 3 4869.333 4876. 4765. 4733.3330 4992.6670 4688.3330 4990.0 
 
Table represents the mean value of three readings for proliferation assay of human dernal fibroblast (HDF) for each experiment (EXP), with 
experiment done in triplicate at day 0. PRP/PPP from diabetic patient, with 1% BSA as the diluent media. Proliferation measured as fluorescence of 
Alamar blue . 
 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 15225.670 17896. 15832. 14823.0 11934.330 6268.6670 629.0 
EXP 2 16619.670 16798. 14956. 13922.0 11249.670 5943.0 670.66670 
EXP 3 12948.670 15468. 11946. 8852.333 7951.6670 734.33330 116.66670 
 
Table represents the mean value of three readings for proliferation assay of HDF for each experiment (EXP), with experiment done in triplicate at day 
5.  PRP/PPP from diabetic patient, with 1% BSA as the diluent media. Proliferation measured as fluorescence of Alamar blue dye 
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Exp. 
Repeats 
Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 0.8220652 2.557255 1.297512 0.9736841 0.2113268 0.4681818 0.1254093 
EXP 2 0.9903786 1.369905 1.112543 0.9852337 0.8599617 1.077666 0.7255532 
EXP 3 1.299008 1.299119 1.530721 1.026845 1.026550 0.5382216 0.05412615 
Table represents N- fold increase (derived from data from day 0 and day 5 above) of HDF proliferation assay with PRP/PP from diabetic patient with 
1% BSA as the diluents media. 
 
Treatment Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 
Cont 10% 0.521137 0.526406 0.861687 1.118666 1.175634 1.306982 
PRP 10% 0.440331 0.372725 0.861687 0.938643 0.947486 1.201527 
PRP 5% 0.498876 0.391294 0.751412 0.796107 1.037223 1.089046 
PPP 0.551951 0.467411 0.890793 0.863293 1.147179 0.995886 
Table represents proliferation of HDF with 10% FCS as the diluents media over 5 days Proliferation measured as redox reaction of Alamar blue dye. 
 
  
 
 
281 
Exp. 
Repeats 
Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 5536.0 4798.0 4788.0 4733.3330 4992.6670 4688.3330 4990.0 
EXP 2 5362.667 4876.0 4879.0 4239.0 4943.3330 4887.3330 4803.667 
EXP 3 4869.3330 4876.0 4765.0 4733.3330 4992.6670 4688.3330 4990.0 
 
Table represents the mean value of three readings for proliferation assay of HDF for each experiment (EXP), with experiment done in triplicate at day 
0. PRP/PPP from healthy volunteers, with 1% BSA as the diluent media. Proliferation measured as fluorescence of Alamar blue dye 
 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 15225.670 17896.0 15832.0 14823.0 11934.330 6268.667 629.0 
EXP 2 16619.670 16798.0 14956.0 13922.0 11249.670 5943.0 670.6667 
EXP 3 12948.670 15468.0 11946.0 8852.3330 7951.6670 734.3333 116.6667 
 
Table represents the mean value of three readings for proliferation assay of HDF for each experiment (EXP), with experiment done in triplicate at day 
5. PRP/PPP from healthy volunteers, with 1% BSA as the diluent media. Proliferation measured as fluorescence of Alamar blue dye 
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Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 2.750302 3.729887 3.306600 3.131620 2.390372 1.337078 0.1260521 
EXP 2 3.099143 3.445037 3.065382 3.284265 2.275726 2.301801 0.1396156 
EXP 3 2.659229 3.172272 2.507030 1.870211 1.592669 1.696054 0.0233801 
Table represents N- fold increase (derived from day 0 and day 5 measurement above) of HDF proliferation assay with PRP/PP from healthy volunteers 
with 1% BSA as the diluents media. 
 
Exp. 
Repeats 
Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 14039.67
0 
12782.0 12547.670 13129.0 13033.0 12816.0 12466. 
EXP 2 14149.00 12891.330 12657.0 13238.330 13142.33 12925.330 12930. 
Table represents the mean value of three readings for proliferation assay of HDF following serum starvation for each experiment (EXP), with 
experiment done in triplicate at day 0.  PRP/PPP from diabetic patient, with 1% BSA as the diluent media. Proliferation measured as fluorescence of 
Alamar blue dye 
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Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 1839.7780 26919.78 16287.440 19966.890 19910.0 12694.670 7547.2220 
EXP 2 1716.7780 26769.78 16164.440 19843.890 10868.0 12571.670 7424.2220 
 
Table represents the mean value of three readings for proliferation assay of HDF following serum starvation for each experiment (EXP), with 
experiment done in triplicate at day 5.  PRP /PPP from diabetic patient, with 1% BSA as the diluent media. Proliferation measured as fluorescence of 
Alamar blue dye 
 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 0.1310414 2.106070 1.298045 1.520823 1.527661 0.9905329 0.6054245 
EXP 2 0.1213356 2.076572 1.277115 1.498972 0.8269462 0.9726382 0.5741858 
 
Table represents N- fold increase (derived from day 0 and day 5 measurement above) of HDF proliferation assay with no serum (serum starvation assay) with 
PRP/PP from healthy volunteers with 1% BSA as the diluents media. 
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Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 495.50 512.33330 502.50 506.66670 515.00 513.33330 509.00 
EXP 2 1443.4440 1489.7220 1448.833 1444.7780 1475.3890 1437.7780 1433.3890 
EXP 3 11721.0 11720.00 11689.00 11622.330 11625.670 11647.00 11621.00 
 
Table represents the mean value of three readings for proliferation assay of HDF following serum starvation for each experiment (EXP), with 
experiment done in triplicate at day 0.  PRP/ PPP  from diabetic patient, with 1%FCS as the diluents media. Proliferation measured as fluorescence of 
Alamar blue dye 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 407.33330 1310.1670 652.00 493.33330 108.83330 240.3333 63.83330 
EXP 2 1429.5560 2040.7780 1611.8890 1423.4440 1268.7780 1549.4440 1040.0 
EXP 3 15225.670 19225.70 17892.60 14823.00 11934.330 6268.6670 629.00 
 
Table represents the mean value of three readings for proliferation assay of HDF following serum starvation for each experiment (EXP), with 
experiment done in triplicate at day 5.  PRP /PPP from diabetic patient, with 1%FCS as the diluent  media. Proliferation measured as fluorescence of 
Alamar blue dye 
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Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 0.9919342 1.086145 0.771805 0.7889527 0.6556302 0.3568295 0.5570968 
EXP 2 0.8220652 2.557255 0.7160861 0.9736841 0.3407767 0.4681818 0.1254093 
EXP 3 1.570052 2.163292 1.589769 0.9548309 1.783480 1.324648 0.880870 
  
Table represents N- fold increase (derived from day 0 and day 5 measurement above) of HDF proliferation assay from PRP/PP from Diabetic patient 
with 1% FCS as the diluents media. 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 1570.3330 1580.6670 1544.0 1547.8330 1545.3330 1558.1670 1550.0 
EXP 2 495.50 512.33330 502.5 506.66670 515.00 513.3330 509.0 
EXP 3 1573.8330 1547.3330 1521.5 1564.500 1571.8330 1516.00 1533.330 
 
Table represents the mean value of three readings for proliferation assay of HDF following serum starvation for each experiment (EXP), with 
experiment done in triplicate at day 0.  PRP/PPP from healthy donor, with 1%FCS as the diluent media. Proliferation measured as fluorescence of 
Alamar blue dye 
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Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 1557.6670 1716.8330 1191.6670 1221.1670 1013.1670 556.00 863.50 
EXP 2 407.33330 1310.1670 359.83330 493.3330 175.50 240.3330 63.83330 
EXP 3 2471.0 3347.3330 2418.8330 1493.8330 2803.3330 2008.1670 1350.6670 
 
Table represents the mean value of three readings for proliferation assay of HDF following serum starvation for each experiment (EXP), with 
experiment done in triplicate at day 5.  PRP /PPP  from healthy donor, with 1%FCS as the diluents media. Proliferation measured as fluorescence of 
Alamar blue dye 
 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 2.885078 2.557255 1.297512 0.9736841 0.2113268 1.070346 0.275049 
EXP 2 0.2821954 1.369905 1.112543 0.9852337 0.8601885 0.1671561 0.04453315 
EXP 3 1.299008 1.653728 1.539502 1.268115 0.5348692 0.5382216 0.05412615 
  
Table represents N- fold increase (derived from day 0 and day 5 measurement above) of HDF proliferation assay from  PRP/PP from healthy donor 
with 1% FCS as the diluents media. 
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                                                               RAW DATA FROM HUMAN KERATINOCYTE PROLIFERATION ASSAY 
Treatment Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 
Cont 10% 0.277379 0.444046 0.583561 0.592119 0.553609 0.399544 
PRP 10% 0.331287 0.366328 0.519991 0.452106 0.505873 0.426165 
PRP 5% 0.338445 0.23643 0.443991 0.43135 0.417512 0.358521 
PPP 0.342773 0.374817 0.492153 0.495471 0.357425 0.402465 
 
Table represents proliferation of Human epithelial keratinocyte (HEK) with 10% FCS as the diluents media over 5 days Proliferation measured as 
redox reaction ( measured as absorbance) of Alamar blue dye. 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 7782.6670 7370.8330 8013.1670 7770.1670 8034.1670 8065.1670 7785.50 
EXP 2 3704.3330 3762.1670 4026.50 3431.0 3710.8330 3720.1670 4014.8330 
EXP 3 10007.00 10000.0 9988.0 9901.333 9998.0 9986.3330 9888.0 
 
Table represents the mean value of three readings for proliferation assay of HEK following each experiment (EXP), with experiment done in triplicate 
at day 0.  PRP /PPP from diabetic patient, using  1% FCS as the diluents media. Proliferation measured as fluorescence of Alamar blue dye 
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Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 8276.1670 9347.333 3097.6670 3270.833 3493.1670 631.66670 399.16670 
EXP 2 8584.1670 6519.00 6890.1670 2424.0 2130.0 128.50 127.83330 
EXP 3 43961.330 9754.000 5452.00 2968.6670 1229.6670 1085.3330 876.0 
 
Table represents the mean value of three readings for proliferation assay of HEK following each experiment (EXP), with experiment done in triplicate 
at day 5. PRP /PPP  from diabetic patient, with 1% FCS as the diluents media. Proliferation measured as fluorescence of Alamar blue dye 
 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 1.063410 1.268152 0.3865721 0.4209476 0.4347889 0.07832035 0.05127053 
EXP 2 2.317331 1.732778 1.711205 0.7064996 0.5739951 0.03454146 0.03184025 
EXP 3 4.393058 0.975400 0.545855 0.299825 0.1229913 0.1086818 0.08859223 
 
Table represents N- fold increase (derived from day 0 and day 5 measurement above) of HEK proliferation assay from PRP/PP from diabetic patient 
with 1% FCS as the diluents media 
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Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 3088.1670 2772.50 2974.3330 2980.3330 3055.3330 2716.50 2719.0 
EXP 2 857.83330 1261.833 948.16670 965.0 854.83330 1032.1670 902.66670 
EXP 3 1628.6670 1877.0 1699.1670 1685.6670 1662.3330 1643.6670 1506.1670 
 
Table represents the mean value of three readings for proliferation assay of HEK following each experiment (EXP), with experiment done in triplicate 
at day 0.  PRP /PPP from healthy donor,  with 1% FCS as the diluents media. Proliferation measured as fluorescence of Alamar blue dye 
 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 2836.0 2148.0 2080.3330 2004.6670 1169.8330 1370.330 1660.0 
EXP 2 2323.1670 1382.0 1279.1670 899.66670 860.33330 37.83330 35.3330 
EXP 3 3381.1670 1435.1670 1263.0 1058.500 1429.6670 1701.6670 129.0 
 
Table represents the mean value of three readings for proliferation assay of HEK following each experiment (EXP), with experiment done in triplicate 
at day 5.  PRP /PPP  from healthy donor, with 1% FCS as the diluent media. Proliferation measured as fluorescence of Alamar blue dye 
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Exp.Repeat Cont1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 0.918344 1.135437 0.6994284 0.6726319 0.382882 0.504448 0.6105186 
EXP 2 2.708180 1.095232 1.349095 0.9322971 1.006434 0.0366543 0.0391433 
EXP 3 2.076033 0.764607 0.7433054 0.6279414 0.860037 1.035287 0.0856479 
Table represents N- fold increase (derived from day 0 and day 5 measurement above) of HEK proliferation assay from  PRP/PP from healthy donor 
with 1% FCS as the diluents media. 
 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 12647.330 12645.9 12706. 12732.000 12503.000 12647.000 12600. 
EXP 2 6391.333 6400.0 6456. 6501.333 6398.667 6466.333 6400. 
EXP 3 6044.667 6074.0 6098. 6120.000 6165.330 6217.000 6200. 
Table represents the mean value of three readings for proliferation assay of HEK following each experiment (EXP), with experiment done in triplicate 
at day 0.  PRP /PPP  from healthy donor, with 1% BSA as the diluent media. Proliferation measured as fluroscence of Alamar blue dye 
 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
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EXP 1 16935.70 17863.0 16543.0 15284.0 8816.333 6081.3330 3000.0 
EXP 2 18279.67 16754.0 13245.0 2109.333 899.667 938.6670 543.0 
EXP 3 33969.00 4532.0 3214.0 2891.660 1809.000 976.6667 543.0 
 
Table represents the mean value of three readings for proliferation assay of HEK following each experiment (EXP), with experiment done in triplicate 
at day 5.  PRP /PPP  from healthy donor, with 1% BSA as the diluent media. Proliferation measured as fluroscence of Alamar blue dye. 
 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 1.395156 0.889989 0.6786143 0.301643 0.1229246 0.1086818 0.1107161 
EXP 2 1.985956 1.098433 0.7348731 0.3170366 0.1346806 0.1323955 0.1333333 
EXP 3 2.194840 0.9074096 0.6358422 0.270973 0.1443678 0.2176334 0.2091807 
 
Table represents N- fold increase (derived data from day 0 and day 5 measurement above) of HEK proliferation assay from PRP/PP from healthy donor 
with 1% BSA as the diluents media. 
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EXP 1 10007.0 9999.0 9988.0 9901.33 9998.0 9986.333 9845.0 
EXP 2 9091.0 9001.0 9222.0 9102.00 9236.667 9099.00 9000.0 
EXP 3 8643.0 8435.0 8543.0 8654.00 8700.0 8620.0 8605.0 
 
Table represents the mean value of three readings for proliferation assay of HEK following each experiment (EXP), with experiment done in triplicate 
at day 0.  PRP /PPP  from diabetic patient, with 1% BSA as the diluents media. Proliferation measured as fluorescence of Alamar blue dye. 
 
Exp.Repeats Cont 1% PRP 5% PRP 
10% 
PRP 25% PRP 50% PPP unaPPP 
EXP 1 13961.33 8899.0 6778.0 2986.667 1229.0 1085.333 1090.0 
EXP 2 18054.33 9887.0 6777.0 2885.667 1244.0 1204.667 1200.0 
EXP 3 18970.00 7654.0 5432.0 2345.000 1256.0 1876.000 1800.0 
 
Table represents the mean value of three readings for proliferation assay of HEK following each experiment (EXP), with experiment done in triplicate 
at day 5.  PRP /PPP  from diabetic patient, with 1% BSA as the diluents media. Proliferation measured as fluorescence of Alamar blue dye. 
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Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 1.339073 1.412553 1.301983 1.200440 0.7051374 0.4808518 0.2380952 
EXP 2 2.860072 2.617812 2.051580 0.3244462 0.1406023 0.1451622 0.08484375 
EXP 3 5.619664 0.7461311 0.5270581 0.4724935 0.293415 0.1570961 0.08758064 
 
Table represents N- fold increase (derived from day 0 and day 5 measurement above) of HEK proliferation assay from PRP/PP from diabetic donor 
with 1% BSA as the diluents media. 
 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 1.339073 1.412553 1.301983 1.200440 0.7051374 0.4808518 0.2380952 
EXP 2 2.860072 2.617812 2.051580 0.3244462 0.1406023 0.1451622 0.08484375 
EXP 3 5.619664 0.7461311 0.5270581 0.4724935 0.293415 0.1570961 0.08758064 
 
Table represents N- fold increase (derived from day 0 and day 5 measurement above) of NEB-1 cell  proliferation assay from  PRP/PP from diabetic 
patient with 1% FCS as the diluents media.  
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Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP 
EXP 1 30249.67 31345.0 29887.7 29998.0 31000.0 30008.0 
EXP 2 41882.67 38972.0 37876.0 41222.0 41000.0 40231.0 
 
Table represents the mean value of three readings for proliferation assay of NEB-1 cell following each experiment (EXP), with experiment done in 
triplicate at day 0.  PRP /PPP  from healthy donor, with 1% FCS as the diluents media. Proliferation measured as fluorescence of Alamar blue dye. 
 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 
25% 
PRP 50% PPP 
EXP 1 79653.0 36789.0 25123.0 24137.33 16332.70 1359.0 
EXP 2 73207.0 31000.0 29876.0 28230.0 11993.67 2211.0 
 
Table represents the mean value of three readings for proliferation assay of NEB-1 cell following each experiment (EXP), with experiment done in 
triplicate at day 5.  PRP /PPP  from healthy donor, with 1% FCS as the diluent media. Proliferation measured as fluorescence of Alamar blue dye 
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Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 2.633186 1.173680 0.8405799 0.8046313 0.5268613 0.1107161 0.04528792 
EXP 2 1.747907 0.7954429 0.7887844 0.6848285 0.2925285 0.1333333 0.05495762 
Table represents N- fold increase (derived from day 0 and day 5 measurement above) of NEB-1 cell proliferation assay from PRP/PP from healthy 
donor with 1% FCS as the diluent media 
                           RAW DATA FOR HUMAN UMBILICAL VEIN ENDOTHELIA CELL (HUVEC) PROLIFERATION ASSAY 
Cell density / well Mean fluor at 4hrs Mean fluor at 
16hrs 
10000 3450.5 934 
40000 6951 6470.25 
80000 7236.75 5871 
100000 8132.75 6963.25 
400000 7646.75 10411 
800000 7238 11532 
Table represents mean fluroscence of three seperate triplicate reading for standard optimization plot of HUVEC proliferation at 4hrs and 16hrs 
respectively. 
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Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 1351.50 1214.50 1228.1670 1198.50 1236.167 1079.333 1056.0 
EXP 2 1351.50 1214.50 1228.1670 1198.50 1236.167 1079.333 1045.0 
EXP 3 1491.3330 1589.833 1498.50 1414.50 1527.0 1249.333 1200.0 
 
Table represents the mean value of three readings for proliferation assay of Ea.Hys cell following each experiment (EXP), with experiment done in 
triplicate at day 0.  PRP /PPP  from diabetic patient, with 1% FCS as the diluents media. Proliferation measured as fluorescence of Alamar blue dye 
 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 3081.0 1555.3330 2193.1670 2293.0 1936.0 444.8330 340.0 
EXP 2 4355.8330 3340.8330 8071.1670 4408.80 5150.0 957.6670 579.0 
EXP 3 9174.50 913.16670 7099.1670 6744.330 7340.1670 98.0 89.0 
 
Table represents the mean value of triplicate readings for proliferation assay of Ea.Hys cell following each experimental (EXP), with experiment done in 
triplicate at day 5.  PRP /PPP from diabetic patient, with 1% FCS as the diluent media. Proliferation measured as fluorescence of Alamar blue dye 
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Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 2.497878 2.418869 2.907276 2.933071 2.083313 1.389751 1.361212 
EXP 2 3.273142 5.271666 5.391776 4.372150 3.377024 0.9713662 0.8701304 
EXP 3 1.400537 3.036481 1.085896 1.139566 0.1125828 0.5481893 0.4247505 
 
Table represents N- fold increase (derived from day 0 and day 5 measurement above) of  Ea.hys cell proliferation assay  from  PRP/PPP from Diabetic 
patient with 1% FCS as the diluents media. 
 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 1218.1670 1308.3330 1362.1670 1310.3330 1381.50 1418.0 1243.50 
EXP 2 1496.1670 1389.8330 1498.50 1414.50 1527.0 1449.330 1244.8330 
EXP 3 993.66670 1031.8330 984.0 1024.50 954.8330 869.8330 1252.500 
 
Table represents the mean value of three readings for proliferation assay of Ea.Hys cell following each experiment (EXP), with experiment done in triplicate at 
day 0.  PRP /PPP from healthy donor,  with 1% FCS as the diluent media. Proliferation measured as fluorescence of Alamar blue dye 
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Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 
25% 
PRP 50% PPP unaPPP 
EXP 1 3042.8330 2725.6670 3995.330 3809.50 3341.6670 1770.6670 1692.6670 
EXP 2 4897.1670 4693.50 6551.6670 7626.67 8049.8330 1407.8330 2783.1670 
EXP 3 1391.6670 116.16670 1121.3330 1112.50 1899.3330 476.8330 532.00 
 
Table represents the mean value of three readings for proliferation assay of Ea.Hys cell following each experiment (EXP), with experiment done in 
triplicate at day 5.  PRP /PPP  from healthy donor, with 1% FCS as the diluents media. Proliferation measured as fluorescence of Alamar blue dye 
 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 2.497878 2.418869 2.907276 2.933071 2.083313 1.389751 1.361212 
EXP 2 3.273142 5.271666 5.391776 4.372150 3.377024 0.9713662 0.8701304 
EXP 3 1.400537 3.036481 1.085896 1.139566 0.1125828 0.5481893 0.4247505 
  
Table represents N- fold increase (derived from day 0 and day 5 measurement above) of  Ea.hys cell proliferation assay  from  PRP/PPP from healthy 
donor with 1% FCS as the diluents media. 
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Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 1351.50 1214.50 1228.1670 1198.50 1236.1670 1079.3330 1222.0 
EXP 2 1351.50 1214.50 1228.1670 1198.50 1236.1670 1079.3330 1190.0 
EXP 3 1491.3330 1589.8330 1498.50 1414.50 1527.0 1249.3330 1340.0 
 
Table represents the mean value of three readings for proliferation assay of HUVEC cell following each experiment (EXP), with experiment done in 
triplicate at day 0.  PRP /PPP from diabetic patient, with 1% EMG as the diluent  media. Proliferation measured as fluorescence of Alamar blue dye 
  
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 3081.0 1555.3330 2193.1670 2293.0 3936.0 444.8330 234.0 
EXP 2 3355.8330 3340.8330 5071.1670 4408.830 5150.0 957.6670 456.0 
EXP 3 7174.50 913.16670 5099.1670 6744.330 7340.167 98.0 80.00 
 
Table represents the mean value of three readings for proliferation assay of HUVEC cell following each experiment (EXP), with experiment done in 
triplicate at day 5.  PRP /PPP  from diabetic patient, with 1% EMG as the diluents media. Proliferation measured as fluorescence of Alamar blue dye 
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Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 2.279689 3.184036 1.913225 1.785724 1.280636 0.4121372 0.1914894 
EXP 2 2.483043 4.166104 3.678626 4.129053 2.750789 0.8872764 0.3831933 
EXP 3 4.810797 4.806920 4.767998 3.402848 0.574379 0.07844186 0.05970149 
 
Table represents N- fold increase (derived from day 0 and day 5 measurement above) of  HUVEC cell proliferation assay  from  PRP/PPP from diabetic 
patient with 1% EMG as the diluents media 
 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 1218.1670 1308.3330 1362.1670 1310.330 1381.50 1418.0 1243.50 
EXP 2 1496.1670 1389.8330 1498.50 1414.50 1527.00 1449.330 1244.8330 
EXP 3 993.66670 1031.8330 984.0 1024.50 954.8330 869.8330 1252.50 
 
Table represents the mean value of three readings for proliferation assay of HUVEC cell following  each experiment (EXP), with experiment done in 
triplicate at day 0.  PRP /PPP  from healthy donor, with 1% EMG as the diluents media. Proliferation measured as fluorescence of Alamar blue dye 
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Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 3042.8330 2725.6670 3995.3330 3809.50 3341.6670 1770.6670 1692.6670 
EXP 2 4897.1670 4693.50 6551.6670 7626.667 8049.8330 1407.8330 2783.1670 
EXP 3 1391.6670 116.16670 1121.3330 1112.500 1899.3330 476.8330 532.0 
 
Table represents the mean value of three readings for proliferation assay of HUVEC cell following each experiment (EXP), with experiment done in 
triplicate at day 5.  PRP /PPP  from healthy donor, with 1% EMG as the diluents media. Proliferation measured as fluorescence of Alamar blue  
 Exp 
Repaets 
Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP unaPPP 
EXP 1 2.497878 2.418869 2.907276 2.933071 2.083313 1.037142 0.5570301 
EXP 2 3.273142 5.271666 3.270885 2.370148 1.938003 0.9713662 0.4684701 
EXP 3 1.400537 3.036481 1.085896 1.130589 0.1125828 0.5481893 0.4247505 
 
Table represents N- fold increase (derived from day 0 and day 5 measurement above) of  HUVEC cell proliferation assay  from  PRP/PPP from healthy 
donor with 1% EMG as the diluents media 
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                                                                              RAW DATA FOR SCRATCH ASSAY WITH HEK AND NEB-1 CELL 
Exp Repeat Cont 1% PRP 5% PRP 10% PPP 
Exp1 404.6033 457.4217 451.0634 384.9325 
Exp 2 360.7825 223.6500 319.6775 186.1067 
Exp3 225.5800 457.4217 364.0550 425.3258 
 
Table represents triplicate reading from each expriemental repeats with NEB-1 cell after been treated with mitomycin. The wound gap was measured in 
micron meter (μm). 
 
Exp Repeat Cont 1% PRP 5% PRP 10% PPP 
Exp1 108.5863 95.1557 147.0213 65.6550 
Exp 2 225.5800 457.4217 364.0550 425.3258 
Exp3 332.1392 213.5884 208.2942 105.9109 
 
Table represents mean triplicate reading from each experimental repeats with NEB-1 cell without mitomycin treatment. The final wound gap was 
measured in micron meter (μm). 
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Exp Repeat Cont 1% PRP 5% PRP 10% PPP 
Exp1 53.0 230.17830 139.7550 117.86250 
Exp 2 263.25050 298.30740 317.14620 296.12330 
Exp3 365.95170 396.99670 411.74720 363.97330 
 
Table represents triplicate reading from each experimental repeats with HEK after been treated with mitomycin. The wound gap was measured in 
micron meter (μm). 
Exp Repeat Cont 1% PRP 5% PRP 10% PPP 
Exp1 53.52750 190.17830 139.75500 117.86250 
Exp 2 133.66620 122.56170 130.33940 89.88889 
Exp3 133.66620 122.56170 130.33940 89.88889 
 
Table represents mean triplicate reading from each experimental repeats with NEB-1 cell without mitomycin treatment. The final wound gap was 
measured in micron meter (μm). 
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Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP 
EXP 1 30.31929 156.52 122.7914 50.62143 45.71714 26.90214 
 
Table represents mean triplicate reading from each experimental repeats with HDF cell without mitomycin treatment. The final wound gap was 
measured in micron (μm). 
                                                              RAW DATA FROM TRANSWELL MIGRATION ASSAY 
Exp Repeat Cont 1% PRP 25% PRP 50% PPP 
Exp1 711.33330 1445.0 1326.0 1535.3330 
Exp 2 405.00 706.0 641.66670 709.33330 
Exp3 405.33330 1035.0 643.66670 376.33330 
 
Table represents mean triplicate reading from each experimental repeats with EA.hys cell in transwell migration assay. Migration cell was quantified 
with Alamar blue cell quantification technique (measured as fluorescence of alamar blue in the redox reaction) 
 
 
Exp 
Repeat 
Cont 1% PRP 25% PRP 50% PPP 
  
 
 
305 
Exp1 61.580540 18.508810 19.371920 17.063610 
Exp  58.054260 29.910090 26.557900 24.096190 
Exp3 1.442500 2.930200 2.688900 3.113400 
 
Table represents mean triplicate reading from each experimental repeats with NEB-1 cell in transwell migration assay. Migration cell was quantified 
with Alamar blue cell quantification technique (measured as % absorbance of alamar blue in the redox reaction) 
 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP 
EXP 1 208.833300 538.00 422.166700 251.00 203.500 174.50 
EXP 2 228.500 455.666700 252.00 239.16670 213.83330 179.0 
EXP 3 162.833300 430.666700 202.00 95.666660 80.666660 109.0 
Exp 4 289.545400 960.8700 799.636400 730.63640 196.27270 146.090 
 
Table represents mean triplicate reading from each experimental repeats with HUVEC  in transwell migration assay. Migration cell was quantified with 
Alamar blue cell quantification technique (measured as fluorescence of alamar blue in the redox reaction) 
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                                                                                        RAW data for angiogenesis ASSAY 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP 
EXP 1 73.4 105.0 71.6 57.75 56.350 10.20 
EXP 2 81.0 96.4 61.4 71.80 52.550 13.40 
EXP 3 70.2 69.2 102.6 59.55 58.947370 14.15 
 
Table represents the mean value of six separates analysis of each micrograph from an angiogenesis well plate for Nodal formation during HUVEC 
angiogenesis. Each experimental was performed in triplicate.  
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP 
EXP 1 42.50 59.625 41.6 25.2 23.850 2.55 
EXP 2 46.30 58.750 33.1 28.5 24.100 4.25 
EXP 3 40.20 50.000 40.0 26.7 24.738 6.05 
 
Table represents the mean value of six separates analysis of each micrograph from an angiogenesis well plate for Mesh formation during HUVEC 
angiogenesis. Each experimental was performed in triplicate.   
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Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP 
EXP 1 6963.8710 9198.7700 6234.3160 4446.9350 9170.540 2422.1580 
EXP 2 8526.4220 9033.3850 5449.4870 5170.5400 7070.7710 3207.1230 
EXP 3 6905.5560 8228.2060 8444.0880 9217.9000 1004.5460 4119.0220 
 
 Table represents the mean value of six separates analysis of each micrograph from an angiogenesis well plate for skeletal length measurement 
(measured in micron) during HUVEC angiogeneis. Each experimental was performed in triplicate 
 
Exp.Repeats Cont 1% PRP 5% PRP 10% PRP 25% PRP 50% PPP 
EXP 1 203375.40 294780.40 472445.90 550849.10 613908.30 3095.720 
EXP 2 293639.30 303633.30 393469.10 670918.50 459896.80 6499.1820 
EXP 3 297071.90 353114.70 380821.50 543891.50 614472.90 4929.6940 
 
Table represents the mean value of six separates analysis of each micrograph from an angiogenesis well plate for cellular are cover (measured in micron 
square) during HUVEC angiogeneis. Each experimental was performed in triplicate. 
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 Quantification of microvessel density from biopsied chronic diabetic wound using CD 31 through immunonistochemistry technique (Graphic 
representation in Chapter 5)   
Patient’s ID Day 0 Day 8 Week 4 Week8 
P1 77.25 60 44 23 
P2 51.25 40.5 35.5 29 
P3 47 35 31.5 28.75 
Table represent the mean mircovessel density from 4 separates counts under rectangular area  per high power fields. P1-P3 represents patients that 
achieved complete re-epithelisation 
Patient’s ID Day 0 Day 8 Week 4 Week 8 
P4 26.75 24.75 20.25 15.75 
P5  25.25 20.25 18 14 
P6 39.25 31.0 27.5 nil 
P7 29.5 26.75 nil nil 
Table represents the mean microvessel density from 4 separates counts under specified rectangular area per high power fields. P4—P7 represents 
patients that were unable to achieved complete re-epithelisation. Patients P6 and P7 dropped out of the study before the nd of the 16 weeks follow up. 
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                                         Biochemical parameters of  the Diabetic patients with chronic foot ulcers treated with PRP Gel 
Patients ID Age Gender HB g/dl WBC PLT count PLT conc WBC in PLT conc 
P1 45 M 10.9 10.1 310 1210 31.1 
P2 58 M 13.7 9.4 120 1100 20.5 
P3 59 M 12.7 10.3 358 2300 30.4 
P4 66 M 12.2 6.4 280 1230 16.9 
P5 68 M 13.1 12.1 323 2430 49.9 
P6 53 M 7.4 10 293 1500 34 
P7 50 M 12.6 9.1 273 2757 23.6 
Table represents biochemical parameters from patients before commencing treatment, M- male, HB – Haemoglobin (g/dl), WBC –white cell count (x1000/ml), 
PLT- platelet count (x1000/ml), PLT conc- Platelet count after concentration through the platelet separate and concentrating system, WBC in PRP  conc- white 
cell count in  concentrated Platelet. 
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Patient’s 
ID 
day 0 day 8 Wk2 Wk4 Wk6 Wk8 Wk10 Wk12 Wk14 Wk16 
P1 4.6 4.8 4.4 2.9 1.7 1.6 1.2 0.4 0.2 0 
P2 32.1 25 24.7 19.2 26 19 6.8 4.1 1.7 1.2 
P3 14.3 13.8 13 18.2 19 16 16 10.3 9.8 9 
P4 2.5 2.6 2.8 2.3 2.6 3.3 3.5 3.2 1.4 4.1 
P5 1.8 1.3 3 3 2.4 2.8 2.4 3.3 2.5 2.7 
P6 4.6 3.6 3.5 3.7       
P7 16.6 16.2 15.8        
Table represents measurement of wound area (cm
2
) using computerized wound tracer (vistrak). Graphic representation can be found in Chapter 6. 
Patients P 6 and P7 dropped out of the study before the end of the 16 weeks follow up.
  
 
 
311 
 
REFERENCES 
Abbott, C.A., Carrington A.L, Ashe H, et al. (2002). The Northwest Diabetes Foot Care Study: 
Incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. 
Diabet  Med., 19, 377–84. 
Adams, J.C., Watt F.M (1991): Expression of 131, 133, 134, and 15 integrins by human epidermal 
keratinocytes and non-differentiating keratinocytes. J Cell Biol, 115: 829-841 
Adler, S. C. and  Kent, K. J. (2002). Enhancing Wound Healing With Growth Factors. Facial Plast 
Surg Clin North Am, 10, 129-46. 
Adolphe, C. and  Wainwright, B. (2005). Pathways To Improving Skin Regeneration. Expert Rev 
Mol Med, 7, 1-14. 
Ahmed, S. A., Gogal, R. M., Jr. and  Walsh, J. E. (1994). A New Rapid And Simple Non-
Radioactive Assay To Monitor And Determine The Proliferation Of Lymphocytes: An Alternative 
To [3h]Thymidine Incorporation Assay. J Immunol Methods, 170, 211-24. 
Agren MS, Steenfos HK, Dabelsteen S,  Hansen JB, Dabelsteen E. (1999). Proliferation and 
mitogenic response to PDGF-BB of fibroblasts isolated from chronic venous leg ulcers is ulcer-age 
dependent. J Invest Dermatol, 112, 463-9. 
Alonso, L. & Fuchs, E. (2003). Stem Cells Of The Skin Epithelium. Proc Natl Acad Sci U S A, 100 
Suppl1, 11830-5. 
Alsousou J, Thompson M, Hulley P, Noble A, Willett K.(2009).The biology of platelet –rich plasma 
and its application in trauma and orthopedic surgery J.Bone Joint Surg Br. 9,: 987-96. 
Akingboye AA, Giddins S, Gamston P, Tucker A, Navsaria H, Kyriakides C (2010) Application of 
autologous derived-platelet rich plasma gel in the treatment of chronic wound ulcer: diabetic foot 
ulcer. J Extra Corpor Technol .42,20-9. 
Andree, C., Swain, W. F., Page, C. P., Macklin, M. D., Slama, J., Hatzis, D. & Eriksson, E. (1994). 
In Vivo Transfer And Expression Of A Human Epidermal Growth Factor Gene Accelerates Wound 
Repair. Proc Natl Acad Sci U S A, 91, 12188-92. 
Andriessen M.P., Van Bergen B.H., Spruit K.J., Go I.H., Schalkwijk J, Van De Kerkhof P.C,. (1995) 
Epidermal Proliferations Is Not Impaired In Chronic Venous Ulcers. Acta Derm Venerol 75,459-462 
Anitua, E., Andia, I., Ardanza, B., Nurden, P. and Nurden, A. T. (2004). Autologous Platelets As A 
Source Of Proteins For Healing And Tissue Regeneration. Thromb Haemost, 91, 4-15. 
Ansel, J. C., Luger, T. A., Lowry, D., Perry, P., Roop, D. R. & Mountz,J. D. (1988). The Expression 
And Modulation Of Il-1 Alpha In Murine Keratinocytes. J. Immunol, 140, 2274-8. 
  
 
 
312 
Arnold, I. and  Watt, F. M. (2001). C-Myc Activation In Transgenic Mouse Epidermis Results In 
Mobilization Of Stem Cells And Differentiation Of Their Progeny. Curr Biol, 11, 558-68. 
Armstrong L.C, And Bornstein P. (2003). Thrombspodin 1 And 2 Function As Inhibitors Of 
Angiogenesis. Matrix Biol ,22,63-71 
Attinger CE, Cooper P, Blume P, 2001. et. al, The safest surgical incisons and amputation  using the 
angiosome concept and Doppler  on arterial-arterial connections of the foot and ankle . Foot Ankle 
Clin. North Am., 6,745 
Auerbach, W. & Auerbach, R. (1994). Angiogenesis Inhibition: A Review. Pharmacol Ther, 63, 
265-311. 
Auerbach, R., Lewis, R., Shinners, B., Kubai, L. and Akhtar, N. (2003). Angiogenesis Assays: A 
Critical Overview. Clin Chem, 49, 32-40. 
Baggiolini, M. (1998). Chemokines And Leukocyte Traffic. Nature, 392, 565-8. 
Barrandon, Y. and  Green, H. (1987). Three Clonal Types Of Keratinocyte With Different Capacities 
For Multiplication. Proc Natl Acad Sci U S A, 84, 2302-6. 
Basu P, Ghosh RN, Grove LE, Klei L, Barchowsky A (2008), Angiogenic potential of 3-nitro-4-
hydroxy benzene arsenic Acid ( roxarsone). Environment Health Perpesct 116, 520-523. 
Bauer J, Margolis M, Schrenier C, Edgell CJ, Azizkhan J, Lazarowski E, Juliano RL.(1992). In Vitro 
Model Of Angiogensis  Using A Human Endothlium -Derived Permanent Cell Line: Contributions 
Of Induced Gene Expression, G-Prteins, And Integrins. J Cell Physiol 153,437-449 
Bayreuther, K., Rodemann, H. P., Hommel, R., Dittmann, K., Albiez, M. & Francz, P. I. (1988). 
Human Skin Fibroblasts In Vitro Differentiate Along A Terminal Cell Lineage. Proc Natl Acad Sci 
USA, 85, 5112-6. 
Beer H, Gassmann M, Munz B, Munz B, Steiling H, Engelhardt F, Bleuel K, Werner S (2000) . 
Expression and function of keratinocytegrowth and activin in skin morphogenesis and cutaneous 
wound repair. J Investig Dermatol Symp Proc, 5, 34–9. 
Bertrand-Duchesne M-P, Grenier D., Gagnon G. (2010) .Epidermal Growth Factor Releasedfrom 
Platelet-Rich Plasma Promotes Endothelial Cell Proliferation In Vitro. J Periodont Res; 45, 87–93. 
Bennett, N. T. & Schultz, G. S. (1993). Growth Factors And Wound Healing: Part Ii. Role In 
Normal And Chronic Wound Healing. Am J Surg, 166, 74-81. 
Berton, G., Laudanna, C., Sorio, C. & Rossi, F. (1992). Generation Of Signals Activating Neutrophil 
Functions By Leukocyte Integrins: Lfa-1 And Gp150/95, But Not Cr3, Are Able To Stimulate The 
Respiratory Burst Of Human Neutrophils. J Cell Biol, 116, 1007-17. 
Bergan. J. (2007). Molecular Mechanisms In Chronic Venous Insufficiency, Ann.  Vasc. Surg, 21, 
260–266. 
  
 
 
313 
Bielecki T, Gazdzik T.S., Szczepanski T. (2006). What do we use: platelet-rich plasma or platelet- 
rich gel? Bone; 39,1388. 
Bielecki T. M,  Gazdzik T. S, Arendt  J, Szczepanski T, Król W, Wielkoszynski. T. (2007). 
Antibacterial Effect Of Autologous Platelet Gel Enriched With Growth Factors And Other Active 
Substances ; An In Vitro Study. J Bone Joint Surg [Br],89, 417-20. 
Bir SC, Esaki J, Marui A, Yamahara K, Tsubota H, Ikeda T, Sakata R. (2009) Angiogenic properties 
of sustained release platelet-rich plasma: characterization in-vitro and in the ischemic hind limb of 
the mouse. J Vasc Surg 50,870-879.e2 
Bornstein P and Sage E.H. Thrombospondins. (1994)  Methods Enzymol 245, 62-85 
Borzini P, Mazzucco L.(2007) Platelet- rich plasma  (PRP) and platelet derivatives for topical 
therapy. What is true from the biologic view points? ISBT Sci Ser 2, 272-81. 
Boulton A. J. (2004). Pressure and the diabetic foot: clinical science and offloading techniques. Am J 
Surg 187, 17S-24S 
Boulton, A. J., Vileikyte, L., Ragnarson-Tennvall, G. & Apelqvist, J. (2005). The Global Burden Of 
Diabetic Foot Disease. Lancet, 366, 1719-24. 
Bourguignon LY, Ramez M, Gilad E, et al. (2006) Hyaluronan-CD44 interaction stimulates 
keratinocytedifferentiation, lamellar body formation/secretion, and permeability barrier homeostasis. 
J Invest Dermatol, 126,1356–1365 
Boyden, S. (1962) The Chemotactic Effect Of Mixtures Of Antibody And Antigen On 
Polymorphonuclear Leucocytes. J Exp Med, 115, 453-66 
Brandt, E., Ludwig, A., Petersen, F. & Flad, H. D. (2000). Platelet-Derived Cxc Chemokines: Old 
Players In New Games. Immunol Rev, 177, 204-16. 
Brakebusch, C., Grose, R., Quondamatteo, F., Ramirez, A., Jorcano, J. L., Pirro, A., Svensson, M., 
Herken, R., Sasaki, T., Timpl, R., Werner, S. & Fassler, R. (2000). Skin And Hair Follicle Integrity 
Is Crucially Dependent On Beta 1 Integrin Expression On Keratinocytes. Embo J, 19, 3990-4003. 
Brady C, Vang S, Christensen K,  Isler J, Vollstedt K, Holt D (2006). Use of  platelet gel in bariatric 
surgery.  J Extra corpor Technol,38, 161-164.    
Breitkreutz D, Stark HJ, Mirancea N, Tomakidi P, Steinbauer H, Fusenig NE. (1997) Integrin and 
basement membrane normalization in mouse grafts of human keratinocytes--implications for 
epidermal homeostasis. Differentiation, .61, 195-209. 
Brem H, Tomic-Canic M.(2007) Cellular and molecular basis of wound healing in diabetes J of Clini 
invest. 117, 1219-1222 
Brink T: (1995) Induration of the diabetic foot pad: another risk factor for recurrent neuropathic 
plantar ulcers. Biomed Technik,  40, 205–209,  
  
 
 
314 
Bucalo, B., Eaglstein, W. H. & Falanga, V. (1993). Inhibition of Cell proliferation by Chronic 
Wound Fluid. Wound Repair Regen, 1, 181-6. 
Burgeson, R. E. (1993). Type VII Collagen, Anchoring Fibrils, And Epidermolysis Bullosa. J Invest 
Dermatol, 101, 252-5. 
Carter, S. B. (1967) Haptotaxis And The Mechanism Of Cell Motility. Nature, 213, 256-60 
Carter WG, Wayner EA, Bouchard TS, Kaur P.(1990) The role of integrins a2131 and a3131 in cell-
cell and cellsubstrate adhesion of human epidermal cells. J Cell Biol, 110, 1387-1404 
Carter WG, Ryan MC, Gahr PJ (1991) Epiligrin, a new cell adhesion ligand for integrin a3131 in 
epithelial basement membranes. Cell , 65,599-610 
Cassidy LK, Finney AS, Ellis WC, Spiwak AJ, Riley JB(2005) Quantifying platelet gel coagulation 
using Sonoclot and Thrombelastograph hemostasis analyzer. J Extra Corpor Technol. 37, 48-51. 
Carter WG, Ryan MC, Gahr PJ  (1991). Epiligrin, a new cell adhesion ligand for integrin alpha 3 
beta 1 in epithelial basement membrane. Cell 65, 599-610. 
Carter WG, Wayner EA, Bouchard TS, Kaur P (1990b) The role of integrins a2b1 and a3b1 in cell-
cell and cell substrate adhesion of human epidermal cells. J Cell Biol 110, 1387– 1404 
Caulin, C., Ware, C. F., Magin, T. M. & Oshima, R. G. (2000). Keratin-Dependent, Epithelial 
Resistance To Tumor Necrosis Factor-Induced Apoptosis. J Cell Biol, 149, 17-22. 
Celotti. F, Colciago. A,  Negri-Cesi.P, Pravettoni.A,  Zaninetti.R,  Sacchi.M.C (2006) Effect of 
platelet-rich plasma on migration and proliferation of SaOS-2 osteoblasts: role of platelet-derived 
growth factor and transforming growth factor-β. Wound Rep Reg .14, 195–202 
Cha D. P. O‘Brien, E.A. O‘Toole,  D.T. Woodley, and L.G. Hudson. (1996). Enhanced modulation 
of keratinocyte motility by TGFa relative to EGF. J. Investig. Dermatol, 106,590–597. 
Chang, H. Y., Chi, J. T., Dudoit, S., Bondre, C., Van De Rijn, M., Botstein, D. & Brown, P. O. 
(2002). Diversity, Topographic Differentiation, And Positional Memory In Human Fibroblasts. Proc 
Natl Acad Sci U S A, 99, 12877-82. 
Chen, M., O'toole, E. A., Li, Y. Y. & Woodley, D. T. (1999). Alpha 2 Beta 1 Integrin Mediates 
Dermal Fibroblast Attachment To Type Vii Collagen Via A 158-Amino-Acid Segment Of The Nc1 
Domain. Exp Cell Res, 249, 231-9. 
Chen, S. M., Ward, S. I., Olutoye, O. O., Diegelmann, R. F. & Kelman Cohen, I.(1997). Ability Of 
Chronic Wound Fluids To Degrade Peptide Growth Factors Is Associated With Increased Levels Of 
Elastase Activity And Diminished Levels Of  Proteinase Inhibitors. Wound Repair Regen, 5, 23-32. 
Choi, BH, Zhu SJ, Kim BY, Huh JY, Lee SH, Jung JH. (2005). Effect of platelet-rich plasma (PRP) 
concentration on the viablility and proliferation of alvelolar bone cells. An in vitro study. Int. Oral . 
Maxillofac. Surg.34, 420. 
  
 
 
315 
Christiano A. M, Greensapn D.S, LeeS, Uttio J. (1994) Cloning of human human type VII collagen. 
J Biol Chem . 269, 20256-20262 
Chu, P., Wu, E. & Weiss, L. M. (2000). Cytokeratin 7 And Cytokeratin 20 Expression In Epithelial 
Neoplasms: A Survey Of 435 Cases. Mod Pathol, 13, 962-72. 
Clark, R. A. (1990). Fibronectin Matrix Deposition And Fibronectin Receptor Expression In Healing 
And Normal Skin. J Invest Dermatol, 94, 128s-134s. 
Clark-Lewis, I., Dewald, B., Geiser, T., Moser, B. & Baggiolini, M. (1993). Platelet Factor 4 Binds 
To Interleukin 8 Receptors And Activates Neutrophils When Its N Terminus Is Modified With Glu-
Leu-Arg. Proc Natl Acad Sci U S A, 90, 3574-7. 
Clark RAF: Wound Repair: Overview And General Considerations. In: Clark R (Ed.) Molecular 
And Cellular Biology Of Wound Repair. Newyork: Plenumpress, (1996); P3-50 
Clark RAF: Fibronectin matrix deposition and fibronectin receptor expression in healing and normal 
skin. (1990) J Invest Dermatol, 96:128S-134S 
Clark, R. A., An, J. Q., Greiling, D., Khan, A. & Schwarzbauer, J. E. (2003). Fibroblast Migration 
On Fibronectin Requires Three Distinct Functional Domains. J  Invest Dermatol, 121, 695-705. 
Cochran, D. L. & Wozney, J. M. (1999). Biological Mediators For Periodontal  Regeneration. 
Periodontol 2000, 19, 40-58. 
Coffey, R. J., Jr., Derynck, R., Wilcox, J. N., Bringman, T. S., Goustin, A. S., Moses, H. L. & 
Pittelkow, M. R. (1987). Production And Auto-Induction Of Transforming Growth Factor-Alpha In 
Human Keratinocytes. Nature, 328,  817-20. 
Conlon, K.C., L. Sclafani, G.R. DiResta, and M.F. Brennan. (1994). Comparisonof transcutaneous 
oximetry and laser Doppler flowmetry as noninvasivepredictors of wound healing after excision of 
extremity soft-tissue sarcomas. i (St. Louis). 115:335–340. 
Cooper DM, Yu EZ, Hennessey P, Ko F, Robson MC. (1994). Determination of endogenous 
cytokines in chronic wounds. Ann Surg; 219: 688–92 
Cormack, D. H. (1987). The integumentary system. In Ham‘s Histology, 9th edn., pp. 450-474. 
Philadelphia: J.B. Lippincott Company. 
Cotsarelis, G., Sun, T. T. & Lavker, R. M. (1990). Label-Retaining Cells Reside In The Bulge Area 
Of Pilosebaceous Unit: Implications For Follicular Stem Cells, HairCycle, And Skin Carcinogenesis. 
Cell, 61, 1329-37. 
Cross K, Mustoe T. (2003) Growth factors in wound healing. Surg Clin North Am, 83,531–45. 
Dargis V, Pantelejeva O, Jonushaite A, Vileikyte L, Boulton AJ. (1999). Benefits of a 
multidisciplinary approach in the management of recurrent diabeticfoot ulceration in Lithuania: a 
prospective study. Diabetes Care, 22,1428-31. 
  
 
 
316 
de Berker D, Dean D, Leigh IM, Burge S (1995). Keratin expression in discoid lupus erythematosus. 
Exp Dermatol. 4,350-6. 
Decline F, Rousselle P J. (2001) Keratinocyte migration requires alpha2beta1 integrin-mediated 
interaction with the laminin 5 gamma2 chain.Cell Sci.114,811-23. 
Defranzo A. J, Argenta L. C, Marks M. 2001 et al. The use of vaccum- assisted closure therapy for 
the treatment of lower- extremity wound with exposed bone. Plast. Resconstr.Surg 108, 1184 
Dohan D. M, Choukroun J, Diss A, Dohan S.L, Dohan A. J, Mouhyi J, Gogly B. (2006)  Platelet-
rich fibrin (PRF): a second-generationplatelet concentrate. Part III: leucocyte activation: a new 
feature for platelet concentrates?Oral Surg Oral Med Oral Pathol Radiol Endod,101, 51-5. 
Drew A.F, Liu J.M, Davidson J.M, Daugherty C.C, Degen JL (2001). Wound healing defects in 
mice lacking fibrinogen. Blood, 97, 3691–3698 
Drinkwater S. L, Smith A, Sawyer BM, Burnand K.G (2002).  Effect of  venous ulcer exudates on 
angiogenesis in vitro. Br J  Surg , 89, 709-13. 
Dubay, D. A. & Franz, M. G. (2003). Acute Wound Healing: The Biology Of Acute Wound Failure. 
Surg Clin North Am, 83, 463-81. 
Eckes, B., Zigrino, P., Kessler, D., Holtkotter, O., Shephard, P., Mauch, C. & Krieg, T. (2000). 
Fibroblast-Matrix Interactions In Wound Healing And Fibrosis. Matrix Biol, 19, 325-32. 
Ehrlich M, Rao J, Pabby A, , Goldman M. P  (2006). Improvement in the appearance of wrinkles 
with topical transforming growth factor beta (1) and 1-ascorbic acid. Dermatol Surg, 32, 618e25 
Ehrenreich M, Ruszczak Z.(2006) Update on tissue-engineered biological dressings. Tissue 
Eng. 122407-24.  
El-Gedaily, A., Schoedon, G., Schneemann, M. & Schaffner, A. (2004). Constitutive And Regulated 
Expression Of Platelet Basic Protein In Human Monocytes. J Leukoc Biol, 75, 495-503. 
Eppley, B. L., Woodell, J. E. & Higgins, J. (2004). Platelet Quantification And Growth Factor 
Analysis From Platelet-Rich Plasma: Implications For Wound Healing. Plast Reconstr Surg, 114, 
1502-8. 
Evans D, Land L. (2001).Topical negative pressure for treating chronic wounds: a systematic 
review. Br J Plast Surg. ,54,3238-42 
Everts, P. A., Overdevest, E. P., Jakimowicz, J. J., Oosterbos, C. J., Schonberger, J. P., Knape, J. T. 
& Van Zundert, A. (2007). The Use Of Autologous Platelet-Leukocyte Gels To Enhance The 
Healing Process In Surgery, A Review. Surg Endosc, 21, 2063-8. 
Everts PA, Knape JT, Weibrich, Schönberger JP, Hoffmann J, Overdevest EP, Box HA, van Zundert 
A (2006). Platelet-rich plasma and platelet gel: A review. J Extra Corpor Technol., 38,174–87. 
Falanga, V. (2005). Wound Healing And Its Impairment In The Diabetic Foot. Lancet, 366, 1736-43. 
  
 
 
317 
Fiedler J, Etzel N, Brenner RE. (2004) To go or not to go: migration of human mesenchymal 
progenitor cells stimulated by isoforms of PDGF. J Cell Biochem, 93, 990–8. 
Finch, P. W., Rubin, J. S., Miki, T., Ron, D. & Aaronson, S. A. (1989).Human Kgf Is Fgf-Related 
With Properties Of A Paracrine Effector Of Epithelial Cell Growth. Science, 245, 752-5. 
Fleischmajer, R., Macdonald, E. D., 2nd, Contard, P. & Perlish, J. S. (1993). Immunochemistry Of A 
Keratinocyte-Fibroblast Co-Culture Model For Reconstruction Of Human Skin. J Histochem 
Cytochem, 41, 1359-66. 
Franke, W. W., Cowin, P., Schmelz, M. & Kapprell, H. P. (1987). The Desmosomal Plaque And The 
Cytoskeleton. Ciba Found Symp, 125, 26-48.Freedberg, Pp. 133-144. New York: Mc Graw-Hill 
Health Professions Division. 
Freedberg I.M, Tomic-Canic  M, Komine M, Blumenberg M (2001) Keratins and the keratinocyte 
and the keratinocyte activation cycle. J Invest Dermatol, 116, 633-640 
Froum SJ, Wallace SS, Tarnow DP, Cho SC (2002). Effect of plateletrichplasma on bone growth 
and osseointegration in humanmaxillary sinus grafts: three bilateral case reports. Int J Periodont 
Rest Dent 22,45-53 
Fuchs, E. (1990). Epidermal Differentiation: The Bare Essentials. J Cell Biol, 111, 2807-14. 
Fuchs, E. (1995). Keratins And The Skin. Annu Rev Cell Dev Biol, 11, 123-53.  
Fukamizu J, Grinnell F. (1990) Spatial organization of extracellular matrixand fibroblast activity: 
Effects of serum, TGF-beta and fibronectin. Exp Cell Res,190, 276–82. 
Furman MI, Liu L, Benoit SE, Becker RC, Barnard MR, MichelsonAD (1998). The cleaved peptide 
of the thrombin receptor is a strong platelet agonist. Proc Natl Acad Sci USA,  95, 3082-3087. 
Faries P.L, Teodorescu V.J, Morrissey N. J, Hollier L.H, Marin M. L. (2004)The role of surgical 
revascularization in the management of diabetic foot wounds. Am Surg, 187:34S-37S. 
Gailit, J. & Clark, R. A. (1994). Wound Repair In The Context Of Extracellular Matrix. Curr Opin 
Cell Biol, 6, 717-25. 
Geogan P, Johnson G, Vincent R.(1995) Effects of serum protein and colloid on AB assay  in cell 
culture. Toxic Invitro 9, 257-266. 
Goldman R. (2004). Growth factors and chronic wound healing: Past, Present, and Future. Adv skin 
wound care ,17, 24-35. 
Gold M. H, Goldman M.P, Biron J. (2007).  Efficacy Of Novel Skin Cream Containing Mixture Of 
Human Growth Factors And Cytokines Forskin Rejuvenation. J Drugs Dermatol, 6,197-201. 
Gosiewska, A., Yi, C. F., Brown, L. J., Cullen, B., Silcock, D. & Geesin, J. C. (2001). Differential 
Expression And Regulation Of Extracellular Matrix-Associated Genes In Fetal And Neonatal 
Fibroblasts. Wound Repair Regen, 9, 213-22. 
  
 
 
318 
Grant WP, Jerlin EA, Pietrzak WS, Tam HS   (2005). The utilization of autologous growth factors 
for the facilitation of fusion in complex neuropathic fractures in the diabetic population. Clin Podiatr 
Med Surg. 22,561–584 
Grant M, Jerdan J, Merimere T (1987). Insulin-like growth factor-I modulate  endothelial cell 
chemotaxis. J Clin Endocrinol Metab, 65, 370–1. 
Grazul-Bilska, A. T., Luthra, G., Reynolds, L. P., Bilski, J. J., Johnson, M. L., Adbullah, S. A., 
Redmer, D. A. & Abdullah, K. M. (2002). Effects Of Basic Fibroblast Growth Factor (Fgf-2) On 
Proliferation Of Human Skin Fibroblasts In Type Ii Diabetes Mellitus. Exp Clin Endocrinol 
Diabetes, 110, 176-81. 
Grazian F, Ivanovski S, Cei S, Ducci F, Tonetti, M and Gabriele M. (2006). The in vitro effect of 
different PRP concentrations on osteoblasts and fibroblast. Clin. Oral Implants Res.17, 212;117-124. 
 Green, K. J. & Jones, J. C. (1996). Desmosomes And Hemidesmosomes: Structure And Function Of 
Molecular Components. FASEB J, 10, 871-81. 
Grinnell, F. (1994). Fibroblasts, Myofibroblasts, And Wound Contraction. J Cell Biol, 124, 401-4. 
Grose, R., Hutter, C., Bloch, W., Thorey, I., Watt, F. M., Fassler, R., Brakebusch, C. & Werner, S. 
(2002). A Crucial Role Of Beta 1 Integrins For Keratinocyte Migration In Vitro And During 
Cutaneous Wound Repair. Development, 129, 2303-15. 
Grossman, R. M., Krueger, J., Yourish, D., Granelli-Piperno, A., Murphy, D. P., May, L. T., Kupper, 
T.S., Sehgal, P. B. & Gottlieb, A. B. (1989). Interleukin 6 Is Expressed In High Levels In Psoriatic 
Skin And Stimulates Proliferation Of Cultured Human Keratinocytes. Proc Natl Acad Sci U S A, 86, 
6367-71. 
Grotendorst G, Soma Y, Takehara K, Charette M (1989) . EGF and TGF-alpha are potent chemo 
attractants for endothelial cells and EGF-like peptides are present at sites of tissue regeneration. J 
Cell Physiol., 139,617–23. 
Gruber R, Karreth F, Kandler B, Fuerst G, Rot A, Fischer M.B, Watzek G. (2004).Platelet-released 
supernatants increase migration and proliferation, and decrease osteogenic differentiation of bone 
marrow-derived mesenchymal progenitor cells under in vitro conditions. Platelets, 15: 29–35. 
Gu D.L, Nguyen T, Gonzalez A.M, Printz M.A, Pierce G.F, Sosnowski B.A, Phillips M.L, Chandler 
L.A. (2004) Adenovirus encoding human platelet-derived growth factor-B delivered in collagen 
exhibits safety, biodistribution, and immunogenicity profiles favorable for clinical use. Mol Ther, 9, 
699–711 
Guidolin .D, Vacca .A, Nussdorder G.G, Ribatti D (2004), A new image analysismethod based on 
topological and fractal parametes to evaluate the angiostatic acitivity of docetaxel by using the 
matrigel assay invitro. Microvascular research 672,17-24 
Guler H. P, Zapf J, Scheiwiller E, Friesch E.R. (1988)Recombinant human insulin-like growth I 
stimulate growth and has distinct effects on organ size in hypophysectomized rats. Proc Natl Acad 
Sci USA, 85, 4889–93. 
  
 
 
319 
Haake, A.R., Holbrook, K (1999). The structure and development of skin. In Fitzpatrick's 
dermatology in general medicine, ( ed.T.B. Fitzpatrick and I.M Freedberg), pp. 70-114. New York: 
Mc Graw-Hill Health Professions Division. 
Hamill K. J, McLean W.H. (2005). The alpha -3 polypeptide chain of laminin 5:insight into wound 
healing responses from the study of genodermatoses. Clin Exp Dermatol 30: 398-404. 
Harper, R. A. and  Grove, G. (1979). Human Skin Fibroblasts Derived From Papillary And Reticular 
Dermis: Differences In Growth Potential In Vitro. Science, 204, 526-7. 
He, Z. & King, G. L. (2004). Microvascular Complications Of  Diabetes. Endocrinol Metab Clin 
North Am, 33, 215-38, Xi-Xii. 
Hertle MD, Adams JC, Watt FM (1991)Integrin expression during human epidermal development in 
vivo and in vitro. Development, 112,193-206 
Hemler, M. E. (1990). VLA proteins in the integrin family: structures, functions, and their role on 
leukocytes. Annu Rev Immunol, 8, 365-400. 
Herouy Y, Mellios P, Bandemir E, Stetter C, Dichmann S, Idzko M, et al. (2000). Autologous 
platelet-derived wound healing factor promotes angiogenesis via v&beta3-integrin expression in 
chronic wounds. Int J Mol  Med, 6, 515-9. 
Hilton J.R, Williams D.T, Beuker B, Miller D.R, Harding K.G. (2004)Wound dressings in diabetic 
foot disease. Clin Infect Dis, 39,S100-3 
Hodivala K.J, Watt F.M (1994). Evidence that cadherins play a role in the downregulation of 
integrin expression that occurs during keratinocyte terminal differentiation. J Cell Biol, 124,589-600 
Hopkinson, I., Anglin, I. E., Evans, D. L. & Harding, K. G. (1997).Collagen Vii Expression In 
Human Chronic Wounds And Scars. J Pathol, 182, 192-6.  
Holt, J. C. & Niewiarowski, S. (1985). Biochemistry Of Alpha Granule Proteins.Semin Hematol, 22, 
151-63. 
Hosgood, G. Wound healing. (1993) The role of platelet-derived growth factor and transforming 
growth factor beta. Vet. Surg. 22, 490,  
Howell, J. M. (1992). Current And Future Trends In Wound Healing. Emerg Med  Clin North Am, 
10, 655-63. 
Hsu CW, Yuan K, Tseng CC. (2009). The negative effect of platelet-rich plasma on the growth of 
human cells is associated with secreted thrombospondin-1.  Oral Surg Oral Med Oral Pathol Oral 
Radiol Endod.107,185-92.  
Hynes, R. O. (2002). Integrins: Bidirectional, Allosteric Signaling Machines. Cell, 110, 673-87. 
Hynes RO (1992) Integrins: versatility, modulation, and signalingin cell adhesion. Cell 69, 11–25 
  
 
 
320 
Iruela- Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD. (1999) inhibition of 
angiogenesis by thrombospondin -1 is mediated by 2 independent regions within the type 1 repeats. 
Circulation,100,1423-31 
Izadnegahdar, M. F., Rathanaswami, P. & Shah, R. M. (1999). Effects Of Egf And Tgfbeta1 On C-
Myc Gene Expression And Dna Synthesis In Embryonic Hamster Palate Mesenchymal Cells. Anat 
Rec, 254, 453-64. 
Jensen, U. B., Lowell, S. & Watt, F. M. (1999). The Spatial Relationship Between Stem Cells And 
Their Progeny In The Basal Layer Of Human Epidermis: A New View Based On Whole-Mount 
Labelling And Lineage Analysis. Development, 126, 2409-18. 
Jimenez B. Volprex OV, Crawford SE, Febbraio I, Silverstein RL, Bouck N,(2000) Signals leading 
to apoptosis- dependent inhibitions of neovascularization by thrombospondin-1. Nature Med. 6, 41-
48 
Jones, P. H. & Watt, F. M. (1993). Separation Of Human Epidermal Stem Cells From Transit 
Amplifying Cells On The Basis Of Differences In Integrin Function And Expression. Cell, 73, 713-
24. 
Jones PH, Harper S, Watt FM (1995) Stem cell patterning and fate in human epidermis. Cell 80:83–
93 
 
Jones J.C.R, Kurpakus MA, Cooper HM, Quaranta V(1991): A function for the integrin a6,B4 in the 
hemidesmosome. Cell Regul, 2:427-438 
Juhlin, L. (1997). Hyaluronan In Skin. J Intern Med, 242, 61-6. 
Juliano RL, Haskill S (1993) Signal transduction from the extracellular matrix. J Cell Biol 120:577–
585 
Junge K,  Klinge U,  Rosch R et al., 2004 .Decreased collagen type I/III ratio in patients with 
recurring hernia after implantationof alloplastic prostheses, Langenbeck’s Archives of Surgery, 
vol.389, no. 1, pp. 17–22,. 
Kakudo N, Minakata N, Mitsui T, Kushida S, Notodihardjo FZ and Kusumoto K. (2008). 
Proliferation -promoting effect of platelet-rich plasma on human adipose -derived stems cells and 
human dermal fibrobast. Plast and Reconstr surg , 122,1352-1360 
Karashima T, Watt FM (2002).  Interaction of periplakin and envoplakin with intermediate 
filaments.  J Cell Sci. 115:5027-37. 
Kasper, B., Brandt, E., Brandau, S. & Petersen, F. (2007). Platelet Factor 4 (Cxc Chemokine Ligand 
4) Differentially Regulates Respiratory Burst, Survival, And Cytokine Expression Of Human 
Monocytes By Using Distinct Signaling Pathways. J Immunol, 179, 2584-91. 
Kaya G, Rodriguez I, Jorcano JL, Vassalli P, Stamenkovic I. (1997) Selective suppression of CD44 
in keratinocytes of mice bearing an antisense CE44 transgene driven by a tissue-specific promoter 
  
 
 
321 
disrupts hyaluronate metabolism in the skin and impairs keratinocyte proliferation. Genes 
Dev,11,996–1007. 
Kevy, SV, Jacobson MS. (2004). Comparison of the methods for point of care preparation 
autologous platelet gel. J Extra Corpor Technol ,36, 28-35 
Kevy, SV, Jacobson MS, Fagnant A. Preparation of growth factor enriched autologous platelet gel. 
Presented at the 27
th
 Annual Meeting of the Society for Biomaterial, St. Paul, Minn April 26 2001. 
Kim, S., Wong, P. & Coulombe, P. A. (2006). A Keratin Cytoskeletal Protein Regulates Protein 
Synthesis And Epithelial Cell Growth. Nature, 441, 362-5. 
Kilian O, Flesch I, Wenisch S et.al.   (2004). Effects of platelet growth factors on human 
mesenchyma stem cells and human endothelial cells in vitro. Eur J. Med Res. 9,337. 
Kleinman, H. K., Mcgarvey, M. L., Hassell, J. R., Star, V. L., Cannon, F. B., Laurie, G. W. & 
Martin, G. R. (1986) Basement Membrane Complexes With Biological Activity. Biochemistry, 25, 
312-8. 
 
Kleinman, H. K., Mcgarvey, M. L., Liotta, L. A., Robey, P. G., Tryggvason, K. & Martin, G. R. 
(1982) Isolation And Characterization Of Type Iv Procollagen, Laminin, And Heparan Sulfate 
Proteoglycan From The Ehs Sarcoma. Biochemistry, 21, 6188-93. 
Knighton DR,  Fiegel (1993): Growth Factors And Repair Of Diabetic Wounds,In M.E Levin, 
O‘neal Jh. (Eds): The Diabetic Foot. Mosby Year Book, St. Loius  Pp 247-257. 
Kocaoemer A, Kern S, Kluter H, and Bieback K. (2007) Human AB serum and thrombin activated 
platelet -rich plasma are suitable altrenatives to fetal calf serum fro the expansion of mesenchymal 
stem cells from adipose tissue. Stem Cells 25, 1270 
Konig, A. & Bruckner-Tuderman, L. (1992). Transforming Growth Factor-Beta Stimulates Collagen 
Vii Expression By Cutaneous Cells In Vitro. J Cell Biol, 117, 679-85. 
Krijgsveld J, Zaat SA, Meeljdik J, van Veelen PA, Fang G, Poolman B et. al.,  (2000). 
Thrombocidines, microbicidal proteins fromhuman blood platelets, are C-terminal deletion products 
of CXC chemokines. J Biol Chem, 275,20374-81. 
Kubota, S., Kawata, K., Yanagita, T., Doi, H., Kitoh, T. & Takigawa, M. (2004). Abundant 
Retention And Release Of Connective Tissue Growth  Factor (Ctgf/Ccn2) By Platelets. J Biochem, 
136, 279-82. 
Kubota Y. Kleinman HK, Martin GR, Lawley TJ (1988). Role of laminin andbasement membrane in 
the morphological  differentiation of human endothelial cells into capillary-like structures. J. cell 
Biol, ,107-1589 
Lacoste E, Martineau I, Gagnon G (2003). Platelet concentrates:effects of calcium and thrombin on 
endothelial cell  proliferation and growth factor release. J Periodontol 74:1498-1507 
  
 
 
322 
Lajtha, L. G. (1979). Stem Cell Concepts. Differentiation, 14, 23-34. 
Larjava, H., Salo, T., Haapasalmi, K., Kramer, R. H. & Heino, J. (1993). Expression Of Integrins 
And Basement Membrane Components By Wound Keratinocytes. J Clin Invest, 92, 1425-35. 
Larjava H, Zhou C, Larjava I, Rahemtulla F.(1992)Immunolocalization of ,B1 integrins in human 
gingival epithelium and cultured keratinocytes. Scand J Dent Res,100, 266-273 
Latkowski, J.M., Freedberg, I.M. (1999) . Epidermal cell kinetics, epidermal differential, and 
keratinization. In fitzpatrick's dermatology in general medicine ,( ed. T.B. Fitzpatrick's and I.M 
Freedberg), pp. 133-144. New York: McGraw-Hill Health Professions Division. 
Lawrence W, Diegelmann R. (1994) Growth factors in wound healing. Clin Dermatol,12,157–69. 
Ledent E, Wasteson A.(1995). Berlin G. Growth factor release during preparation and storage of 
platelet concentrates. Vox Sang, 68,205-9. 
Legrand C, Dubernard V, Rabhi-Sabile S, Morandida da  Silva V. (1997). Functional and clinical 
significance of thrombospondin Platelet, 8, 211-223 
Lehto . M, Sims T.J, and  Bailey A.J,  1985 ―Skeletal muscle injury— molecular changes in the 
collagen during healing,‖ Research in Experimental Medicine,  185 95–106. 
Li, A., Simmons, P. J. & Kaur, P. (1998). Identification And Isolation Of Candidate Human 
Keratinocyte Stem Cells Based On Cell Surface Phenotype. Proc Natl Acad Sci US A, 95, 3902-7. 
Liechty, K. W., Adzick, N. S. & Crombleholme, T. M. (2000). Diminished Interleukin 6 (Il-6) 
Production During Scarless Human Fetal Wound Repair. Cytokine, 12, 671-6. 
Lobmann R, Ambrosch A, Schultz G, Waldmann K, Schiweck S, Lehnert H (2002).Expression od 
matrix metalloproteinases and their inhibitors in the wounds of diabetics and non-diabetic patients. 
Diabetologica 45,1011- 1016 
Löndahl M, Katzman P, Nilsson A, Hammarlund C. (2010). Hyperbaric oxygen therapy facilitates  
healing of chronic foot ulcers in patients with diabetes. Diabetes Care. ,33, 998-1003 
Lovelock JE, Bishop  MW (1959). Prevention of freezing damage to living cells by dimethyl 
sulphoxide. Nature,183 :1394-5. 
Lunstrum, G. P., Sakai, L. Y., Keene, D. R., Morris, N. P. & Burgeson,R. E. (1986). Large Complex 
Globular Domains Of Type Vii Procollagen Contribute To The Structure Of Anchoring Fibrils. J 
Biol Chem, 261, 9042-8. 
Lyle, S., Christofidou-Solomidou, M., Liu, Y., Elder, D. E., Albelda, S. & Cotsarelis, G. (1998). The 
C8/144b Monoclonal Antibody Recognizes Cytokeratin 15 And  Defines The Location Of Human 
Hair Follicle Stem Cells.  J Cell Sci, 111 , 3179-88. 
Maas-Szabowski, N. and Fusenig, N. E. (1996). Interleukin-1-Induced Growth  Factor Expression In 
Postmitotic And Resting Fibroblasts. J Invest Dermatol, 107, 849-55. 
  
 
 
323 
Macieira-Coelho, A. & Azzarone, B. (1982). Aging Of Human Fibroblasts Is A Succession Of 
Subtle Changes In The Cell Cycle And Has A Final Short Stage With Abrupt Events. Exp Cell Res, 
141, 325-32. 
Margolis, D. J., Kantor, J., Santanna, J., Strom, B. L. & Berlin, J. A. (2001). Effectiveness Of 
Platelet Releasate For The Treatment Of Diabetic Neuropathic Foot Ulcers. Diabetes Care, 24, 483-
8. 
Marinkovich, M. P., Keene, D. R., Rimberg, C. S. & Burgeson, R. E. (1993). Cellular Origin Of The 
Dermal-Epidermal Basement Membrane. Dev Dyn, 197, 255-67. 
Marinkovich MP, Lunstrum GP, Burgeson RE (1992) The anchoring filament protein kalinin is 
synthesized and secreted as a high molecular weight precursor. J.Biol Chem 276, 17900-17906 
Marshall JF, Rutherford DC, Happerfield L, Hanby A, McCartney AC, Newton-Bishop J, Hart IR.  
(1998) Comparative analysis of integrins in vitro and in vivo in uveal and cutaneous melanomas. Br 
J Cancer. 77, 522-9. 
Massague J. The TGF-beta family of growth and differentiation factors. Cell. 1987;49:437–8. 
Martineau I, Lacoste E, Gagnon G (2004). Effects of calcium and thrombin on growth factor release 
from platelet concentrates: kinetics and regulation of endothelial cell proliferation. Biomaterials, 
25,44894–44502. 
Martin, P. (1997). Wound Healing--Aiming For Perfect Skin Regeneration. Science,  276, 75-81. 
Martin, P., Hopkinson-Woolley, J. & Mccluskey, J. 1992. Growth  Factors And Cutaneous Wound 
Repair. Prog Growth Factor Res, 4, 25-44. 
Marx R E. (2001) Platelet-rich plasma (PRP) What is PRP and what is not PRP? Implant Dent,10, 
225–8. 
Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR   (1998) Platelet –
rich plasma: Growth factor enhancement for bone grafts. J Oral Maxillofacila Surg, 85,  638-46. 
Mast, B. A., Diegelmann, R. F., Krummel, T. M. & Cohen, I. K. (1992). Scarless  Wound Healing In 
The Mammalian Fetus. Surg Gynecol Obstet, 174, 441-51. 
Mazzucco L, Medici D, Serna M, Panizza R, Rivara G, Orecchia S, Libener R, Cattana E, Levis A, 
Betta PG, Borzini P. 2004. The use of autologous platelet gel to treat difficult to heal wounds: A 
pilot study. Transfusion, 44,1013–1018. 
McGee G, Davidson JM, Buckley A ,Sommer A, Woodward SC, Aquino AM, Barbour R, 
Demetriou AA(1998). Recombinant basic fibroblast growth factor accelerates wound healing. J Surg 
Res, 45,145–53. 
Mcgowan, S. E. (1992). Extracellular Matrix And The Regulation Of Lung  DevelopmentAnd 
Repair. FASEB J, 6, 2895-904. 
  
 
 
324 
Mcgrath, J. A., Leigh, I. M. & Eady, R. A. (1992). Intracellular Expression Of  Type Vii Collagen 
During Wound Healing In Severe Recessive Dystrophic Epidermolysis Bullosa And Normal Human 
Skin. Br J Dermatol, 127, 312-7. 
Mcguire PG and Seeds NW. (1989). The interaction of plasminogen activator with reconstituted 
basement membrane matrix and extracellular macromolecules  produced by cultured epithelial cells. 
J.Cell Biochem  40: 215. 
 
 Mercurio AM, Rabinovitz I, Shaw LM. (2001). The alpha 6 beta 4 integrin and  epithelial cell   
  migration. Curr OPIN Cell Biol 13, 541-545. 
Messadi DV, Doung HS, Zhang Q, Kelly AP, Tuan TL, Reichenberger E. Le AD (2004) Activation 
of NFkappa B signal pathwyas in keloid fibroblast. Arc dermatli Res. 296, 125-33 
Meier, P., Finch, A., Evan, G. (2000). Apoptosis In Development. Nature, 407,  796-801. 
Meigel, W. N. (1997). How Safe Is Oral Isotretinoin? Dermatology, 195, suppl 1, 22-8;  38-40. 
MILLPLEX 
TM
 MAP kit  .www.millpore.com/techilibrary/index.do 
Moll, R., Divo, M.;  Langbein, L. (2008). The Human Keratins: Biology And Pathology. Histochem 
Cell Biol, 129, 705-33. 
Morasso, M. I.;  Tomic-Canic, M. (2005). Epidermal Stem Cells: The Cradle Of  Epidermal 
Determination, Differentiation And Wound Healing. Biol Cell, 97, 173-83. 
Moulin, V., Auger, F. A., Garrel, D. & Germain, L. (2000). Role Of Wound Healing Myofibroblasts 
On Re-Epithelialization Of Human Skin. Burns, 26, 3-12. 
Movafagh S, Hobson JP, Spiegel S, Kleinman HK, Zukowska Z (2006) Neuropeptide Y induce 
migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2,Y5 receptors. 
FASEB J 20,1924-1926 
Mulder. G,  Tallis .A.J, Marshall V.T,   Mozingo .D et.al. (2009). Treatment of nonhealing diabetic 
foot ulcers with a platelet-derived growth factor gene-activated matrix (GAM501): Results of a 
Phase 1/2 trial. Wound Rep Reg,  17, 772–779 
Myllyharju, J. & Kivirikko, K. I. (2001). Collagens And Collagen-Related Diseases. Ann Med, 33, 7-
21. 
Nassar, T., Sachais, B. S., Akkawi, S., Kowalska, M. A., Bdeir, K.,  Leitersdorf, E., Hiss, E., 
Ziporen, L., Aviram, M., Cines, D., Poncz, M. & Higazi, A. A. (2003) Platelet Factor 4 Enhances 
The Binding Of Oxidized Low-Density Lipoprotein ToVascular Wall Cells. J Biol Chem, 278, 6187-
93. 
Nehls, V. and Drenckhahn, D. (1995). A Novel, Microcarrier-Based In Vitro Assay for rapid and 
reliable quantification of three-dimensional cell migration and  angiogenesis. Microvasc Res, 50, 
311-22. 
  
 
 
325 
Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z 1(999). Vascular endothelial growth (VEGF) and 
its receptors. FASEB J, 13, 9-22. 
Nwomeh, B. C., Liang, H. X., Cohen, I. K. & Yager, D. R. (1999). Mmp-8 Is The predominant 
Collagenase In Healing Wounds And Nonhealing Ulcers. J Surg Res, 81, 189-95. 
Nwomeh, B. C., Liang, H. X., Diegelmann, R. F., Cohen, I. K. & Yager, D. R. (1998). Dynamics of 
the matrix metalloproteinases MMP-1 and MMP-8 in acute open human dermal wounds. Wound 
Repair Regen, 6, 127-34. 
Okuda K, Kawase T, Momose M, Murata M, Saito Y Suzuki H et .al. (2003). Platelet -rich plasma 
contains hihg levels of platelet drived growth factors and transforming growth factors-β and 
modulates the proliferation of peridontally related cells in vitro.  J Periodontol, 74, 849-57 
O'Brien J, Wilson I, Ortaon T, Pognan F.(2000) investigation of the Alamar Blue (resazurin) 
fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem. 267,5421-6  
Odland, G., and  R. Ross. (1968). Human wound repair. I. Epidermal regeneration. J. Cell Biol. 
39:135–151. 
Olashaw NE, O'keefe EJ, and Pledger WJ. (1986) Platelet derived growth factormodulates epidermal 
growth factor receptors by a mechanism  distinct from that of phorbol esters. Proc. Natl.Acad.Sci. 
USA, 83,3834 
Olsen, D. R. & Uitto, J. (1989). Differential Expression Of Type Iv Procollagen And Laminin Genes 
By Fetal Vs Adult Skin Fibroblasts In Culture: Determination Of Subunit Mrna Steady-State Levels. 
J Invest Dermatol, 93, 127-31. 
Oshima, R. G. (2007). Intermediate Filaments: A Historical Perspective. Exp Cell Res, 313, 1981-94. 
Oster, S. K., Marhin, W. W., Asker, C., Facchini, L. M., Dion, P. A., Funa, K., Post, M., Sedivy, J. 
M. & Penn, L. Z. (2000). Myc Is An Essential Negative Regulator Of Platelet-Derived Growth 
Factor Beta Receptor Expression. Mol Cell Biol, 20, 6768-78. 
O‘Toole E.A, Marinkovich M.P, Peavey C.L, Amieva M.R, Furthmayr H, Mustoe T.A, Woodley 
D.T .(1997). Hypoxia increases human keratinocyte motilityon connective tissue. J Clin Invest, 
100:2881–2891 
Paladini R.D, Takahashi K, Bravo N.S, Coulombe P.A .(1996). Onset of re-epithelisation after skin 
injury correlates with a reorganisation of keratin after skin injury correlates with a reorganization of 
keratin filaments in wound edges keratinoctes: defining a potential role of keratin 16. J cell Biol 132 
381-397 
Palolahti, M., Lauharanta, J., Stephens, R. W., Kuusela, P. &  Vaheri, A. (1993). Proteolytic Activity 
In Leg Ulcer Exudate. Exp Dermatol, 2, 29-37. 
Panetti TS, Chen H, Misenheimer T.M, Getzler S.B , Mosher D.F. (1997)Endothelial cell 
mitogenesis induced inhibition by thrombospondin-1 and thrombospondin -2 by LPA. J Lab Clin 
Med,129,208-16 
  
 
 
326 
Pecoraro, R. E., Reiber, G. E. & Burgess, E. M. (1990). Pathways To Diabetic Limb  Amputation. 
Basis For Prevention. Diabetes Care, 13, 513-21. 
Pellegrini, G., Ranno, R., Stracuzzi, G., Bondanza, S., Guerra, L.,  Zambruno, G.,  Micali, G. & De 
Luca, M. (1999). The Control Of Epidermal Stem Cells (Holoclones) In The Treatment Of Massive 
Full-Thickness Burns With Autologous Keratinocytes  Cultured On Fibrin. Transplantation, 68, 
868-79. 
Pervushina, O., Scheuerer, B., Reiling, N., Behnke, L., Schroder, J.  M., Kasper, B., Brandt, E., 
Bulfone-Paus, S. & Petersen, F. (2004). Platelet Factor 4/Cxcl4 Induces Phagocytosis And The 
Generation Of Reactive Oxygen Metabolites In Mononuclear Phagocytes Independently Of Gi 
Protein Activation Orintracellular Calcium Transients. J Immunol, 173, 2060-7. 
Pestonjamasp,  K., M.R. Amieva, C.P. Strassel, W.M. Nauseef, H. Furthmayr, and E.J. Luna. 
(1995). Moesin, ezrin and p205 are actin-binding proteins associated with neutrophil plasma 
membranes. Mol. Biol. Cell. 6:247–259. 
Petersen, F., Brandt, E., Lindahl, U. & Spillmann, D. (1999). Characterization Of A Neutrophil Cell 
Surface Glycosaminoglycan That Mediates Binding Of Platelet Factor 4. J Biol Chem, 274, 12376-
82. 
Petersen, M.J., D.T. Woodley, G.P. Stricklin, and E.J. O‘Keefe. (1990). Enhanced synthesis of 
collagenase by human keratinocytes cultured on type I or type IV collagen. J. Investig. Dermatol. 
94:341–346. 
Pierce, G. F., Mustoe, T. A., Altrock, B. W., Deuel, T. F.& Thomason, A. (1991). Role Of Platelet-
Derived Growth Factor In Wound Healing. J Cell Biochem, 45, 319-26. 
Pham H, Armstrong DG, Harvey C, Harkless LB, Giurini JM, Veves A (2000) Screening techniques 
to identify people at risk for diabetic foot ulceration: a prospective multicenter trial. Diabetes Care 
23,606– 611,  
Pilcher, B.K,. J.A. Dumin, B.D. Sudbeck, S.M. Krane, H.G. Welgus, and W.C. Parks. (1997). The 
activity of collagenase-1 is required for human keratinocyte migration on a type I collagen matrix. J. 
Cell Biol,1371445–1457. 
Pitei DL, Foster A, Edmonds M.(1999)The effect of regular callus removal on foot pressures. J Foot 
Ankle Surg, 38251–255. 
Porter R.M, Lunny D.P, Ogden P.H, Morley S.M, McLean W.H, Evans A, Harrison D.L, Rugg E.L, 
Lane E.B.  (2000). K15 expression implies lateral differentiation within stratified epithelial basal 
cells.    Lab Invest. 80,1701-10. 
Posionen  T l. (2008)Human Retinal Miller Cells Synthesize Collagens Of The Vitreous Aand 
Vitreoretinal Interface In Vitro. Mol Vis ,14, 652-660. 
Pulkkinen, L. & Uitto, J. (1999). Mutation Analysis And Molecular Genetics Of  Epidermolysis 
Bullosa. Matrix Biol, 18, 29-42. 
  
 
 
327 
Raghow, R. (1994). The Role Of Extracellular Matrix In Postinflammatory Wound  Healing And 
Fibrosis. FASEB J, 8, 823-31. 
Ragnarson Tennvall G, Apelqvist J (2004). Health-economic consequence of diabetic foot lesion. 
Clin Infect Dis,39 S132–9. 
Ralfkiaer E, Thomsen K, Vejlsgaard GL(1991).Expression of a cell adhesion protein (VLA 1) in 
normal and diseased skin. Br J Dermatol, 124,527-532 
Rajan. V , Murray. R.Z, (2008).The duplicitous nature of inflammation in wound repair, Wound 
Practice and Research, 16, 122–129,. 
Regauer S, Seiler GR, Barrandon Y, Easley KW, Compton CC.(1990).Epithelial origin of cutaneous 
anchoring fibrils. J Cell Biol, 111,2109-2115 
Reiber, G. E., Vileikyte, L., Boyko, E. J., Del Aguila, M., Smith, D. G., Lavery, L. A.& Boulton, A. 
J. (1999). Causal Pathways For Incident Lower-Extremity Ulcers In Patients With Diabetes From 
Two Settings. Diabetes Care, 22, 157-62. 
Rheinwald J.G, Green H. (1975). Serial cultivation of strains of human epidermalkeratinocytes: the 
formation of keratinizing colonies from single cells. Cell, 6,331-43. 
Risau, W. (1997). Mechanisms of angiogenesis. Nature, 386, 671-4. 
Robson, M. C., Mustoe, T. A. & Hunt, T. K. (1998). The Future Of Recombinant  Growth Factors In 
Wound Healing. Am J Surg, 176, 80s-82s. 
Robson, M. C., Phillips, L. G., Lawrence, W. T., Bishop, J. B., Youngerman, J. S., Hayward, P. G., 
Broemeling, L. D. & Heggers, J. P. (1992). The Safety And Effect Of Topically Applied 
Recombinant Basic Fibroblast Growth Factor On The Healing Of  Chronic Pressure Sores. Ann 
Surg, 216, 401-6; 406-8. 
Rogers, M. A., Langbein, L., Praetzel-Wunder, S., Winter, H. &  Schweizer, J. (2006). Human Hair 
Keratin-Associated Proteins (Kaps). Int Rev Cytol, 251, 209-63. 
Rousselle P, Lunstrum G. P, Keene D.R, Burgeson R.E: Kalinin: an epithelium-specific basement 
membrane adhesion molecule that is a component of anchoring filaments. J Cell Biol (1991), 
114:567-576 
Rucinski, B., Niewiarowski, S., Strzyzewski, M., Holt, J. C. & Mayo, K. H. (1990). Human Platelet 
Factor 4 And Its C-Terminal Peptides: Heparin Binding And  Clearance From The Circulation. 
Thromb Haemost, 63, 493-8. 
Rugeeiero, F.J, Comte C, Cabanas, Garrone R (1996). Structural Requirements For  Alpha 1 Beta 1 
And Alpha 2 Beta 1 Integrin Mediated  Cell Adhesion To Collagen V. J.Cell Sci 1009, 1865-1874 
Russ JC, 1995. The image processing handbook. CRC Press. 
  
 
 
328 
Ryynanen, J., Sollberg, S., Parente, M. G., Chung, L. C.,  Christiano, A. M. & Uitto, J. (1992). Type 
Vii Collagen Gene Expression By Cultured Human Cells And In Fetal Skin. Abundant Mrna And 
Protein Levels In  Epidermal Keratinocytes. J Clin Invest, 89, 163-8. 
Sachais, B. S., Higazi, A. A., Cines, D. B., Poncz, M. & Kowalska, M.A. (2004).Interactions Of 
Platelet Factor 4 With The Vessel Wall. Semin Thromb Hemost, 30, 351-8. 
Sachais, B. S., Kuo, A., Nassar, T., Morgan, J., Kariko, K., Williams,  K. J., Feldman, M., Aviram, 
M., Shah, N., Jarett, L., Poncz, M., Cines,D. B. & Higazi, A. A. (2002). Platelet Factor 4 Binds To 
Low-Density Lipoprotein Receptors And Disrupts The Endocytic Machinery, Resulting In Retention 
Of Low-Density Lipoprotein On The Cell Surface. Blood, 99, 3613-22. 
Sappino, A. P., Schurch, W. & Gabbiani, G. (1990). Differentiation RepertoireOf Fibroblastic Cells: 
Expression Of Cytoskeletal Proteins As Marker Of Phenotypic Modulations. Lab Invest, 63, 144-61. 
Saratzis N, Saratzis A, Melas N and Kiskinis D. (2008) Non- activated autologous platelet-rich 
plasma for the prevention of inguinal wound-related complications after endovascular repair of 
abdominal aortic aneurysms. J. Extra Corpo Technol,40, 52-6. 
Schaffner, A., Rhyn, P., Schoedon, G. & Schaer, D. J. (2005). Regulated Expression of  Platelet 
Factor 4 In Human Monocytes-Role Of  Pars As A Quantitatively Important Monocyte Activation 
Pathway. J Leukoc Biol, 78, 202-9. 
Scheuerer, B., Ernst, M., Durrbaum-Landmann, I., Fleischer, J.,Grage-Griebenow, E., Brandt, E., 
Flad, H. D. & Petersen, F. (2000). The Cxc-Chemokine Platelet Factor 4 Promotes Monocyte 
Survival And Induces  Monocyte Differentiation Into Macrophages. Blood, 95, 1158-66. 
Schafer, I. A., Pandy, M., Ferguson, R. & Davis, B. R. (1985). Comparative observation Of 
Fibroblasts Derived From The Papillary And Reticular Dermis Of Infants And Adults: Growth 
Kinetics, Packing Density At Confluence And Surface Morphology. Mech Ageing Dev, 31, 275-93. 
Schwartz MA. (1992). Transmembrane signalling by integrins. Trends Cell Biol, 2,304-308 
Schweizer, J., Bowden, P. E., Coulombe, P. A., Langbein, L., Lane, E. B., Magin, T. M., Maltais, L., 
Omary, M. B., Parry, D. A., Rogers, M. A. & Wright, M. W. (2006). New Consensus Nomenclature 
For Mammalian Keratins. J Cell Biol, 174, 169-74. 
Segura, I., Serrano, A., De Buitrago, G. G., Gonzalez, M. A., Abad, J. L., Claveria, C., Gomez, L., 
Bernad, A., Martinez, A. C. & Riese, H. H. (2002) Inhibition Of Programmed Cell Death Impairs In 
Vitro Vascular-Like Structure Formation And Reduces In Vivo Angiogenesis. FASEB J, 16, 833-41.  
Sekido Y, Morishima Y, Ohya, K (1987). Activity of platelet-derived growth factor (PDGF) in 
platelet concentrates and cryopreserved platelets determined by  PDGF bioassay. Vox Sang, 52,27-
30. 
Senet P, Bon F.X, Benbunan M, Bussel A, Traineau R, Calvo F, Dubertret L, Dosquet C.  (2003). 
Randomized trial and local biological effect of autologous platelets used as adjuvant therapy for 
chronic venous leg ulcers. J Vasc Surg, 38, 1342-8. 
Seung ,J.L.(2000) Cytokine delivery and tissue engineering. Yonsei Med J, 41,704-19 
  
 
 
329 
Seul M, O' Gorman, Sammon M.J,. (2002). Parctical Algorithms For Image Analysis, Cambridge 
Univ Press, New York. 
Shah, M., Foreman, D. M. & Ferguson, M. W. (1995). Neutralisation Of Tgf-Beta 1 And Tgf-Beta 2 
Or Exogenous Addition Of Tgf-Beta 3 To Cutaneous Rat Wounds Reduces Scarring. J Cell Sci, 108 
, 985-1002. 
Shaw, J. E., Van Schie, C. H., Carrington, A. L., Abbott, C. A. & Boulton, A. J. (1998). An Analysis 
Of Dynamic Forces Transmitted Through The Foot In Diabetic Neuropathy. Diabetes Care, 21, 
1955-9. 
Shimizu, H., McDonald, J.N., Gunner, D.B., Black, M.M, Bhogal B., Leigh I.M., Whitehead, P.C, 
Eady RA. (1990). Epidermolysis bullosa acquisita antigen and the carboxy terminus of type VII 
collagen have a common immunolocalization to anchoring fibrils and lamina densa of basement 
membrane.  Br J Dermatol, 122, 577-85 
Singer, A. J. & Clark, R. A. (1999). Cutaneous Wound Healing. N Engl J Med, 341, 738-46. 
Smola, H., Thiekotter, G. & Fusenig, N. E. (1993). Mutual Induction Of Growth Factor Gene 
Expression By Epidermal-Dermal Cell Interaction. J Cell Biol, 122, 417-29. 
Somasundaram R, Schuppan D. (1996)Type I, II, III, IV, V, and VI collagens serve as extracellular 
ligands for the isoforms of platelet-derived growth factor (AA, BB, and AB). J Biol Chem , 271, 
26884–91. 
Sonnenberg, A., Calafat, J., Janssen, H., Daams, H., Van Der  Raaij-Helmer, L. M., Falcioni, R., 
Kennel, S. J., Aplin, J. D., Baker, J.,(1991). Integrin alpha 6/beta 4 complex is located in 
hemidesmosomes, suggesting a major role in epidermal cell-basement membrane adhesion. J Cell 
Biol. 113(4),907-17. 
Sorrell, J. M. and  Caplan, A. I. (2004). Fibroblast Heterogeneity: More Than Skin Deep. J Cell Sci, 
117, 667-75. 
Sorrell, J.M., Barber, M.A. and Caplan, A.I. (2004). Site-matched papillary and reticular human 
dermal fibroblast differ in their  release of specific growth factors/ cytokines and in their interaction 
with keartioncytes . J cell Physiol 200,134-45 
Spurzem, J.R, Gupta J, Veys T, Kneifl, K.R, Rennard ,S.I, et al. (2002) Activation of protein kinase 
A accelerates bovine bronchial epithelial cell migration. Am J Physiol Lung Cell Mol Physiol 282, 
L1108–1116. 
Stanley AC, Osler T. Senescence and the healing rates of venous ulcers (2001). J Vasc Surg, 33, 
1206-11. 
Stacey, M.C, Mata, S.D, Trengove, N.J, Mather, C.A.  (2000). Randomised double-blind placebo 
controlled trial of topical autologous platelet lysate in venous ulcer healing. Eur J Vasc Endovasc 
Surg, 20, 296–301. 
  
 
 
330 
Steed ,D.L, Attinger, C, Colaizzi, T, Crossland, M, Franz M, Harkless L, Johnson A, Moosa H, 
Robson M, Serena T, Sheehan P, Veves A, Wiersma-Bryant L. (2006) Guidelines for the treatment 
of diabetic ulcers. Wound Repair Regen  14, 680–92. 
Steed, D. L. (1995). Clinical Evaluation Of Recombinant Human Platelet-Derived Growth Factor 
For The Treatment Of Lower Extremity Diabetic Ulcers. Diabetic Ulcer Study Group. J Vasc Surg, 
21,  79-81. 
Steed, D.L. (2006) Clinical evaluation of recombinant human platelet-derived growth factor for the 
treatment of lower extremity ulcer. Plast. Reconstr Surg, 117,143S-151S. 
Steed, D. L., Donohoe, D., Webster, M. W. & Lindsley, L. (1996). Effect Of Extensive Debridement 
And Treatment On The Healing Of Diabetic Foot Ulcers. Diabetic Ulcer Study Group. J Am Coll 
Surg, 183, 61-4. 
Stojadinovic, O., Brem, H., Vouthounis, C., Lee, B., Fallon, J., Stallcup, M., Merchant, A., Galiano, 
R. D. & Tomic-Canic, M. (2005). Molecular Pathogenesis Of Chronic Wounds: The Role Of Beta-
Catenin And C-Myc In The Inhibition Of Epithelialization And Wound Healing. Am J Pathol, 167, 
59-69. 
Streit, M, Braathen, L.R. (2000). Apligraf-a living human skin equivalent for the treatment of 
chronic wounds. Int J Artif Organs,23,831-3 
Switalska, H.I, Niewiarowski S, Tusynski, G.P, Rucinski B, Schmaier AH, Morinelli TA et.al. 
(1985)  Radioimmunoassay of human platelet thrombospodin: different patterns of thrombopsondin 
and beta-thromboglobulin antigen secretion and clearance from the circulation. J . Lab Clin Med, 
106,690-700 
Tabata Y. (2003) Tissue regeneration based on growth factor release. Tissue Eng, 9,5-15  
Tajima, S. & Pinnell, S. R. (1981). Collagen Synthesis By Human Skin Fibroblasts In Culture: 
Studies Of Fibroblasts Explanted From Papillary And Reticular Dermis. J Invest Dermatol, 77, 410-
2. 
Tang, Y.Q, Yeaman, M.R, Selsted, M.E. (2002) Antimicrobial peptides from human platelets. Infect 
Immun,70, 6524-33 
Tarnuzzer, R. W. & Schultz, G. S. (1996). Biochemical Analysis Of Acute And Chronic Wound 
Environments. Wound Repair Regen, 4, 321-5. 
Tawes RL Sydorak GR, Du Vall TB. (1994).Autologous fibrin glue: the last step in operative 
hemostasis. Am J Surg ,168, 120-2. 
Taylor S, Folkman J. (1982). Protamine is an inhibitor of angiogenesis. Nature 297,307-312 
Tennenbaum T, Li L, Belanger AJ, DeLuca LM, Yuspa SH (1996) Selective changes in laminin 
adhesion and a6b4 integrin regulation are associated with the initial steps in keratinocyte maturation. 
Cell Growth & Differentiation ,7,615–628 
  
 
 
331 
The structure and the development of skin. In Fitzpatrick‘s dermatology in general medince. (ed. 
T.B fITzpatrick and I.M fReedberg), pp 70-114. New York: McGraw-Hill Health Professions 
Division) 
Todaro, G. J., Wolman, S. R., Green, H. (1963) Rapid Transformation Of Human Fibroblasts With 
Low Growth Potential Into Established Cell Lines By Sv40. J Cell Physiol, 62, 257-65. 
Tranquillo, R. T. & Murray, J. D. (1992). Continuum Model Of  Fibroblast-Driven Wound 
Contraction: Inflammation-Mediation. J Theor Biol, 158, 135-72. 
Trengove, N. J., Bielefeldt-Ohmann, H. & Stacey, M. C. (2000). Mitogenic Activity And Cytokine 
Levels In Non-Healing And Healing Chronic Leg Ulcers. Wound Repair Regen, 8, 13-25. 
Trentgrove  N.J, Stacey M. C,  Macauley S  1999 et .al, Analysis of the acute and chronic wound 
enivorments: The role of proteases and their inhibitors . Wound Repair Regen, 7, 442 
Tuhkanen, A.L, Agren, U.M, Tammi, M.I, Tammi, R.H. (1999) CD44 Expression marks the onset of 
keratinocytestratification and mesenchymal maturation into fibrous dermis in fetal human skin. J 
HistochemCytochem 47, 1617–1624 
Uhl E, Rösken F, Sirsjö A, Messmer K (2003) Influence of platelet-derived growth factor on 
microcirculation during normal and impaired wound healing. Wound Repair Regen.11, 361-7. 
Uitto, J. & Christiano, A. M. (1992). Molecular Genetics Of The Cutaneous Basement Membrane 
Zone. Perspectives On Epidermolysis Bullosa And Other Blistering Skin Diseases. J Clin Invest, 90, 
687-92. 
Uitto, J And Richard, G (2004). Progrees In Epidermiolysis Bullosa: Genetic Classification And 
Clinical Implications. Am J Med. Genet.C. Semin. Med.Gnet ,131,.61-74. 
Usui, M.L, Mansbridge, W.N, Carter, W.G, Fujita M, Olerud,  J.E. (2008) Kerationcyte migration, 
proliferation and differntiation in chronic ulcers from patients with Diabetes and Normal wounds. J 
of Histochem. 56, 687-696 
Usiu, M.L, Underwood, R.A, Mansbridge J.N, Muffrey, L.A, Carter, W.G, Olerund JE. (2005) . 
Morphological evidence for the role of suprabasal keratinocytes in wound reepithelization. Woun 
Repair Regen. 13, 468-479 
Vande Berg, J. S., Rudolph, R., Hollan, C. & Haywood-Reid, P. L. (1998). Fibroblast Senescence In 
Pressure Ulcers. Wound Repair Regen, 6, 38-49. 
Vande Berg, J. S., Smith, P. D., Haywood-Reid, P. L., Munson, A. B., Soules, K. A. & Robson, M. 
C. (2001). Dynamic Forces In The Cell Cycle Affecting Fibroblasts In Pressure Ulcers. Wound 
Repair Regen, 9, 19-27 
Vartanian R.K, Weidner N (1995).  Endothelial cell proliferation in prostatic carcinoma and prostatic 
hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell proliferation. 
Lab Invest, 73,844-50. 
  
 
 
332 
V. Rajan and R. Z. Murray, (2008). The duplicitous nature of inflammation in wound repair, Wound 
Practice and Research,  16,122–129,  
Veves A, Falanga V, Armstrong DG, Sabolinski ML. (2001) Graftskin, a human skin equivalent, is 
effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective 
randomized multicenter clinical trial. Diabete Care,24,290-5 
Visitrak For Wound Measurement , (WWW. Smith-Nephew.Com) 
Von Hundelshausen, P., Koenen, R. R., Sack, M., Mause, S. F., Adriaens, W., Proudfoot, A. E., 
Hackeng, T. M. & Weber, C. (2005). Heterophilic Interactions Of Platelet Factor 4 And Rantes 
Promote Monocyte Arrest On Endothelium. Blood, 105, 924-30 
Vukicevic, S., Kleinman, H. K., Luyten, F. P., Roberts, A. B., Roche, N. S. & Reddi, A. H. (1992) 
Identification Of Multiple Active Growth Factors In Basement Membrane Matrigel Suggests 
Caution In Interpretation Of Cellular Activity Related To Extracellular Matrix Components. Exp 
Cell Res, 202, 1-8. 
Wagner FW Jr. (1987) The diabetic foot. Orthopedics; 10:163-72 
Waikel, R. L., Kawachi, Y., Waikel, P. A., Wang, X. J. & Roop, D. R. (2001). Deregulated 
Expression Of C-Myc Depletes Epidermal Stem Cells. Nat Genet, 28, 165-8. 
Wang, Y., He, H., Zigler, J. S., Jr., Iwata, T., Ibaraki, N., Reddy, V. N. & Carper, D. (1999). Bfgf 
Suppresses Serum-Deprivation-Induced Apoptosis In A Human Lens Epithelial Cell Line. Exp Cell 
Res, 249, 123-30. 
Wang C, Tammi M, Tammi R. (1992). Distribution of hyaluronan and its CD44 receptor in the 
epithelia of human skin appendages. Histochemistry, 98, 105–112. 
Wahl S, Hunt D, Wakefield L,McCartney-Francis N, Wahl LM, Roberts AB, Sporn MB. (1987). 
Transforming growth factor type beta induces monocyte chemo taxis and growth factor production. 
Proc Natl Acad Sci USA, 84,5788-92 
Waschke, J. (2008). The Desmosome And Pemphigus. Histochem Cell Biol, 130, 21-54. 
Watt, F. M. (1989). Terminal Differentiation Of Epidermal Keratinocytes. Curr Opin Cell Biol, 1, 
1107-15. 
Weibrich G, Kleis W.K. G , Hafner G. (2002) Growth factor levels in the platelet-rich plasma 
produced by 2 different methods: curasan-type kit verus PCCS PRP system.Int J Oral Maxillofac 
Imp.; 17:184-190 
Weibrich, G, Kleis W.K.G, Hafner G, Hitzler W.E. (2002) Growth factor levels in platelet-rich 
plasma and correlations with donor age, sex and platelet count. J Cranio. Max . Fac. Surg; 30:97-
102 
Weibrich G, Hansen T, Kleis W, Buch R, Hitzler WE. (2004) Effect of platelet concentration in 
platelet-rich plasma on periimplant bone regeneration. Bone, 34, 665–671 
  
 
 
333 
Welch, M. P., Odland, G. F. & Clark, R. A. (1990). Temporal Relationships Of F-Actin Bundle 
Formation, Collagen And Fibronectin Matrix Assembly, And Fibronectin Receptor Expression To 
Wound Contraction. J Cell Biol, 110, 133-45. 
Wen-Cheng Lo, Jeng-Fong Chiou, Juri G. Gelovani, Mei-Leng Cheong, Chi-Ming Lee et.al 
(2009).Transplantation of Embryonic Fibroblasts Treated with Platelet-Rich Plasma Induces 
Osteogenesis in SAMP8 Mice Monitored by Molecular Imaging . J Nucl Med; 50:765–773 
Werner, S. & Grose, R. (2003) .Regulation Of Wound Healing By  Growth Factors And Cytokines. 
Physiol Rev, 83, 835-70 
Werner S, Krieg T. (2007) Smola H. Keratinocyte -fibrolast interactions in wound healing J.  of 
Iinvest dermal,127, 998-1008 
Wess T.J (2005). Collagen  fibril form and function. Advances in Protein Chemistry,70, . 341–374,  
Xu, H., Czerwinski,. P, Hortmann, M, Sohn H.Y, Forstermann U, Li H, ( 2008) Protein Kinase C 
alpha promotes angiogenic activity of human endothelial cells via induction of vascular endothelial 
growth factors. Cardivas Res 78, 349-355 
Xu, J. & Clark, R. A. (1996). Extracellular Matrix Alters Pdgf Regulation Of Fibroblast Integrins. J 
Cell Biol, 132, 239-49 
Yager, D. R. & Nwomeh, B. C. (1999). The Proteolytic Environment Of Chronic Wounds. Wound 
Repair Regen, 7, 433-41. 
Yager, D.R, Zhang, L.Y, Liang H. X, Diegelman, R.F, Cohen, I. K. (1996) Wound fluids from 
human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to 
surgical wound fluids. J Invest Dermatol, 107,743–748 
Yeaman MR. (1997). The role  of platelets in antimicrobial host defense. Clin Infect Dis, 25:951-70. 
Young, M.J, Coffey J, Taylor P.M, Boulton, A.J.M (1995). Weight bearing ultrasound in diabetic 
and  rheumatoid arthritis patients. Foot, 5,76 –79,  
Yu, G., Rux, A. H., Ma, P., Bdeir, K. & Sachais, B. S. (2005). Endothelial Expression Of E-Selectin 
Is Induced By The Platelet-Specific Chemokine Platelet Factor 4  Through Lrp In An Nf-Kappab-
Dependent Manner. Blood, 105, 3545-51. 
Zegers M.M, Forget M.A, Chernoff J, Mostov KE, terBeest M. B, et al. (2003) Pak1 and PIX 
regulate contact inhibition during epithelial wound healing. Embo J  22, 4155–4165. 
Zhu, S. J., Choi, B.H.,  Jung, J.H., Lee, S.H., Huh., J. Y., You, T.M., Lee, H.J., Li, J.  (2006) A 
comparative histologic analysis of tissue-engineered bone  using platelet-rich plasma and platelet-
enriched fibrin glue. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 102,175-179. 
 Zimmermann, R., Jakubietz, R., Jakubietz, M., Strasser, E., Schlegel, A., Wilfang, J,, Eckestein, R., 
(2001): Different preparation methods to obtain platelet components as asource of growth factors for 
application. Transfusion,41,1217-1224 
  
 
 
334 
Zoller M, Gupta P, Marhaba R, Vitacolonna M, Freyschmidt-Paul P. (2007)Anti-CD44-mediated 
blockade of leukocyte migration in skin-associated immune diseases. J Leukoc Biol,82,57–71 
 
 
 
 
 
  
 
 
335 
PUBLISHED REVIEW ARTICLE ON AUTOLOGOUS DERIVED PLATELET GEL 
 
  
 
 
336 
 
  
 
 
337 
 
  
 
 
338 
 
  
 
 
339 
 
  
 
 
340 
 
 
  
 
 
341 
 
  
 
 
342 
 
  
 
 
343 
 
  
 
 
344 
 
 
  
 
 
345 
 
 
 
 
 
 
 
 
 
